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Abstract 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder, currently 
there are no disease modifying treatments. It is thought that microRNAs may be implicated 
in pathogenesis of PD. In this thesis the function of three microRNAs, which may be relevant 
to PD, were investigated in zebrafish. These miRNAs are: miR-133b, thought to be involved 
in development of dopaminergic neurons through its target PITX3; miR-205, which has been 
shown to regulate the PD-associated gene LRRK2; and miR-155, a key regulator of immune 
and inflammatory processes. Despite being more evolutionarily distant to humans than 
rodent models, the zebrafish has emerged as an effective model of human disease due it its 
low cost, fast development and transparency. A further aim of this thesis was to develop a 
high throughput imaging strategy to assess dopaminergic neuron number in the developing 
zebrafish brain, which can be used as a screening tool to identify potentially therapeutic 
compounds. 
The effect of both miR-133b and miR-205 knockdown on the number of dopaminergic 
neurons was investigated. In wild type zebrafish miR-205 knockdown causes a slight but 
significant decrease in dopaminergic neurons whereas miR-133b knockdown causes a 
significant increase in dopaminergic neuron number. In a previously established zebrafish 
model of PD, miR-133b knockdown completely rescued a 15% decrease in dopaminergic 
neuron number. The expression of miR-155 was assessed in three different zebrafish models 
of PD. While no change was observed in pink1- or parkin-deficient zebrafish, an increase in 
this miRNA and related inflammatory markers was observed in both larvae and juvenile 
brains of gba1-deficient zebrafish. As this miRNA and inflammatory markers are shown to be 
upregulated before any neuron loss is detectable in these zebrafish, it is possible that 
miR-155-related inflammation contributes to neurodegeneration. A stable miR-155 mutant 
line was also generated which will be used to determine whether genetic ablation of this 
miRNA has a protective effect in gba1-deficient zebrafish. 
A fluorescent reporter line expressing GFP in monoaminergic neurons has been validated for 
study of dopaminergic neurons. A fluorescence-based method developed using this line was 
able to reproduce data using a previously established in situ hybridisation-based method for 
neuron counting. To allow for more time and cost effective mounting of embryos for imaging, 
a mould has been developed. Use of this mould to mount embryos allows for high 
throughput imaging of the developing brain. 
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The miRNAs presented in this study may have therapeutic potential in PD through 
modulation of dopaminergic neuron survival or by regulating the expression of PD-
associated genes. The development of a high throughput screening process may allow a PD-
related drug or toxin screen to be performed in our group in the near future.  
v 
 
Contents 
Chapter 1. Introduction .................................................................................................. 1 
Chapter 2. Materials and Methods................................................................................ 44 
Chapter 3. Investigating the role of miR-133b in dopaminergic neuron development and 
survival ........................................................................................................................ 78 
Chapter 4. Investigating the interaction between miR-205 and lrrk2 in zebrafish ......... 132 
Chapter 5. miR-155 and the role of neuroinflammation in neurodegeneration ............. 156 
Chapter 6. Developing a high throughput imaging system for zebrafish larval brains .... 178 
Chapter 7. General Discussion .................................................................................... 210 
Bibliography .............................................................................................................. 221 
 
  
vi 
 
List of Figures 
Chapter 1 
Figure 1. Parkinson's disease incidence and total prevalence in the UK. .............................................. 4 
Figure 2. Clinical symptoms and time course of Parkinson’s disease progression. ............................... 8 
Figure 3. Neuronal circuits for control of motor activity. .................................................................... 10 
Figure 4. Overview of genetic variants associated with Parkinson's disease. ...................................... 15 
Figure 5. Cellular processes involved in Parkinson's disease pathology. ............................................. 17 
Figure 6. The adult zebrafish brain. ...................................................................................................... 29 
Figure 7. miRNA biogenesis and post-transcriptional repression. ....................................................... 34 
Figure 8. DNA methylation, histone modification and the structure of chromatin. ............................ 36 
Figure 9. miRNAs thought to be involved in the pathogenesis of Parkinson's disease. ....................... 42 
Chapter 2 
Figure 10. Fin clipping of embryos. ...................................................................................................... 49 
Figure 11. Using a graticule to measure injection volume. .................................................................. 50 
Figure 12. Regions of the pri-miRNA transcript and MO design. ......................................................... 50 
Figure 13. Injecting into the ventricles of a 24hpf embryo. ................................................................. 52 
Figure 14. Plasmid map of dual reporter plasmid. ............................................................................... 66 
Figure 15. Location of th+ neurons in 2 and 5dpf zebrafish. ................................................................ 70 
Chapter 3 
Figure 16. Identification of a feedback loop between miR-133b and PITX3 in midbrain dopaminergic 
neurons. ....................................................................................................................................... 81 
Figure 17. Summary of PITX3 network. ................................................................................................ 83 
Figure 18. Polymorphisms conferring a significant risk or protective effect for PD in the PITX3 genetic 
locus. ........................................................................................................................................... 85 
Figure 19. Protein homology and genetic locus synteny between human and zebrafish pitx3. .......... 86 
Figure 20. Polymorphisms conferring a significant risk or protective effect for PD in the miR-133b 
containing genetic locus. ............................................................................................................. 88 
Figure 21. Possible mechanism of action of cocaine through miR-133b in zebrafish embryos. .......... 89 
Figure 22. Design of a WISH probe for pitx3. ....................................................................................... 90 
Figure 23. Conservation of miR-133b across species. .......................................................................... 91 
Figure 24. Gene synteny in the region surrounding human and zebrafish miR-133b. ........................ 92 
Figure 25. Spatial expression of miR-133b at 3dpf. ............................................................................. 93 
Figure 26. Expression and localisation of pitx3. ................................................................................... 93 
Figure 27. Knockdown of miR-133b using MO at 3dpf. ....................................................................... 95 
Figure 28. The effect of miR-133b knockdown on th mRNA levels. ..................................................... 95 
Figure 29. miR-133b knockdown results in an increase of th+ dopaminergic neurons at 3dpf. .......... 96 
vii 
 
Figure 30. Dopaminergic neuron number in uninjected and control MO injected embryos. .............. 96 
Figure 31. Knockdown of miR-133b in pink1-/- embryos rescues th+ dopaminergic neuronal loss. .... 97 
Figure 32. Knockdown of miR-133b in MPP+ treated zebrafish is unable to rescue th+ dopaminergic 
neuronal loss. .............................................................................................................................. 98 
Figure 33. The effect of miR-133b knockdown on number of th+ dopaminergic neurons at 36 and 
48hpf. .......................................................................................................................................... 99 
Figure 34. miR-133b levels after miRNA mimic injection. .................................................................. 101 
Figure 35. FITC dextran injections into zebrafish ventricles. .............................................................. 102 
Figure 36. miR-133b levels after injection of miRNA mimic into ventricles. ...................................... 102 
Figure 37. Number of th+ dopaminergic neurons after miR-133b mimic injection. .......................... 103 
Figure 38. Localisation of miR-133b after miR-133b mimic injection. ............................................... 104 
Figure 39. A potential miR-133b binding site in zebrafish pitx3 3’UTR. ............................................. 105 
Figure 40. Dual reporter plasmid maps. ............................................................................................. 106 
Figure 41. GFP and RFP fluorescence with control reporter plasmid. ............................................... 107 
Figure 42. MOs targeting pitx3. .......................................................................................................... 109 
Figure 43. Testing of Abcam Pitx3 antibody. ...................................................................................... 110 
Figure 44. Initial testing of custom antibodies for Pitx3. ................................................................... 111 
Figure 45. Optimisation of antibody incubation time. ....................................................................... 112 
Figure 46. Antibody ab164 specifically detects a band at 32kDa. ...................................................... 113 
Figure 47. Antibody ab164 specifically detects zebrafish Pitx3. ........................................................ 114 
Figure 48. miR-133b knockdown does not increase pitx3 mRNA levels at 3dpf. ............................... 115 
Figure 49. Assessment of miR-133b-pitx3 interaction using reporter plasmid. ................................. 116 
Figure 50. miR-133b knockdown does not increase Pitx3 protein levels at 3dpf. ............................. 117 
Figure 51. EdU incorporation into proliferating neurons. .................................................................. 118 
Figure 52. EdU incorporation into proliferating neurons in early development. ............................... 119 
Figure 53. EdU and TH in WT and miR-133b morphants.................................................................... 120 
Figure 54. neurogenin1 WISH and EdU staining at 13hpf. ................................................................. 121 
Chapter 4 
Figure 55. Lrrk2 domain structure, domain functions and mutations associated with PD. ............... 134 
Figure 56. Conservation of amino acid sequences and functional domains of LRRK2 between human 
and zebrafish. ............................................................................................................................ 137 
Figure 57. Design of a WISH probe for lrrk2. ...................................................................................... 139 
Figure 58. Conservation of miR-205 across species. .......................................................................... 140 
Figure 59. Spatial expression of miR-205 at 3dpf. .............................................................................. 140 
Figure 60. Expression and localisation of lrrk2. .................................................................................. 141 
Figure 61. Knockdown of miR-205 using MO. .................................................................................... 142 
Figure 62. miR-205 knockdown has no effect on th mRNA levels at 3dpf. ........................................ 142 
Figure 63. miR-205 knockdown results in a small decrease in th+ dopaminergic neurons at 3dpf. .. 143 
viii 
 
Figure 64. Validated and predicted binding sites for miR-205 in lrrk2 3’UTR. ................................... 143 
Figure 65. RT-PCR analysis of the effect of the lrrk2 MOs. ................................................................ 145 
Figure 66. Effect of lrrk2 MOs on the lrrk2 transript. ......................................................................... 145 
Figure 67. Initial testing of Lrrk2 antibody. ........................................................................................ 147 
Figure 68. Investigating the specificity of the Lrrk2 antibody using MOs. ......................................... 147 
Figure 69. miR-205 knockdown has no effect on lrrk2 mRNA levels at 3dpf. .................................... 149 
Figure 70. miR-205 knockdown has no effect on Lrrk2 protein levels at 3dpf................................... 149 
Chapter 5 
Figure 71. Conservation of miR-155 across species. .......................................................................... 159 
Figure 72. Stability of zebrafish U6 snRNA and miR-24 in a range of samples................................... 163 
Figure 73. Reliability of qPCR results using accurate RNA quantification. ......................................... 164 
Figure 74. miR-155 expression levels are increased in gba1 mutant brains and larvae. ................... 164 
Figure 75. Spatial expression of miR-155 in gba1 mutants. ............................................................... 165 
Figure 76. miR-155 expression is not altered in PD zebrafish larvae and adult brains. ..................... 166 
Figure 77. Expression of inflammatory markers in gba1 mutant brains and larvae. ......................... 168 
Figure 78. CRISPR/Cas9 gene editing system. .................................................................................... 169 
Figure 79. CRISPR sites in miR-155 region. ......................................................................................... 170 
Figure 80. Analysis of efficacy of miR-155 CRISPRs. ........................................................................... 171 
Figure 81. Design and efficacy of miR-155 gRNA5. ............................................................................ 172 
Chapter 6 
Figure 82. Comparison of strategies for drug discovery. ................................................................... 181 
Figure 83. Neuronal groups labelled by the ETvmat2:GFP reporter line. .......................................... 184 
Figure 84. Image analysis process with ETvmat2:GFP embryos. ....................................................... 186 
Figure 85. th+ dopaminergic neuron counts and fluorescence intensity in WT and miR-133b 
morphants. ................................................................................................................................ 188 
Figure 86. th+ dopaminergic neuron counts and fluorescence intensity in WT and MPP+ treated 
embryos. .................................................................................................................................... 189 
Figure 87. Image analysis methods with WT and pink1-/- embryos. .................................................. 191 
Figure 88. Using a 3D printed mould for zebrafish orientation for imaging. ..................................... 194 
Figure 89. Testing high throughput imaging of zebrafish embryos using the IN Cell Analyzer 2000. 196 
Figure 90. Testing different concentrations of agarose to make wells. ............................................. 199 
Figure 91. Fluorescence intensity measurements using new mounting and imaging technique. ..... 200 
Figure 92. Contribution of area and intensity to total fluorescence intensity reading in WT and miR-
133b morphants. ....................................................................................................................... 203 
Figure 93. Comparison of standard deviation from image analysis data from mould mounted and 
individually mounted zebrafish embryos. ................................................................................. 206 
Figure 94. Potential drug screening pipeline...................................................................................... 209 
ix 
 
List of tables 
Chapter 1 
Table 1. Prevalence of non-motor symptoms of Parkinson’s disease and related pathology. ............ 11 
Table 2. Monogenic forms of Parkinson’s Disease. .............................................................................. 12 
Table 3 Comparison of zebrafish with other model organisms. .......................................................... 26 
Chapter 2 
Table 4. Morpholinos used in this study. ............................................................................................. 51 
Table 5. miRNA mimics used in this study............................................................................................ 52 
Table 6. PCR/RT-PCR primers used in this study. ................................................................................. 56 
Table 7. qPCR primers used in this study ............................................................................................. 57 
Table 8. Taqman assays used in this study. .......................................................................................... 58 
Table 9. Primers used to generate WISH probes. ................................................................................ 60 
Table 10. Exiqon LNA probes used. ...................................................................................................... 61 
Table 11. Antibodies used for fluorescent WISH and IHC. ................................................................... 64 
Table 12. Components of the Click-IT® kit for EdU staining. ................................................................ 65 
Table 13. Primers used for generation and analysis of reporter plasmids. .......................................... 68 
Table 14. Antibodies used for western blotting. .................................................................................. 73 
Table 15. Peptide epitopes of custom antibodies ................................................................................ 74 
Table 16. Primers and ultramers used in CRISPR generation. .............................................................. 75 
Chapter 3 
Table 17. Potential targets of miR-133b of interest in Parkinson’s disease. ...................................... 130 
Chapter 5 
Table 18. Inflammatory markers increased in GD patients, gba1 deficient mouse brains and PD 
patients with GBA mutations. ................................................................................................... 167 
Table 19. Mutations caused by miR-155 CRISPR5. ............................................................................. 173 
Chapter 7 
Table 20. Selected miRNA therapies currently in development. ....................................................... 219 
  
x 
 
Abbreviations 
-/-: homozygous mutant 
+/-: heterozygous 
+/+: wild type 
3’UTR: 3’ untranslated region 
6-OHDA: 6-hydroxydopamine 
AADC: aromatic amino acid decarboxylase 
BBB: blood brain barrier 
Cas9: CRISPR associated protein 9 
cDNA: complementary DNA 
CNS: Central nervous system 
COR: C-terminal of ROC (domain of LRRK2) 
CpG: cytosine-phosphate-guanine (a dinucleotide of C followed by G) 
CRISPR: Clustered regularly interspaced short palindromic repeats 
CSF: cerebrospinal fluid 
D2: dopamine receptor 2 
DAT: dopamine transporter 
dpf: days post-fertilisation 
EAE: experimental autoimmune encephalitis 
EDS: excessive daytime sleepiness 
EdU: 5-ethynyl-2'-deoxyuridine 
EMT: epithelial to mesenchymal transition 
ENU: N-ethyl-N-nitrosurea 
EOPD: early onset PD 
ER: endoplasmic reticulum 
ESCs: embryonic stem cells 
EtOH: ethanol 
FOV: field of view 
GAP: GTPase activating protein 
GBA: glucocerebrosidase 
gDNA: genomic DNA 
GFP: green fluorescent protein 
GPRD: General Practice Research Database 
gRNA: guide RNA 
GWAS: genome-wide association study 
hpf: hours post-fertilisation 
HTT: huntingtin 
IHC: immunohistochemistry 
iPSCs: induced pluripotent stem cells 
LMP: low melting point 
LNA: locked nucleic acid 
LOPD: late onset PD 
LPS: lipopolysaccharide 
LRRK2: leucine rich repeat kinase 2 
MCI: mild cognitive impairment 
MDS-UPDRS: Movement Disorders Society unified Parkinson's disease rating scale 
MeOH: methanol 
miRNA/miR-: microRNA 
MND: motor neuron disease 
MO: morpholino 
xi 
 
MPP+: 1-methyl-4-phenylpyridinium 
MPTP: 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine 
mRNA: messenger RNA 
NPC: non-pathogenic control 
OR: odds ratio 
PBS: phosphate buffered saline 
PCR: polymerase chain reaction 
PD: Parkinson’s disease 
PDD: Parkinson’s disease with dementia 
PFA: paraformaldehyde  
PINK1: PTEN-induced putative kinase 1 
PITX3: pituitary homeobox 3/paired-like homeodomain 3 
pri-miRNA: primary microRNA 
PTU: phenylthiourea 
qPCR: quantitative real time PCR 
RBD: REM sleep behaviour disorder 
REM: rapid eye movement 
RFP: red fluorescent protein 
RISC: RNA induced silencing complex 
ROC: Ras-like G-domain (domain of LRRK2) 
RT-PCR: reverse transcription PCR 
siRNA: small interfering RNA 
SNCA: ɑ-synuclein 
TALEN: transcription activator-like effector nucleases 
TH: tyrosine hydroxylase 
UPS: ubiquitin-proteasome system 
VMAT2: vesicular monoamine transporter 2 
WISH: whole mount in situ hybridisation 
WT: wild type 
  
1 
 
Chapter 1. Introduction 
  
2 
 
 
Contents 
1.1 Parkinson’s Disease ............................................................................................... 3 
Incidence and economic burden of Parkinson’s disease ......................................... 4 
Symptoms, diagnosis and treatment of Parkinson’s disease .................................. 5 
Pathology of Parkinson’s disease ............................................................................. 9 
Causes and pathogenesis of Parkinson’s Disease .................................................. 12 
1.2 Models of Parkinson’s disease ............................................................................. 18 
Human cell culture models .................................................................................... 18 
Mammalian toxin induced models ........................................................................ 20 
Mammalian genetic animal models ....................................................................... 21 
Non-mammalian models of PD .............................................................................. 23 
1.3 Zebrafish as a model of neurodegenerative disease ............................................. 25 
Suitability of zebrafish as a model organism ......................................................... 25 
Zebrafish genetic tools ........................................................................................... 26 
Zebrafish as a model of neurodegeneration .......................................................... 28 
1.4 microRNAs and human disease ........................................................................... 32 
Discovery and biogenesis of miRNAs ..................................................................... 33 
Epigenetics and non-coding RNAs ......................................................................... 35 
miRNA involvement in neurodegeneration ........................................................... 38 
miRNAs relevant to Parkinson’s disease ................................................................ 39 
1.5 Aims and hypotheses .......................................................................................... 43 
 
  
3 
 
1.1 Parkinson’s Disease 
Parkinson’s Disease (PD) is a common neurodegenerative disorder, affecting approximately 
1% of the population in the western world (de Lau & Breteler 2006). The prevalence of PD is 
second only to Alzheimer’s disease which affects approximately 4% of over 65s in Europe 
(Qiu et al. 2009). 
PD was first described in 1817 by James Parkinson, after whom the disease is named. In his 
famous essay “An Essay on the Shaking Palsy” he systematically described 6 patients 
suffering with this condition. The disorder was not named Parkinson’s disease until the mid-
1800s when Jean-Martin Charcot refined Parkinson’s early description and disseminated this 
information internationally. Parkinson had predicted that the “shaking palsy” was due to 
lesions in the cervical spinal cord (Parkinson 1817, subsequently reprinted in Parkinson 
2002). We now know that many of the symptoms of PD are attributable to the progressive 
loss of dopaminergic neurons within the substantia nigra pars compacta. Although the 
disease is clinically defined by the characteristic motor symptoms, many non-motor 
symptoms are also associated with PD.  
Since the clinical recognition of PD nearly 200 years ago tremendous effort has been put into 
understanding the causes and pathogenesis of this disease. However, there is still much that 
is unknown about this disorder. There are currently no disease modifying treatments for PD. 
Treatments, such as the dopamine precursor levodopa, are available to alleviate symptoms 
of the disease. Although treatment with levodopa is initially effective it becomes less 
effective over time and is associated with a number of side effects. The heterogeneous 
nature of PD has complicated drug discovery efforts as the pathology of the disease in 
patients may vary considerably (Kalia & Lang 2015). This highlights the need for a greater 
understanding of the range of pathologies associated with PD. In time this may allow for 
“personalised” medication. 
In recent years, many advances have been made in the discovery of genetic risk factors for 
PD, developing research techniques and new animal models for study of PD (Shulman et al. 
2011). As Shulman and colleagues state: “fortunately, the confusion that accompanies the 
crest of a rapidly advancing wave of discovery is usually transient, and in its wake comes a 
deeper understanding”. We can be cautiously optimistic that new treatments for PD will be 
available in the not too distant future. 
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Incidence and economic burden of Parkinson’s disease 
In the UK the incidence of PD, as calculated in 2009 by the charity Parkinson’s Disease UK, 
was 27.4 persons per 10,000 of the population over 20 years of age (Parkinson’s UK 2009). 
Within the UK, this equates to a total of close to 127,000 cases of PD. The study performed 
by Parkinson’s Disease UK calculated a higher prevalence of PD compared to others, which 
have reported a varied prevalence of between 10.5 to 17.8 persons with PD per 10,000 of 
the population in the UK (Hobson et al. 2005; Mutch et al. 1986). The variance between these 
studies is likely to be due to the small and geographically distinct populations used to 
calculate disease prevalence and the bias introduced by particular characteristics of these 
populations. The study performed by Parkinson’s Disease UK used data from the General 
Practice Research Database (GPRD). In 2009, the GPRD contained data for over 7% of the 
population (3.4 million persons) and was considered representative of the UK population 
(Williams et al. 2012). Figure 1 shows the incidence and prevalence of PD in discrete age 
groups. 
 
Figure 1. Parkinson's disease incidence and total prevalence in the UK. Reproduced from Parkinson’s UK (2009) 
PD is primarily a disease of the elderly with the majority of sufferers being over 70 years of 
age (Figure 1). Classical PD presents in people 60 years or older (Halliday & McCann 2010). A 
small number of patients who develop the disease before the age of 40 are classified as early-
onset PD (EOPD) patients. EOPD is more commonly linked to familial PD (Schrag & Schott 
2006).  
Familial PD, defined as those cases where a first degree relative is also affected by PD, 
accounts for approximately 10% of all cases. The remaining 90% of cases are referred to as 
“sporadic” PD (Thomas & Flint Beal 2007). The single largest risk factor for sporadic PD is age. 
As the worldwide life expectancy increases the number of cases of PD, and other diseases of 
the elderly, will also increase. In rapidly developing nations such as China and India the 
number of PD cases is predicted to more than double by 2030 (Dorsey et al. 2007). Although 
the total population of the western world is rising less rapidly than that of developing 
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nations, the elderly population is growing more rapidly than any other age group. In 2010 
there were approximately 10 million over 65s in the UK, 1/6th of the total population. This is 
expected to increase to approximately 19 million by 2050, equating to one in four people 
being in this age group (Cracknell 2010). The increased number of PD cases, which will 
inevitably result from the aging population, will result in increased pressure on primary care 
givers and an increased financial burden on patients and their health and social care systems. 
Furthermore, increased physical and emotional strain will be placed on patients and their 
families as these services are stretched. 
In 2010 the total cost per PD patient in the UK over the course of their illness was calculated 
to be over €20,000. The majority of the cost of PD stems from what is termed as “direct non-
medical” costs which includes the cost of social services, special accommodation and related 
care. This accounts for approximately 75% of the total cost of the disease. The remaining 
25% is made up of direct medical costs and indirect costs for example early retirement 
(Fineberg et al. 2013).  
The development of better drugs and other treatments to slow disease progression will not 
only help to improve the quality of life of PD sufferers and their families, but may also help 
to reduce the total cost of PD by increasing the independence of PD patients and thus limiting 
the “direct non-medical” costs. 
Symptoms, diagnosis and treatment of Parkinson’s disease 
PD is a chronic and progressive disorder with a highly variable disease course. Like many 
neurodegenerative diseases PD is clinically heterogeneous; some suggest that PD is likely to 
be a collection of related disorders rather than one distinct disease. In this section the major 
symptoms of the disease will be introduced. However, it is worth noting that not all patients 
develop all of the symptoms listed here in the same order, or indeed at all. Many efforts have 
been made to classify different subtypes of PD based on clustered clinical features, and in 
time this may aid research into distinct pathologies and aid treatment recommendations for 
individuals (Marras & Lang 2012). 
PD has been traditionally regarded as a motor disorder and the motor symptoms are 
regarded as the cardinal symptoms of the disease. Bradykinesia, one of the main motor 
symptoms, describes a slowness of movement. This overarching symptom is also related to 
many secondary motor symptoms including: hypophonia (soft speech), hypomimia (reduced 
degree of facial expressions), micrographia (small, bunched handwriting), shuffling gait and 
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dysphagia (problems with swallowing) (Jankovic 2008). Together these symptoms may cause 
difficulty for patients in everyday activities. Resting tremor is the most apparent symptom 
and typically presents asymmetrically. Tremor characteristically disappears with movement 
or sleep (Askenasy & Yahr 1990; Sternberg et al. 2013). Rigidity is also a major motor feature 
and is often associated with pain. Shoulder pain is a common first manifestation of PD which 
is often, understandably, misdiagnosed as shoulder injury or arthritis (Stamey et al. 2008). 
Postural instability and freezing are further motor symptoms that mainly occur in later stages 
of the disease. These are common causes of falls and related injuries in PD sufferers (Williams 
et al. 2006).  
With regard to motor symptoms, there are currently thought to be two major subtypes of 
PD: tremor dominant PD and non-tremor dominant PD. There are also patients who are 
intermediate of these two groups. Tremor-dominant PD patients demonstrate a relative 
absence of the other symptoms of PD; this is also associated with relatively slow disease 
progression. Non-tremor dominant PD patients generally display more dominant 
bradykinesia and rigidity (Marras & Lang 2012). While not all PD patients develop all of the 
above motor symptoms initially, the majority will suffer from them over the course of the 
disease. Some studies suggest that up to 25% of patients never experience a resting tremor 
(Hughes et al. 1993), however another study found that in all PD cases confirmed by autopsy 
a resting tremor had been detected at some stage in the disease course (Rajput et al. 1991). 
There are a range of drugs available to treat motor symptoms. The most common of these is 
levodopa, a precursor to many catecholaminergic neurotransmitters. Treatment with 
levodopa is usually delayed for as long as the patient’s quality of life is considered adequate. 
Although this treatment is initially effective in reducing motor symptoms and many patients 
benefit for several years, it is associated with potential motor complications such as 
dyskinesias (impairment of voluntary movement). Direct dopamine agonists are also 
effective for treatment but over time may result in peripheral oedema, impulse control 
disorders and excessive drowsiness (Massano & Bhatia 2012). Deep brain stimulation is also 
used as a treatment to alleviate motor symptoms in carefully selected patients (Lang et al. 
2006). 
Although less well known, PD also results in many non-motor symptoms that are equally 
damaging to patients’ quality of life. Common non-motor symptoms include sensory 
abnormalities such as anosmia (loss of sense of smell), visuospatial abnormalities, autonomic 
dysfunction, sleep disturbances and depression. Many of these non-motor symptoms 
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present early in the course of PD and may precede motor symptoms by many years 
(Zesiewicz et al. 2006). 
Pre-motor or prodromal phase symptoms may include constipation, sleep disturbances such 
as rapid eye movement (REM) sleep behaviour disorder (RBD) and excessive daytime 
sleepiness (EDS), impaired olfaction, visual dysfunction (for example impaired colour vision) 
and depression (Khoo et al. 2013). Less frequent bowel movements (<1 per day) have been 
shown to increase risk for PD approximately three-fold (Savica et al. 2009). Those who suffer 
with clinical depression are twice as likely to be diagnosed with PD in later life and 
approximately 70% of patients who experience both impaired colour vision and RBD develop 
PD or dementia within 5 years (Postuma et al. 2011; Noyce et al. 2012). The presence of 
these symptoms suggests that the pathology of PD begins well before the onset of motor 
symptoms. With further research these symptoms and the related pathology may be used 
to aid earlier diagnosis of PD. 
With the progression of the disease and worsening of motor symptoms, further non-motor 
symptoms may manifest. Constipation is again a common complaint and other autonomic 
symptoms such as urinary incontinence and orthostatic hypotension (low blood pressure 
upon standing, resulting in dizziness or light-headedness) are present in some patients with 
advanced PD (Pfeiffer 2012). Cognitive impairment and dementia is also common in late 
stage PD; up to 80% of patients who have had PD for 20 years develop dementia (Hely et al. 
2008). As well as dementia, a wide range of neuropsychiatric problems are associated with 
PD. These can be severely disabling and result in increased admission to nursing or care 
homes. In one study the 10-item Neuropsychiatric Inventory was used to assess over 500 PD 
patients with dementia (PDD). This study identified that nearly 90% of patients present with 
at least one NPI symptom, the most common of these were depression, apathy, anxiety and 
hallucinations (Aarsland et al. 2007).  
Finally, further features of late-stage PD include both motor and non-motor complications. 
Impulsive and obsessive-compulsive behaviours and psychosis have been associated with 
PD. Although the pathology of these behaviours is not well understood they may be 
attributed to dopamine dysregulation and use of dopaminergic drugs (Spencer et al. 2011; 
Friedman 2013). Again, although there are currently no therapies that alter the disease 
course, there are available treatment options to manage the non-motor symptoms of PD. 
These are reviewed in detail by Kalia & Lang (2015). Figure 2 summarises the clinical 
symptoms and disease progression of PD. 
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Figure 2. Clinical symptoms and time course of Parkinson’s disease progression. EDS = excessive daytime 
sleepiness, RBD = REM sleep behaviour disorder, MCI = mild cognitive impairment. Reproduced with permission 
from Kalia & Lang (2015). 
Currently, there are no simple diagnostic tests or biomarkers to aid the diagnosis of PD. 
Therefore, diagnosis is based on clinical presentation of the disease and the ruling out of 
alternate causes of the displayed symptoms. The diagnostic process is often hindered by the 
heterogeneous clinical presentation of the disease (Jankovic 2008). 
Diagnosis is based on the presence of two or three characteristic motor symptoms of the 
disease; bradykinesia plus either resting tremor or rigidity. Using these symptoms alone does 
not distinguish PD from other forms of Parkinsonism such as multiple system atrophy, and 
progressive supranuclear palsy (Hughes et al. 1992). Additional criteria for diagnosis such as 
a positive response to levodopa treatment aid a correct diagnosis. The UK Parkinson’s 
Disease Society Brain Bank provides a panel of exclusion criteria and supportive prospective 
criteria to aid diagnosis and distinguish PD from other similar disorders. However, this is still 
mostly based on the motor symptoms and includes many symptoms which are often present 
late in the disease course such as postural instability (Hughes et al. 1992). Berg and 
colleagues argue that PD needs to be redefined and suggest a three tiered approach taking 
into account clinical features, pathological findings and genetic and molecular mechanisms. 
Within the clinical tier, which will aid diagnostic efforts, they suggest that more emphasis 
needs to be placed on the non-motor symptoms that often precede the characteristic motor 
symptoms. However, the authors concede that this process will be challenging and more 
research needs to be performed to allow integration of the current body of knowledge to 
produce a comprehensive new definition of PD (Berg et al. 2013).  
There are several rating scales to aid assessment of disease progression. The 5-stage Hoehn 
and Yahr scale is often used to compare groups of patients. Stage 0 indicates no signs of 
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disease and patients reach stage 5 when they are wheelchair or bedridden unless assisted. 
The Unified Parkinson’s Disease Rating Scale (UPDRS), which assesses the overall disability 
of PD sufferers, is perhaps the most widely used and well established scale (Ebersbach et al. 
2006). This scale was updated in 2007 by the Movement Disorder Society (now known as the 
MDS-UPDRS) to include a section for the non-motor symptoms of PD (Goetz et al. 2007). 
Pathology of Parkinson’s disease 
The motor symptoms of PD strongly correlate with the loss of dopamine producing neurons 
in the substantia nigra and the related dopamine deficiency (Shulman et al. 2011). The 
neurons of the substantia nigra have ascending projections into the striatum. This signalling 
modulates neuronal circuits within the basal ganglia which facilitate movement. There are 
two neuronal circuits from the striatum, direct and indirect, which together regulate motor 
activity (Figure 3). The direct pathway stimulates motor activity and is stimulated by 
dopamine signalling. The indirect pathway inhibits motor activity and is inhibited by 
dopamine signalling. Therefore a loss of dopamine signalling from the substantia nigra 
results in a loss of motor activity through both pathways (Obeso et al. 2008). 
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Figure 3. Neuronal circuits for control of motor activity. This figure shows a coronal section of the brain. Neuron 
populations involved in control of motor activity are labelled. The “direct” and “indirect” neuronal circuits which 
stimulate and inhibit motor signalling and are modulated by dopamine signalling from the substantia nigra (Sub. 
Nigra) are shown. 
Alongside dopaminergic neuron loss, another major pathological hallmark of PD is the 
presence of Lewy bodies. Lewy bodies are inclusions of aggregated, abnormally folded 
proteins and are present in the majority of PD patients (Kalia & Lang 2015). Aggregates of 
PD-related proteins ɑ-synuclein and Microtubule-associated protein tau (Tau) been shown 
to be the major components of Lewy bodies (Spillantini et al. 1997; Ishizawa et al. 2003). 
Prion-like spreading of Lewy body pathology has also been suggested as Lewy bodies have 
been identified within the grafted neurons of patients who had received healthy neuron 
transplants into their putamen (Visanji et al. 2013). It has also been suggested that it is 
pre-fibrillar ɑ-synuclein intermediates which are harmful and that Lewy bodies are formed 
as a protective mechanism to remove this harmful protein (Dehay et al. 2015). 
In the majority of cases Lewy bodies emerge in a predictable pattern within affected brains. 
These are grouped into Braak stages (Braak et al. 2003). In the pre-motor stages of the 
disease protein inclusions may be present in the olfactory bulb, dorsal motor nuclei of the 
vagal and glossopharyngeal nerves in the brainstem, and the pontine tegmentum. 
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Subsequently, as the motor symptoms of PD emerge, inclusions reach the substantia nigra, 
regions of the ventral forebrain, the hypothalamus, thalamus and regions of the cortex. As 
the disease progresses the pathology in these regions worsens (Braak et al. 2003). 
ɑ-synuclein deposits are also present in the enteric nervous system. This is connected to the 
brain by the vagal nerve. However whether Lewy pathology begins here and spreads to the 
brain or vice versa is unclear (Del Tredici & Braak 2012). The pathology related to the non-
motor symptoms of PD and the prevalence of these symptoms is summarised in Table 1. 
Table 1. Prevalence of non-motor symptoms of Parkinson’s disease and related pathology. Adapted with 
permission from Berg et al. (2013). 
Symptom Prevalence Related pathology 
Olfactory dysfunction >80% 
 
Presence of Lewy bodies within in the 
olfactory bulb, amygdala and perirhinal 
cortex. 
Visual dysfunction Up to 90% Dopamine deficit within the retina 
Thinning of retinal nerve fibre. 
Sleep disorders: 
REM sleep behaviour 
disorder 
 
30-50% 
Presence of Lewy bodies in the nuclei of 
the lower brainstem. 
Autonomic dysfunction: 
Constipation 
Urinary dysfunction 
 
50-80% 
27-39% 
Lesions in the autonomic brainstem region 
and peripheral post-ganglionic neurons. 
Depression 30-40% Deficit of norepinephrine and serotonin in 
locus coeruleus and raphe nuclei. 
Cognitive decline/ 
dementia 
80% of PD 
patients with 20 
year disease 
course 
The spread of fibrillar ɑ-synuclein 
pathology to limbic and neocortical 
structures. 
Up to 50% develop amyloid plaques and 
tau-tangles.  
 
A future goal for PD research is to develop treatments which are able to slow or even halt 
the progression of the disease. As approximately 60-80% of dopaminergic neurons are 
already lost by the time motor symptoms present (Miller & O’Callaghan 2015), there is a 
great need for new diagnostic tools and biomarkers to halt PD in its earliest stages.  
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Causes and pathogenesis of Parkinson’s Disease 
The majority of PD cases are of unknown cause and are thought to arise from complex 
interplay between environmental and genetic risk factors (Shulman et al. 2011). As the era 
of genetic research has developed much progress has been made in determining genetic risk 
factors for PD. Studies of familial PD have also identified a number of 
monogenically-inherited forms of the disease (Verstraeten et al. 2015). In this section the 
known genetic and environmental causes and risk factors will be introduced. 
The discovery of disease causing genes has proved extremely useful to aid understanding of 
the pathogenesis of the disease. Study of the function of these genes give researchers an 
insight into dysregulated pathways in PD. The effect of mutations in these genes may also be 
studied in animal models (Kalia & Lang 2015). So far, six genes have been associated with 
autosomal dominant forms of PD and four genes are linked to autosome recessive forms of 
PD, these are listed in Table 2. 
Table 2. Monogenic forms of Parkinson’s Disease. 
Gene Full protein name Type of PD References 
Autosomal dominant inheritance of PD 
SNCA ɑ-synuclein Early onset PD 
(EOPD) 
(Polymeropoulos et al. 1997; 
Singleton et al. 2003) 
LRRK2 Leucine-rich repeat 
kinase 2 
Late onset PD 
(LOPD) 
(Di Fonzo et al. 2005) 
VPS35 Vacuolar protein 
sorting 35 
LOPD (Zimprich et al. 2011) 
EIF4G1 Eukaryotic translation 
initiation factor 4-γ1 
LOPD (Chartier-Harlin et al. 2011) 
DNAJC13 Receptor-mediated 
endocytosis 8 
LOPD (Vilariño-Güell et al. 2014) 
CHCHD2 Coiled-coil-helix-coiled-
coil-helix domain 
containing 2 
LOPD (Funayama et al. 2015) 
Autosomal recessive inheritance of PD 
Parkin Parkin Juvenile and EOPD (Kitada et al. 1998) 
PINK1 PTEN-induced putative 
kinase 1 
EOPD (Bonifati et al. 2005) 
DJ-1 DJ-1 EOPD (Bonifati et al. 2003) 
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Table 2  continued  
ATP13A2 ATPase Type 13A2 Atypical PD/Kufor-
Rakeb syndrome 
(Di Fonzo et al. 2007) 
 
SNCA, which encodes the ɑ-synuclein protein, was the first PD gene to be discovered 
(Polymeropoulos et al. 1997). Missense mutations in SNCA and multiplications of the SNCA-
containing genetic locus have been shown to cause PD (Singleton et al. 2003; Chartier-Harlin 
et al. 2004; Polymeropoulos et al. 1997). These mutations are thought to result in a toxic gain 
of function by increasing the likelihood of aggregation of the ɑ-synuclein protein (Devine et 
al. 2011). 
Mutations in LRRK2 underlie the most common form of dominantly inherited PD. The G2019S 
mutation in this gene has shown to be responsible for up to 4% of all familial PD cases. 
However, prevalence of LRRK2-related PD varies considerably among different populations 
(Healy et al. 2008). Mutations in LRRK2 are also thought to result in toxic gain of function. 
However, they are not completely penetrant, with 25% of carriers remaining disease free at 
79 years (Kumari & Tan 2009). The function of LRRK2 is discussed in more detail in the 
introduction to Chapter 4. 
The most recent genes found to be associated with autosomal dominant PD are VPS35, 
EIF4G1, DNAJC13 and CHCHD2. A single missense mutation in VPS35 (Asp620Asn) has been 
identified in three families and segregates with PD. Three further missense mutations in this 
gene may confer a risk for PD. VPS35 is a mediator of retrograde transport from the 
endosome to the trans-Golgi network (Zimprich et al. 2011). Recent evidence suggests that 
VPS35 dysfunction prevents lysosomal degradation of ɑ-synuclein (Miura et al. 2014). Two 
missense mutations in EIF4G1, which encodes a translation initiation factor, have also 
recently been implicated in PD. These mutations result in impaired binding of EIF4G1 to EIF4E 
and EIF3E, suggesting a dominant negative loss of function mechanism of pathology. This 
may prevent cells from responding rapidly to stress through alteration of translation of 
mRNAs which aid cell survival (Chartier-Harlin et al. 2011). DNAJC13 functions in similar 
pathways to VPS35. A missense mutation in this gene was discovered to segregate with the 
disease in a family of Dutch–German–Russian Mennonite ancestry (Vilariño-Güell et al. 
2014). Finally, the most recent gene to be implicated in autosomal dominant forms of PD is 
CHCHD2, this encodes a mitochondrial protein (Funayama et al. 2015). As mutations in 
DNAJC13 and CHCHD2 have been identified very recently, further independent studies are 
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required to validate the association of these genes with PD and suggest mechanisms as to 
how mutations in these genes result in pathogenesis. 
Mutations in Parkin, PINK1 and DJ-1 have been associated with autosomal recessive 
inheritance of PD (Kitada et al. 1998; Bonifati et al. 2005; Bonifati et al. 2003). Autosomal 
recessively inherited PD is more frequently an early onset disorder, with an age of onset of 
less than 40 years. Mutations in Parkin are the most common cause of EOPD; however the 
reported prevalence of these mutations in EOPD has varied considerably between studies 
(Lücking et al. 2000; Brooks et al. 2009). A study using a large UK cohort and a systematic 
review of many previous studies calculated that mutations in Parkin are present in 8.6% of 
EOPD cases. Mutations in PINK1 and DJ1 are rarer, and mutations in these genes are thought 
to be responsible for 3.7% and 0.4% of EOPD cases, respectively (Kilarski et al. 2012). These 
genes are all associated with mitochondrial pathways, providing an insight into important 
pathways underlying PD (Dodson & Guo 2007).  
Rare mutations in number of other genes including ATP13A2 are also associated with 
autosomal recessive PD. Patients carrying mutations in these genes often present with 
atypical features. For example, mutations in ATP13A2 were originally demonstrated to result 
in a Parkinsonian disorder known as Kufor-Rakeb syndrome (Ramirez et al. 2006). This is an 
early onset disorder which presents with many typical features of PD with additional 
symptoms such as severe dementia, pyramidal signs and supranuclear gaze palsy. Studies 
have also identified mutations in this gene which are responsible for more typical EOPD with 
limited atypical symptoms (Di Fonzo et al. 2007).  
The study of whole genomes and linkage analyses in families with inherited PD has facilitated 
the discovery of these rare mutations which confer high risk for the disease. However, 
familial PD is only responsible for approximately 10% of all cases (Thomas & Flint Beal 2007). 
Genetic risk factors also play a role in sporadic PD and a large number of genetic risk factors 
for PD have been identified. Genome-wide association studies (GWAS) using large number 
of subjects and subsequent meta-analyses have the power to identify common and medium 
frequency genetic variants which confer a small or medium increased risk for PD. Common 
variants in LRRK2 and SNCA which confer a higher risk of PD (Satake et al. 2009) have been 
identified as well as over 25 other genetic risk loci for PD (Verstraeten et al. 2015). The 
average odds ratio (OR) for these common variants is approximately 1.3. Figure 4 
summarises the frequency and risk confered by known genetic variants associated with PD. 
Additionally, a comprehensive database, PDGene, lists a large number of polymorphisms 
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thought to be associated with PD has been created using data from a large, recent meta-
analysis of GWAS (Nalls et al. 2014; Lill et al. 2012) 
 
 
Figure 4. Overview of genetic variants associated with Parkinson's disease. This schematic indicates the 
penetrance and frequency of genetic variants associated with PD. A small number of rare alleles have been found 
that confer high risk for PD, while a larger number of common genetic variants have been shown to confer a small 
increased risk for PD. There are a number of intermediates (shown in the yellow circle). Genes in bold are 
pleomorphic, that is both rare high risk variants and common low risk variants are present at the same loci. 
Adapted with permission from Verstraeten et al. (2015). 
A small number of variants have been identified with intermediate frequency and higher 
ORs. Mutations in glucocerebrosidase (GBA) are an important risk factor in PD. In the UK, 
approximately 4% of sporadic PD patients carry a mutation in this gene (Neumann et al. 
2009). GBA mutations increase risk for PD approximately 20-fold, with GBA-related PD being 
very similar to idiopathic PD but with a slightly earlier age of onset and increased likelihood 
of cognitive decline (Schapira 2015). GBA is involved in glycolipid metabolism, and patients 
who are homozygous for mutations in this gene develop the lysosomal storage disorder 
Gaucher’s disease. Heterozygous mutations in a related gene, SMPD1, have also been 
associated with a relatively high risk for PD in Ashkenazi Jewish population (OR = 9.4) (Gan-
Or et al. 2013). Homozygous mutations in SMPD1 are causative of another lysosomal storage 
disorder Niemann-Pick disease. The involvement of these genes in the risk for PD suggests 
an important role of lysosomal pathways. 
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Identification of genes involved in PD, together with pathological findings in PD patients, has 
helped determine some of the important cellular pathways that may underlie the disease. 
As discussed above a major pathological hallmark of PD is Lewy body pathology. The 
presence of protein aggregates in PD implicates impairment of protein folding and protein 
clearing mechanisms within the cell. These mechanisms include the ubiquitin-proteasome 
system (UPS) and autophagy pathways. Together these pathways function to degrade 
misfolded proteins, aggregates and dysfunctional organelles. Many PD genes, or risk variants 
for PD are involved in these pathways. Parkin is an E3 ubiquitin-ligase; addition of ubiquitin 
to proteins targets them for degradation, and thus mutations in Parkin may prevent the 
proper the degradation of its targets. Parkin has many targets linking it to both regulation of 
mitochondrial function and modulation of endoplasmic reticulum (ER) stress (Shin et al. 
2011; Imai et al. 2001). Interestingly, ɑ-synuclein has also been identified as a target of Parkin 
(Shimura et al. 2001), however Lewy body pathology is often absent in Parkin-related PD 
(Poulopoulos et al. 2012). As previously mentioned, GBA and SMPD1 are both involved in 
lysosomal function. A potential pathogenic feedback loop between GBA and ɑ-synuclein has 
been identified. Accumulation of the GBA substrate glucosylceramide can stabilise ɑ-
synuclein, while ɑ-synuclein is able to inhibit GBA activity (Mazzulli et al. 2011). LRRK2, 
VPS35, DNAJC13 and ATP13A2 are all thought to have roles in the lysosomal pathway.  
Changes in mitochondrial function and mitophagy (a specialised form of autophagy which 
degrades dysfunctional mitochondria) are other key pathogenic pathways in PD (Ryan et al. 
2015). Mitochondrial dysfunction is a key feature of many neurodegenerative diseases. It has 
been associated with PD since the early 1980s when it was found that a neurotoxin which 
causes Parkinsonism inhibits mitochondrial complex I (Langston et al. 1983; Nicklas et al. 
1985). This discovery has proved to be very important as mitochondrial inhibitors, such as 
rotenone and MPP+, are now commonly used to mimic PD in animal models (Blesa & 
Przedborski 2014). In post mortem brain tissue from PD patients mitochondrial complex I 
activity was discovered to be reduced by approximately 30% (Schapira et al. 1989). Adding 
weight to the pathogenic role of mitochondrial dysfunction and impaired clearance of 
damaged mitochondria, many PD-associated genes act within these pathways. PINK1 is a key 
detector of mitochondrial damage and is thought to be able to activate the mitophagy 
pathway through interacting with Parkin (Eiyama & Okamoto 2015). Although the function 
of DJ-1 is less clear, this protein is also thought to be involved in the mitophagy pathway 
(McCoy & Cookson 2011). 
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Other involved pathways and cellular functions which may be dysregulated in PD include the 
protein and membrane trafficking pathway, synaptic function, transmission of dopamine 
signalling and inflammation (this is introduced more detail in Chapter 5). Figure 5 shows the 
key cellular pathways involved in PD pathogenesis and lists the PD-associated genes involved 
in these pathways. 
 
 
Figure 5. Cellular processes involved in Parkinson's disease pathology. Multiple genes have been associated with 
PD, this figure summarises their involvement in the many cellular processes that are implicated in PD pathology. 
Reproduced with permission from Kalia & Lang (2015). 
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Other non-genetic risk factors and protective factors have been identified, although the 
mechanisms of many of these are not well understood. Rural living and agricultural 
occupation confer an increased risk of PD; this may be related to increased pesticide 
exposure and well water drinking which are also known risk factors. Other factors that 
increase risk are prior head injury and beta-blocker use. Of these, pesticide exposure confers 
the highest risk. Protective factors include, smoking, coffee intake, alcohol consumption, use 
of non-steroidal anti-inflammatory drugs and calcium channel blocker use (Noyce et al. 
2012). Understanding the mechanisms behind these risk factors and determining the 
interplay between them and genetic causes may help identify those who are at greater risk 
of PD. 
Although a large number of genetic risk factors have been identified by GWAS studies, the 
overall heritability of PD is only estimated at approximately 27% (Keller et al. 2012). It is clear 
that there are unidentified genetic and environmental factors which increase the risk of 
developing PD.  
1.2 Models of Parkinson’s disease 
As it is not possible to study the pathophysiology of PD progression in human patients, cell 
and animal models are used to aid understanding of the cellular mechanisms underlying 
dopaminergic neuron vulnerability. Through greater understanding of the underlying 
mechanisms of PD it is hoped that potential drug targets will be discovered. Large scale drug 
screens can also be performed in some model systems. In this section the models currently 
in use to study PD will be introduced. Zebrafish models of PD will not be discussed in this 
section, but will be introduced in detail in section 1.3. 
Human cell culture models 
Advantages of cell culture models derived from human tissue include the ability to study of 
sporadic PD and their suitability for small molecule screening. The power of using human 
dermal fibroblasts taken from patient skin biopsies has been demonstrated. Mitochondrial 
dysfunction has been observed in fibroblasts taken from patients with mutations in Parkin 
and LRRK2 (Mortiboys et al. 2008; Mortiboys et al. 2010). Mitochondrial read outs were 
recently used for a drug screen which identified many drugs which were able to rescue the 
mitochondrial function in these cells. It is hoped that the UDCA, a drug identified as beneficial 
in this study and which already in clinical use for some liver disorders may be taken into 
clinical trials for PD patients in the near future (Mortiboys et al. 2013). A major limitation of 
fibroblasts is that they are not a relevant cell type. Although they do display some underlying 
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features of PD, such as mitochondrial dysfunction, they do not display the same vulnerability 
to these changes as neurons. They also may not express the same complement of genes as 
the relevant neurons and therefore may not be able to model some gene-gene interactions. 
It is not possible to extract live neurons from patients, however, progress with production of 
induced pluripotent stem cells (iPSCs), which can be reprogrammed from fibroblasts, offers 
a major opportunity for the study of otherwise inaccessible cell types. iPSC-derived 
dopaminergic neurons, reprogrammed from somatic cells, have been characterised and are 
neurophysiologically similar to mature dopaminergic neurons. They are also susceptible to 
the PD-associated toxin MPTP (Hartfield et al. 2014). Unlike animal models where, typically, 
only one genetic alteration is made, iPSCs reprogrammed from patient cells contain the 
whole disease genome and have endogenous levels of gene expression. This may aid 
researchers understanding of the mechanisms behind sporadic PD and sub-types of PD 
resulting from defects in different cellular mechanisms. 
One of the first iPSC models of genetic PD were cells derived from a patient containing a 
triplication of SNCA. Dopaminergic neurons derived from these cells exhibited PD-related 
phenotypes such as ɑ-synuclein accumulation and oxidative stress (Byers et al. 2011). The 
effects of mutations in PINK1, Parkin and LRRK2 on mitochondria have also been studied 
using iPSC-derived dopaminergic neurons. Cells derived from patients carrying PINK1 
mutations displayed reduced translocation of Parkin to the mitochondria after 
depolarisation of mitochondria (Seibler et al. 2011). Dopaminergic neurons containing 
mutations in Parkin demonstrated upregulation of monoamine oxidases and increased 
oxidative stress. Reduced dopamine uptake by Parkin-mutant cells compared to cells derived 
from healthy controls was also observed (Jiang et al. 2012). LRRK2 mutations increased DNA 
damage in the mitochondrial genome (Sanders et al. 2014), increased oxidative stress and 
elevated levels of ɑ-synuclein (Nguyen et al. 2011). 
iPSCs have been used to study differences between monozygotic twins discordant for PD. 
Both twins carried a mutation in GBA. Dopaminergic neurons derived from both twins 
demonstrated elevated ɑ-synuclein protein levels. Decreased levels dopamine levels were 
observed in cells from the affected twin. Monoamine oxidase B (MAO-B) was upregulated in 
the affected twin but not the unaffected twin; this may be due to epigenetic mechanisms. 
Inhibition of MAO-B and upregulation of GBA rescued the ɑ-synuclein and dopmaine 
phenotype (Woodard et al. 2014).  
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Neuronal cells derived from iPSCs have also been transplanted into other animal models of 
PD. This has been performed in a toxin-induced rat model of PD and in non-human primates. 
Human iPSC-derived neuronal stem cells transplanted into the rat striatum differentiated 
and integrated into the brain. This resulted in an improvement of motor impairment 
displayed in these rats (Han et al. 2015). In non-human primates, iPSCs derived from a 
Cynomolgus monkey differentiated to a dopaminergic phenotype were transplanted into the 
same animal after Parkinsonism was induced using MPTP. These neurons survived for at least 
2 years (the duration of the study) and resulted in improvement of the motor features of the 
MPTP-treated monkeys (Hallett et al. 2015). These early studies suggest that neuronal 
transplant using iPSCs may be possible in the future. 
Although iPSCs have not yet yielded any novel mechanistic insight study, the use of iPSCs to 
study PD is still in its early stages. As they are more widely used and new protocols developed 
they are likely to be a powerful model and may also be used for drug screening (Jacobs 2014).  
Mammalian toxin induced models 
The classical PD-inducing toxin is MPTP. This is a by-product of synthetic heroin production 
and was discovered in the early 1980s when a group of drug addicts developed Parkinsonism 
after injecting synthetic heroin contaminated with this by-product (Langston et al. 1983). 
MPTP is up-taken specifically into dopaminergic neurons through the dopamine transporter 
(DAT) and is metabolised to MPP+. MPP+ localises to mitochondria where it is able to inhibit 
mitochondrial complex I (Javitch et al. 1985; Richardson et al. 2007). 
The particular strength of MPTP treatment is the specific and reproducible effect on the 
nigrostriatal system. MPTP-treated monkeys demonstrate PD-like motor defects and display 
features similar to the non-motor symptoms of PD patients including cognitive impairment 
and sleep disturbances. A specific loss of dopaminergic neurons in the substantia nigra and 
only mild loss of neurons in other regions is observed in MPTP-treated monkeys. Although 
no protein inclusions have been identified in these models ɑ-synuclein mRNA and protein 
levels have been shown to be increased (Porras et al. 2012). MPTP is also used in other 
organisms, particularly the mouse. Although MPTP-mice do display motor defects and 
degeneration of dopaminergic neurons, they do not develop protein inclusions or presence 
non-motor features (Taylor et al. 2011). 
Another classical toxin-induced PD model is the 6-hydroxydopamine (6-OHDA) treated rat. 
This model was developed earlier than MPTP models and a method for inducing loss of 
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dopaminergic neurons in rats using this toxin was first published in 1972 (Breese & Traylor 
1972). 6-OHDA is a hydroxylated form of dopamine. 6-OHDA confers specific neurotoxicity 
to dopaminergic neurons in a similar manner to MPTP. It is transported into dopaminergic 
neurons through DAT where it causes oxidative stress and inhibits mitochondrial respiration 
(Rodriguez-Pallares et al. 2007). Unlike MPTP, 6-OHDA is unable to cross the blood brain 
barrier and therefore requires injection directly into the brain of animal models. The effects 
of this toxin are similar to those of MPTP and specific loss of dopaminergic neurons without 
presence of Lewy bodies is observed (Bové & Perier 2012).  
Other toxin-induced models of PD include rotenone and paraquat models. Due to the 
increased risk of PD associated with pesticide exposure, the effect of these toxins, which are 
both present in some pesticides, on animal models is of interest (Nisticò et al. 2011). Like 
MPP+, rotenone is a mitochondrial complex I inhibitor while paraquat causes oxidative 
stress. Unlike MPTP and 6-OHDA models, rotenone and paraquat administration in rodents 
is able to induce intracellular inclusions resembling Lewy bodies (Manning-Bog et al. 2002; 
Sherer et al. 2003). 
The toxin-induced PD models have proved invaluable in the last 3 decades for study of 
cellular pathways involved in advanced PD. While these models are unable to mimic the 
aetiology of PD, the involvement of mitochondrial function, oxidative stress, inflammation, 
and protein degradation pathways have been studied in these models (Bové & Perier 2012; 
Broom et al. 2011; Vila et al. 2008; McCormack et al. 2005). This has allowed for advances in 
our understanding of the mechanisms which may be behind dopaminergic neuron death. 
Limitations of toxin-induced models include the acute onset, lack of Lewy body pathology (in 
the majority of models), non-motor features and limited reproducibility in certain models 
(Bové & Perier 2012). Toxin-induced models are less useful for study of early symptoms of 
PD and for drug discovery efforts due to the acute nature of cell death. Another inherent 
issue with performing drug screening in toxin induced models is the possibility of drug-drug 
interactions obscuring a meaningful effect.  
Mammalian genetic animal models 
The discovery of monogenically-inherited PD genes and the development of genome editing 
techniques have enabled researchers to create mammalian models which may better 
simulate the processes which underlie genetic forms of PD. Knockout, conditional and 
systemic and knock-in animal models for many PD related genes have been generated. The 
continued development of molecular tools such as the Cre-LoxP system, viral vectors and the 
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CRISPR/Cas9 system has revolutionised the generation of genetic animal models (Feil et al. 
2009; Löw & Aebischer 2012; Yang 2015).  
As SNCA- and LRRK2-related PD are thought to be due to toxic gain of function of the encoded 
proteins, animal models overexpressing the mutant, or wild type (WT), forms of these genes 
are most commonly used. Expression of these genes can be induced in specific tissues by 
placing the transgene under control of a tissue-specific promoter.  
Overexpression of SNCA has been studied in mice, rats, and non-human primates. Many 
transgenic SNCA mouse models have been created with mixed results. The phenotype of 
SNCA transgenic mice varies depending on the promoter, level of over expression and 
whether WT or mutated SNCA is used (Blesa & Przedborski 2014). Tetracycline-induced 
transgenic mice which overexpress mutant SNCA under the PITX3 promoter display robust 
neurodegeneration and motor phenotypes. Other relevant pathologies observed in this 
model included the presence of ɑ-synuclein inclusions, reduced dopamine release and an 
impairment of the autophagy/lysosome pathway (Lin et al. 2012). Rat models of SNCA-
related PD, using viral-vectors to drive expression of SNCA, have generally proved to be more 
robust. The majority of these models demonstrate progressive loss of dopaminergic neurons, 
a motor phenotype and ɑ-synuclein inclusions in stage-like manner. These inclusion are 
observed in the striatal axons and termini before cell body pathology appears (Decressac et 
al. 2012; Lo Bianco et al. 2002). Non-human primate models of SNCA-associated PD have 
been shown to be valuable models of PD. These models display a gradual worsening of motor 
coordination. Upon histological analysis, prominent degradation of striatal dopaminergic 
fibres was observed and ubiquitin containing aggregates were detected (Eslamboli et al. 
2007). Early cognitive defects and anxiety phenotypes have also been observed in transgenic 
monkeys showing that these may be useful models for study of the pre-motor stages of the 
disease (Niu et al. 2015).  
Knockout models of LRRK2, aiming to elucidate the function of this large complex gene, have 
failed to identify any neuronal loss. This suggests that this gene is not required for healthy 
neuronal function (Hinkle et al. 2012). Conversely, a neuroprotective role of LRRK2 
knockdown has been suggested. LRRK2-deficient rats were resistant to the 
neurodegeneration induced by lipopolysaccharide (LPS, an inflammatory stimulant which 
can induce dopaminergic neuron loss) treatment, through reducing the inflammatory 
response (Daher et al. 2014). Knock-in and overexpression (of both mutant and WT LRRK2) 
models in mice have again produced variable results. Some studies did not detect any neuron 
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loss while others observed neurodegeneration in an age dependant manner (Ramonet et al. 
2011; Tong et al. 2009; Herzig et al. 2011). This variation may be due to the method used for 
overexpression, and the level of overexpression achieved. For example, viral-vector based 
models demonstrate the largest degree of neurodegeneration (Lee et al. 2010). Whether the 
neurotoxic effect of this is due to increased kinase activity or due to the absolute levels of 
LRRK2 is disputed. This is discussed in detail in Chapter 4.  
PINK1, Parkin and DJ-1 knock-out mouse models have also been generated. These models 
typically display a moderate decrease in striatal dopaminergic levels but do not model 
neurodegeneration or major motor defects (Yamaguchi & Shen 2007; Akundi et al. 2011; 
Gispert et al. 2009; Kitada, Pisani, et al. 2009). Mitochondrial dysfunction and abnormal 
expression of inflammatory genes, however, has been observed in PINK1 deficient mice 
(Akundi et al. 2011; Gispert et al. 2009). Unexpectedly, a triple knockout of all three genes 
was also unable to model nigral degeneration (Kitada, Tong, et al. 2009). One mouse model 
generated using a bacterial artificial chromosome to express truncated Parkin in 
dopaminergic neurons demonstrated age-dependant and progressive dopaminergic neuron 
loss, accumulation of ɑ-synuclein and motor symptoms (Lu et al. 2009). A similar 
neurodegenerative effect was seen as a result of overexpression of both WT and mutant 
Parkin in rats (Van Rompuy et al. 2014). Knockouts of these three genes have also been 
generated in rats. In contrast to the mice models, both PINK1 and DJ-1 deficient rats display 
progressive nigral degeneration with up to 50% of dopaminergic neurons being lost by 8 
months; related motor impairments are also observed. However this is not seen in Parkin-
deficient rats (Dave et al. 2014). 
Non-mammalian models of PD 
Small genetically tractable models such as the fruit fly Drosophila melanogaster and teleost 
fishes have also been used to model PD. As well as their genetic tractability other advantages 
of these models include their small size and low cost which makes them amenable to small 
molecule screens.  
Both knockout models of recessive loss of function mutations and knock in models of 
dominant gain of function mutations have been created in Drosophila. Although flies have a 
relatively simple nervous system they do possess a population of dopaminergic neurons and 
there are well developed techniques to study neurophysiology (reviewed by West et al. 
(2015). Drosophila models of PD have been instrumental in the implication of mitochondrial 
dysfunction and provided a demonstration that pink1 and parkin act in the same pathway 
24 
 
(Yang et al. 2006; Park et al. 2006). Knockout of either pink1 or parkin in Drosophila both 
display a shortened lifespan, locomotor defects derived from the degeneration flight 
muscles. This degeneration is thought to be related to mitochondrial dysfunction. 
Dopaminergic neurons were shown to degenerate in the pink1 knockout model but not the 
parkin knockout model (Greene et al. 2003; Yang et al. 2006). The parkin knockout model 
also developed male sterility which was also related to mitochondrial dysfunction. 
Drosophila models expressing mutant forms of human SNCA and LRRK2 have also been 
developed. These models have a shortened life-span, locomotor dysfunction, protein 
inclusions similar to Lewy-bodies, and specific loss of dopaminergic neurons (Liu et al. 2008). 
SNCA Drosophila models are reviewed by Mizuno et al. (2011).  
Although Drosophila are a useful model to study cellular mechanisms, they are an 
invertebrate model and limitations of this model result from evolutionary distance from 
humans.  
As well as zebrafish being a popular model for human disease (which will be discussed in 
detail in the following section) the medaka (Oryzias latipes), a Japanese freshwater fish has 
been utilised to study PD. Both toxin-induced and genetic models have been studied. As well 
as the standard PD toxins MPTP and 6-OHDA, lysosome and proteasome inhibitors have been 
used to model PD in medaka. Treatment with lysosome and proteasome inhibitors resulted 
in widespread protein inclusions and diencephalic dopaminergic neurons appeared to be 
more vulnerable to these inclusions. Specific loss of the dopaminergic neurons and a 
locomotor defect was observed (McNaught et al. 2004; Matsui, Ito, et al. 2010). Treatment 
with MPTP and 6-OHDA both resulted in reduced swimming and specific dopaminergic 
neuron loss, however protein inclusions were not detected (Matsui et al. 2009; Matsui, Ito, 
et al. 2010). 
Loss of function mutations in pink1 and parkin have also been created in medaka. However, 
the phenotype of these fish is mild and no dopaminergic neuron loss was detectable. Despite 
the lack of neurodegeneration, a late-onset decrease in spontaneous movement and a 
slightly decreased lifespan is observed in pink1 mutant medaka (Matsui, Taniguchi, et al. 
2010). Double pink and parkin mutants develop a more severe phenotype; this model 
displays a late-onset locomotion defect, a decrease in dopamine levels and a 30% decrease 
in dopaminergic neurons by 12 months. Mitochondrial dysfunction including enlarged 
mitochondria and reduced complex I and II activity function was detected at 12 months 
(Matsui et al. 2013).  
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1.3 Zebrafish as a model of neurodegenerative disease 
The zebrafish (Danio rerio) is a small tropical freshwater fish native to the Himalayan region. 
It has been growing in popularity as a model of human disease over the past two decades 
after being initially developed as a model of development in the 1970s and 80s (Streisinger 
et al. 1981). Despite being less closely related to humans than their rodent, or indeed non-
human primate counter-parts, the zebrafish hosts many advantages as a model for 
biomedical research. These advantages allow the zebrafish to be used as a powerful addition 
to existing models. Due to being classed as a “lower vertebrate”, zebrafish play an important 
role in the modern scientific and social climate where the 3Rs (replacement, reduction and 
refinement) movement aims to limit the number of animals used for research purposes. In 
this section both the advantages of the zebrafish as a model for neurodegenerative disease 
and what has been learnt from these models will be introduced. 
Suitability of zebrafish as a model organism 
Zebrafish embryos develop rapidly, with a full body plan established by 24 hours post-
fertilisation (hpf). By 5 days post-fertilisation (dpf) the majority of development is complete. 
Embryos develop ex utero and are transparent. These are the qualities that first made them 
attractive as a model of development. The optical clarity of the zebrafish allows live imaging 
to be performed. When coupled with the use of fluorescent reporter lines this allows real-
time imaging of developing pathologies and systems. 
Zebrafish are cost-effective to house in large numbers and are capable of producing large 
numbers of progeny all year round. A single female can produce hundreds of eggs per week 
and breeding can be easily controlled by a light cycle. Sexual maturity is reached after 2.5-3 
months resulting in a short generation time allowing mutant colonies to be established 
quickly. Despite the obvious differences between humans and zebrafish, they are a 
vertebrate model and over 70% of human genes have a recognisable orthologue in zebrafish 
(Howe et al. 2013).  
The zebrafish offers a compromise between complexity and practical simplicity, representing 
an intermediate between rodent models, which, being mammals, are more closely related 
to humans than invertebrate models as Drosophila. Table 3 summarises the main strengths 
and weaknesses of fly, zebrafish and rodent models. 
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Table 3 Comparison of zebrafish with other model organisms. Reproduced with permission from Lieschke & 
Currie (2007). NB: since this figure was originally published advances in genome editing technology have allowed 
targeted gene modification to also be a relative strength in zebrafish models. 
 
Drug screening capabilities are a major advantage of zebrafish models, especially for PD 
where the effect of small molecules on a distinct, relevant population of neurons can be 
studied at an early age. Many of the qualities described above make zebrafish particularly 
suitable for use in phenotypic drug screening. These particular qualities and the specific 
advantages of phenotypic drug screening are described in detail in chapter 6. 
Zebrafish genetic tools 
A range of different genetic tools are now available to generate genetic models of disease 
using zebrafish. Due to the availability of large numbers of zebrafish embryos, large forward 
and reverse genetic screens are feasible using zebrafish. Large scale N-ethyl-N-nitrosurea 
(ENU) mutagenesis can be used to generate mutations at random; the generated mutants 
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may then be characterised and the responsible gene identified. The Cambridge-based Sanger 
Centre is undertaking the Zebrafish Mutation Project which aims to create a loss of function 
mutation for each of the zebrafish’s 26,000 protein-coding genes. To do this ENU 
mutagenesis is combined with high throughput exome sequencing (Kettleborough et al. 
2013).  
More recently precise genome editing techniques have been developed. The first of these 
were zinc-finger nucleases, which were quickly followed by more cost-effective TALEN 
(transcription activator-like effector nucleases) and CRISPR/Cas9 (clustered-regularly-
interspaced-short-palindromic-repeats/CRISPR associated protein 9) systems. These systems 
are now widely used to generate both knockout mutant zebrafish lines quickly and easily. 
They also have the power to generate specific point mutations and knock-in mutant lines 
through homology directed repair (Auer & Del Bene 2014). Details of the CRISPR/Cas9 
system, which was utilised in this thesis, are described in detail in Chapter 5 section 5.4. 
Techniques are also available to allow generation of fluorescent reporter lines and drive 
expression of transgenes (for example mutated human genes responsible for disease). 
Transgenes can be expressed transiently by injection of mRNA or stable transgenic lines can 
be created by driving integration of a transgene-containing plasmid into the zebrafish 
genome. This is possible by exploiting the tol2 transposon to drive insertion events 
(Kawakami et al. 2004). Expression of transgenes may be driven by endogenous elements, 
known as the enhancer trap method which is dependent on insertion of the transgene in 
close proximity to a regulatory elements (Wen et al. 2008). Transgenes may be also placed 
under the control of a promoter of choice which is inserted alongside the transgene. There 
are numerous examples of this technique in zebrafish research and most have demonstrated 
that expression is similar to the endogenous gene expression pattern of the promoter 
(Bandmann & Burton 2010). Conditional expression of transgenes is also possible using the 
Cre-LoxP and GAL4-UAS systems (Halpern et al. 2008; Hans et al. 2009).  
Morpholinos (MOs) are a form of steric-block antisense oligonucleotides which are 
commonly used to generate transient knockdown of protein-coding and miRNA genes. They 
have been shown to be more specific and stable than siRNAs (Summerton 2007) and have 
proved to be a popular tool for generating fast, cost-effective knockdowns. Currently there 
are over 7000 publications using MOs (the MO publication database is accessible at 
http://www.gene-tools.com/morpholino-publication-database). For knockdown of protein 
coding genes, MOs can either be designed against the ATG start site to prevent translation 
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of the mRNA or to intron-exon/exon-intron splice sites to disrupt proper processing of the 
mRNA. MOs can be designed to a number of regions within the pri-miRNA to prevent proper 
splicing of this transcript into the mature miRNA (Eisen & Smith 2008). Some MOs have been 
shown to induce off-target toxic effects though p53 activation, and therefore care must be 
taken with investigation of cell death when using MOs (Robu et al. 2007). Another limitation 
of using MOs is that although knockdown is induced quickly the effect is transient and usually 
wears off after 3-5dpf. 
This year (2015) two important publications which compared MO knockdowns to stable 
mutant lines have highlighted the need for care to be taken when investigating the effect of 
mutations. Kok and colleagues investigated the similarity of MO induced mutants with stable 
lines and found that many of these did not phenocopy one another (Kok et al. 2015). 
However it has recently emerged that deleterious mutations induced by the CRISPR/Cas9 
system in certain genes resulted in the upregulation of compensatory genes, thus no 
phenotype was observed, whereas MO knockdown of the same gene did not and the effect 
of knockdown could be investigated (Rossi et al. 2015). 
Zebrafish as a model of neurodegeneration 
Of particular interest for research into neurodegenerative disorders the zebrafish brain 
shares some anatomical similarities with the human brain. A distinct fore-, mid- and hind-
brain is present in the zebrafish. The telecephalon, diencephalon and cerebellum are clearly 
represented, however unlike human or rodent brains the zebrafish brain only contains a 
rudimentary cortex. The peripheral nervous and enteric nervous system is also present. 
Zebrafish also possess specialised sensory organs such as the eye, ear and olfactory system. 
Although zebrafish do display “higher” behaviours these are abstracted and simplified 
compared to human behaviours. However, laboratory tests exist to assess motor ability, 
anxiety, memory and social behaviours (Lieschke & Currie 2007). Figure 6 shows a diagram 
of the major regions of the adult zebrafish brain. 
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Figure 6. The adult zebrafish brain. The purple shaded area shows the location of the dopaminergic neurons with 
ascending projections into the subpallium (analogous to the human striatum). 
Models of Alzheimer’s disease, Huntington’s disease, Motor Neuron Disease (MND) and PD 
have been established in zebrafish (Henshall et al. 2009; Schiffer et al. 2007; Bai et al. 2007; 
Paquet et al. 2009; Babin et al. 2014). The majority of these studies stated an overarching 
aim for using the disease model for compound screening to identify potential therapeutics 
for the disease of interest. As mentioned above (and in chapter 6) the ease of use of zebrafish 
in drug screening efforts is one of the major advantages of this model organism. 
A CAG repeat expansion in huntingtin is the genetic cause of all cases of Huntington’s disease. 
The zebrafish has been used to study the function of huntingtin by generating a knockdown 
of this gene (Henshall et al. 2009). A zebrafish expressing a mutated form of human 
huntingtin has also been created. Similarly to human Huntington’s disease, this mutant 
protein formed aggregates in the zebrafish. This model has been used to screen compounds 
which may lessen the toxicity the aggregated protein (Schiffer et al. 2007). Zebrafish have 
also been used to investigate the toxic effects of Tau. Tau pathology is relevant to both 
Alzheimer’s disease, frontotemporal dementia and PD. Various transgenic lines expressing 
mutant forms of the Tau-encoding gene MAPT have been generated, and these models 
demonstrate relevant pathological features including hyper-phosphorylation of Tau, tangle 
formation and neurodegeneration in the spinal cord (Bai et al. 2007; Paquet et al. 2009). 
Many genetic models of MND have been generated using zebrafish (Babin et al. 2014). The 
two most common genetic forms of MND involve mutations in C9ORF72 and SOD1. 
Expression of the disease causing GGGGCC repeat expansion of C9ORF72 in zebrafish results 
in RNA foci and neuronal death (Lee et al. 2013). SOD1 models, including mutated zebrafish 
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sod1 and transgenic of human mutant SOD1, demonstrate hallmarks of MND. Increased 
oxidative stress, alteration at the neuro-muscular junctions and motor neuron loss was 
observed in these models (Ramesh et al. 2010; Da Costa et al. 2014). 
Both genetic and toxin-induced zebrafish models of PD have also been established. Zebrafish 
possess a small population of ascending dopaminergic neurons with projections to the 
subpallium (analogous to the human striatum). Unlike in the human brain where these 
neurons are present in the substantia nigra in the midbrain, in zebrafish this population of 
neurons is present in the posterior tuberculum in the basal diencephalon (see Figure 6) (Rink 
& Wullimann 2001). In the embryonic brain this population is detectable by 18hpf and is an 
analogous position to the adult population (Rink & Wullimann 2002). In zebrafish embryos 
these neurons are easily identifiable by performing staining techniques (whole mount in situ 
hybridisation or immunohistochemistry) for markers of dopaminergic neurons. Fluorescent 
reporter lines which label this neuronal population are also available (Wen et al. 2008; Xi, Yu, 
et al. 2011). This allows the easy study of this neuron population. The use of one of these 
reporter lines, the ETvmat2:GFP line which expresses GFP in monoaminergic neurons, is 
described in Chapter 6. A recent paper describes a transgenic zebrafish which expresses 
mCherry in the mitochondria of dopaminergic neurons (Noble et al. 2015). This is likely to be 
a valuable tool for study of the mitochondrial phenotype in zebrafish models of PD. 
Zebrafish are susceptible to the toxin MPP+. Treatment of zebrafish larvae with this toxin 
results in the specific loss of dopaminergic neurons and motor defects (Sallinen et al. 2009; 
Bretaud et al. 2004). 6-OHDA has also been used to model PD in zebrafish. Larvae treated 
with this toxin displayed locomotor defect with reduced total swimming distance and an 
increase in time spent in the bottom portion of the tank being observed. While the number 
of dopaminergic neurons was not quantified, expression of tyrosine hydroxylase (th), a 
marker of dopaminergic neurons, was demonstrated to be decreased after treatment. 
Treatment with Sinemet, a widely used drug for PD sufferers which contains levodopa, and 
Vitamin E, which has been used as an alternative therapy for PD, rescues the locomotor 
defect and th decrease in 6-OHDA treated zebrafish (Feng et al. 2014). However beneficial 
effects of vitamin E in PD patients have not been proven (Ricciarelli et al. 2007). The ease of 
toxin treatments in zebrafish are another benefit of this experimental system as they 
permeable and easily uptake compounds placed in the water. 
Loss of function studies to model genetic forms of PD have also been performed in zebrafish. 
Zebrafish possess functional orthologues of many PD-associated genes. However they do not 
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possess a functional orthologue of SNCA. Rather than this being regarded as a limitation of 
zebrafish models of PD, it is seen as a unique opportunity to study the effects of PD-
associated genes independent of SNCA-related pathology. Two studies induce a knockdown 
of parkin using a MO strategy (Flinn et al. 2009; Fett et al. 2010). Fett and colleagues did not 
observe any dopaminergic neuronal loss whereas Flinn and colleagues identified a specific 
loss of dopaminergic neurons (no change in pan neuronal marker HuC or numbers of motor 
neurons was observed) at 3dpf. This may be due to the increased level of knockdown 
achieved by Flinn and colleagues. Although no swimming abnormalities were detected, 
abnormal mitochondria and a complex I defect was observed parkin morphants (Flinn et al. 
2009). Rodent models of Parkin deficiency do not display dopaminergic neuron loss, thus 
making the zebrafish the first vertebrate model to display dopaminergic neuron loss with 
parkin deficiency.  
Another PD-associated gene which has been studied in zebrafish is lrrk2. Knockdown studies 
of lrrk2 using MOs have been inconclusive. As regulation of lrrk2 in zebrafish is one of the 
focuses of this thesis, these studies are discussed in chapter 4. pink1 deficiency has also been 
studies using the MO strategy. Three independent groups have reported varying 
phenotypes. These range from a lack of dopaminergic loss but increases sensitivity to MPTP 
to a small decrease in dopaminergic neuron number to a 30% decrease in dopaminergic 
neuron number. The studies which observed a loss of dopaminergic neurons also reported 
either embryonic lethality in the morphants or developmental delay, deformity and 
increased apoptosis (Anichtchik et al. 2008; Xi et al. 2010; Sallinen et al. 2010). The 
discrepancies between the findings of these studies are likely to be due to off-target effects 
of the MO used in the latter studies and variation in the level of knockdown achieved.  
To further study the effects of pink1 deficiency a mutation generating a premature stop 
codon in zebrafish pink1 was identified from an ENU mutagenesis screen (Flinn et al. 2013). 
By 3dpf a 25% decrease in dopaminergic neuron number is observed in pink1 deficient 
zebrafish larvae. By 18 months old a 50% decrease was observed indicating a progressive loss 
of neurons. At 3 years a motor defect is seen in pink1-deficient zebrafish. Although the 
dopaminergic neuron number has not been quantified at this age the motor defect suggests 
that a dopaminergic neuron loss has progressed further. Mitochondrial defects in both larval 
and adult tissue are also apparent in this model. Mitochondria appear enlarged and a 
deficiency in complex I and III activity is present. Increased microglial activation in pink1 
deficient zebrafish suggests the involvement of inflammatory pathways. This model has also 
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been used to identify a novel pathway which may be involved in PD pathogenesis. tigarB, an 
inhibitor of glycolysis, was shown to be upregulated in pink1 deficient zebrafish. Knockdown 
of tigarB was able to rescue the decrease in dopaminergic neurons observed in this model 
(Flinn et al. 2013). Overall, this model represents many features which are similar to human 
PD. As this model demonstrates a clear and easily quantifiable dopaminergic phenotype at 
3dpf it has potential to be used in drug screening efforts to identify compounds which are 
able to rescue this phenotype.  
1.4 microRNAs and human disease 
microRNAs (miRNAs) are short non-coding RNAs which are able to post-transcriptionally 
regulate a large number of target genes through binding to target sites in the 3’UTR (He & 
Hannon 2004). miRNAs may target multiple transcripts and at least half of all human protein 
coding genes are thought to be regulated by a miRNA (Gurtan & Sharp 2013). This leaves 
tremendous scope for miRNA to be involved in the pathogenesis of disease.  
Expression changes of miRNAs have been identified in the large majority of human diseases 
by miRNA profiling strategies. Rare miRNA gene variants have also been associated with 
some diseases (Cammaerts et al. 2015). It has also been shown that some miRNAs circulate 
in body fluids and display high levels of stability. These miRNA may be useful as biomarkers 
of disease (Kim 2015). As miRNAs are able to target many genes each, it is possible that 
therapies targeting miRNAs may be used as a “system level” therapy to rectify or change the 
expression levels of many genes in a pathway.  
Normal development of the central nervous system (CNS) requires a highly regulated and 
precise coordination of many pathways. A large number of miRNAs have been shown to be 
expressed in the brain, therefore it is likely that they play an important role in CNS 
development and maintenance of neural populations. A number of studies have shown that 
preventing the proper biosynthesis of miRNA by removal of Dicer, many neural populations 
display defects in proliferation and/or increased levels of apoptosis (Huang et al. 2010; Davis 
et al. 2008; McLoughlin et al. 2012; Kim et al. 2007). Loss of Dicer also results in death of 
post-mitotic neurons (Schaefer et al. 2007; Kim et al. 2007).  
The dopaminergic neuron population is no exception to this. In order to investigate the role 
of miRNAs in the development of midbrain dopaminergic neurons Kim and colleagues 
deleted Dicer in embryonic stem cells (ESCs) which were then induced to differentiate to a 
midbrain dopaminergic neural phenotype. In the ESC cultures which were Dicer deficient, 
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the dopaminergic phenotype was not detectable, as measured by expression of 
dopaminergic markers such as TH. Although other neuronal classes, such as the GABAergic 
neurons were also reduced, the development of these populations were not as severely 
affected. These findings were then replicated in vivo by creation of a conditional Dicer 
mutant; where Dicer was specifically deleted in DAT expressing neurons. Mice deficient for 
Dicer specifically in the midbrain dopaminergic neurons displayed progressive loss of 
dopaminergic neurons and developed a motor phenotype reminiscent of PD (Kim et al. 
2007). These data suggest that miRNAs have an important role in the development and 
maintenance of neuronal populations which are lost in neurodegenerative diseases including 
PD. Therefore dysregulation of miRNAs may contribute to disease progression. In this section 
the relationship between miRNA and epigenetics and the involvement of miRNAs in 
neurodegenerative disorders will be introduced. 
Discovery and biogenesis of miRNAs 
miRNAs were first identified in the nematode worm Caenorhabditis elegans (Lau et al. 2001; 
Lee & Ambros 2001) and are well conserved in both plant and animal species. The miRBase 
database provides researchers with a searchable repository of known miRNA sequences and 
related annotation. This was set up in 2002 with just 218 entries. Now in its 21st version, 
miRBase contains nearly 30,000 entries (Kozomara & Griffiths-Jones 2014). A standard 
annotation system for naming new miRNA has also been introduced (Ambros et al. 2003).  
The mature miRNA sequence, which is 21-25 bp in length, is derived from one arm of the 
primary transcript hairpin (pri-miRNA). miRNAs genes may be located in introns and are 
transcribed alongside their host gene, while others are located in intergenic regions. A single 
transcript may give rise to many mature miRNAs or a single miRNA (Marco et al. 2013). Figure 
7 shows the microRNA biogenesis pathway and mechanism of post-transcriptional 
repression. The small interfering RNA (siRNA) pathway is also shown. siRNAs have many 
similarities to miRNAs. They are both dependant on Dicer for their maturation and are both 
able to post-transcriptionally regulate their targets through incorporation into the RNA 
induced silencing complex (RISC). Key differences are that siRNA are cleaved from fragments 
of double stranded RNA rather than processed from a single RNA transcript which forms a 
hairpin. This double stranded RNA may be exogenous or may be a bi-directionally transcribed 
endogenous RNA. siRNAs form a perfect duplex with their target and direct the cleavage of 
this mRNA, whereas miRNAs form imperfect duplex with a binding site in the 3’UTR of their 
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target. miRNAs most commonly repress their targets through translational repression, 
however some are able to direct mRNA cleavage (He & Hannon 2004). 
 
 
Figure 7. miRNA biogenesis and post-transcriptional repression. miRNA genes may be singular and transcribed 
alone or may be clustered and many miRNA cleaved from one transcript. The pri-miRNA, which folds into a hairpin 
secondary structure is cleaved in the nucleus by Drosha into a ~70bp pre-miRNA. This is exported from the nucleus 
to the cytoplasm by Exportin 5 the pre-miRNA undergoes further processing by Dicer. A miRNA:miRNA* duplex is 
formed. This duplex is then unwound and one strand is preferentially assembled into the RNA induced silencing 
complex (RISC). miRNAs target mRNAs in a specific manner by binding to partially complementary target sites 
within the 3’UTR of its targets. This results in either translational repression or mRNA cleavage. The siRNA 
biogenesis pathway is also shown. Reproduced with permission from He & Hannon (2004). 
 
Validation of miRNA targets is costly and time consuming, therefore online programs to 
predict miRNA:mRNA interactions play an important role in identifying potential interactions 
of interest. As miRNA pairing with mRNA target sites is not perfectly complementary, 
prediction programs which can accurately identify likely miRNA targets have been 
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challenging to produce. A small region of the miRNA, nucleotides 2-8, is known as the seed 
sequence. This region is required for pairing with target sites (Lewis et al. 2003). The four 
main aspects which are common features for target prediction programs are 
complementarity of the seed region, conservation of the binding site, free energy and site 
accessibility. Although prediction software is a valuable tool which can predict potential 
targets with increasing accuracy, there are still major limitations which prevent them, so far, 
from being used for network analysis. The limitations of these tools are based on the 
weighting and number of factors used for prediction. Also, relatively few target prediction 
tools are able to incorporate information about the expression patterns of the miRNA and 
target of interest (Peterson et al. 2014). Databases of experimentally validated miRNA:mRNA 
interactions, such as miRTarBase, are also available as a tool for researchers (Hsu et al. 2014). 
Epigenetics and non-coding RNAs 
Epigenetics is defined as heritable changes in gene expression which do not involve alteration 
of the coding sequence. In 2007 Adrian Bird offered an alternate definition of epigenetics to 
ease confusion over the issue of heritability, especially regarding post-mitotic tissues. This 
definition is “the structural adaptation of chromosomal regions so as to register, signal or 
perpetuate altered activity states” (Bird 2007). This definition highlights the responsive, 
rather than proactive, nature of epigenetics to external or internal stimuli. 
The two main epigenetic mechanisms are DNA methylation and histone modification. DNA 
methylation, addition of a methyl group to position 5 of the pyrimidine ring of cytosine, 
occurs at CpG sites (cytosine-phosphate-guanine) to create 5-methylcytosine (Razin & Riggs 
1980). Large groups of CpG sites within close proximity to one another are known as CpG 
islands; these are found in approximately 70% of the promoters of mammalian genes 
(Saxonov et al. 2006). Methylation in the promoter region of the gene results in 
transcriptional repression. This is thought to have evolved as a protection mechanism against 
transposable elements and viral DNA (Bird 2002). As well as the known repressive action of 
methylation in promoter regions and in regions containing transposable elements or viral 
DNA, methylation is also detected in other regions. Large scale genomic mapping of DNA 
methylation has revealed DNA methylation in areas including transcriptional start sites and 
gene bodies. The effect of DNA methylation appears to be region specific as methylation in 
gene bodies is thought to be associated with active expression (Jones 2012).  
Figure 8 shows DNA methylation (Figure 8A), the structure of chromatin and post-
translational modification of histones tails. Figure 8B shows the nucleosome. This is made up 
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of DNA (red) wound around an octamer of histones (green). This octamer includes two of 
each histone H2A, H2B, H3 and H4. Post-translational modifications of the amino-terminal 
histone tails, which extend out from the structure can affect chromatin folding and/or can 
act as binding sites for other transcription factors. In Figure 8C histone tails are shown in dark 
green and modifications represented as coloured circles. The most well characterised 
histone modifications are acetylation and methylation. These are known to direct chromatin 
to a more transcriptionally active and more repressed state, respectively. Other histone 
modifications include sumoylation, phosphorylation and ubiquitination. This diverse histone 
code allows for fine tuning of gene expression (Jenuwein & Allis 2001). Figure 8C and D show 
how the DNA folds into a heterochromatin fibre; this is a tightly folded chromatin structure 
which prevents transcription factors accessing the genes in this region. Figure 8C shows the 
conformation of nucleosome referred to as “beads-on-a-string” formation. This is an active 
conformation of DNA which can be accessed by transcription factors allowing genes in this 
region to be expressed (Swygert & Peterson 2014). 
 
 
Figure 8. DNA methylation, histone modification and the structure of chromatin. A shows methylation of 
cytosine at a CpG site (cytosine followed by guanine). B shows the nucleosome, that is, DNA wrapped around an 
octamer of histone proteins. C shows various histone modifications (represented by coloured circles) present on 
the protruding histone tails. In C the chromatin is in the so-called “beads-on-a-string” formation which is 
transcriptionally active. D shows the folding of chromatin into a tightly packed fibre called heterochromatin. Genes 
in this region are in a transcriptionally repressed state. 
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Non-coding RNAs, including miRNAs have also historically been included as an epigenetic 
mechanism. Although there is no doubt that the effect of miRNAs is crucial for the regulation 
of gene expression, the increased understanding of their mechanism of action means that 
they are now not widely viewed as an epigenetic mechanism themselves but as a separate 
gene regulation mechanism which acts alongside epigenetics (Sætrom et al. 2007). Key 
differences between the mechanism of miRNAs and the classical epigenetic mechanisms are 
that miRNAs act to repress their targets post-transcriptionally, and as they are not directly 
associated with chromatin, that miRNAs are not inherited in the same manner as DNA and 
chromatin modifications. The initial inclusion of miRNAs being an epigenetic mechanism may 
stem from the discovery of this class of non-coding RNA in C. elegans. Unlike in other 
organisms, in C. elegans the effect of a miRNA is maintained for long periods of time and can 
even passed onto offspring to maintain gene repression (Grishok et al. 2000). The persistence 
of non-coding RNA species in C. elegans is driven by the presence of an RNA dependant 
polymerase. This allows the continued production of RNA without de novo expression of 
additional RNAs (Sætrom et al. 2007). In mammals the average half-life of miRNAs has been 
shown to be approximately 5 days (Gantier et al. 2011).  
A recent study has shown that miRNAs may be responsible, at least partly, for the inheritance 
of behavioural phenotypes induced by early trauma in mice. The behavioural effects, namely 
reduced avoidance and fear phenotype, of early traumatic stress were detectable in both the 
mice exposed to trauma (F1) and their offspring (F2). Some behavioural abnormalities were 
also detected in the F3 generation. Changes in miRNAs present in the sperm of the F1 mice 
compared to control were detected. To determine whether these miRNA changes were 
responsible for the behavioural phenotypes RNAs were purified from the sperm of F1 males 
and injected into wild type fertilised oocytes. Interestingly, the behavioural phenotype of the 
injected mice was similar to the F2 mice (Gapp et al. 2014). These data suggest that miRNAs 
play a role in transmission of behavioural phenotypes. However, in the F2 mice there were 
no changes in sperm miRNA, therefore the transmission of the behavioural phenotype to the 
F3 generation is by a different mechanism.  
miRNAs have been shown to regulate genes involved in adding or removing histone 
modifications or methyl groups to DNA. For example, miR-29 has been shown to modulate 
DNA methylation by targeting DNA methyltransferases (Fabbri et al. 2007). Similarly, other 
non-coding RNA species are able to directly recruit polycomb repressive complexes, which 
are involved in chromatin remodelling via placing of repressive histone modifications. The 
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most notable example of this is Xist which has an essential role in X-chromosome inactivation 
in mammals (Peschansky & Wahlestedt 2014). Transcription of miRNAs may also be 
regulated by epigenetic mechanisms. To aid further study and increase understanding of the 
interaction of miRNAs and epigenetic mechanisms, a database, named EpimiR, has been 
created to collate information about mutual regulation between miRNAs and epigenetic 
mechanisms (Dai et al. 2014).  
miRNA involvement in neurodegeneration 
Although the involvement of miRNAs in human disease is most widely studied in the field of 
cancer, their involvement in neurodegenerative disorders is becoming increasingly apparent. 
Dicer, one of the key enzymes on microRNA biogenesis, is essential for proper development 
of the brain and for the maintenance of post-mitotic neurons (Petri et al. 2013). Several 
studies demonstrate that specific deletion of Dicer in a particular neuronal cell type results 
in the malformation or death of population of cells. This is true for dopaminergic neurons 
(Kim et al. 2007), motor neurons (Haramati et al. 2010) and Purkinje neurons of the 
cerebellum (Schaefer et al. 2007). Conditional loss of Dicer in the adult mouse forebrain 
results in the death of hippocampal neurons and cellular shrinkage in the cortex (Hébert et 
al. 2010; Davis et al. 2008), while Dicer ablation in Wnt-expressing neurons resulted in 
malformation of the midbrain and cerebellum (Huang et al. 2010). As miRNAs have such an 
important role in the survival of specific neuronal cell types it is no surprise that 
dysregulation of particular miRNAs have also been specifically implicated in many 
neurodegenerative disorders, including PD (discussed in detail in the next section), 
Huntington’s disease, Alzheimer’s disease and MND.  
Gross transcriptional dysregulation is a key feature of Huntington’s disease and this extends 
to miRNA dysregulation. A large number of miRNAs have been identified by miRNA profiling 
studies (Johnson et al. 2008; Packer et al. 2008; Martí et al. 2010). Alteration of four 
transcription factors, TP53, REST, E2F1 and GATA4, in Huntington’s disease patient brains is 
likely to contribute to the transcriptional dysregulation of miRNAs, and other protein coding 
genes, observed (Sinha et al. 2012). miR-9/miR-9* may be involved in Huntington’s disease 
pathology through their targets REST and coREST (Packer et al. 2008). In Huntington’s disease 
patients REST is no longer sequestered in the cytoplasm and therefore can enter the nucleus 
and have a repressive effect its target genes (Buckley et al., 2010). Therefore, the reduced 
levels of miR-9/miR-9* observed in Huntington’s disease patients may contribute to the 
transcriptional dysregulation observed. 
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miR-9 has also been implicated in both Alzheimer’s disease; addition of amyloid-β peptides 
to primary neuron cultures result in the downregulation of this miRNA. In Alzheimer’s 
disease miR-9 dysregulation may be involved in pathology through its target SIRT1 which is 
associated with the accumulation of hyperphosphorylated forms of Tau (Schonrock et al. 
2010). Other miRNAs which have been consistently identified as dysregulated in Alzheimer’s 
disease are: miR-107, miR-29, miR-181, miR-34, miR-106 and miR-146. Many of these 
miRNAs are implicated in the regulation of genes associated with Alzheimer’s pathology 
(Goodall et al. 2013). 
MND-associated proteins TDP-43 and FUS have been show to interact with components of 
the miRNA biogenesis machinery, thus implicating dysregulation of miRNAs in MND 
pathology. Many miRNA expression changes are observed in MND brain tissue, however 
miRNAs in peripheral tissues are also thought to be important. The muscle-specific miR-206 
is dysregulated in MND patient muscle tissue (Russell et al. 2013). This miRNA is thought to 
be involved in nerve-muscle communication and reinveration of muscles following nerve 
damage (Andrew H Williams et al. 2009). Another miRNA of interest which is thought to be 
involved in MND pathology is miR-155. The involvement of this miRNA in neurodegeneration 
is discussed in chapter 5. 
miRNAs relevant to Parkinson’s disease 
Similarly to other neurodegenerative diseases miRNAs involved in PD have been identified 
by both large profiling screens and by directed studies to identify miRNA which target PD-
associated genes. In this thesis three miRNAs of interest have been studied in zebrafish 
models. These miRNAs are: miR-133b, miR-205 and miR-155. These miRNAs were chosen as 
single, well conserved orthologues of these miRNAs and their major targets are present in 
zebrafish, thus allowing an easier comparison of their function in this model. The function of 
these miRNAs will be introduced briefly here and in more detail in the introduction to their 
respective chapters (Chapters 3, 4 and 5 respectively).  
miR-133b is expressed in the midbrain and has been shown to directly target the 
transcription factor PITX3, which is involved in the development and maintenance of 
dopaminergic neurons. Inhibition of miR-133b in embryonic stem cell cultures resulted in 
increased expression of dopaminergic markers and dopamine release suggesting that this 
miRNA may be able regulate the development of a dopaminergic phenotype (Kim et al. 
2007). This study aims to investigate the effect of miR-133b knockdown on dopaminergic 
neuron development in zebrafish. 
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miR-205 has been shown to directly target the PD-associated gene LRRK2. In the brain 
patients with sporadic PD, increased levels of LRRK2 protein and decreased levels of miR-205 
were detected (Cho et al. 2013). As previously discussed LRRK2 is thought to exert a 
neurotoxic effect through a toxic gain of function. It was originally thought that toxic gain of 
function resulted from increased kinase activity however it is now argued that actual levels 
of LRRK2 protein may be a more important factor (Skibinski et al. 2014). This study aims to 
determine whether miR-205 knockdown in zebrafish results in increased levels of Lrrk2 
protein and whether this has a neurotoxic effect on dopaminergic neurons.  
miR-155 is a master regulator of inflammation and immune function (Vigorito et al. 2013). 
Neuroinflammation is a feature of many neurodegenerative diseases including PD. Increased 
expression of miR-155 has been detected in animal models of and the brains of patients with 
MND, Alzheimer’s disease and MS (Butovsky et al. 2015; Junker et al. 2009; Guedes et al. 
2014; Murugaiyan & Beynon 2011; Alexandrov et al. 2012). The aim of this study is to assess 
whether miR-155 is involved in inflammation in zebrafish models of PD. 
Brain-enriched microRNAs miR-7 and miR-153 have been shown to directly target SNCA using 
a luciferase-tagged reporter plasmid containing the SNCA 3’UTR (Doxakis 2010). In a toxin-
induced mouse model of PD miR-7 levels were decreased, suggesting possible mechanism 
for the observed increase of SNCA levels (Junn et al. 2009). These two miRNAs present 
possible therapeutic targets as they could be used to modify the expression level of SNCA in 
PD patients to reduce its pathogenic load.  
LRRK2 has been shown to interact with Ago proteins, components of the miRNA processing 
pathway (Dächsel et al. 2007). Gehrke and colleagues demonstrated that mutant (G2019S) 
LRRK2 in Drosophila antagonised let-7 and miR-184, potentially through altered binding to 
Ago proteins (Gehrke et al. 2010). This resulted in the increase of E2F1 and DP1 protein 
levels. These proteins are involved in the cell cycle and aberrant expression of these proteins 
affects cell survival (Höglinger et al. 2007). The overproduction of these proteins in G2019S-
LRRK2 Drosophila were shown to be critical for LRRK2 pathogenesis (Gehrke et al. 2010). 
However, the findings presented in this study are yet to be reproduced in a vertebrate model 
system or in patient derived cell models.  
GWAS studies have previously identified an association between single nucleotide 
polymorphisms SNPs within the fibroblast growth factor 20 (FGF20) gene and PD (van der 
Walt et al. 2004). FGF20 is preferentially expressed in the substantia nigra and involved in 
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the maturation and survival of dopaminergic neurons (Murase & McKay 2006). Subsequent 
genetic and functional analysis of SNPs in this region showed that a SNP in the 3’UTR of FGF20 
conferred the highest risk for PD (Wang et al. 2008). The identified SNP is within the 
recognition site for miR-433, thus preventing regulation by this miRNA which results in 
increased translation of FGF20. The increased levels of FGF20 protein correlated with 
increased ɑ-synuclein levels in both cell models and PD patient brain (Wang et al. 2008). 
However, the interaction of FGF20 with ɑ-synuclein or the association of the SNP in the 
miR-433 binding site with PD was not confirmed by a further study (Wider et al. 2009).  
Two related miRNAs which were identified by miRNA profiling of PD patient brains are miR-
34b/c. These miRNAs have been shown to be downregulated in PD patient brain in both early 
and advanced neuropathological stages. Therefore these changes are not thought related to 
treatment. The function of miR-34b/c was further studied in vitro in differentiated SH-SY5Y 
dopaminergic neurons. In these cells depletion of either miR-34b or miR-34c reduced cell 
viability and also altered mitochondrial function (Miñones-Moyano et al. 2011). This study 
also suggests that PD related genes DJ1 and Parkin may be indirect targets of miR-34b/c. 
miR-34 has also been associated with aging in Drosophila. Loss of miR-34 resulted in 
accelerated brain aging, neurodegeneration and decreased survival (N. Liu et al. 2012). miR-
34b and related miR-34a have also been implicated in Huntington’s disease and Alzheimer’s 
disease (Gaughwin et al. 2011; Zovoilis et al. 2011). 
Finally, a group of miRNAs are thought to be involved in PD pathogenesis through their 
involvement in autophagy. These miRNAs are upregulated in PD brain and have been shown 
to target components of chaperone-mediate autophagy, LAMP-2A and hsc70, which are 
decreased in PD brain. Transfection of these miRNAs into an SH-SY5Y cell line which 
overexpresses ɑ-synuclein resulted in decreased protein levels of LAMP-2A and hsc70 and 
increased accumulation of ɑ-synuclein (Alvarez-Erviti et al. 2013). Figure 9 summarises the 
involvement of these miRNAs in the pathogenesis of PD. 
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Figure 9. miRNAs thought to be involved in the pathogenesis of Parkinson's disease. Adapted from Goodall et 
al. (2013).  
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1.5 Aims and hypotheses 
This main aim of this thesis is to study the effect of three miRNAs implicated in PD 
pathogenesis in zebrafish.  These miRNAs are miR-133b, miR-205 and miR-155. 
Aim 1: Investigate the role of miR-133b in dopaminergic neuron development and survival. 
Hypothesis: Knockdown of miR-133b will increase dopaminergic neuron number through its 
target pitx3. I further hypothesise that knockdown of miR-133b will be able to rescue 
dopaminergic neuron loss observed in a previously validated zebrafish model of PD 
Aim 2: Investigate the interaction between miR-205 and lrrk2 in zebrafish. 
Hypothesis: Knockdown of miR-205 will result in increased protein levels of its target Lrrk2. 
Increased levels of Lrrk2 protein will have a neurotoxic effect on dopaminergic neurons. 
Aim 3: Investigate the role of miR-155 and neuroinflammation in neurodegeneration. 
Hypothesis: miR-155, a marker of and driver of inflammation, will be upregulated in the 
brains of zebrafish models of PD and Gaucher’s disease. 
 
A further aim of this thesis is to develop a method allowing quantification of the number 
dopaminergic neurons a high throughput format.  
Hypothesis: The development of such a method will facilitate future in vivo drug and toxin 
screens.  
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Chapter 2. Materials and Methods 
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2.2 Materials 
Unless otherwise stated, all chemicals are obtained from Sigma-Aldrich (Gillingham, UK); all 
enzymes and buffers from New England Biolabs; all plastic consumables from STARLAB Ltd 
(Milton Keynes, UK); and all polymerase chain reaction (PCR) primers and other DNA 
oligomers from Integrated DNA Technologies. 
2.3 Zebrafish  
2.3.1 Adult zebrafish husbandry 
All adult zebrafish are housed in aquaria at the Bateson Centre at the University of Sheffield. 
Zebrafish are housed in tanks at a density of no more than four zebrafish per litre at a 
constant temperature of 28oC on a 14 hour light-10 hour dark cycle.  
All experimental procedures are carried out in accordance with the UK Home Office Animals 
(Scientific Procedures) Act 1986 under project licence PPL 70/8437 held by Professor Oliver 
Bandmann and Personal Licence PIL I04FA191D held by Lisa Trollope. 
2.3.2 Zebrafish lines 
Unless otherwise stated all zebrafish referred to as wild type or WT are AB wild type zebrafish 
with the exception of wild type zebrafish which are the non-mutant siblings of any of the 
mutant lines used. Other zebrafish lines used in this study are: 
The ETvmat2:GFP line, this line has green fluorescent protein (GFP) inserted between exon 
2 and 3 of vesicular monoamine transporter 2 (vmat2) using the enhancer trap method (Wen 
et al. 2008). This line expresses GFP in monoaminergic neurons. This line is used with both a 
WT and pink1-/- background. 
The pink1-/- mutant line. This line was generated from an ENU mutagenesis screen. A mutant 
containing a premature stop codon in the kinase domain of pink1 was identified. 
Homozygote pink1 mutant zebrafish are viable so homozygote mutants are generated from 
a homozygote incross. The WT siblings of these mutants, generated from a previous 
heterozygote in-cross are used as controls. The features of this mutant line are described in 
the following publication from the Bandmann lab (Flinn et al. 2013). 
The glucocerebrosidase1 (gba1) mutant line. As homozygous gba1 mutant zebrafish cannot 
produce viable progeny. Zebrafish which are heterozygous for the gba1 mutation are in-
crossed to generate embryos which are either WT (gba1+/+), heterozygous (gba1+/-) or 
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homozygous (gba1-/-) for the gba1 mutation. This line was generated by TALEN mutagenesis 
(Keatinge et al. 2015). 
2.3.3 Collection and maintenance of zebrafish embryos 
To collect embryos, either a marble tray is placed in the tank the previous evening to 
stimulate mating at the start of the light cycle in the morning, or, if embryos required careful 
staging, for example for injecting, zebrafish are pair mated by placing a male and a female 
on either side of a divided tank overnight. In the morning at the desired time the divider is 
removed and zebrafish are allowed to mate for the required time before the embryos are 
collected. 
Embryos and larvae are kept at a constant temperature of 28oC in 1x E3 media (500μM NaCl, 
17μM KCl, 33μM CaCl and 33μM MgSO4, with 2 drops per litre methylene blue antifungal 
agent added) in 10cm petri dishes, at a density of no more than 60 zebrafish per plate 
(approximately 40ml).  
With all embryos collected, especially those which have undergone injection at the one cell 
stage, the embryos are monitored at 8 hours post-fertilisation (hpf) when any unfertilised 
embryos can be identified and removed. Again, at 24hpf any dead embryos are removed, 
and a note is made if there is significant death in the injected group compared to control. To 
prevent any further death of embryos the E3 media is replaced.  
If the embryos are to be used for imaging, and therefore a lack of pigmentation is desirable, 
phenylthiourea (PTU) is added at a final concentration of 4.3mM to the E3 media when then 
embryos are 8-24 hours old to prevent pigment from forming.  
In accordance with the UK Home Office Animals (Scientific Procedures) Act 1986 larvae are 
not kept past 5.2dpf unless they are being raised to adulthood. To cull, live embryos are 
anaesthetised in tricaine (0.016%) before disposal in bleach. 
2.3.4 Zebrafish anaesthesia 
Tricaine or MS222 (PharmaQ Hampshire) is made up at a stock of 0.4% (w/v) in deionised 
distilled water. For embryo manipulation and sedation a 0.016% solution is used (that is 
420µl of 0.4% stock solution is added to 10ml of E3 media. A lower concentration of 0.003% 
is used for mounting of zebrafish for imaging to induce a light sedation. 
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2.3.5 Genotyping of zebrafish larvae 
In this study this technique was used to determine the genotype of embryo from an incross 
of gba1 heterozygous mutants. 3dpf zebrafish larvae are anaesthetised in 0.016% tricaine. 
The anaesthetised larvae are placed under a Leica L7 dissecting microscope. A small section 
of tail is cut using a scalpel (Figure 10). This small section of tail is removed in 2μl of E3 media 
and placed in a 96 well PCR plate, the embryo is placed in the corresponding well of a regular 
96-well plate. DNA is extracted from the tail section by the gDNA extraction method 
described in section 2.7.1. Once the genotypes have been determined the embryos are 
separated back into 10cm petri dishes by genotype. 
 
Figure 10. Fin clipping of embryos. The red line shows where a small section of the tail is cut. DNA is extracted 
from this section of tail. The scale bar represents 500µm. 
2.4 Microinjection of zebrafish embryos 
Microinjection of zebrafish embryos is a useful technique allowing various compounds, 
including Morpholinos for short-term knockdown of specific genes and the nucleoside 
analogue EdU (5-ethynyl-2'-deoxyuridine) for labelling proliferating cells (see section 1.4) to 
be injected into the zebrafish embryo at various embryonic stages. 
2.4.1 Preparation of injection apparatus 
Firstly microinjection needles are pulled from borosilicate glass capillaries (Kwik-Fil, World 
Precision Instruments, Inc., Hertfordshire, UK) using a micropipette puller (Model P-97, 
Sutter Instrument Co., USA). 
Gel loading tips are used to pipette the solution which is to be injected into microinjection 
needle. The needle is loaded into the injection stand and adjusted so it can be lowered into 
the field of view of the microscope. The end of the needle is broken using fine tweezers. The 
injector air pump (Pv 820 Pneumatic pico-pump, WPI) is set to timed mode and the pressure 
and injection time can be adjusted to ensure one pump releases exactly 0.5nl or 1nl of 
injection solution. This is done by placing a drop of mineral oil onto a graticule and injecting 
some solution into the oil. The volume of the injected solution can be measured by lining up 
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the edges of the injected ‘bubble’ with the grid on the graticule. Volumes of 0.5nl or 4nl can 
be measured as shown in Figure 11. 
 
Figure 11. Using a graticule to measure injection volume. 
2.5 Transient knockdown of genes by Morpholino  
In order to create short-term knockdowns of particular genes in zebrafish, one cell-stage 
embryos were injected with Morpholino (MO), an antisense technology which prevents the 
correct splicing of the mRNA or primary microRNA (pri-miRNA) transcript. For protein coding 
genes MOs are either designed to target exon-intron/intron-exon boundaries to produce 
splicing defects assayable by RT-PCR. Alternatively, they may be designed to target the 
transcriptional start site to prevent translation of the mRNA. For miRNAs MOs can be 
designed to a number of regions in the pri-miRNA to prevent correct processing of the 
mature miRNA transcript (Figure 12). 
 
Figure 12. Regions of the pri-miRNA transcript and MO design. A shows the regions of a pri-miRNA transcript 
and the cut sites for processing enzymes drosher and dicer. B shows the potential binding sites of MOs which will 
disrupt processing of the pri-miRNA into its mature form. 
All MOs are ordered from Gene Tools (Philomath, OR, USA). On arrival they are immediately 
resuspended to a concentration of 2mM in sterile water and stored at room temperature. 
The MOs used in this study are listed in Table 4. A standard control MO, designed to target 
human beta-globin is also used to control for any toxic effects of MO injection. 
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Once the injection apparatus is set so the required volume can be injected embryos are 
collected at the one cell stage. This is usually 20-40 minutes after the dividers have been 
removed from pair mating tanks or 20-40 minutes after the lights have been turned on in the 
aquarium if marble tanks are being used. If embryos from pair-mating tanks are embryos 
from at least two pairs of zebrafish are collected and pooled. 
MO is made up to the optimal concentration (see Table 4) with distilled water and phenol 
red. 10% phenol red is added to enable the visualisation of the MO solution when it is 
injected to ensure it is injected into the yolk. 1nl of MO solution is injected into the yolk of 
embryos at the one cell stage. Injected embryos, and uninjected controls from the same 
batch of embryos are then left to develop at the desired time point. 
Table 4. Morpholinos used in this study. 
Target gene &  
region of MO binding 
Sequence Amount injected  
(in 1nl) 
miR-133b 
miRNA/guide region 
5’-CAGCTGGTTGAAGGGGACCAA-3’ 1.8ng 
miR-205 
overlapping loop 
5’-TGATTGAACAACTACACAGACTCCG-3’ 5ng 
Standard control MO 
(human beta-globin) 
5’-CCTCTTACCTCACAGTTACAATTTATA-3’ Same as the MO it is 
controlling. 
lrrk2  
Kinase domain 
5’-CCCCTTCAGTATAAAACAC-3’ 8ng 
lrrk2  
WD40 domain 
5’-AAATCTGCATGTTTTAGCACCTGGT-3’ 8ng & 10ng 
pitx3  
start site 
5’-CGGTCTAGTGGAGGTAATCCTCGAA-3’ 2ng 
pitx3  
exon2-intron2 
boundary 
5’-GACATAAATATGAACTGACCACTGT-3’ 4ng 
 
2.6 Injection of miRNA mimic into embryos 
A miRNA mimic is injected into embryos to determine the downstream effect of an up-
regulation of this particular miRNA.  
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Firstly, the mimic is injected into the yolk in one-cell stage embryos, 1nl of 20mM mimic was 
chosen as the working concentration. The stock solution of miRNA mimic is diluted to the 
desired concentration with nuclease-free water and 10% phenol red to ensure the injected 
solution is visible. In order to allow persistence of miRNA mimic in the zebrafish brain the 
miRNA mimic is injected into the brain ventricles of 24 hour old embryos. These embryos are 
dechorionated, anaesthetised in 0.016% tricaine then mounted in 1% low melting point 
(LMP) agarose in a petri dish; this is to prevent leakage of the injection solution. The 
microinjection needle is able to penetrate the LMP agarose and enter the ventricle while the 
zebrafish embryo is in a lateral orientation (Figure 13). At this age 1nl of 10mM mimic is 
injected.  
Table 5. miRNA mimics used in this study. 
miRNA Sequence Company/cat no 
miR-133b  5’-UUUGGUCCCCUUCAACCAGCUA-3’ QIAGEN/MSY0001831 
 
 
Figure 13. Injecting into the ventricles of a 24hpf embryo. The zebrafish is manipulated into a lateral orientation 
within the LMP agarose and the microinjection needle penetrates the ventricles from the side. The mimic is 
visualised using phenol red. 
2.7 Nucleic acid extraction and polymerase chain reaction (PCR) 
2.7.1 gDNA extraction 
Genomic DNA (gDNA) is extracted from tissue (i.e. whole embryos, embryo fin clip or adult 
fin clips) by boiling in sodium hydroxide. Depending on the amount of tissue from which 
gDNA is being extracted 30-100µl NaOH is added to the tissue, the sample is heated to 95oC 
for 5 minutes before being vortexed vigorously to break up any remaining tissue. One tenth 
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of a volume 1M Tris HCl pH8 is added to neutralise the solution. The sample is then 
centrifuged at 1000xg for 1 minute to pellet any large debris. The supernatant is used for 
downstream applications.  
2.7.2 RNA Extraction 
2.7.2.1 From zebrafish embryos 
RNA is extracted from zebrafish embryos using the trizol method. Around 20 embryos are 
placed into a 1.5ml Eppendorf tube and washed with DEPC-treated water. In a fume hood, 
250μl TRI reagent® is added to the embryos and they are immediately homogenised by 
passing through a 25g needle. The sample is incubated for 3 minutes at room temperature. 
50μl chloroform is added then tubes are inverted gently 10 times to mix. After a 3 minute 
incubation at room temperature the sample is centrifuged for 15 minutes at 16000xg at 4oC. 
After centrifugation layers separating the sample have formed; the top aqueous phase 
containing RNA, the interphase containing DNA and the lower organic phase containing 
protein and lipids. The aqueous phase is removed and is placed into a fresh Eppendorf tube. 
An equal volume of isopropanol is added. The tube is inverted gently to mix then incubated 
at room temperature for 10 minutes. The sample is centrifuged for 15 minutes at 16000xg 
at 4oC to collect the RNA pellet. The supernatant is removed completely taking care not to 
disturb the pellet. To wash 150μl of 75% ethanol is added to the pellet and centrifuged at 
4500xg for 5 minutes at 4oC. The supernatant is removed completely then the RNA pellet is 
left to air-dry for around 3 minutes in the fume hood, or until all the excess ethanol has 
evaporated. The pellet is then resuspended in 15μl sterile DEPC-treated water, the 
concentration and purity of the RNA is determined using a nanodrop spectrophotometer 
(NanoDrop ND-100, Labtech International). The RNA is only used if the 260/230 and 260/280 
ratios are above 2.0, indicating the RNA is free from contamination; if these ratios are lower 
lithium chloride precipitation to remove contamination is performed (section 2.7.2.3). RNA 
is stored at -80oC.  
2.7.2.2 RNA extraction from zebrafish brains 
RNA is extracted from zebrafish brains using the trizol method. The method differs from the 
method described above at the following steps. RNA was extracted from 1-2 brains in an 
1.5ml Eppendorf tube, after TRI reagent® is added the brains are first broken up by passing 
through a 19g needle 20 times, they are then further homogenised by passing through a 25g 
needle 20 times. After homogenisation they are incubated with trizol for 5 minutes before 
addition of chloroform. The rest of the protocol is performed as above until the last step 
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where an extra ethanol wash is added (that is, remove supernatant, add 150μl 75% EtOH and 
centrifuge at 7000xg for 5 minutes). 
2.7.2.3 Lithium Chloride precipitation for RNA clean-up 
If the extracted RNA is not clean, as indicated by the 260/230 and 260/280 ratios given by 
the nanodrop, the RNA is cleaned up using LiCl precipitation. 30μl RNAse free H2O and 25μl 
LiCl precipitation solution (7.5M LiCl and 50mM EDTA pH8.0) (Ambion) is added to the 
contaminated RNA, this is mixed thoroughly and incubated at -20oC for 30 minutes. This is 
then centrifuged at 13000xg for 15 minutes at 4oC, the supernatant is removed and the pellet 
is washed with 100μl 75% EtOH as in the trizol protocol. The pellet is then resuspended in 
10-20μl water and analysed using a nanodrop spectrophotometer.  
2.7.3 cDNA synthesis 
Complementary DNA (cDNA) is synthesised using the Verso cDNA synthesis kit (Thermo 
Scientific) according to the manufacturer’s instructions. Briefly, 4µl of 5X reaction buffer, 2µl 
dNTP, 1µl RNA primer, 1µl enhancer and 1µl Verso enzyme mix is added to 11µl of RNA 
(maximum 1µg RNA in a 20µl reaction). This reaction is incubated at 42oC for 30 minutes then 
at 95oC for 2 minutes. cDNA is either used immediately for reverse transcription PCR (RT-
PCR) or quantitative real-time PCR (qPCR) or stored at -20oC. 
2.7.4 PCR/RT-PCR 
On arrival primers are diluted to a 10μM working stock. In a 10μl reaction 5μl Biomix (Bioline) 
is used with 1μl of each the forward and reverse primer (working concentration 1μM), 1μl 
gDNA/cDNA template and 2μl ddH2O. To optimise primer annealing temperature a gradient 
PCR is set up with temperatures between 55-65oC. The general temperature cycle is as 
follows: 93oC for 3 minutes followed by 30 cycles of 95oC for 30 seconds, annealing 
temperature for 30 seconds and 72oC for 1 minute, then to finish the reaction is incubated 
for 5 minutes of 72oC. 
2.7.5 DNA gel electrophoresis 
DNA gel electrophoresis is used to visualise PCR products and restriction digest products. To 
observe the DNA product 2μl of the reaction is run on a 1-2% agarose gel. The gel is made by 
dissolving agarose powder in TAE buffer (40mM Tris, 20mM acetic acid, 1mM EDTA) at the 
desired concentration (1-2% depending on expected DNA fragment size). Two drops of 
ethidium bromide are added per 100ml of agarose and mixed by swirling the molten agarose 
gel taking care to avoid splashing. The agarose is allowed to cool the poured into a gel mould 
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with a comb allowing wells to be formed. Once the gel has set the comb is removed and the 
DNA product can be loaded into the wells. If the DNA product is not present in a solution 
which contains loading dye (such as Biomix) 1/5th of a volume 5x loading dye is added to 
ensure that the DNA product sinks into the well and can be seen. Samples are 
electrophoresed at 150V for 15-30 minutes. DNA bands are visualised under UV light using 
the BIODOC ITTM imaging system (UVP). 
2.7.6 qPCR 
Quantitative PCR (qPCR) is used to quantitatively measure relative amounts of specific mRNA 
transcripts. A fluorescent dye (SYBR) which intercalates with double-stranded DNA is utilised 
and the fluorescence intensity is measured after each cycle to measure the quantity of PCR 
product. The number of cycles taken for the fluorescence intensity to reach the threshold 
intensity is calculated, this is called the Ct value.  
To optimise PCR primers used for qPCR, primer pairs are tested at a range of concentrations 
between 100nM and 500nM. Secondly a standard curve is created using a range of 
concentrations of cDNA to ensure that the primer efficiency is close to 100% (±10%) and that 
there is a single peak on the dissociation curve, indicating only one product is being 
produced. Once the primers have been optimised the lowest successful concentration of 
primer and a concentration of cDNA that falls within the linear range of the standard curve 
is used in subsequent reactions.  
Each 20μl reaction mixture contains 10μl SYBR green (Agilent), primer and cDNA at desired 
concentration, made up to 20μl with nuclease free dH2O. The reactions are loaded into a 
qPCR plate (Geneflow) and the plate is briefly centrifuged to ensure the reaction mixture is 
in the bottom of the wells. The plate is loaded into the qPCR machine (Stratagene Mx3000P) 
and the reaction is cycled through 40 cycles of 30s at 95oC followed by 1 minute at 60oC. At 
the end of the cycles a melt curve is performed. Data are analysed using Stratagene MxPro 
3000P (Stratagene). 
Zebrafish ef1ɑ is used as a reference gene. Fold changes are calculated using the delta-delta-
Ct (ddCt) method. To calculate fold changes using this method the Ct value for the reference 
gene is subtracted from the Ct value for the gene of interest, this gives the delta-Ct value 
(dCt). To calculate the delta-delta-Ct (ddCt) value, the dCt value of the controls is subtracted 
from the dCt value of the “treated” or “mutant” groups. To calculate the fold change the 
following formula is used: fold change = 2(-ddCt) 
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2.7.7 Primers used for PCR/RT-PCR/qPCR 
Primers are designed using Primer3 software v4.0.0 (http://primer3.ut.ee/) and a primer 
BLAST (NCBI) was performed to ensure the designed primers are specific for the gene of 
interest. 
Table 6. PCR/RT-PCR primers used in this study. 
 
 
  
Primer set Sequence 
miR-205 region FWD 5’-AACCAAAGTGAGGTGGATGG-3’ 
REV 5’- GCCTGCATTGATCCGTGTAT-3’ 
miR-133b region FWD 5’-TGTTTGCTCTACATCCATGGA-3’ 
REV 5’-ACATCAGCCAACACATTAAGCT-3’ 
Irrk2 kinase domain FWD 5’-GAGACGCTGCTGAAGAAA-3’ 
REV 5’-GCAACTCACTGGGAAACT-3’ 
Irrk2 WD40 domain FWD 5’-ATGTTTATTCGTTCGGTCTG-3’ 
REV 5’-AGTGTCCCGTCTGCTGTG-3’ 
pitx3  
5’UTR-exon4 
FWD 5’AGCCTTCACTCTCCGCTAAA-3’ 
REV 5’-GCGGGCTTACATTCATGGAG-3’ 
miR-155 region 
 seq and CRISPR1-4 analysis 
FWD 5’-GGCATGATGGAAACTGTGCT-3’  
REV 5’-TCACACTCCAGCATGTCTTCT-3’  
miR-155  
CRISPR5 analysis primers 
FWD 5’-GTGGATGTGCGTTGATCTCC-3’ 
REV 5’-GATGTTCAGACGGTTCGCTC-3’ 
gba1 genotyping primers  FWD 5’-AAAGCAGCACGATATGTCCA -3’  
REV 5’-ATGTCATGGGCGTAGTCCTC-3’ 
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Table 7. qPCR primers used in this study 
 
2.7.8 miRNA taqman assays 
Taqman assays are used to quantify the expression levels of miRNAs in zebrafish. These 
assays include a specific reverse transcription primer per miRNA and a single stem-loop qPCR 
primer. 
RNA is extracted using the trizol method as described in section 2.7.2. RNA concentration is 
accurately quantified using the QuantiFluorTM RNA system (Promega) and the Qubit® 
fluorometer (Life Technologies). Exactly 100ng of total RNA is reverse-transcribed using the 
Taqman microRNA reverse transcription kit (Applied Biosystems) subsequently qPCR is 
performed using Taqman miRNA assays (Applied Biosystems). As with regular primers the 
qPCR is tested by running a standard curve of different cDNA concentrations to assess primer 
efficiency, the assays are only accepted if the efficiency is between 90-110%. 
 
Primer set for qPCR Sequence Primer concentration 
used for qPCR 
Zebrafish ef1α  
(reference gene) 
FWD 5’-TGGTACTTCTCAGGCTGACT-3’ 
REV 5’- TGACTCCAACGATCAGCTGT-3’ 
100nM 
Zebrafish pitx3  FWD 5’-CCGGCAAAGGACACATTTCA-3’ 
REV 5’-GGCTTGCTGGTTCCTTTCTC-3’ 
100nM 
Zebrafish lrrk2  FWD 5’-GCGCATACATCTAGAGCAGC-3’ 
REV 5’-CGTTTCTCTCATTCTGCGGG-3’ 
100nM 
Zebrafish th FWD 5’-GAGGAGAGCGATGGAAAAGC-3’ 
REV 5’-ATCCTTTGGTTTTCGGCTGG-3’ 
100nM 
Zebrafish CXCL8-l1 FWD 5’-TTAGAGATCCTTGCCACCTTGA-3’ 
REV 5’-TCCGGGCATTCATGGTTTTC-3’ 
100nM 
Zebrafish CXCL8-l2 FWD 5’-GCTGGATCACACTGCAGAAA-3’ 
REV 5’-TGCTGCAAACTTTTCCTTGA-3’ 
500nM 
Zebrafish tnfa  FWD 5’-GCGCTTTTCTGAATCCTACG-3’ 
REV 5’-TGCCCAGTCTGTCTCCTTCT-3’ 
300nM 
Zebrafish tnfb FWD 5’-TCCTCAGACCACGGAAAAGTG-3’ 
REV 5’-CCACCCATTTCAGCGATTGTC-3’ 
300nM 
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Table 8. Taqman assays used in this study. 
Taqman assay Sequence (mature miRNA) Cat number 
miR-133b 5’-UUUGGUCCCCUUCAACCAGCUA-3’ 002247 
miR-205 5’-UCCUUCAUUCCACCGGAGUCUG-3’ 000509 
miR-155 5’-UUAAUGCUAAUCGUGAUAGGGG-3’ 000479 
miR-146a 5’-UGAGAACUGAAUUCCAUAGAUGG-3’ 005396_mat 
miR-24 5’-UGGCUCAGUUCAGCAGGAACAG-3’ 000402 
U6 small RNA 5’-GTGCTCGCTACGGTGGCACATATACTAAAATTGGAT
CGATACAGAGAAGATTAGCATGGCCCCTGCGAAAGGA
TGACACGCAAATCCGTGAAGCGCTCCATATTGCT-3’ 
custom assay 
 
2.8 MPP+ exposure 
MPP+ is a mitochondrial toxin that specifically targets the dopaminergic neurons. It is used 
to induce dopaminergic neuronal cell loss such as is seen in PD.  
Embryos are exposed to a low dose, 3mM, of MPP+ at 48hpf or a high dose of 6mM at 24hpf, 
which is then replaced at 48hpf. Embryos treated with MPP+ are kept protected from light 
until they are fixed at 72hpf (see section 2.9). 
2.9 Embryo fixation 
In order to preserve embryos for whole mount in situ hybridisation or immunohistochemistry 
experiments 4% paraformaldehyde (PFA) in 1x phosphate buffered saline (PBS) is used as a 
fixative. 
Embryos older than 18hpf are manually dechorionated with sharp tweezers, placed in a 
1.5ml Eppendorf tube in groups of 20. All E3 media is removed before 1ml 4% PFA in PBS is 
added. Embryos younger than 24hpf are left inside their chorions. Embryos are incubated 
with agitation in PFA for 2 hours at room temperature or overnight at 4oC. PFA is removed 
and the embryos are dehydrated in 100% methanol for 20 minutes at room temperature, 
fixed embryos are then stored at -20oC. 
If necessary, to remove excess pigment the embryos are bleached with 10% H2O2 and 0.5% 
KOH for 15 minutes directly after the PFA incubation, then gradually transferred into 100% 
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methanol (MeOH) via a 5 minute wash in 50% methanol in PBT (PBS with 0.1% tween-20) 
before dehydrating in 100% MeOH for 20 minutes. They are then stored at -20oC. 
2.10 Whole Mount in situ Hybridisation 
Whole mount in situ hybridisation (WISH) is used to visualise the expression pattern of 
various mRNAs and miRNAs in zebrafish embryos. 
2.10.1 Synthesis of WISH riboprobes 
Primers are designed to the cDNA sequence of a gene to generate a product 500-1000bp in 
length. A BLAST (NCBI) search is performed comparing the expected PCR product to the 
zebrafish transcriptome to ensure this is not present in any other genes. SP6 and T7 
promoters (SP6 promoter: 5’-GATTTAGGTGACACTATAG-3’, T7 promoter: 5’-
TAATACGACTCACTATAGGG-3’) are attached to the start of each primer to create a PCR 
product with SP6/T7 promoter on the start/end. These are used to initiate transcription so 
riboprobes both complementary (antisense) to the mRNA and the same sequence (sense) as 
the mRNA can be produced. The antisense probe is used to detect specific expression of the 
gene of interest while the sense probe is used as a control. RT-PCR reaction is performed to 
amplify a region of the cDNA (see section 2.7.4). The PCR products are then purified using 
the QIAquick PCR purification kit (QIAGEN) according to manufacturer’s instructions. Briefly, 
5 volumes of PB buffer is added to the PCR product and added to spin column, this is 
centrifuged at max speed (16000rcf) for 1 minute, the flow through is removed and 750μl PE 
buffer is added to the column, the column is then centrifuged again to wash the column. The 
flow through is removed then centrifuged once more to remove any remaining wash buffer. 
20-30μl ddH2O is added and incubated in the column for 1 minute then centrifuged to elute 
the purified PCR product. The concentration of purified PCR product is then checked using 
the nanodrop spectrophotometer. 
The transcription reaction is then performed. Between 300-500ng of PCR product is diluted 
to 13μl with ddH2O and 2μl 10x transcription buffer, 2μl 10x DIG labelled oligonucleotides, 
1μl RNAse inhibitor and 2μl of either SP6 or T7 polymerase (Roche) are added. This reaction 
is mixed thoroughly by pipetting then incubated for 2 hours at 37oC. To degrade DNA, 2μl 
DNAseI (Roche) is added and the mixture is incubated for a further 20 minutes at 37oC. To 
check the transcription reaction has worked 2μl of the mixture is run on a 1.5% agarose gel 
(15mins 150V). If RNA is present it is then purified by adding a mixture of 60μl 100% EtOH 
and 10μl 7.5M ammonium acetate, both ice cold, and inverting to mix. The mixture is then 
centrifuged for 15 minutes at 16000xg at 4oC to collect the RNA pellet. The supernatant is 
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removed completely taking care not to disturb the pellet. 100μl 100% ethanol is added to 
wash the pellet and centrifuged at 16000xg for 15 minutes at 4oC. The ethanol is removed 
without disturbing the pellet and the remaining ethanol is allowed to evaporate. The pellet 
is resuspended in 20μl nuclease free water. The concentration of the RNA is assessed using 
a nanodrop spectrophotometer. The concentrations of the sense and antisense probes are 
adjusted to ensure they are equal. This final solution is diluted 2.3x in formamide (Ambion). 
For use in WISH 100µl probe is added to 900µl of hybdridisation buffer, the remaining probe 
is stored at -80oC. 
Table 9. Primers used to generate WISH probes. SP6/T7 promoter sequence in bold and start/stop codon 
underlined. 
 
2.10.2 Labelling of Exiqon LNA WISH probes for miRNA 
Unlabelled locked nucleic acid (LNA) WISH probes for a selection of miRNAs were purchased 
from Exiqon. 
To label the miRNA LNA probes the DIG Oligonucleotide 3’-End labelling kit is used (Roche). 
100pmoles of unlabelled probe is diluted in ddH2O to a final volume of 10μl. This is placed 
on ice and the following solutions from the labelling kit are added: 4μl reaction buffer, 4μl 
CoCl2, 1μl DIG UTP and 0.5μl (200units) terminal transferase. The mixture is mixed carefully 
by pipetting then incubated at 37oC for 30 minutes. 5μl 0.1M EDTA pH8.0 is added to stop 
the reaction and the mixture is placed on ice. To purify the labelled probe and remove any 
unincorperated label IllustriaTM MicroSpinTM G-25 (GE Healthcare Life Sciences) columns are 
used. The columns are prepared by vortexing to resuspend the resin. The cap is then 
loosened and the bottom closure removed and the column was vortexed at 750rcf for 1 
minute. The prepared column is then placed in a new sterile collection tube, the labelled 
WISH probe 
primers 
Sequence  
lrrk2 FWD 5’-GATTTAGGTGACACTATAGCGGGAGCAAAACCAAAGACA-3’ 
REV 5’-TAATACGACTCACTATAGGGTCAAAGTGCAGCAAGACACC-3’ 
pitx3 FWD 5’-TAATACGACTCACTATAGGGCGGTAGAGGTGATGGATTTTA-3’ 
REV 5’-GATTTAGGTGACACTATAGGAAATCTAGACGCATCGCTTTCA-3’ 
 
neurogenin1 FWD 5’-TAATACGACTCACTATAGGGGACGCGTGCCATTATCTTCA-3’ 
REV 5’-GATTTAGGTGACACTATAGGGTGATGAAGACGACGAGGA-3’ 
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probe is added to the resin and the purified probe is eluted by centrifuging the column for 2 
minutes at 750rcf. The labelled, purified probe is then stored at -20oC. 
Table 10. Exiqon LNA probes used. 
miRNA Sequence Product code 
miR-206 5’-ACACACTTCCTTACATTCCA-3’ 88081-00 
miR-205 5’-CAGACTCCGGTGGAATGAAGGA-3’  18099-00 
miR-133b 5’-TAGCTGGTTGAAGGGGACCAAA-3’ 38579-00 
miR-155 5’-CCCCTATCACGATTAGCATTAA-3’ 35129-00 
 
2.10.3 Whole mount in situ hybridisation 
On the first day of whole mount in situ hybridisation (WISH) fixed embryos (see section 2.9) 
are rehydrated by successive 5 minute incubations in 75% MeOH in PBT, 50% MeOH in PBT, 
25% MeOH in PBT, then 4 consecutive 5 minute washes in PBT. Embryos 24hpf and older are 
then digested in 10μl/ml proteinase K. The length of the incubation is dependent on the age 
of the embryos: 1dpf - 8 minutes, 2dpf – 18 minutes, 3dpf – 30 minutes, 4dpf – 40 minutes, 
5dpf – 50 minutes. Embryos younger than 24hpf are not digested with proteinase K. The 
embryos are then re-fixed in 4% PFA in PBS for 20 minute and are washed 3 x 5 minutes with 
PBT. HybA (50% formamide, 5xSCC (750mM NaCl and 75mM trisodium citrate), 50μl/ml 
heparin, 0.1% Tween-20, 500μl/ml tRNA, pH6) is preheated to 68oC for RNA probes or 30oC 
below the stated RNA Tm for the Exiqon LNA miRNA WISH probes and added to the embryos. 
The embryos are pre-hybridised for 5 hours at the hybridisation temperature then the probe 
is added and hybridised overnight. Exiqon LNA probes are diluted 100x in HybA to give a final 
concentration of 50nM, RNA probes are diluted in HybA to give a final concentration of 0.8-
1ng/μl. 
On the second day of WISH, post hybridisation washes are performed at the hybridisation 
temperature. Firstly the embryos are briefly washed in HybB (HybA without heparin or tRNA) 
then embryos are transferred into 2xSSC (100mM NaCl and 30nM trisodium citrate at pH7) 
via successive 15 minute washes in 75% HybB in 2xSSC, 50% HybB in 2xSSC, 25% HybB in 
2xSSC then 100% 2xSSC. Two 30 minute washes in 0.2x SSC are then performed at 
hybridisation temperature. The following washed are performed at room temperature on 
the shaker, the embryos are transferred into PBT via successive 10 minute washes in 75% 
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0.2xSSC in PBT, 50% 0.2xSSC in PBT, 25% 2xSSC in PBT then in 100% PBT. Next the embryos 
are blocked in PBT with 2mg/ml BSA and 2% sheep serum for 3 hours, then incubated with 
anti-DIG-AB FAB fragments (Roche) at 4oC overnight (5000x dilution in blocking solution). 
On the third day of WISH, all washes are carried out on the rocker and the embryos are 
protected from light. Firstly the embryos are washed 6x 15 minutes in PBT, they are then 
equilibrated in NTMT (0.1M TrisHCl, 50mM MgCl, 0.1M NaCl, 0.1% Tween-20) via 2x 5 minute 
washes in NTMT in Eppendorf tubes. They are then transferred into a 12 well plate and one 
further 5 minute wash in NTMT is performed. The NTMT is then removed and staining 
solution (3.5μl BCIP and 4.5μl NBT (Roche) per ml NTMT) is added. The staining is monitored 
using the dissection microscope every 15 minutes. When staining is sufficient the staining 
solution is removed and the embryos are washed 3x 5 minutes in PBT. If any background 
staining has occurred the embryos can be cleared by bringing to 100% MeOH for 10-15 
minutes or until the background staining has cleared, via a 5 minute wash in 50% MeOH. 
Once background staining has cleared the embryos are washed in 50% MeOH for 5 minutes 
then 3x 5 minute washes in PBT. The embryos are then moved back into eppendorf tubes 
and re-fixed for 20 minutes in 4% PFA in PBS. Finally, they are washed 3x 5 minutes in PBT 
then transferred into 75% glycerol for storage via 10 minute washes in 25% glycerol and 50% 
glycerol. Embryos are stored at 4oC. 
2.11 Immunohistochemistry 
Immunohistochemistry (IHC) is used to detect protein expression spatially in the zebrafish 
embryo. In this study it was used combined with either WISH, to detect co-localisation of 
mRNA and protein, and EdU staining to detect co-localisation of protein and proliferating 
cells. 
2.11.1 Basic immunohistochemistry protocol  
Fixed embryos are rehydrated and permeabilised by the desired method: either the method 
performed as part of the WISH protocol (section 2.10.3) or the EdU detection protocol 
(section 2.12), these protocols are performed until the blocking step when the following 
protocol is used. 
To block, embryos are incubated for overnight at 4oC in PBDT (PBS with added 0.5% triton-
100, 1% DMSO and 1% BSA) with 2% sheep serum (PBDTss) or 5% normal goat serum 
(PBDTngs). The primary antibody is diluted in PBDTss/ngs and incubated with the embryos 
overnight at 4oC with gentle agitation. 
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On the second day of staining the antibody solution is removed and the embryos are washed 
6 x 20 minutes in PBDT. Secondary antibodies are then diluted in PBDT and incubated with 
the embryos at room temperature for 2 hours. The embryos are washed for 4 consecutive 
20 minutes in PBDT followed by one 20 minute wash in PBT before re-fixing in 4% PFA in PBS 
and finally transfer into 75% glycerol for storage.  
2.11.2  Combined fluorescent WISH and IHC 
This technique is used to determine whether an mRNA and a protein are present in the same 
region by combining WISH to detect and visualise mRNA and IHC to detect and visualise 
protein.  
The protocol is very similar to the single WISH protocol but differs in the following ways. At 
the end of day2 anti-DIG POD (Roche), to detect the dig-labelled nucleotides of the WISH 
probe and the antibody for the gene of interest are incubated with the embryos overnight 
at 4oC. After the primary antibody incubation the embryos are washed 6x 15 minutes with 
PBDT. To develop the staining of the WISH probe embryos are washed 3x 5 minutes in TNT 
(0.1M Tris-HCl pH7.5, 0.15M NaCL and 0.05% Tween20) before incubating in TSA-cy3 (Perkin-
Elmer) for 2 hours. Embryos are then washed 3x 5minuts in TNT and once in PBDT for 30 
minutes before incubation with an Alexafluor tagged secondary antibody overnight at 4oC. 
All washes are performed in the dark with gentle shaking. After the overnight antibody 
incubation the embryos are washed 4x 15 minutes in PBT then refixed for 20 minutes in 4% 
PFA in PBS. Finally, they are washed 3x 5 minutes in PBT then transferred into 75% glycerol 
for storage via 5 minute washes in 25% glycerol and 50% glycerol. Embryos are stored at 4oC. 
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Table 11. Antibodies used for fluorescent WISH and IHC. 
Target (and tag) Species and type Dilution factor  Company, Cat number 
TH Rabbit 1:500 Millipore ab152 
TH Mouse 1:2000 Immunostar 
GFP Rabbit 1:1000 Torrey pines (TP01) 
Digoxigenin-POD 
tagged 
 1:5000 Roche 
Secondary Antibodies 
Anti-mouse 
Alexafluor-568 
goat 1:500 Invitrogen A21043 
Anti-rabbit 
Alexafluor-488 
goat 1:500 Invitrogen A11034 
Anti-mouse 
Alexafluor-488 
goat 1:500 Invitrogen A21121 
Anti-rabbit 
Alexafluor-568 
goat 1:500 Invitrogen A11035 
 
2.12 EdU exposure and staining 
EdU treatment was performed on either ETvmat:GFP;WT or WT zebrafish in order to detect 
proliferating neurons around the diencephalic catecholaminergic cluster, located by IHC for 
GFP or TH respectively. After treatment the embryos are fixed at the required time point. 
EdU is detected by the Click-iT® EdU Imaging kit (Invitrogen) and GFP/TH is detected using 
IHC (described in section 1.3). 
5nl of 5mM EdU (2 volumes 10mM EdU:1 volume 0.3x Danieau’s Soluion:1 volume Phenol 
Red) is injected into the yolk of embryos at various time points (the preparation of 
microinjection equipment is described in section 2.4). The embryos are then left to develop 
at 28oC until the desired age is reached. At this point the embryos are fixed in 4% PFA in PBS 
for 2 hours at room temperature then dehydrated in 100% methanol. They are then stored 
at -20oC for at least 12 hours. 
To detect EdU labelled cells the embryos are rehydrated the by successive 5 minute washes 
in 75% MeOH in PBT, 50% MeOH in PBT, 25% MeOH in H2O. To permeabilise the embryos an 
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acetone crack is performed. To do this the embryos are suddenly incubated for 10 minutes 
in ice-cold acetone at -20oC. One quick wash in H2O then 3 consecutive 5 minute washes in 
PBT are performed before the embryos are incubated in 1ml of Click-iT® reaction solution, 
protected from light, at room temperature for 3 hours. The Click-iT® reaction solution is 
made up as following and is used within 15 minutes of preparation: 
Table 12. Components of the Click-IT® kit for EdU staining. 
Reaction component Storage details Per 1ml of reaction 
solution 
Click-iT® reaction buffer Kit component D – stored at 
4oC 
43μl 
H2O  886μl 
CuSO4 Kit component E – stored at 
4oC 
20μl 
Alexa-fluor® 647 azide Kit component B – stored at -
80oC 
1μl 
Reaction buffer additive Kit component F – stored at -
80oC 
50μl 
 
After incubation in the Click-iT® reaction solution one wash in PBS is performed followed by 
4 consecutive 15 minute washes in PBT. The protocol for IHC to detect GFP signal is then 
followed, beginning with an overnight blocking step in PBDT + 5% sheep serum (see IHC 
section 1.3). 
2.13 Generation of a fluorescent reporter for miRNA target analysis 
A reporter plasmid was generated to determine whether miR-133b is able to target pitx3 in 
zebrafish. A control dual reporter plasmid was kindly provided by the Giraldez lab. This 
plasmid contains both red fluorescent protein (RFP) and GFP. Downstream of RFP is a 
multiple cloning site into which a mock 3’UTR containing two perfect miR-133b binding sites 
have been placed, labelled on the plasmid map as miR-133b PTx2). GFP is present as a control 
as it is does not have a 3’UTR therefore is not under the control of any miRNA.        Figure 14 
shows a plasmid map.  
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       Figure 14. Plasmid map of dual reporter plasmid. 
The control plasmid displayed above will express RFP under the control of miR-133b as the 
3’UTR contains binding sites for this miRNA. To validate a specific miRNA-target interaction 
it is possible to clone in the 3’UTR of any gene of interest downstream of RFP between the 
Xho1 and Not1 restriction sites. This will help to determine whether this gene can be 
regulated by a particular miRNA. In this study the regulation of pitx3 by miR-133b is being 
investigated. Therefore the 3’UTR of pitx3 was cloned downstream of RFP in this vector.  
2.13.1 Cloning of the pitx3 3’UTR into the reporter plasmid 
Firstly, primers were designed to amplify the whole of the 3’UTR from the pitx3 and to add 
a restriction site to each end so it is possible to cut both the plasmid and the PCR product 
with the same enzymes to allow targeted ligation. Xho1 and Not1 are the restriction enzymes 
used at the start and end of the 3’UTR fragment, respectively. The 3’UTR is amplified by PCR 
then both the PCR product and the plasmid are cut with the relevant restriction enzymes. 
The restriction reaction mix is as follows, 5μl 10x NEBuffer 4, 5μl 10x BSA, PCR product, 10U 
each restriction enzyme, the reaction mix is made up to 50μl with sterile water. The digestion 
products are then run on a 1% agarose gel at 100V for 30 minutes. The correct products are 
cut from the gel using a razor blade and are then extracted using the QIAGEN gel extraction 
kit according to the manufacturer’s instructions. The digested 3’UTR and reporter vector are 
then ligated using NEB quick ligase using a 3:1 molar ratio of PCR product to linearised 
plasmid with a total of 100ng of DNA in the reaction. The reaction mixture is as follows: 5μl 
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buffer, 1μl enzyme, appropriate amounts of PCR and plasmid, made up to 10μl with sterile 
nuclease-free water. The reaction is incubated at room temperature for 5 minutes for 
ligation take place. The ligated vector and 3’UTR is then transformed into competent DH5β 
cells (NEB). 
The transformation protocol is as follows: the competent cells are defrosted on ice for 30 
minutes, 5μl of the ligation reaction is gently pipetted onto 50μl competent cells. The cells 
are incubated on ice for 30 minutes then heat-shocked at 42oC for 30 seconds. The cells are 
then incubated on ice again for 5 minutes to allow them to cool. Next the cells are recovered 
by placing 1ml of SOC media (NEB) and incubate at 37oC with agitation for 1 hour. Using 
aseptic technique, 100μl of the growth mixture is spread onto Ampicillin LB Agar plates. The 
rest of the cells are pelleted by centrifuging at 4000g for 1 minute and then re-suspended in 
100μl media then this is all spread on a second agar plate. The plates are incubated overnight 
at 37oC to allow colonies to grow. 
To produce plates 1 litre of LB-Agar (MP Biomedicals) is autoclaved then Ampicillin added to 
a final concentration of 0.1%. LB-Agar is cooled then plates are poured, left to set then dried 
at 37oC. 1 litre of LB-Agar contains 10g tryptone, 5g yeast extract, 0.5g NaCl and 15g Agar. 
Several colonies are picked for screening to check for correct ligation. This is done by picking 
a small amount of the colony and placing it into a PCR using primers to regions either side of 
the insert. Therefore if the ligation has been successful the product will be the size of the 
3’UTR plus the small region either side. 2-6 colonies that yield the correct size PCR product 
are selected and grown overnight at 37oC with agitation in 50ml LB (MP Biomedicals) with 
ampicillin.  
The following day the plasmid is midi-prepped from the overnight culture, following 
manufacturer’s instructions (QIAGEN). The plasmid is then analysed digestion with Xho1 and 
Not1 and finally by direct sequencing with to assess the insert is as expected. 
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Table 13. Primers used for generation and analysis of reporter plasmids. 
 
2.13.2 Injection of the reporter plasmid and analysis of results 
1nl of injection solution containing 1nl of 50ng/µl of plasmid, 50ng/µl tol2 mRNA and either 
control MO, no MO or miR-133b MO is injected into one-cell stage zebrafish embryos. In 
some cells the plasmid will be incorporated into the genome. In these cells and descendants 
of these cells, GFP will be expressed freely as there are no regulatory sequences downstream 
of it. RFP will be expressed unless it is repressed by any post-transcriptional mechanism due 
to binding sites present in its 3’UTR.  
Injected zebrafish embryos are imaged after 48 hours to assess fluorescence of GFP and RFP 
(see section 2.14.3). To determine whether a miRNA (in this case miR-133b) is able to interact 
with binding sites in the 3’UTR the ratio of RFP fluorescence intensity to GFP fluorescence 
intensity in plasmid containing cells is measured in the presence and absence of the miRNA 
of interest. In the presence of the miRNA of interest, if the miRNA is able interact with sites 
in its 3’UTR downstream of RFP, the levels of RFP will be reduced and therefore the RFP:GFP 
ratio will be reduced. In the absence of the miRNA of interest, or if this miRNA is not able to 
interact with binding sites in the 3’UTR downstream of RFP, RFP will not be repressed and 
the RFP:GFP ratio will be close to 1. 
To measure the RFP:GFP ratio, a region containing GFP, and therefore expressing the 
plasmid, is selected. The fluorescence intensity of both GFP and RFP this region is measured 
using ImageJ. The ratio is calculated by dividing the RFP fluorescence intensity by the GFP 
fluorescence intensity.  
Primer Sequence 
For sequencing multiple cloning site downstream of RFP and analysis of insert: 
AG plas RFP end FWD 
AG plas RFP polyA REV 
5’-AAGACCGACATCAAGCTGGA-3’ 
5’-TCACTGCATTCTAGTTGTGGT-3’ 
Zebrafish pitx3 3’UTR: 
Fwd primer + Xho1 (red) 
Rev primer + Not1 (red) 
 
5’-CAACTCGAGAAGCGATGCGTCTAGATTTCGA-3’  
5’-ATAAGAATGCGGCCGCTGAGACAAAGCAGGCTACACCAGGA-
3’ 
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2.14 Imaging of stained/fluorescent embryos 
2.14.1 Imaging embryos after WISH 
To capture images of zebrafish embryos and larvae after WISH a Nikon SMZ150 
stereomicroscope was used. Embryos are placed in a watch glass in 75% glycerol and 
manipulated into the correct orientation using a mounted needle. At least 10 
embryos/larvae from each group are imaged before selection of a representative image. 
To take representative images of the larvae after WISH for th the Olympus Upright 
Epifluorescent microscope was used. In order to generate a colour image 3 bright field 
images were taken, one using each of the blue, red and green filters. The images are then 
combined to give a colour image. 
2.14.2 Confocal microscopy for imaging fixed fluorescent embryos  
To capture images of embryos after IHC, fluorescent WISH and EdU staining embryos are 
mounted dorsally onto microscope slides in glycerol and subsequently imaged using a Nikon 
Eclipse Ti confocal microscope. 
2.14.3 Spinning disc confocal microscopy for imaging of live embryos 
In order to capture images of live embryos expressing a fluorescent construct an 
UltraViewVoX spinning-disk confocal microscope (PerkinElmer Life and Analytical Sciences) 
was used. Anesthetised embryos are mounted in the desired orientation on a glass coverslip 
in 1% LMP agarose. 
2.14.4 High throughput imaging of fluorescent embryos 
Mounting and individually imaging fluorescent embryos is a time consuming part of the 
experimental process. In order to increase the speed of imaging embryos and move towards 
a more high throughput imaging system a mould was created to create wells in agarose in a 
96 well plate which are able to hold embryos in a dorsal position. The mould was designed 
by Westhoff and colleagues (2013), it was originally milled from brass, however a 3D printed 
version of the mould was later published (Wittbrodt et al. 2014).  
The 3D printed mould, using the published design, was printed by WeDo3DPrinting 
(Sheffield, UK). In order to create wells in a 96 well plate 100μl of 1.6% LMP agarose in E3 
(no methylene blue) is pipetted into each well of a Greiner μclear black walled 96 well. The 
mould is then placed into the 96 well plate and the agarose is left to set for around 15 
minutes. Care is taken when removing the mould to ensure it is not tilted to disrupt any of 
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the wells. The moulds are used immediately or 50μl of E3 is pipetted into each well to prevent 
them drying out, the moulds can be stored in this state in the fridge for up to 24 hours.  
Before mounting embryos are first anaesthetised in a low dose of tricaine (0.003%) before 
being transferred to the wells in the 96 well plate in a total of 150μl E3 media. To orient the 
zebrafish they are observed under a dissecting microscope and carefully adjusted using a 
mounted needle. Images are captured using an UltraViewVoX spinning-disk confocal 
microscope (PerkinElmer Life and Analytical Sciences). 
2.15 Assessment of dopaminergic neuron number 
2.15.1 Counting of dopaminergic neurons after WISH for th 
To assess the number of th+ dopaminergic neurons WISH for th is performed on 3dpf 
embryos. The heads of stained embryos are mounted dorsally onto microscope slides in 
glycerol. The Zeiss Axioplan microscope using a Plan-Neo FLUAR 20x/0.5 objective (Carl Zeiss 
Ltd, Jena, Germany) was used to visualise and count stained th+ neurons. Only neurons from 
from Wulliman-Rink groups (1, 2, 4 & 5) were counted as these groups have ascending 
projections into the subpallium (analogous to the striatum in humans) thus representing the 
function of the neurons in the substantia nigra in humans (Figure 15) (Rink & Wullimann 
2002).  
 
Figure 15. Location of th+ neurons in 2 and 5dpf zebrafish. This figure shows the location of th expressing neurons 
at 2dpf (A) and 5dpf (B). In this study neurons from groups 1, 2, 4 and 5 are counted. OB = olfactory bulb, Tel = 
telencephalon and LC = locus coeruleus. Figure is adapted with permission from Rink & Wullimann (2002). 
 
 
71 
 
To avoid bias the investigator is blinded to the identity/genotype of the embryo being 
counted. In all experiments a minimum of 10 embryos are counted per group and the 
experiment is performed at least 3 times. The mean number of dopaminergic neurons in 
each group is calculated per biological repeat. The mean number of dopaminergic neurons 
is calculated for each group from each biological replicate. The average dopaminergic neuron 
count of the control groups is set to 100%; all other values are expressed as a percentage of 
this value. 
2.15.2 Using the ETvmat2:GFP reporter line to assess dopaminergic neuron 
number 
A number of methods can be used to assess the dopaminergic neuron number using the 
ETvmat2:GFP reporter line. The development of these methods is described in detail in 
Chapter 6. 
Images of live zebrafish embryos containing the ETvmat2:GFP transgene are captured using 
the UltraViewVoX spinning-disk confocal microscope (PerkinElmer Life and Analytical 
Sciences). These images were processed in ImageJ. The image is cropped around the 
diencephalic catecholaminergic cluster and a substack is created which only contains 
neurons from this group. 
Three methods of assessing dopaminergic neuron number can be performed using these 
processed images. Firstly, a maximum projection image can be created. From this image an 
intensity threshold is set. The mean fluorescence intensity of the region above the threshold 
and the number of pixels reaching the threshold value is measured. This values are multiplied 
together to give the total fluorescence intensity of the area above threshold value as a 
measure of dopaminergic neuron number. Secondly, the total fluorescent intensity reading 
can be measured from each slice of the substack. This method prevents loss of data where 
two neurons are present in the same X and Y position but different Z position. The total of 
these values can be used as a measure of dopaminergic neuron number. Thirdly, the number 
of dopaminergic neurons present in the substack image can be counted. 
2.16 Western Blotting 
In this study western blotting was used to determine Lrrk2 and Pitx3 protein levels in 
zebrafish embryos. 
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2.16.1 Extracting protein from zebrafish embryos 
Whole embryos up to 3dpf are deyolked before extraction of protein. For brain-specific 
proteins such as Pitx3 the head of the 3dpf embryo is removed using a scalpel and protein 
extraction was performed on heads only to enrich for this protein of interest; in this case 
deyolking is not necessary.  
4μl per embryo or 2μl per head of 2x Laemmli buffer (4% SDS, 10% 2-mercaptoethanol, 
0.0004% bromophenol blue and 0.125M Tris-HCl pH 6.8) is added to the deyolked 
embryos/heads. Embryos/heads are passed through a 200μl pipette tip 5 times to break 
them up before sonication. Embryos/heads are sonicated 3x 10s with a 10 second rest 
between bursts at 25% amplitude. To remove any debris the samples are centrifuged at 4oC 
for 5mins at 13000rcf and the supernatant collected into a new Eppendorf tube. Samples are 
either used immediately for western blotting or stored at -80oC. 
2.16.1.1 Deyolking zebrafish embryos 
Up to 50 3dpf embryos are placed in a 1.5ml Eppendorf tube and the E3 media removed. 1ml 
of deyolking buffer (55mM NaCl, 1.8mM KCl and 1.25mM NaHCO3) is added to each 
Eppendorf tube. Embryos are shaken for 5 minutes on a bench top vortex at 1000rpm. 
Embryos are centrifuged at 300g for 1 minute, the supernatant is carefully removed and 
discarded and replaced with 1ml wash buffer (110mM NaCl, 3.5mM KCl, 2.7mM CaCl2 and 
10mM TrisHCl pH8.5). Embryos are shaken for a further 2 minutes on a bench top vortex at 
1000rpm before embryos are pelleted as above. One further wash is performed as above 
then all the wash buffer is removed. Deyolked embryos are then either snap frozen and 
stored at -20oC or immediately used for sample preparation.  
2.16.2 Western blotting 
Before loading into the gel the samples (between 10 and 40μl for optimisation) are heated 
to 95°C for 2 minutes then centrifuged briefly to ensure all of the sample is at the bottom of 
the tube. 
The samples are then loaded into wells of a poly acrylamide gel alongside a protein ladder 
(Precision Plus Protein™ Dual Color Standard, BioRad). Pre-cast 4-15% polyacrylamide gels 
were used (BioRad). Electrophoresis is performed at a constant voltage of 150V for 30-45 
minutes. 
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Once complete the protein is transferred from the gel to a polyvinylidine fluoride membrane 
(Merck Millipore). The membrane is briefly soaked in methanol then the transfer apparatus 
are assembled in transfer buffer (25mM Tris-base, 190mM glycine, 5-10% methanol). 
Proteins are transferred to the PVDF membrane by application of either 250mA (constant 
amps) for 1 hour or 90mA overnight. The membrane is then blocked with 5% non-fat milk 
powder (Marvel) in TBST (20mM Tris, 150mM NaCl and 0.1% tween pH7.6) blocking solution 
for 1-2 hours before incubation with the primary antibody. The membrane was incubated 
with the primary antibody for either 2 hours at room temperature or at 4°C overnight. The 
membrane is washed three times for 10 minutes in TBST before incubation with secondary 
antibody with an HRP tag for an hour at room temperature. The membrane is then washed 
again three times for 10 minutes in TBST. To visualise the protein the EZ-ECL 
Chemiluminescence detection kit for HRP (Biological Industries, Kibbutz Beit Haemek, Israel) 
was used according to manufacturer’s instructions. The G:box (Syngene) was used for 
imaging. As a loading control the membrane was re-probed for Tubulin. The membrane was 
incubated with the anti-Tubulin antibody overnight at 4°C. The washes, incubation with 
secondary antibody and visualisation were performed as described above. 
Table 14. Antibodies used for western blotting. 
Protein Species and type Dilution factor  Company, Cat number 
Pitx3  Rabbit 
monoclonal 
1:500 Abcam ab134920 
Pitx3 (custom) Rabbit polyclonal 1:50 Eurogentec custom made 
antibody DSX-SUPR 
Lrrk2  Mouse 
monoclonal 
1:1000 NeuroMab N241A_34 
Lrrk2 (custom) Rabbit polyclonal Not yet determined Eurogentec custom made 
antibody DSX-SUPR 
Tubulin  Mouse 
monoclonal 
1:1000  Sigma T9026 
Secondary Antibodies 
Goat anti-rabbit 
with HRP tag 
Goat 1:5000 BIO-RAD #1706515 
Goat anti-mouse 
with HRP tag 
Goat 1:1000 BIO-RAD #1706516 
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2.16.2.1 Design and production of custom made antibodies  
As commercially available antibodies specific to zebrafish Lrrk2 and Pitx3 were not available 
Eurogentec (Seraing, Belgium) were commissioned to produce custom antibodies for these 
proteins. 
Eurogentec’s peptide design service was used to generate a number of peptides from the 
supplied region of interest which are suitable for use as epitopes. These peptides were then 
assessed to ensure they are unique to the protein of interest using BLAST (NCBI). Per protein 
of interest two peptides specific to that protein were chosen. Polyclonal antibodies against 
these peptide epitopes were raised in rabbit. The antibodies were affinity purified against 
the peptide they were raised against before they were supplied. 
Upon arrival the antibody was mixed with one volume of glycerol and stored at -20oC. 
Table 15. Peptide epitopes of custom antibodies 
Protein target/ 
antibody code 
Peptide sequence Stock concentration 
of antibody 
Pitx3 ab164 Ac-ALSLSDSGTPQHDPGC-NH2 0.3mg/ml 
Pitx3 ab165 H-CKGQDNSDTEKSHQNH-NH2 0.36mg/ml 
Lrrk2 ab887 Ac-VAVQGKLPDPVKDYGC-NH2 0.2mg/ml 
Lrrk2 ab888 Ac-PSSLSDHRPVIELPHC-NH2 0.14mg/ml 
 
2.17 CRISPR/Cas9 genome editing technique 
The CRISPR/Cas9 system is a method of generating stable mutant lines by inducing directed 
double stranded breaks in the DNA. 
2.17.1 Design and purification of ultramers 
CRISPR sites are identified by locating PAM sites (NGG) within the DNA. Cas9 nuclease will 
cut 3bp upstream of this sequence. Cas9 cut sites present within a restriction site were 
chosen as if the CRISPR generates a mutation the restriction site will be disrupted. The 
sequence of the 18bp upstream of the identified CRIPSR site is used as a template, the 
reverse complement of this sequence is then placed into a gRNA template (see the 
underlined sequences in Table 16). The rest of this template contains the sequence for the 
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guide RNA which recruits Cas9 and the T7 promoter (shown in bold) from which the guide 
RNA is transcribed. 
Table 16. Primers and ultramers used in CRISPR generation. For ultramers the underlined region is the target 
sequence and bold sequence is the T7 promoter. 
Primer/ultramer Sequence 
General primers for 
ultramer amplification 
FWD 5’- AAAGCACCGACTCGGTGCCAC-3’ 
REV 5’-GCGTAATACGACTCACTATAG-3’ 
miR-155 upstream 
Mwo1 gRNA1 
 
5’-AAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGACT
AGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACCAGCAGATTC
TGCTCCTGCCCTATAGTGAGTCGTATTACGC-3’ 
miR-155 exon Bsl1 
gRNA2 
 
5’-AAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGACT
AGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACGGTGCAGGTT
TAATGCTACCCTATAGTGAGTCGTATTACGC-3’ 
miR-155 exon Bsl1 
gRNA3 
 
5’-AAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGACT
AGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACGCACCAGGA
GATCAACGCCCCTATAGTGAGTCGTATTACGC-3’  
miR-155 downstream 
Mwo1 gRNA4 
5’-AAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGACT
AGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACTAAAAGCAAC
AAGTTGACCCCTATAGTGAGTCGTATTACGC-3’ 
miR-155 exon 
Hpy188III gRNA5
  
5’-AAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGACT
AGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACATCACGATTA
GCATTAAACCTATAGTGAGTCGTATTACGC-3’ 
 
Upon arrival the ultramers are resuspended in 40μl dH2O to a final concentration of 100μM. 
Ultramers are amplified with a standard set of primers in a 100μl PCR (50μl Biomix red, 38μl 
dH2O, 5μl each forward and reverse primer and 2μl ultramer). The PCR reaction is 40 cycles 
using a 60oC annealing temperature. 2μl of the PCR reaction is electrophoresed on an 
agarose gel to ensure amplification has been successful. The remainder of the PCR is purified 
using the min-elute PCR purification (QIAGEN) according to manufacturer’s instructions. The 
PCR product is eluted in 20μl of dH2O then the concentration is measured using a nanodrop 
spectrophotometer. The amplified and purified ultramer can be stored at -20oC until it is 
needed. 
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2.17.2 Transcription of gRNA from ultramer 
Transcription of the gRNA from the purified ultramer is performed using the 
MEGAshortscript T7 kit (Life Technologies). The transcription reaction mixture is as follows: 
2μl buffer, 2μl each dNTP, 2μl enzyme, 1μl amplified ultramer (at least 30ng) and 7μl 
nuclease free water. The reaction is incubated at 37oC for at least 2 hours. After this 
incubation period 1μl of DNAse is added to degrade the remaining ultramer. At this point 1μl 
of the mixture is run on an agarose gel to ensure the reaction has been successful. If RNA is 
present nuclease-free water is added to make up the reaction volume to 100μl. To purify the 
RNA 33μl ice cold 10M NH4Ac and 350μl ice cold EtOH are mixed then added to the RNA. 
The RNA is precipitated in this mixture for at least 2 hours at -80oC. The RNA is pelleted by 
centrifuging at 13000rcf for 30 minutes at 4oC, the supernatant is removed and the pellet is 
washed in 70% EtOH as in the RNA extraction protocol (Section 2.7.2). The final pellet is air 
dried then resuspended in 10μl nuclease-free water. A 10x dilution of the RNA is made and 
the concentration of this dilution is measured using a nanodrop spectrophotometer. The 
gRNA is diluted to a concentration of 4-8µg/µl and stored at -80oC. 
2.17.3 Injection of CRISPR 
The gRNA is injected into one-cell stage embryos alongside Cas9 protein (NEB). The injection 
mixture contains 1µl of gRNA (4-8µg/µl), 1µl of Cas9 protein (stock concentration 18µM) and 
0.5µl phenol red. 1nl of this mixture is injected into the yolk of one-cell stage embryos. The 
embryos are incubated in petri dishes at 28oC until 5dpf when they are transferred to tanks 
in the aquarium. 
2.17.4 Determination of CRISPR efficiency 
At 1dpf DNA is extracted from 8 CRISPR injected embryos and 8 uninjected embryos using 
the method described in section 2.7.1. PCR is performed on each sample with primers which 
surround the region which the CRISPR targets. The PCR products are electrophoresed on an 
agarose gel to determine if any large deletions are detectable. Secondly, the PCR products 
are digested with the relevant restriction enzyme. If the CRISPR is working effectively the 
restriction site is likely to be disrupted therefore an undigested band should still be present. 
The higher the ratio of undigested product to digested product, the more efficient the 
CRISPR.  
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2.17.5 TOPO® TA cloning to determine mutations generated 
As injection of the CRISPR can generate a large number of different mutations within an 
individual embryo TOPO® TA cloning was performed to separate these mutations so they 
could be analysed individually. This helps determine the types of mutation generated by a 
particular CRISPR and whether they are likely to disrupt the function of the target gene. 
The PCR products from CRISPR injected embryos are pooled and purified using the QIAquick 
PCR purification kit (QIAGEN) according to manufacturer’s instructions. 4µl of the purified 
PCR product is combined with 1µl of the TOPO® vector and 1µl of a 4x dilution of the salt 
solution from the TOPO® TA cloning kit (Life Technologies). This reaction is incubated at room 
temperature for 30 minutes. This mixture is transformed into competent DH5β cells (NEB). 
This transformation protocol has previously been described in section 2.13.  
The growth mixture was spread, under sterile conditions, on ampicillin-containing agar 
plates and incubated overnight at 37oC. Several colonies are picked for colony PCR. This is 
performed by picking a small amount of the colony and placing it into a PCR using the primers 
listed above to screen for mutations. Large insertions or deletions are visible after 
electrophoresis of the PCR product. Restriction digests were also performed to determine 
whether smaller mutations present disrupted the restriction site. If mutations were deemed 
to be present by analysis of the size of the PCR product or disruption of the restriction site 
the PCR product was sent for direct sequencing by the Core Genomics Facility at the Royal 
Hallamshire Hospital, Sheffield. Sequence data was analysed using FinchTV Version 1.4.0 
(Geospiza, Inc.). 
2.18 Statistical tests and analysis 
All data analysis and statistical tests were performed using Graphpad prism V6.02 
(Graphpad). The number of biological replicates of the experiments is denoted by the n 
number. Unless otherwise stated error bars represent the standard deviation of the mean. 
All data is analysed with an unpaired t-test, one way ANOVA or two way ANOVA unless 
otherwise states. Significance values are denoted as follows. Not significant (ns) p>0.05, * 
p<0.05, ** p<0.01, *** p<0.001.  
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Chapter 3. Investigating the role of miR-133b in 
dopaminergic neuron development and survival 
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3.1 Introduction 
The implication of miR-133b in dopaminergic neuron development 
miR-133b has been shown to be specifically expressed in midbrain dopaminergic neurons 
and depleted in the brain of PD patients. The confirmation of this finding in dopaminergic 
neuron deficient mouse models led to the identification of Pitx3 as a potential regulator of 
miR-133b. Overexpression of Pitx3 in ESC cultures resulted in an increase in miR-133b 
precursor expression. It was confirmed that Pitx3 could regulate the miR-133b promoter 
using a luciferase reporter assay (Figure 16A). The study continued to demonstrate that 
miR-133b upregulation in ESC cultures resulted in a loss of dopaminergic markers and 
dopamine release and inhibition had the opposite effect, thus implicating miR-133b as a 
regulator of dopaminergic neuron development and function. Finally, Pitx3 was validated as 
a direct target of miR-133b using a luciferase reporter assay (Figure 16B), thus identifying a 
feedback loop between PITX3 and miR-133b in dopaminergic neurons (Kim et al. 2007).  
 
Figure 16. Identification of a feedback loop between miR-133b and PITX3 in midbrain dopaminergic neurons. 
This figure summarises the evidence for the feedback loop between miR-133b and PITX3. A shows evidence for 
regulation of the miR-133b promoter by PITX3. Upstream regulatory sequences from miR-133b or miR-133a were 
placed upstream of a luciferase reporter. The effect of addition of GFP, Pitx3 and Nurr1 containing vectors on 
luminescence was measured. No vector was able to increase luminescence from the miR-133a-luciferase construct 
and only Pitx3 was able to increase luminescence from the miR-133b-luciferase construct, thus confirming the 
specific upregulation of miR-133b by Pitx3 through this upstream regulatory element. B shows the validated 
binding site of miR-133b in the PITX3 3’UTR. C is a cartoon summarising the feedback loop between miR-133b and 
Pitx3. This figure is reproduced and adapted with permission from supplementary figures 4D, 6A and 6D of Kim et 
al. (2007). 
 
PITX3 in dopaminergic neuron development and disease 
In the mammalian system, PITX3 and NURR1 are master regulators of a sub-set of genes 
required for dopaminergic neurons. These genes are TH, aromatic amino acid decarboxylase 
(AADC), VMAT2, DAT and dopamine receptor 2 (D2); together these are responsible for the 
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synthesis, transport, detection and re-uptake of dopamine (Hwang et al. 2009; Jacobs et al. 
2009; Lebel et al. 2001). NURR1 and PITX3 appear to work in concert to regulate these genes, 
and are able to target the same regions in the promoters of TH, VMAT2, D2 and DAT (Jacobs 
et al. 2009). NURR1 is able to directly regulate PITX3 through a binding site in the Pitx3 
promoter, in the absence of NURR1, Pitx3 expression is reduced (Volpicelli et al. 2012). 
Similarly, in the absence of PITX3, NURR1 exists in a repressed state through interactions 
with SMRT. SMRT interacts with HDACs to deacetylate and therefore repress their target 
genes. These data suggest that NURR1 requires PITX3 for activation by weakening the 
interaction of NURR1 with the SMRT repressive complex (Jacobs et al. 2009). PITX3 and 
NURR1 are essential for the development of midbrain dopaminergic neurons. PITX3 or 
NURR1 deficiency results in the loss of dopaminergic neurons specifically in the substantia 
nigra or the entire midbrain, respectively (Nunes et al. 2003; Castillo et al. 1998).  
Transcription factors involved in specification of the dopaminergic phenotype have been 
shown to regulate PITX3. LMX1A and LMX1B have been shown to have a cooperative role in 
the specification of neural progenitors in the mammalian midbrain, through overlapping and 
cross-regulatory functions (Yan et al. 2011; Chung et al. 2009). Lmx1a forms an auto-
regulatory loop with Wnt1 and is able to positively regulate Pitx3 expression through direct 
binding elements within the Pitx3 promoter (Chung et al. 2009). This study also showed that 
Lmx1b was also able to bind the Pitx3 promoter, thus confirming the previous suggestion of 
an interaction by Smidt and colleagues who found that that Lmx1b-deficient mice were not 
able to induce expression of Pitx3 (Smidt et al. 2000). Another transcription factor capable 
of regulating Pitx3, is FOXP1. FOXP1 was identified as being differentially expressed in the 
PITX3 positive cells in embryonic mouse midbrain. In ESCs overexpression of Foxp1 resulted 
in an increase in development of PITX3 positive cells, subsequently a binding site for FOXP1 
was identified in the Pitx3 promoter (Konstantoulas et al. 2010).  
Neurotrophic factors GDNF and BDNF are also implicated in the Pitx3 regulatory network. 
Two studies by Peng and colleagues place GDNF upstream of PITX3 and show that both GDNF 
and BDNF are regulated by PITX3 (Peng et al. 2007; Peng et al. 2011). Upregulation of these 
neurotrophic factors by PITX3 during development and adulthood illustrates its role in 
maintenance, as well as the development of, dopaminergic neurons. 
Interestingly, and unexpectedly, PGC1ɑ has been shown to be a negative regulator of Pitx3. 
Overexpression of PGC1ɑ resulted in downregulation of Pitx3 and increased sensitivity to 
MPTP toxicity. The authors suggest that this is due, in part, to decreased levels of BDNF, a 
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downstream target of PITX3. They discuss that as PGC1ɑ is a promising target for 
neuroprotection, the mechanism of PCG1ɑ regulation of PITX3 must be studied further (Clark 
et al. 2012).  
Pitx3 is also able to positively regulate expression of the retinoic acid (RA) producing enzyme 
Aldehyde dehydrogenase (Adh2). Adh2 is specifically expressed in dopaminergic neurons of 
the substantia nigra, these neurons specifically rely on Pitx3 for survival. Interestingly it was 
shown that through restoration of RA signalling in Pitx3-deficient mouse embryos, these 
neurons were able to survive, thus highlighting the importance of Adh2 and RA in this 
population of neurons (Jacobs et al. 2011).  
These data show that in the mammalian system, PITX3, as well as NURR1, is an important 
regulator which is involved in the terminal differentiation, survival and maintenance of 
dopaminergic neurons. The PITX3 network is summarised in Figure 17. 
 
 
Figure 17. Summary of PITX3 network. This figure summarises the known activators, inhibitors and downstream 
targets of PITX3. Arrows represent an activation effect, blunt headed arrows represent an inhibitory effect and 
double headed arrows indicate a feedforward loop where a positive interaction has been identified in both 
directions.  
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Altered expression levels of PITX3 have been associated with PD (H. Liu et al. 2012). This 
study measured the expression levels of PITX3 and NURR1 in peripheral blood lymphocytes 
of a cohort of over 250 Chinese PD sufferers and over 200 healthy controls. A significant 
decrease in the expression levels of both of these markers was detected in PD patients. 
A number of SNPs in PITX3 have been identified and their association with PD been 
investigated. In 2014, a meta-analysis was published which investigated the association 
between the three most commonly reported PITX3 polymorphisms and PD (Jiménez-Jiménez 
et al. 2014). The meta-analysis did not find any of these polymorphisms to be significantly 
associated with LOPD, however a significant association between two of the polymorphisms 
and EOPD in Caucasians was revealed (Jiménez-Jiménez et al. 2014). 
Four further polymorphisms were mentioned in this study, these were not included in the 
meta-analysis as they have only been investigated by two groups or fewer. Three of these 
polymorphisms were not determined to be associated with PD by these studies, however, 
the fourth polymorphism, C219>A, was determined to have an OR of 5.01 (p<0.001) in 
Chinese population (Gui et al. 2012). 
Moreover, the PDGene database (accessible at www.pdgene.org), recognises a number of 
polymorphisms which confer a significant risk (OR>1) or protective effect (OR<1) for PD in 
the PITX3 genetic locus, shown in Figure 18. PDGene is a comprehensive data database 
aiming to provide extensive information on genetic association results from the most recent 
and largest meta-analyses of GWAS (Nalls et al. 2014). The original database is described in 
Lill et al. (2012). The presence of these polymorphisms further suggests that PITX3 or the 
other genes present within this region may play a role in the development of PD. 
The other genes present within the PITX3-containing locus are NOLC1, ELOVL3 and GBF1. 
None of these genes have been previously associated with PD. Briefly, their functions are: 
NOLC1, synthesis of rRNA and the biosynthesis of ribosomes; ELOVL3, elongation of fatty 
acid chains; and, GBF1 is a guanine nucleotide exchange factor involved in vesicular 
trafficking. 
85 
 
 
Figure 18. Polymorphisms conferring a significant risk or protective effect for PD in the PITX3 genetic locus. A 
shows the genes within the genomic region surrounding PITX3 on chromosome 10. B shows all polymorphisms 
which confer a significant risk or protective effect for PD. From PDGene, accessed August 2015 (Lill et al. 2012; 
Nalls et al. 2014). Legend: within ethnicity, C = Caucasian. Allele contrast “x” vs “y”, “x” refers to the allele with a 
protective or risk effect and “y” denotes the reference allele with an OR of 1. 1000G, allele frequency data from 
the 1000 genomes project. CEU, Utah residents with European ancestry. CHB, Han Chinese in Beijing. JPT, Japanese 
in Tokyo. OR = Odds ratio. I2 = amount of heterogeneity between study-specific results that is beyond chance. CI 
= confidence interval. 
Aphakia, meaning absence of a lens, mice harbour a naturally occurring mutation in the 
promoter of Pitx3 (Semina et al. 2000). These mice demonstrate the progressive loss of 
dopaminergic neurons during development (Hwang et al. 2003). They also display motor 
impairments which can be ameliorated by levodopa (Van Den Munckhof et al. 2006). 
Additionally, these mice perform poorly in a number of cognitive tasks (Ardayfio et al. 2009). 
Taken together these finding show that aphakia mice display many symptoms that resemble 
those of PD. 
Other functions of PITX3 include eye development, this is indicated by the failure of lens 
development in Aphakia mice. These mice naturally developed this phenotype which was 
later attributed to the deletion of a region upstream of Pitx3 (Semina et al. 2000). In humans, 
mutations in Pitx3 have been shown to be responsible for autosomal dominant congenital 
cataracts, presence of lens opacity of varying severity at birth, and anterior segment 
dysgenesis, the failure of normal development of the anterior segment of the eye (Verdin et 
al. 2014). While the role PITX3 plays in lens development is not fully understood studies in 
Aphakia mice demonstrate that a loss of proliferation and increased apoptosis is identifiable 
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at an early age. Expression of crystallins is also altered and the differentiation of lens cells is 
abnormal (Medina-Martinez et al. 2009). These data show that proper expression of Pitx3 in 
the developing eye is critical for normal lens development. 
Pitx3 in zebrafish 
Zebrafish Pitx3 shares many similarities with human PITX3. Firstly, it shares 63% amino-acid 
similarity with human PITX3 (Figure 19A). Secondly, the genetic locus of zebrafish pitx3 (on 
chromosome 13) is syntenic to the region of human chromosome 10 which contains PITX3 
(Figure 19B). Thirdly the expression pattern of zebrafish resembles the expression pattern 
described by mammalian studies. That is, a high level of expression is present in the 
developing lens and brain (Shi et al. 2005). Shi and colleagues aimed to identify the conserved 
function of Pitx3 with respect to lens development in zebrafish. The authors found that the 
pitx3 morphant phenotype includes defects in eye development, reminiscent of the Aphakia 
mouse phenotype. pitx3-deficient zebrafish also exhibit loss of differentiated neurons in the 
retina. This suggests a novel function of Pitx3 in zebrafish (Shi et al. 2005). This study also 
hints towards a conserved role in zebrafish brain development. 
 
Figure 19. Protein homology and genetic locus synteny between human and zebrafish pitx3. A shows the protein 
homology between human, mouse, zebrafish and xenopus Pitx3. Green denotes conserved amino acids between 
all species and yellow denotes conservation between zebrafish and xenopus. The homeobox domain is shown in 
bold. Figure reproduced with permission from (Shi et al. 2005). B shows region synteny between the pitx3 
containing locus in humans and zebrafish. Zebrafish do not possess an orthologue of ELOVL3, however the 
orthologues of NOLC1 is also present on chromosome 13, 2.4Mb away from pitx3.  
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Although the development of the dopaminergic system is well studied in the mammalian 
system, it is not as well characterised in zebrafish. In zebrafish, Pitx3 and Nurr1 do not seem 
to have the same roles in the differentiation of dopaminergic neurons as no co-localisation 
of TH and Pitx3 or Nurr1 is detectable in the diencephalic dopaminergic neurons (Filippi et 
al. 2007). However, they seem to have conserved roles in the maintenance of neural 
progenitors. pitx3 knockdown by MO causes extensive, non-specific apoptosis in the 
zebrafish head and eye which can be ameliorated by concurrent knockdown of p53 (Filippi 
et al. 2007). Knockdown of zebrafish lmx1b orthologues causes a significant decrease in pitx3 
expression levels and a significant loss of dopaminergic neurons in both the diencephalon 
and the hindbrain. This suggests that Pitx3 and Lmx1b have some conserved roles in 
dopaminergic progenitor survival in zebrafish.  
Functions of miR-133b 
miR-133b is often referred to as a muscle-specific miRNA. Through interaction with a number 
of its targets it plays a role in myoblast differentiation, cardiomyocyte proliferation, cardiac 
hypertrophy and the cardiac conduction system. Moreover, dysregulation of miR-133b has 
been associated with a number of muscle diseases (Andrew H. Williams et al. 2009). 
miR-133b is thought to be transcribed in a bicistronic transcript with another “muscle-
specific” miRNA, miR-206. MyoD, a transcription factor which plays a role in the regulation 
of muscle differentiation, has been shown to activate transcription of the bicistronic 
miR-133b/miR-206 transcript (Rosenberg et al. 2006).  
miR-133b is now also recognised to have important roles other than those related to muscle 
(Kim et al. 2007; Chen et al. 2014; Guo et al. 2014). It has been suggested that miR-133b acts 
as a tumour suppressor and is downregulated in a number of cancers (Chen et al. 2014; Duan 
et al. 2013; Zhao et al. 2014). Significant downregulation of miR-133b was identified in 
colorectal cancer (Duan et al. 2013). This study validated CXCR4 as a direct target of miR-133b 
and suggests that downregulation of miR-133b releases CXCR4 from repression thus allowing 
it to promote tissue invasion and cancer-cell survival. In gastric cancer cell lines 
overexpression of miR-133b was able to inhibit metastasis. This metastatic-inhibition has 
been suggested to be through repression of a number of targets, including Gli1, FSCN1 and 
SP1 (Guo et al. 2014; Zhao et al. 2014; Qiu et al. 2014). 
As discussed above miR-133b has also been implicated in the regulation of development of 
dopaminergic neurons (Kim et al. 2007). A recent large meta-analysis of GWAS studies has 
identified a number of polymorphisms within the miR-133b containing genetic locus (Lill et 
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al. 2012; Nalls et al. 2014). However, the effect of these polymorphisms has not been 
functionally validated. 
 
Figure 20. Polymorphisms conferring a significant risk or protective effect for PD in the miR-133b containing 
genetic locus. A shows the genes within the genomic region surrounding miR-133b on chromosome 6. B shows all 
polymorphisms which confer a significant risk or protective effect for PD. From PDGene, accessed August 2015 
(Lill et al. 2012; Nalls et al. 2014). Legend: within ethnicity, C = Caucasian. Allele contrast “x” vs “y”, “x” refers to 
the allele with a protective or risk effect and “y” denotes the reference allele with an OR of 1. 1000G, allele 
frequency data from the 1000 genomes project. CEU, Utah residents with European ancestry. CHB, Han Chinese 
in Beijing. JPT, Japanese in Tokyo. OR = Odds ratio. I2 = amount of heterogeneity between study-specific results 
that is beyond chance. CI = confidence interval. 
In zebrafish, the function of miR-133b in muscle formation appears to be conserved. 
Disruption of miR-133b in zebrafish embryonic development interferes with sarcomeric actin 
organisation and a large number of muscle specific mRNAs were identified as direct targets 
of miR-133b (Mishima et al. 2009). Similar to the repressive role that miR-133b is thought to 
play in metastasis and cell survival in human cancer tissue, depletion of miR-133b in zebrafish 
has been shown to aid appendage and heart regeneration (Yin et al. 2008; Yin et al. 2012). 
The regeneration process may require some of the same pathways as cancer cells use to 
spread and invade. In contrast to the inhibitory function of miR-133b in fin regeneration 
miR-133b has been shown promote recovery of spinal cord injury in zebrafish (Yu et al. 2012). 
This difference in function is likely to reflect the differences in miRNA targets present in 
different tissues. In zebrafish miR-133b is upregulated after spinal cord injury, this is not the 
case in mammals, thus suggesting that the increased regenerative capacity of the zebrafish 
spinal cord compared to mammals may lie in the altered regulatory pathways that allow pro-
regenerative factors to be expressed after spinal cord injury (Yu et al. 2012). 
The function of miR-133b in regulation of dopaminergic phenotype also appears to be 
conserved in zebrafish. Work carried out by the Rodriguez group on addictive substances in 
zebrafish support the notion that pitx3 is a target of miR-133b in zebrafish (Simon-Sanchez 
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et al. 2009; Barreto-Valer et al. 2012). In their study treatment of zebrafish embryos with 
cocaine or morphine resulted in an increase in dopamine receptors and a decrease in 
miR-133b expression. To test the hypothesis that this occurs through the interaction of 
miR-133b with pitx3, 100pg of pitx3 3’UTR was injected into zebrafish embryos. If miR-133b 
is able to bind the pitx3 3’UTR one would expect the exogenous 3’UTR to bind all of the free 
miR-133b thus releasing endogenous pitx3 from repression. At 24 hours post injection of the 
pitx3 3’UTR the levels of miR-133b, pitx3 and Pitx3 targets th and dat were assessed by qPCR. 
Levels of free miR-133b were decreased and pitx3, th and dat were increased. This data 
suggests that miR-133b is able to interact with the 3’UTR of pitx3 in zebrafish.  
 
Figure 21. Possible mechanism of action of cocaine through miR-133b in zebrafish embryos. This figure 
summarises the findings of Barreto-Valer et al. They showed that exposure of zebrafish embryos to cocaine or 
microinjection of the 3’UTR of pitx3 resulted in a decrease in miR-133b levels and an increase in pitx3 and a number 
of its downstream targets: th, dat, drd2a and drd2b. This figure is reproduced from Barreto-Valer et al. (2012). 
 
In this chapter the role of miR-133b in dopaminergic neuron development in zebrafish will 
be investigated. I hypothesise that, through an interaction with pitx3, knockdown miR-133b 
will result in increased development of dopaminergic neurons which may be protective in 
zebrafish models of PD. 
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3.2 Characterisation of zebrafish miR-133b and pitx3 
In this section the homology of zebrafish miR-133b is explored and the expression patterns 
of miR-133b and pitx3 are determined. For an interaction between miR-133b and pitx3 to be 
possible they must share spatial and temporal expression. 
3.2.1 Optimisation 
3.2.1.1 WISH probe for pitx3 
The design principles of WISH probes are described in detail in section 2.10. As pitx3 is a 
relatively small gene consisting of only 4 exons a WISH probe for pitx3 was designed to target 
the whole protein coding region of the gene. Forward and reverse primers designed to 
amplify the whole coding region of gene tagged with the T7 or SP6 promoter respectively 
(Figure 22). From this PCR product an antisense and sense control probe can be transcribed. 
Staining developed within 3 hours using the antisense WISH probe transcribed from the PCR 
product described. Within the same time scale, WISH performed with the sense control 
probe did not produce any staining, therefore indicating that staining produced with the 
antisense probe is specific for pitx3. 
 
 
Figure 22. Design of a WISH probe for pitx3. The gene and cDNA sequence of pitx3 are shown in this schematic. 
The location of the primers which amplify a region of the cDNA are shown. The resulting PCR product is used as a 
template from which the WISH probe is transcribed. The location of the start and stop codons are noted. Orange 
represents UTR and blue represents the protein coding region. 
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3.2.2 Results 
3.2.2.1 miR-133b sequence is conserved in zebrafish 
miR-133b is highly conserved across a wide range of species (miR-Base and Ensembl). There 
is good homology between the human and zebrafish miR-133b sequences, over the whole 
coding region there is an 80% similarity over 100% of the zebrafish sequence (the human 
sequence is 35bp longer). The mature miRNA sequence of zebrafish miR-133b is 100% 
homologous to human miR-133b (Figure 23A and B).  
 
 
Figure 23. Conservation of miR-133b across species. A shows the sequence alignment of the whole miR-133b 
exon from human and zebrafish and B shows the mature miRNA sequences of human and zebrafish miR-133b. 
 
Another indicator of conserved function between orthologues is gene synteny in the 
genomic loci of the gene of interest. The genomic loci of human and zebrafish miR-133b was 
compared. Human miR-133b is present of chromosome 6 and zebrafish miR-133b is present 
on chromosome 20. The immediate region, within 10kb of miR-133b, in both humans and 
zebrafish is remarkably similar (Figure 24). Although the gene order is reversed, miR-133b is 
close to miR-206 in both species. In humans miR-206 is present approximately 4.5kb 
upstream of miR-133b and in zebrafish it is approximately 1.2kb downstream of miR-133b. 
In both humans and zebrafish miR-133b is present within the coding region of another gene, 
in humans this is annotated as LINCMD1, however in zebrafish this has not yet been 
annotated. In zebrafish, unlike in humans, miR-206 is also present within this gene. 
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Figure 24. Gene synteny in the region surrounding human and zebrafish miR-133b. This figure shows the genes 
present in the immediate region around miR-133b in humans and zebrafish. 
 
3.2.2.2 Expression and localisation of miR-133b 
In humans, miR-133b was determined to have specific expression in the midbrain (Kim et al. 
2007). To determine the miR-133b expression pattern in zebrafish WISH was performed. A 
LNA probe specific for miR-133b was used. As shown in Figure 25, miR-133b has strong 
expression in the somites and is also expressed in the developing lens and pharyngeal arches. 
Although the expression does not appear to be restricted to any specific region, miR-133b is 
expressed in the brain in zebrafish.  
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Figure 25. Spatial expression of miR-133b at 3dpf. This figure shows the spatial expression pattern of miR-133b 
at 3dpf, as determined by WISH. Staining is observed in the somites, pharyngeal arches, lens and the brain. 
 
3.2.2.3 Expression and localisation of pitx3 
For an interaction between miR-133b and pitx3 to be possible these genes must be co-
expressed. To determine whether miR-133b and pitx3 share spatial and temporal expression 
patterns, the expression of pitx3 was investigated by WISH at 3dpf and qPCR from 1-5dpf. As 
shown in Figure 26A, pitx3 has a very distinctive expression pattern. It is expressed in specific 
areas of the developing diencephalon and in the pharyngeal arches and lens. The qPCR data, 
shown in Figure 26B, show that the expression of pitx3 is relatively stable throughout 
embryonic and larval development. 
 
 
Figure 26. Expression and localisation of pitx3. A shows the spatial expression pattern of pitx3, as determined by 
WISH. Specific staining is observed in the diencephalon and lens. No staining was observed using a sense control 
probe. B shows the relative temporal expression pattern of pitx3 from 1-5 days post fertilisation, as determined 
by qPCR. Error bars represent standard deviation. 
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The data shown in Figure 25 and Figure 26A indicate that both pitx3 and miR-133b are 
expressed in the developing brain, lens and pharyngeal arches at 3dpf. Therefore, a direct 
physical interaction between these two genes is possible in these regions. 
3.3 Knockdown of miR-133b and effect on dopaminergic neurons 
In order to study the role of miR-133b in dopaminergic neuron development a MO was 
utilised to generate a transient knockdown of this miRNA. Once a knockdown had been 
validated the number of dopaminergic neurons present and miR-133b morphants was 
determined and compared to that of WT of control MO injected larvae. 
3.3.1 Optimisation 
3.3.1.1 Dosage optimisation of MO and validation of knockdown 
There are a range of binding sites within the pri-miRNA transcript to which MOs can be 
designed (see Materials and Methods Figure 12). For miR-133b the MO used targets the 
mature miR-133b sequence. This MO was previously used by Mishima and colleagues; as 
described in the supplementary material of their paper (2009). 
In order to assess the toxicity and optimise the dose of the miR-133b MO, it was injected at 
three different doses into one-cell stage embryos. These were: 0.9ng, 1.8ng and 3.6ng. 
Toxicity tests were performed by visual inspection of the embryos after injection; death rates 
were counted any deformities were noted. At the highest dose, 3.6ng of MO was not well 
tolerated. Embryos injected with this dose had a high death rate, approximately 50% of 
injected embryos 24 hours after injection. At 24hpf the surviving embryos displayed a severe 
developmental delay and gross deformities, including heart oedema, short curled tails and 
very small heads. At the two lower doses (0.9 and 1.8ng MO), the death rate was similar to 
control MO injected embryos; approximately 5-10%. Embryos injected with these doses 
display a mild developmental delay and have slightly smaller heads. However, these defects 
are very minimal and deemed acceptable. The highest tolerated dose, injection of 1.8ng of 
MO, was chosen; this was also the dose used by Mishima and colleagues. As the effects of 
MOs generally begin to wear off after 3dpf, the knockdown of miR-133b was assessed by 
qPCR at 3dpf. As shown in Figure 27, a knockdown of approximately 60% is achieved with 
this MO.  
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Figure 27. Knockdown of miR-133b using MO at 3dpf. A 60% knockdown of miR-133b after injection of MO is 
observed by qPCR. The data shown are from experiments using the chosen dose of MO, that is, 1.8ng miR-133b 
MO. miR-205 is used as reference gene. Error bars represent standard deviation. Data are analysed by an unpaired 
t-test with Welch’s correction, *** = p<0.001. 
 
3.3.2 Results 
3.3.2.1 Effect of miR-133b knockdown on dopaminergic neurons in WTs 
PITX3 has been shown to be a direct target of miR-133b in both mice and humans (Kim et al. 
2007), and therefore it was hypothesised that miR-133b knockdown will increase the level 
of Pitx3 protein in zebrafish embryos. As Pitx3 is thought to play a role in development of the 
dopaminergic system the effect of miR-133b knockdown on the zebrafish dopaminergic 
neuron population was investigated. Firstly, mRNA levels of th were assessed by qPCR in both 
WTs and miR-133b morphants. qPCR analysis demonstrated approximately a 40% increase 
in th mRNA level. These data, displayed in Figure 28 show that there was a trend towards an 
increase in th expression; however, this was not significant. 
 
 
Figure 28. The effect of miR-133b knockdown on th mRNA levels. A 40% increase in th mRNA levels after 
knockdown of miR-133b is observed by qPCR. This is not statistically significant, p>0.05. These data are from 3 
biological replicates. Data is analysed by an unpaired t-test with Welch’s correction. 
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In order to further investigate the effect of miR-133b knockdown on the th+ dopaminergic 
neurons, WISH for th was performed and th+ dopaminergic neurons were counted in WT 
zebrafish injected with either miR-133b MO or a control MO. This experiment revealed a 
significant increase in the number of th+ dopaminergic neurons in the miR-133b knockdown 
embryos compared to the control MO injected embryos. 
 
Figure 29. miR-133b knockdown results in an increase of th+ dopaminergic neurons at 3dpf. A shows a 
representative image of the th+ dopaminergic neurons in both control MO and miR-133b MO injected embryos. 
Scale bar = 100µm. B shows the quantified number of th+ dopaminergic neurons normalised to control MO 
injected, an increase of 20% is observed in miR-133b MO injected embryos. Error bars represent standard 
deviation. These data are from three biological replicates. In each biological replicate the number of dopaminergic 
neurons is counted in 20 embryos and the average taken. Data are analysed with an unpaired t-test with Welch’s 
correction. * = p<0.05. On axis labels, DA = dopaminergic. 
To confirm that the control MO does not cause a decrease in dopaminergic neurons itself, 
hence falsifying the increase in dopaminergic neurons seen with the miR-133b MO, th+ 
neuron counts were compared between WTs and control MO injected embryos. The result 
of this analysis is shown in Figure 30. No change in neuron number is observed, therefore, 
for all future experiments miR-133b MO injected embryos are compared to WT uninjected 
embryos rather than a control MO.  
 
Figure 30. Dopaminergic neuron number in uninjected and control MO injected embryos. These data are from 
three biological replicates. In each biological replicate the number of dopaminergic neurons is counted in 20 
embryos and the average taken. The data shown is normalised to uninjected. There is no significant difference in 
the neuron number between these two groups. Error bars represent standard deviation. On axis label DA = 
dopaminergic. 
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3.3.2.2 miR-133b knockdown is able to rescue dopaminergic neuron loss in pink1-/- 
zebrafish 
Knockdown of miR-133b significantly increases numbers of th+ dopaminergic neurons in WT 
zebrafish. It was hypothesised that this knockdown would be able to rescue the 
dopaminergic neuron loss observed in a previously established pink1-/- zebrafish model of PD 
(Flinn et al. 2013).  
Knockdown of miR-133b in pink1-/- embryos was able to rescue the loss of dopaminergic 
neurons observed in uninjected pink1-/- embryos. There is no significant difference in the 
number of dopaminergic neurons between the pink1-/- with a miR-133b knockdown and WT 
uninjected embryos. This suggests that loss of miR-133b may have protective effect in a 
zebrafish model of PD. 
 
 
Figure 31. Knockdown of miR-133b in pink1-/- embryos rescues th+ dopaminergic neuronal loss. A shows 
representative images of the th+ dopaminergic neurons in injected and uninjected WT and pink1-/- embryos. Scale 
bar = 100µm. B shows the quantified number of th+ dopaminergic neurons normalised to WT uninjected. A 
decrease of 15% is observed in pink1-/- embryos, this decrease is completely rescued by miR-133b MO injection 
into pink1-/- embryos. Error bars represent standard deviation. These data are from five biological replicates. In 
each biological replicate the number of dopaminergic neurons is counted in 20 embryos and the average taken.  
Data are analysed with a 2-way ANOVA with Tukey post-tests. * = p<0.05, ** = p<0.01. On axis labels, DA = 
dopaminergic. 
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3.3.2.3 miR-133b knockdown is unable to rescue dopaminergic neuron loss caused by 
MPP+ exposure 
As miR-133b knockdown is able to rescue the dopaminergic neuron loss seen in a genetic 
zebrafish model of PD, it was investigated whether this knockdown would be able to rescue 
the dopaminergic neuron loss caused by toxin exposure. For these experiments the toxic 
metabolite of MPTP, MPP+, is used as it has previously been shown to be a more potent toxin 
in zebrafish. This is thought to be due to the low levels of monoamine oxidase activity in the 
larval zebrafish brain which may limit conversion of MPTP to MPP+ (Sallinen et al. 2009). It 
has been previously demonstrated that treatment with 3mM MPP+ for 24hrs causes a loss 
of th+ dopaminergic neurons (Bretaud et al. 2004). In this study, under the same condition, 
a similar decrease of th+ dopaminergic neurons was observed after MPP+ treatment. In WT 
embryos, MPP+ treatment resulted in a 17% decrease in th+ dopaminergic neuron number. 
Although miR-133b knockdown is able to rescue the decrease in dopaminergic neuron 
number caused by pink1-deficiency, it is unable to rescue neuronal loss caused by MPP+ 
exposure.  
 
 
Figure 32. Knockdown of miR-133b in MPP+ treated zebrafish is unable to rescue th+ dopaminergic neuronal 
loss. A shows representative images of the th+ dopaminergic neurons in injected and uninjected, treated and 
untreated embryos. Scale bar = 100µm. B shows the quantified number of th+ dopaminergic neurons normalised 
to WT uninjected. In uninjected embryos a decrease of 17% is observed in MPP+ treated embryos. In injected 
embryos there is nearly a 30% decrease in th+ dopaminergic neuron number in the MPP+ treated group, this is 
due to the increase in neuron number in the injected untreated group. Error bars represent standard deviation. 
These data are from three biological replicates. In each biological replicate the number of dopaminergic neurons 
is counted in 20 embryos and the average taken.  Data are analysed with a 2-way ANOVA with Tukey post-tests, 
* = p<0.05 ** = p<0.01. On axis labels, DA = dopaminergic. 
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3.3.2.4 miR-133b knockdown results in an increase in th+ neurons at 48hpf but not 
36hpf 
All previous experiments examining the effect of miR-133b knockdown on th+ dopaminergic 
neuron number have been performed at 3dpf. In order to determine at what age an increase 
in dopaminergic neuron number is detectable, embryos were injected with miR-133b MO 
and subsequently fixed at 24hpf, 36hpf and 48hpf. WISH for th was performed on these 
embryos and the neurons were counted. The 24hpf time point was excluded for technical 
reasons. At this age, the head is small and difficult mount without also including some yolk 
cells, these yolk cells obscure the view of the stained neurons. Also, there is a large variation 
in head size in the miR-133b morphants at this age. Neurons were counted in 36hpf and 
48hpf embryos.  
 
Figure 33. The effect of miR-133b knockdown on number of th+ dopaminergic neurons at 36 and 48hpf. A shows 
representative images of the th+ dopaminergic neurons in both uninjected and miR-133b MO injected embryos at 
36 and 48hpf. Scale bar = 100µm. B and C show the quantified number of th+ dopaminergic neurons normalised 
to uninjected at 36hpf and 48hpf respectively. There is no change in neuron number between the two groups at 
36hpf however at 48hpf a significant increase of 17% is observed in miR-133b MO injected embryos. Error bars 
represent standard deviation. These data are from three biological replicates. In each biological replicate the 
number of dopaminergic neurons is counted in 20 embryos and the average taken. Data are analysed with an 
unpaired t-test with Welch’s correction. ** = p<0.01. On axis labels, DA = dopaminergic. 
 
At 36hpf there is a slight, but non-significant, decrease in dopaminergic th+ dopaminergic 
neuron number in miR-133b morphants (Figure 33A, and B), this is likely to be due to the 
variability in head size and slight developmental delay that these morphants demonstrate. 
At 48hpf there is a significant increase in neuron number between the two groups (Figure 
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33A and C). This suggests that proliferation or maturation of these neurons occurs between 
36 and 48hpf and that miR-133b knockdown has an effect on this process. 
3.3.2.5 Validation of th+ dopaminergic count using a the ETvmat2:GFP reporter line 
To validate the observed neuron increase in miR-133b morphants, as measured by neuron 
WISH for th a second marker of the dopaminergic neuron population was used. The 
ETvmat2:GFP fluorescent reporter line expresses GFP in all vmat2 expressing cells. Vmat2 
transports monoaminergic neurotransmitters, including dopamine, from the cytoplasm to 
the synapses and is therefore expressed in monoaminergic neurons. In Chapter 6 the 
expression of GFP in th+ dopaminergic neurons in the ETvmat2:GFP reporter line was 
validated (Figure 83). To determine whether the observed neuron increase can also be 
detected using this reporter line, thus using a second marker to validate this finding, 
miR-133b MO was injected into ETvmat2:GFP embryos. The method for measuring 
dopaminergic neuron number using this line is discussed in detail in Chapter 6 section 
6.2.1.2. Briefly, in this reporter line all monoaminergic neurons, including the th+ 
dopaminergic neurons are labelled by GFP therefore is possible to approximate neuron 
number by analysing the fluorescence intensity of the GFP in the diencephalic 
catecholaminergic cluster. A significant increase in fluorescence intensity (40%, p<0.01) was 
detected in miR-133b morphants compared to WT embryos (see Chapter 6, section 6.2.2.1 
and Figure 85).  
3.4 Overexpressing miR-133b  
In order to assess whether overexpressing miR-133b has any effects on dopaminergic 
neurons through further repression of its target genes, a synthetic mimic of miR-133b was 
injected into the embryos. To validate the upregulation of miR-133b using this synthetic 
mimic, miRNA levels were assessed both spatially and temporally. Subsequently, to 
determine whether the upregulation of miR-133b has any negative effects on dopaminergic 
neurons, these neurons were counted after WISH for th.  
3.4.1 Optimisation 
3.4.1.1 Initial dosage optimisation 
A synthetic mimic of miR-133b was injected into one-cell stage zebrafish embryos. The 
dosage was optimised by first injecting different concentrations of the mimic at the one cell 
stage and assessing toxicity. Overexpression of the mimic was assessed by qPCR. 1nl of each 
10, 20, 40 and 60μM mimic was injected into one cell stage embryos. Both 10 and 20μM 
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doses were well tolerated by the embryos. Significantly increased death rates were observed 
in embryos injected with 40 or 60μM, therefore the highest tolerated dose, 20μM, was 
chosen for further experiments. The expression levels of miR-133b were assessed by qPCR 
from at 1, 2 and 3 days post fertilisation (Figure 34) 
 
 
Figure 34. miR-133b levels after miRNA mimic injection. miR-133b mimic was injected into the yolk of one-cell 
stage embryos and the expression of miR-133b was assessed by qPCR at 1, 2 and 3dpf. Data are from two 
biological replicates. Error bars represent standard deviation. 
 
Despite the large initial upregulation of miR-133b, just over 4 times the endogenous levels 
of miR-133b, the upregulation is reduced at 2dpf and no upregulation is observed at 3dpf. In 
order to combat this problem and to ensure increased levels of miR-133b in the brain, 
another dose of miR-133b mimic was injected into the ventricles at 1dpf.  
3.4.1.2 Optimisation of ventricle-injection technique and dosage of mimic 
To ensure that ventricle injections were successful and do not damage the embryo, a 
fluorescent construct which has been shown not to leak out of the ventricles was injected 
(Gutzman & Sive 2009); the embryos were imaged three hours later to check the injection 
had been successful. Figure 35 shows a 1dpf embryo with 70,000KDa FITC dextran injected 
into the ventricles, imaged 3 hours after injection. The ventricles are clearly defined from 
both the dorsal and lateral view. The survival rate of injected embryos up to 3dpf was close 
to 100%. These data show that ventricle injections were successful and did not cause damage 
to the embryo. In order to prevent leakage of the injected solution the embryos that were 
to be injected were mounted in 0.8% LMP agarose before injecting. The lack of movement 
of fluid around the injection site prevented leakage of the solution giving better 
overexpression of the miRNA.  
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Figure 35. FITC dextran injections into zebrafish ventricles. 70000kDa FITC dextran was injected into the 
ventricles of a 1dpf zebrafish embryo. The injected embryos were imaged 3 hours post injection. The FITC-dextran 
clearly labels the ventricles in both the dorsal (top) and lateral (bottom) views. Scale bar = 500μm. 
Next, dosage of the mimic to be injected into the ventricles at 1dpf was optimised. Doses of 
1nl of 5, 10 and 20μM were tested. The lower two doses, 5μM and 10μM, were well 
tolerated, whereas death was increased in embryos injected with 20μM mimic. The higher 
tolerated dose of 10μM was used for ongoing experiments. The level of miR-133b was 
assessed at 1dpf, 1dpf + 3 hours after ventricle injection, 2dpf and 3dpf to quantify the 
increase in miR-133b levels. As shown in Figure 36, injection of the mimic into the ventricles 
on top of the initial injection allows the overexpression of miR-133b to persist at a high level 
until 2dpf. A 2fold increase of miR-133b is still present at 3dpf. 
 
Figure 36. miR-133b levels after injection of miRNA mimic into ventricles. The levels of miR-133b after injection 
with miR-133b mimic was assessed by qPCR. Injection of miR-133b mimic into zebrafish embryos at both the one-
cell stage and subsequently into the ventricles at 1dpf results in increased levels of miR-133b at 2dpf and 3dpf. 
1dpf and 2dpf data are from two biological replicates and 1dpf + 3 hours and 3dpf data are from one biological 
replicate. Error bars represent standard deviation. 
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3.4.2 Results 
3.4.2.1 Effect of miR-133b overexpression on dopaminergic neuron number 
After optimisation of the injection technique and qPCR confirmation that the levels of 
miR-133b are increased after injection of the miR-133b mimic, the number of th+ 
dopaminergic neurons at 2 and 3dpf was investigated. It was hypothesised that 
overexpression of miR-133b would cause further repression of target genes and result in a 
decrease in numbers of th+ dopaminergic neurons; however no change in neuron number 
was observed (Figure 37). 
 
 
Figure 37. Number of th+ dopaminergic neurons after miR-133b mimic injection. No change in th+ dopaminergic 
neuron number is observed at 2 or 3dpf in embryos injected with miR-133b mimic. Data is from 1 biological 
replicate with neuron counts performed on 10 embryos per group. Error bars represent standard deviation. On 
axis labels DA = dopaminergic. 
3.4.2.2 Localisation of miR-133b after injection of mimic 
Although the total levels of miR-133b are increased at 1-3dpf, as detected by qPCR, this does 
not confirm spatial location of the miRNA. In order to visualise the location of miR-133b after 
mimic injection, WISH was performed for miR-133b at 1, 2 and 3dpf (Figure 38). From 
observing the spatial location of miR-133b after mimic injection, there is no obvious increase 
in miR-133b in the brain at any age. At 1dpf and 2dpf, slightly darker staining can be seen in 
the tail region. At 2dpf slightly darker staining can be seen in the head of injected embryos. 
At 3dpf no difference in staining levels is obvious. Although by qPCR an increase in miR-133b 
levels was observed, the localisation of the miRNA doesn’t seem to be in the appropriate 
regions at an early enough age to cause further repression of the target genes. 
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Figure 38. Localisation of miR-133b after miR-133b mimic injection. Localisation of miR-133b was assessed by 
WISH. The right panel shows embryos which are injected with 20μM mimic at the one-cell stage and 10μM mimic 
into the ventricles at 1dpf. The left panel shows uninjected embryos. A shows miR-133b staining at 1dpf. The 
staining intensity in the tail is slightly increased however only a very slight change in intensity can be seen in the 
head. B shows 2dpf embryos. In these embryos slightly darker staining can be seen in the head and tail regions. C 
shows a dorsal and lateral view of 3dpf embryo. No change in staining can be seen in these embryos. 
 
3.5 Effect of miR-133b knockdown on pitx3/Pitx3  
PITX3 has been identified as a target of miR-133b in humans and mice (Kim et al. 2007). 
Although the site is not predicted by the miRNA target prediction database TargetScanFish 
(Release 6.2, June 2012), the miRanda algorithm suggests that miR-133b does have binding 
site in the 3’UTR of zebrafish pitx3 (as made available in the miR_Targets database at: 
http://mamsap.it.deakin.edu.au/~amitkuma/mirna_targetsnew/find_mirna.html (Kumar et 
al. 2012)). Moreover, research performed Rodriguez group strongly suggests that this 
interaction is conserved in zebrafish (Sanchez-Simon et al. 2010). To confirm their result and 
to assess the interaction in miR-133b morphant zebrafish, three methods were used to 
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determine whether miR-133b is able to regulate pitx3. These were: qPCR to assess pitx3 
mRNA levels, a reporter plasmid to elucidate whether the interaction is direct and to 
determine the binding site of miR-133b in the 3’UTR of pitx3, and western blotting to assess 
Pitx3 protein levels. 
If the validation of an interaction using the reporter plasmid is successful it is possible to 
validate the binding site by directed mutation of the predicted binding site. To determine 
which region of the pitx3 3’UTR may be a potential binding site of miR-133b, alignment of 
the miR-133b binding site in human PITX3 with the zebrafish pitx3 3’UTR was performed 
using Clustal Omega to identify a region similar to the validated binding sites in the 3’UTR of 
human in the zebrafish pitx3 3’UTR. 
 
Figure 39. A potential miR-133b binding site in zebrafish pitx3 3’UTR. The left panel shows the validated 
interaction between human miR-133b and the 3’UTR of PITX3 (Kim et al. 2007). The right panel shows a potential 
binding site for miR-133b in the 3’UTR of pitx3 in zebrafish. The seed region of miR-133b is highlighted in both 
cases. 
 
3.5.1 Optimisation 
3.5.1.1 Validation of reporter plasmid method using control plasmid 
Another method of determining direct targets of miRNA is to place a fluorescent reporter 
under the control of the 3’UTR of the gene of interest. This technique is described in detail 
by Mishima and colleagues who identified a number targets of miR-133 and miR-1 important 
for the regulation of sarcomeric actin organisation (Mishima et al. 2009).  
To validate the reporter plasmid method, a control construct was tested. This dual reporter 
plasmid containing RFP under the control of a mock 3’UTR containing two perfect miR-133b 
binding sites and GFP with no 3’UTR as a control was kindly provided by Professor Giraldez. 
A plasmid map of this construct is shown in Figure 40A.  
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Figure 40. Dual reporter plasmid maps. A shows a map of the control plasmid containing 2 perfect target sites 
for miR-133b (miR-133b PTx2) downstream of RFP. B shows the sequence of this region and the target sites. C 
shows a map of the dual reporter plasmid with the pitx3 3’UTR downstream of RFP. GFP is not under the control 
of any 3’UTR and is included as a control. 
 
The control plasmid was injected into one-cell stage zebrafish embryos. In some cells the 
plasmid will be incorporated into the genome. In these cells and descendants of these cells, 
GFP will be expressed freely as there are no regulatory sequences downstream of it. In miR-
133b containing cells RFP will be repressed as miR-133b will bind to the binding sites present 
in the 3’UTR downstream of RFP. As these binding sites have perfect complementarity this 
repression is likely to be via mRNA cleavage. When miR-133b is knocked down by co-injection 
of the miR-133b MO, RFP will be freed from repression and therefore plasmid-containing 
cells will display both green and red fluorescence (as shown in Figure 41). To quantify the 
effect of repression of RFP by miR-133b, GFP and RFP fluorescence was measured in muscle 
fibres. As miR-133b is strongly expressed in muscle the repressive effect of miR-133b is 
evident in this tissue (Figure 41A). To quantify this data the ratio between GFP and RFP 
fluorescence intensity can be measured. GFP acts as a loading control and is expressed freely 
in all cells containing the plasmid. To do this GFP positive muscle fibres are identified, i.e. the 
muscle fibres which contain the reporter plasmid. In these cells the fluorescence intensity of 
both GFP and RFP is measured (Figure 41B). 
As there is no difference between the no MO group and the control MO group for 
subsequent experiments using this technique, the control MO was not used. The increase in 
RFP/GFP fluorescence in the miR-133b MO injected group shows that this technique is 
working as expected. 
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Figure 41. GFP and RFP fluorescence with control reporter plasmid. A White arrows indicate muscle fibres 
expressing the reporter plasmid. Asterisks indicate non-muscle cells. In the top two panels the muscle fibres which 
express GFP do not express any RFP. In the bottom panel where miR-133b is knocked down RFP repression is 
released and RFP can be detected in the muscle fibres which express the reporter plasmid. Scale bar = 100μm. B 
shows quantification of RFP and GFP expression, expressed as RFP/GFP fluorescence intensity in the muscle fibres. 
Scale bars represent standard deviation. Data are from three biological replicates. For each biological repeat 
images from 10 injected embryos were analysed. Data were analysed by one was ANOVA with Bonferroni post-
tests. ** = p<0.001. 
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3.5.1.2 Western blotting 
Currently there are no commercially available antibodies designed to detect zebrafish Pitx3. 
However, one commercially available antibody was identified which was raised against a 
portion of human PITX3 with high homology to zebrafish Pitx3. This antibody was tested.  
Morpholinos for pitx3 
In order to test the specificity of antibodies for Pitx3, pitx3 knockdowns were generated using 
MOs. Two MOs were designed for pitx3. Before purchasing the MOs, the sequence of the 
target was confirmed using direct sequencing to confirm that no SNPs are present which may 
prevent MO binding. A BLAST search of the MO sequence against the zebrafish genome was 
also performed to ensure specificity for pitx3. The target sites of these MOs are marked in 
Figure 42A. The first MO is a start site MO (SS MO) which is expected to prevent translation 
of Pitx3 but will not cause any change to the mRNA. The second MO is a splice blocker 
targeting the exon2-intron2 boundary (e2i2 MO). This is predicted to cause an exon skip of 
exon2. As the start site of Pitx3 is present in exon2 this would cause a complete loss of 
protein if exon2 was deleted. The effect of this MO can be assayed by RT-PCR. The primers 
used to assay this potential deletion are shown in Figure 42B. Figure 42C shows a RT-PCR gel 
analysing the effect of the e2i2 MO. Although there is a band at a lower weight than the WT 
transcript, indicating an exon skip transcript, the e2i2 MO does not cause complete loss of 
the wild type transcript; therefore this MO is unlikely to cause a complete loss of Pitx3 
protein.  
Each MO was injected at a range of concentrations to determine the highest tolerated dose 
of the MO. Either 2ng of the SS MO or 4ng of the e2i2 MO was injected into the embryos that 
were subsequently used for western blotting. These concentrations were chosen as the 
highest tolerated dose out of a range of 3 doses previously tested. 
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Figure 42. MOs targeting pitx3. A shows a schematic of un-spliced pitx3 mRNA and the position of the start site 
MO (SS MO) and the exon1-intron2 splice blocking MO (e2i2 MO). The e2i2 MO is predicted to cause a deletion of 
exon2 (which contains the start site of pitx3). The SS MO should prevent translation of Pitx3 but does not alter the 
splicing of the mRNA. The location of the start and stop codons are noted. Orange represents UTR and blue 
represents the protein coding region. B shows the pitx3 cDNA and the location of the primers used to assay the 
effect of e2i2 MO. C shows an RT-PCR gel analysing the effect of the e2i2 MO on the pitx3 transcript. 
 
Testing of a commercially available antibody for Pitx3 
An antibody designed to human PITX3 with an epitope with 84% similarity to zebrafish, 
produced by Abcam, was identified. Although the exact epitope of this antibody is not 
known, it is within the N-terminal region of PITX3. This antibody was tested in zebrafish using 
the conditions recommended by the manufacturer. To determine whether this antibody can 
recognise zebrafish Pitx3 protein lysates from both WT embryos and embryos which had 
been injected with the SS MO, were used. If the antibody can recognise zebrafish Pitx3 a 
band at approximately 32kDa should be detectable in the WT samples but absent in the 
morphant samples.  
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Figure 43. Testing of Abcam Pitx3 antibody. A shows the western blot using the Abcam antibody for Pitx3 on 
protein samples from WT and SS MO injected embryos. The region around 32kDa, the weight of zebrafish Pitx3, 
is highlighted in red and repeated below the main blot. Tubulin was used as a loading control. B shows a summary 
of the results of a BLAST search comparing the N-terminal region of human PITX3, where the epitope of this 
antibody is located, to the zebrafish proteome. The alignments of the top three results are shown. Grey amino 
acids are perfect matches and red amino acids are similar to corresponding amino acid in the human sequence. C 
shows a table summarising the top three results from this BLAST search. The molecular weights (MW) of these 
proteins are also shown.  
 
As shown in Figure 43A although this antibody does detect a band at 32kDa (indicated by a 
red arrow) this is also present in samples from MO-injected embryos, thus this band is not 
Pitx3. Interestingly, there is a large band at 37kDa (indicated by a black arrow) which 
increases in intensity with MO injection. This suggests it is a protein which is upregulated 
when Pitx3 is knocked down. To investigate whether this antibody can recognise any other 
zebrafish proteins a BLAST (NCBI) search was performed comparing the N-terminal region of 
human PITX3 to the zebrafish proteome. The alignments of the top three results, Pitx3, Pitx2 
and Pitx1, are shown in Figure 43B. These alignment results, and the molecular weights of 
these proteins are shown in Figure 43C. These results show that it is possible that the large 
band at 37kDa corresponds to Pitx2, which may be being upregulated to compensate for 
Pitx3 knockdown, and the band at 32kDa corresponds to Pitx1. 
As this antibody does not appear be specific to zebrafish Pitx3, a custom antibody for 
zebrafish Pitx3 was commissioned from Eurogentec (Seraing, Belgium).  
Design and production of a custom Pitx3 antibody 
Two 15-amino acid epitopes, unique to zebrafish Pitx3, assessed by local alignment against 
the zebrafish proteome, using BLAST (NCBI) were chosen. Pitx3 is a small protein with a large 
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homeodomain which is present in many other zebrafish proteins of similar sizes. The most 
unique region of zebrafish Pitx3 is at the N-terminal end. Peptides corresponding to aa15-30 
and aa30-45 of Pitx3 were chosen as the epitopes to raise the antibodies against. The 
antibodies provided were rabbit polyclonal antibodies which had been affinity purified using 
the original epitope. In order to successfully use the custom antibody to quantify levels of 
zebrafish Pitx3, these antibodies first had to be carefully tested to validate their specificity 
for Pitx3. The two antibodies will be referred to as ab164, raised against a peptide 
corresponding to aa15-30 of zebrafish Pitx3 and ab165, raised against a peptide 
corresponding to aa30-45. 
Characterisation of custom Pitx3 antibodies - determining optimal working conditions 
To determine the optimal working conditions of these antibodies they were first tested at a 
range of antibody concentrations and subsequently different incubation times. From the 
initial optimisation experiment the more promising of the two antibodies was chosen to 
develop further.  
Figure 44 shows the first optimisation experiment testing a range of antibody concentrations 
of both ab164 and ab165. From this initial experiment, antibody ab164 seemed the more 
promising candidate as a band could be identified at around 32kDa (indicated by an arrow in 
Figure 44A). All subsequent experiments were carried out with this antibody only. The 
chosen working concentration of the antibody for subsequent experiments was 1:100.  
 
Figure 44. Initial testing of custom antibodies for Pitx3. A western blot was performed using a range of dilutions 
of the custom antibodies for Pitx3 to determine whether they are able to recognise this protein. Protein lysates 
were from de-yolked 3dpf zebrafish. A shows blots testing ab164 at a range of antibody concentrations. The 
bottom panel shows the lower portion of the membrane developed for longer to reveal weaker bands. The arrow 
indicates a band at the expected MW of Pitx3 (32kDa). B shows blots testing ab165 at a range of antibody 
concentrations. No further bands could be detected by developing the membrane for longer and no bands were 
detected at around 32kDa. 
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Next, the optimal incubation time of this antibody was tested. Incubating the antibody with 
the membrane overnight at 4oC produced a stronger and cleaner signal (Figure 45). A range 
of bands can been seen on this membrane close to 37kDa. To identify which of these bands 
is Pitx3 further testing of the antibody specificity was performed. 
 
Figure 45. Optimisation of antibody incubation time. Membranes were incubated with ab164 for either 2hours 
at room temperature or overnight at 4oC to determine optimum incubation conditions. A range of concentrations 
of protein were loaded on the gel. A shows a blot where ab164 is incubated with the membrane for 2 hours at 
room temperature. B shows a blot where ab164 is incubated with the membrane overnight at 4oC. 
 
Characterisation of custom Pitx3 antibody ab164 – validating specificity for Pitx3 
Once the optimal concentration and incubation time with this antibody had been 
established, the specificity of the signal was then tested. To do this, a range of control blots 
were performed and compared against the use of the Pitx3 antibody (ab164). These controls 
are, incubation of the membrane with: primary antibody only; blocked antibody (and 
subsequently secondary antibody), this control involved pre-incubation of the Pitx3 antibody 
with the peptide it was raised to; and, pre-immune serum. Pre-immune serum is serum taken 
from the rabbit before it was immunised with the Pitx3 peptide, therefore it will not contain 
any antibodies specific for zebrafish Pitx3. An appropriate concentration of the pre-immune 
serum was chosen by first performing a dot blot using a range of concentrations of the serum 
to determine which gave a similar level of signal to the primary antibody. Any bands present 
on these control blots are not specific to zebrafish Pitx3. These control blots are shown in 
(Figure 46A).  
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Figure 46. Antibody ab164 specifically detects a band at 32kDa. A range of controls were performed to determine 
the specificity of ab164 for zebrafish Pitx3. As Pitx3 is expressed in the brain of zebrafish embryos to enrich Pitx3 
within the protein sample, protein lysates were collected from heads only (B and C). In all blots the arrow indicates 
a band at 32kDa which is thought to be Pitx3. This band can only be observed in blots which are probed with both 
primary and secondary antibody and not in the control blots indicating that ab164 specifically detects this band. 
A and C show images of a collection of membranes which have been probed with primary antibody and secondary 
antibody, blocked primary antibody and secondary, primary antibody only (A only) and pre-immune serum and 
secondary antibody. These optimisation experiments are designed to examine the specificity of the bands 
observed. B shows a blot where protein samples from whole embryos and heads only are compared. For the blots 
in A protein samples from whole embryos are used; in C protein samples from heads only are used.  
 
The “no secondary” control and blocked antibody controls produced the expected results; 
no visible bands at all and vastly reduced intensity bands, respectively. However, in the pre-
immune serum control it is still possible to see the band around 37kDa which was previously 
thought to be Pitx3. Under closer inspection of the staining it is possible to see that there is 
a faint band below the 37kDa marker, marked with an arrow (Figure 46A). As Pitx3 is a 32kDa 
protein it is likely that this band is Pitx3.  
As Pitx3 is only expressed in the zebrafish brain, in order to enrich Pitx3 in the sample the 
western blot was performed with protein lysates from zebrafish heads only (Figure 46B). As 
expected, performing the western blot with protein from zebrafish heads only enriches the 
band at around 32kDa, indicated with an arrow, and reduces the intensity of the ‘non-
specific’ band at around 37kDa seen in the whole embryo lysates. As the sample was changed 
the previous experiment using blocked antibody and pre-immune serum was repeated 
(Figure 46C). The concentration of the peptide used to block the primary antibody was also 
increased to ensure complete blocking of the antibody. As shown in Figure 46C the strong 
band, indicated by an arrow, in the first panel is not present in the blocked antibody panel. 
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However, the other non-specific bands are present. When the membrane is incubated with 
pre-immune serum rather than primary antibody, a large non-specific band is present above 
37kDa; no other bands are clearly visible. These results are encouraging in that the indicated 
band at 32kDa is specific to the antibody and is likely to be Pitx3. 
To further validate that the observed band is Pitx3, two MOs targeting Pitx3 were injected 
into one-cell stage embryos, and the embryos were collected at 3dpf. Protein was extracted 
from the heads of these embryos only. As both of these MOs cause the embryos to have 
slightly smaller heads, protein from a larger number of heads of injected embryos were 
loaded compared to wild type.  
 
Figure 47. Antibody ab164 specifically detects zebrafish Pitx3. A western blot was performed using samples from 
WT embryos and pitx3 MO injected (both the start site (SS) and exon2-intron2 (e2i2) MOs were used) embryos 
which are expected to have reduced levels of Pitx3 protein. This blot show that the band of interest (indicated by 
an arrow) is present in the WT samples but is not present in samples from SS MO injected embryos and is reduced 
in e2i2 MO injected embryos. This indicates that the band of interest at 32kDa is Pitx3. Tubulin was used a loading 
control. 
The band of interest, indicated by an arrow, is not present in the SS MO samples and is 
reduced in the e2i2 MO samples (Figure 47B). These data show that this band is indeed Pitx3 
validating that this antibody is suitable for measuring Pitx3 protein levels in protein lysates 
from zebrafish embryos. In this section the method for performing western blots using this 
antibody has been optimised, this method will be continued for all experiments using this 
antibody. 
3.5.2 Results 
3.5.2.1 Assessment of pitx3 mRNA levels 
Firstly, the effect of miR-133b knockdown on pitx3 mRNA levels at 3dpf was assessed by 
qPCR (Figure 48). If miR-133b is able to downregulate pitx3 through mRNA cleavage or 
degradation, an increase in pitx3 mRNA level would be expected after knockdown of 
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miR-133b. These data show that there is no significant increase in the mRNA level, therefore 
if miR-133b is able to regulate pitx3 in zebrafish this is by translational repression. 
 
 
Figure 48. miR-133b knockdown does not increase pitx3 mRNA levels at 3dpf. pitx3 mRNA levels were assessed 
at 3dpf by qPCR. Knockdown of miR-133b has no effect of pitx3 mRNA levels at 3dpf. Error bars represent standard 
deviation. Data are from three biological replicates.  
 
3.5.2.2 Using a reporter plasmid to investigate the miR-133b-pitx3 3’UTR interaction 
As expected, the RFP/GFP ratio with the pitx3 reporter plasmid was similar to the control 
reporter plasmid when miR-133b is expressed at normal levels. This suggests that pitx3 is 
under repression by its 3’UTR. However, in the miR-133b knockdown group there was no 
change between the RFP/GFP fluorescence intensity (Figure 12). This suggests that either 
miR-133b is not able to bind to the 3’UTR of pitx3, or that in these cells other miRNAs are 
also repressing pitx3 and removal miR-133b is not enough to release pitx3 from repression.  
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Figure 49. Assessment of miR-133b-pitx3 interaction using reporter plasmid. A reporter plasmid containing RFP 
under the control of the 3’UTR of pitx3 was used to investigate the interaction of miR-133b and pitx3. RFP 
fluorescence did not increase in reporter plasmid containing cells after miR-133b knockdown. A White arrows 
indicate muscle fibres expressing the reporter plasmid. Asterisks indicate non-muscle cells. RFP is not expressed in 
muscle fibres containing the reporter plasmid in either group. Scale bar = 100μm. B shows quantification of RFP 
and GFP expression, expressed as RFP/GFP fluorescence intensity in the muscle fibres. Scale bars represent 
standard deviation. Data are from three biological replicates and analysed by an unpaired t-test with Welch’s 
correction, p>0.05. 
 
3.5.2.3 Assessment of Pitx3 protein levels 
As pitx3 mRNA levels are not increased in miR-133b morphants and the reporter plasmid 
data were inconclusive, the protein levels of Pitx3 were measured to determine whether 
miR-133b is able to regulate pitx3 at the translational level, the protein levels of Pitx3 were 
measured. Protein lysates were collected from the heads of wild type and miR-133b 
morphant embryos at 3dpf.  
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Figure 50. miR-133b knockdown does not increase Pitx3 protein levels at 3dpf. Western blotting was performed 
to investigate the protein levels of Pitx3 in miR-133b morphants and WTs at 3dpf. A decrease in protein levels was 
observed however this was not significant. A shows the western blot where Pitx3 protein levels are compared 
between lysates from WT and miR-133b MO injected embryos. Tubulin was used as a loading control. B shows a 
quantification of this western blot. Pitx3 protein levels are normalised to tubulin levels. Data are from three 
biological replicates and analysed by an unpaired t-test with Welch’s correction, p>0.05. 
 
Unexpectedly, this experiment shows that contrary to Pitx3 protein levels being increased in 
miR-133b morphant embryos they appear to be decreased. Although the decrease in Pitx3 
protein levels is not significant there is clearly a trend in this direction. These data show that 
miR-133b knockdown does not result in an increase in Pitx3 protein levels at this age. 
3.6 Effect of miR-133b knockdown on the proliferation of dopaminergic 
neurons 
In order to assess whether the increase number of neurons in the diencephalic 
catecholaminergic cluster is due to increased proliferation, an EdU exposure and staining 
experiment was performed. EdU is a thymine analogue and, when available, proliferating 
cells will incorporate EdU into the DNA during S-phase. Any cell which proliferates after EdU 
exposure is performed will be labelled. At the desired time point, the embryos are fixed and 
EdU labelling can be visualised. 
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3.6.1 Optimisation 
3.6.1.1 Detemining time points to use for EdU analysis 
To determine at which age the neurons in the diencephalic dopaminergic cluster are born, 
EdU was injected at a range of time points in the development of WT and miR-133b MO 
injected embryos. Embryos were fixed at 2dpf, as this is the earliest age where an increase 
in dopaminergic neurons has been detected. In this experiment the dopaminergic neurons 
were detected by IHC for TH or GFP (where the ETvmat2:GFP line was used).  
As shown in Figure 51 In embryos injected with EdU at 18, 24 and 30hpf, no or very little 
co-localisation was seen between EdU and GFP. In the embryos injected at 12hpf, the GFP+ 
neurons were very close to the EdU labelled cells, however, not all cells are labelled 
indicating that the dopaminergic neurons proliferate before and around 12hpf.  
 
 
Figure 51. EdU incorporation into proliferating neurons. To determine at what age dopaminergic neurons 
proliferate EdU is injected into the yolk of zebrafish embryos at 12, 18 and 30hpf. Embryos are fixed at 48hpf. IHC 
to label GFP+ cells is performed alongside staining for EdU. Representative single slices of injected embryos are 
shown. Scale bar = 100μm.  
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In order to further investigate the time at which these neurons are born, embryos were 
injected with EdU at 6, 8, 10 and 12hpf. Figure 52 shows the localisation of TH+ dopaminergic 
neurons and EdU incorporation. As TH is only present in the cytoplasm and EdU labels the 
nucleus, no direct overlap in staining is seen. However is it easy to identify where the EdU 
labels the nucleus of a TH+ cell. In embryos injected at 6, 8 and 10hpf, all the TH+ neurons 
are labelled with EdU, showing that these neurons were born after the point when the EdU 
was injected. In the embryos which are injected at 12hpf, some TH+ neurons were labelled 
with EdU and others were not, suggesting that a number of neurons proliferate between 10 
and 12 hours and some proliferate later.  
 
 
Figure 52. EdU incorporation into proliferating neurons in early development. To determine at what age 
dopaminergic neurons proliferate EdU is injected into the yolk of zebrafish embryos at 6, 8, 10 and 12hpf. Embryos 
are fixed at 48hpf. IHC to label TH+ cells is performed alongside staining for EdU. Representative single slices of 
injected embryos are shown. Arrows indicate TH+ cells which are not labelled by EdU, indicating these cells 
proliferated before EdU was injected. Scale bar = 100μm. 
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3.6.2 Results 
3.6.2.1 Comparison of proliferation between 12-48hpf in WT and miR-133b morphants 
EdU was injected into both WT and miR-133b MO injected embryos at the time points listed 
above. The staining in both groups was analysed in embryos injected at 12hpf to search for 
any differences in co-localisation of EdU and TH at these ages or if and drastic increase in 
proliferation is evident (Figure 53). In these images the increase in TH+ neurons in the 
miR-133b morphants is evident. In WT embryos it is possible to identify a small number of 
neurons that are TH+ but not stained by EdU. However, in the miR-133b morphants all TH+ 
are also labelled with EdU.  
 
Figure 53. EdU and TH in WT and miR-133b morphants. To examine proliferation of dopaminergic neurons in 
miR-133b morphants and WTs EdU is injected at 12hpf. Injected embryos were fixed at 48hpf. IHC to label TH+ 
cells is performed alongside EdU staining. Arrows indicate TH+ cells which are not labelled by EdU, indicating these 
cells proliferated before 12hpf. Two slices from representative embryos are shown. Scale bar = 100μm. 
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3.6.2.2 Comparison of proliferation between 12-13hpf in WT and miR-133b morphants 
To further investigate the proliferation at an age relevant to the proliferation of the TH+ 
neurons, EdU was injected at 12hpf then embryos were fixed 1 hour later. As TH is not 
detectable at this age, it was not possible to use this marker to identify which cells will 
become dopaminergic. A wish probe for neurogenin1, a marker of dopaminergic neural 
progenitors (Jeong et al. 2006) was tested. Although this probe worked well in older zebrafish 
embryos (Figure 54A), in the EdU injected embryos fixed at 13hpf, well defined fluorescence 
from this probe was not detectable and therefore it was not possible to identify neural 
progenitors. Also, as zebrafish embryos develop rapidly, even within the short EdU exposure 
time of 1 hour between 12 and 13hpf, a large number of cells were labelled (Figure 54B). 
Therefore, it was not possible to identify any increase in proliferation of an individual 
population of neurons.  
 
Figure 54. neurogenin1 WISH and EdU staining at 13hpf. A shows maximum projections image of a co-fluorescent 
WISH (for neurogenin1) and EdU staining experiment in 2dpf embryos. An image of a standard WISH experiment 
with the neurogenein1 probe is also shown for comparison. B shows maximum projections of EdU staining in 13hpf 
WT and miR-133b MO injected embryos. Scale bars = 100μm. 
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3.7 Discussion 
This study aimed to investigate the effect of miR-133b on development and survival of 
dopaminergic neurons in zebrafish. It was hypothesised that through its proposed target 
pitx3, knockdown of miR-133b would increase the number of dopaminergic neurons and 
protect against both endogenous (i.e. genetic) and exogenous (i.e. toxic) deleterious effects 
on dopaminergic neuron survival. 
Characterisation of miR-133b and pitx3 in zebrafish 
In order for miR-133b to regulate pitx3, these genes must be co-expressed. miR-133b 
appears to have diffuse expression within the brain. This is in contrast to human and mice 
studies which found that miR-133b was specifically expressed in the midbrain (Kim et al. 
2007). However, in this study expression was only analysed in adult samples, therefore it is 
possible that this spatial restriction only occurs later in life. Alternatively, this may reflect 
differences in neuron specification in zebrafish. 
Although performing WISH for miR-133b and pitx3 at 3dpf provides important information 
about the expression pattern of these genes and suggests that they are co-expressed in the 
zebrafish brain, it does not provide definitive proof that this is the case as the resolution of 
WISH images is not sufficient. Firstly, a control probe for miR-133b must be used to 
determine that the diffuse staining observed in the brain is specific for miR-133b rather than 
background staining. Secondly, in order to further investigate the co-expression of these 
genes a dual-fluorescence WISH could be performed. This experiment was attempted 
however was not successful. To increase the success of this experiment, sections of the 
zebrafish embryo brain could be made and WISH for miR-133b and pitx3 performed on 
alternate sections. Alternatively, the custom antibody for Pitx3 developed in this study could 
be tested in IHC applications and subsequently combined with fluorescent WISH for miR-
133b. 
Finally, as EdU experiments suggest that the proliferation of dopaminergic neurons occurs 
very early in development, it would be interesting to investigate the expression of both miR-
133b and pitx3 at these early time points. The expression of pitx3 was assessed by qPCR from 
1-5dpf indicating it is detectable at 1dpf, however investigating the spatial expression 
pattern would be more informative. 
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Knockdown of miR-133b and effect of dopaminergic neurons in WTs 
Prior to this study the effect of knockdown of miR-133b on the developing zebrafish embryo 
had not been investigated. Two previous publications have used MOs for miR-133b, however 
these were used to knockdown miR-133b in adult spinal cord injury only, or as a tool to 
investigate miR-133b targets in muscle. The chosen MO was able to produce a 60% 
knockdown of miR-133b at 3dpf and did not result in any obvious toxic off-target effects or 
significant deformity at the chosen dose. 
Knockdown of miR-133b resulted in an increase of th+ dopaminergic neurons in WT embryos. 
This increase in dopaminergic neuron number is likely to be due to the increase in 
development of these neurons rather than an increase in their survival as one would not 
expect any death of these neurons to have occurred by 3dpf in WT embryos. Therefore it is 
likely that targets of miR-133b, which are increased upon knockdown of this miRNA, are 
involved in the development of dopaminergic neurons.  
EdU exposures were performed to investigate whether the observed increase in the number 
dopaminergic neurons was through increased proliferation of neural progenitors. EdU was 
injected at a number of time points to identify a relevant age at which proliferation should 
be further studied. 12hpf was chosen as the most promising time point to study since some, 
but not all, TH+ dopaminergic neurons are labelled with EdU when EdU was injected in WTs 
at this age. This suggests that these neurons are beginning to proliferate during this stage of 
development. 
Injection of EdU at 12hpf was also performed in miR-133b morphants. In the morphant 
embryos analysed, no EdU-negative TH+ cells could be identified. This suggests that TH+ 
neurons proliferate slightly later in the morphants, perhaps due to a mild developmental 
delay. Only a small number of embryos were examined in this experiment, therefore to 
confirm these findings a larger number of embryos would need to be imaged and analysed. 
As EdU is present in the embryos for 36 hours between 12hpf, when the EdU is injected, and 
48hpf when the embryos are fixed, a large number of cells incorporate EdU. This means that 
it is very difficult to identify small increases in proliferation. 
To further investigate the proliferation occurring at around 12hpf, EdU was injected at 12hpf 
then embryos were fixed 1 hour later. This experiment only labeled cells which are 
proliferating within this 1 hour time-frame. As TH is not detectable at this age it was not 
possible to identify neurons of interest using this marker. A WISH probe for neurogenin1, a 
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marker of dopaminergic neural progenitors (Jeong et al. 2006) was tested. Although this 
probe worked well in older zebrafish embryos, in the EdU injected embryos fixed at 13hpf, 
well defined fluorescence from this probe was not detectable. Therefore it was not possible 
to identify neural progenitors. As zebrafish embryos develop rapidly, a large number of cells 
were labelled in this experiment; therefore it was not possible to identify any increase in 
proliferation of an individual population of neurons. 
In order to further investigate an increase in proliferation in the miR-133b morphants, WISH 
for proliferating cell nuclear antigen (PCNA) could be performed. PCNA is a marker of cell 
proliferation and can be used to identify proliferating cells at one particular time point. 
Alongside this, an antibody or fluorescent reporter line for neurogenin1 (McGraw et al. 
2008), or another marker of dopaminergic neural progenitors, could be used to identify and 
count the number of proliferating neural progenitors. Alternatively, if no increase in 
proliferation is detectable, it is possible that rather than more neurons being produced, a 
higher proportion of developing cells are differentiating to a dopaminergic phenotype. It 
would also be interesting to demonstrate whether the observed increase in neurons is 
exclusive to the th+ dopaminergic neurons in the diencephalic dopaminergic cluster. If a 
neuron increase is present in other related neuronal populations this could help elucidate at 
which stage in development an increase in proliferation or differentiation is occurring. 
Knockdown of miR-133b and effect of dopaminergic neurons in zebrafish models of 
PD 
The pink1-deficient zebrafish model of PD has been previously shown to exhibit 
approximately a 20% decrease in dopaminergic neurons at 3dpf. It is unknown whether pink1 
deficiency results in death of dopaminergic neurons or whether development of these 
neurons is impaired. Although a panel of developmental markers was examined in 
pink1-deficient embryos, these were only assessed at 24hpf which is later than when the 
majority of dopaminergic neurons develop (Flinn et al. 2013).  
If the decrease of dopaminergic neurons in pink1-deficient zebrafish is due to death of these 
neurons it is likely that the rescue effect of miR-133b knockdown is due to increased numbers 
of dopaminergic neurons developing initially. A small amount of neuronal death in the 
pink1-deficient miR-133b morphants would then result in the total number of dopaminergic 
neurons being similar to WT embryos at 3dpf. If the pink1-deficiency results in a 
developmental defect, miR-133b knockdown may ameliorate this developmental 
phenotype. This could be investigated by examining the expression of developmental 
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markers in early development. Investigations into the mechanism of dopaminergic neuron 
decrease in pink1-deficient embryos would help determine in what way miR-133b is 
protective to dopaminergic neurons, whether this is through increased development or 
increased survival. These studies would also help determine whether miR-133b knockdown 
may continue to be protective over the life of the zebrafish. By 18 months old pink1-deficient 
zebrafish demonstrate a 50% loss of dopaminergic neurons (Flinn et al. 2013). The effect of 
miR-133b on other features shown to be dysregulated in pink1-deficient zebrafish should 
also be examined. These include the effect on mitochondrial dysfunction and microglial 
count. As knockdown of tigarb, an inhibitor of glycolysis, was also shown to rescue 
dopaminergic neurons in pink1-deficient zebrafish (Flinn et al. 2013). Whether miR-133b is 
able to interact with the tigarb could also be investigated. 
Knockdown of miR-133b was not able to rescue the neuronal loss caused by the exposure of 
the embryos to MPP+. MPP+ and pink1 deficiency both result in inhibition of mitochondrial 
complex I (Flinn et al. 2013; Celardo et al. 2014). It has not yet been determined whether 
miR-133b knockdown has any effect on mitochondrial function. However, while pink1 
deficiency is chronic defect, MPP+ toxin exposure is an acute insult on the dopaminergic 
neurons. Therefore, even if miR-133b is able to exert its rescue effect in pink1-deficient 
zebrafish through increased mitochondrial resistance, this is not enough to provide 
resistance against MPP+. Realistically, rescue of the dopaminergic neuron loss caused by 
MPP+ exposure would have to be through prevention of this toxin entering the neurons, or 
increased clearance of this toxin. miR-133b knockdown does not appear to have the capacity 
to alter sensitivity to MPP+ in this way. 
miR-133b morphants already display an increase in the number of dopaminergic neurons at 
the time of treatment with MPP+ (2dpf), however MPP+ treatment resulted in a similar 
number of dopaminergic neurons by 3dpf in both WTs and morphants, thus showing that 
more neurons are lost in morphants than in WT embryos. This shows that an increased 
number of dopaminergic neurons is does not increase resistance to MPP+. MPP+ related 
neurotoxicity specifically effects dopaminergic neurons as this toxin is able to enter these 
neurons through dat (Hare et al. 2013). Although expression of dat in miR-133b morphants 
has not been tested directly, as expression th and vmat2 are both increased through an 
increased number of neurons, it is likely that dat expression is also increased. Therefore 
rather than the increase in neurons being protective, the total amount of MPP+ entering the 
brain may be proportionate to the number of dat-expressing neurons. To test this hypothesis 
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the number of dat-expressing neurons could be counted in miR-133b morphants and HPLC 
could be utilised to determine the concentration of MPP+ present in the brains of both WT 
and miR-133b morphant embryos after treatment. 
miR-133b overexpression experiments 
No effect of miR-133b mimic injection was observed on the dopaminergic neuron number. 
Although an increase in expression was detected by qPCR, when the spatial expression of 
miR-133b was observed by WISH an increase in miR-133b expression in the brain was not 
evident. This may explain why no change in dopaminergic neuron number was observed. 
Injection of a construct that specifically results in miR-133b expression in the brain by using 
a neuron specific promotor would allow the study of the effects of this on neuron 
development. If a loss of dopaminergic neurons was observed using this approach, careful 
controls would have to be performed to ensure that this loss is not a non-specific toxic effect. 
For example, another unrelated miRNA, or a scrambled miR-133b sequence could be 
introduced in the same way and the effect compared.  
Stable overexpressing lines could also be produced which induce overexpression of 
miR-133b in specific cell types, for example in neural progenitors. Using these lines, it would 
be able to assess the effect of overexpression of this miRNA specifically in developing 
neurons. Conditional overexpressing lines, for example using the Cre-LoxP system, could 
allow the effect of overexpression of this miRNA at different points in development and 
adulthood to be studied. The effect of miR-133b overexpression could be compared with 
conditional knockdowns of predicted targets of miR-133b. This would help determine what 
proportion of any observed phenotype is through a single target or whether a network of 
targets is involved. 
Effect of miR-133b on Pitx3 
The increase in dopaminergic neuron number in miR-133b morphants was hypothesised to 
be due to de-repression of pitx3. Unexpectedly, an increase of neither pitx3 mRNA nor 
protein levels could be detected in miR-133b morphants.  
As miRNAs more commonly direct translational repression of their targets, the lack of an 
increase of pitx3 mRNA levels after miR-133b knockdown was expected. This finding is similar 
to that of Kim and colleagues; they showed that neither overexpression nor inhibition of miR-
133b in embryonic stem cell cultures resulted in a change in Pitx3 mRNA levels. Protein levels 
were shown to be altered in these cells (Kim et al. 2007). However, conversely, the Rodriguez 
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group were able to identify an increase in pitx3 mRNA levels after miR-133b downregulation 
in zebrafish embryos. To elicit a downregulation of miR-133b exogenous pitx3 3’UTR was 
injected into the zebrafish embryos. This was shown to act as a “sponge” for miR-133b and 
free miR-133b levels were decreased (Barreto-Valer et al. 2012; Sanchez-Simon et al. 2010). 
This group did not assess the protein levels of Pitx3. 
While optimisation of an antibody for Pitx3 was in progress, a reporter plasmid which 
contained RFP under the control of the pitx3 3’UTR was used to determine whether miR-
133b was able to regulate RFP through binding sites in the 3’UTR. No change in RFP 
fluorescence was detected after miR-133b knockdown and RFP appeared repressed in both 
WT and miR-133b morphant embryos. This suggests that repressive forces are acting on RFP 
through the pitx3 3’UTR even in the absence of miR-133b. This does not confirm that 
miR-133b cannot repress pitx3, rather, it indicates that there are other repressive forces 
acting on pitx3 in muscle tissue. This is not wholly unexpected as pitx3 is not naturally 
expressed in muscle tissue and therefore there may be factors that prevent it being 
expressed here. Other miRNAs with predicted binding sites in the 3’UTR of pitx3 are miR-
187, miR-145, miR-192, miR-135 and miR-204 (TargetScanFish, release 6.2). Little work has 
been performed to investigate the expression and function of these miRNAs in zebrafish, 
however miR-135 is suggested to have expression in zebrafish muscle (Wienholds & 
Kloosterman 2005). Therefore this is a possible candidate for causing the observed 
repression of RFP through the pitx3 3’UTR in zebrafish muscle. 
To determine whether miR-133b is able to bind the pitx3 3’UTR this reporter plasmid 
experiment should be performed in a tissue where no other repressive forces are acting on 
pitx3. Unfortunately, expression of the reporter plasmid was not detected in the brain. 
Consequently, it was not possible determine whether miR-133b is able to repress pitx3 in 
cells where it these genes are naturally expressed. To drive the expression of the reporter 
plasmid in relevant tissues, the pitx3 promoter could be used in place of the SV40 promoter, 
thus allowing analysis of the miR-133b-pitx3 3’UTR interaction in relevant cells. 
In this study the reporter plasmid method was not able to deliver conclusive results about 
the interaction of miR-133b and the pitx3 3’UTR. If it had been successful this method has 
the potential ability to determine the specific binding site of a miRNA within the 3’UTR. The 
effect of mutagenesis of potential binding sites in the 3’UTR allows the researcher to 
investigate where the miRNA of interest binds to the 3’UTR. Had this experiment been 
successful and a miR-133b binding site in the 3’UTR of pitx3 validated, the next step of this 
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study would have been to design a target protector MO to specifically block the interaction 
of miR-133b and pitx3. This would help determine whether the dopaminergic phenotype 
observed in miR-133b morphants is specific to this interaction. This experimental process is 
described in detail by Staton & Giraldez (2011). 
To examine levels of Pitx3 protein, a custom designed Pitx3 antibody was commissioned and 
subsequently carefully optimised to ensure specificity for zebrafish Pitx3. Unexpectedly, at 
3dpf the Pitx3 protein levels appear to be decreased in miR-133b morphants. The observed 
decrease is not significant however it does show that Pitx3 protein levels are not increased 
in morphants at 3dpf.  
These data are puzzling as previous work in zebrafish suggests that miR-133b is able to 
regulate pitx3 in zebrafish (Barreto-Valer et al. 2012; Sanchez-Simon et al. 2010). These 
studies only assessed the effect at 24 and 48hpf and protein levels of Pitx3 were not 
investigated. A region specific effect of miR-133b on pitx3 was also shown. In all regions 
studied, repression of miR-133b, resulting from treatment with cocaine, was evident at both 
24 and 48hpf. In the brain, pitx3 mRNA levels were increased at both time points. However, 
in whole embryos and peripheral body, pitx3 mRNA levels were increased at 24hpf but 
decreased at 48hpf. The effect of this on downstream targets of Pitx3, including th and dat, 
was also determined. The detection of brain-specific factors, such as pitx3 and markers of 
dopaminergic neurons, in the peripheral body of zebrafish by this study suggests 
contamination of these samples (Barreto-Valer et al. 2012). In the present study, neither th 
nor pitx3 could be detected in the peripheral body of 3dpf zebrafish by WISH.  
A more recent study by the same group also demonstrated a bi-phasic effect of treatment 
with cocaine on expression of th, dat and nurr1 (pitx3 was not examined in this study). They 
showed that treatment with cocaine results in increased expression of these factors at 24hpf 
and a subsequently downregulation at 48hpf (Barreto-Valer et al. 2013). These data suggest 
either a compensatory effect is stimulated by the initial increase of these markers. 
Alternatively, death of dopaminergic neurons may be induced treatment of cocaine by 
48hpf, thus resulting in decrease of these markers. Cocaine has shown to induce neuron 
death in other model systems (Poon et al. 2007). 
It is possible that if there is an interaction between miR-133b and pitx3, this occurs at an 
early age only and subsequently a compensatory mechanism to normalise Pitx3 levels is 
activated. Examination of other transcription factors which are involved in dopaminergic 
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neuron development such as nurr1 and lmx1b should be examined. Kim and colleagues have 
previously showed that the expression of nurr1 was increased by overexpression of miR-
133b, potentially to compensate for the decrease in Pitx3 protein levels (Kim et al. 2007).  
Interestingly, a miR-133b binding site is predicted to be present in the 3’UTR of pitx3 
paralogue pitx2; however this has not been functionally validated. The Pitx3 and Pitx2 
proteins are very similar, differing only in the N-terminal region. In mice a functional 
redundancy between Pitx3 and Pitx2 has been identified in muscle development (L’Honoré 
et al. 2007). The expression of Pitx2 has also been detected in the developing mouse 
midbrain and is required for terminal differentiation of neurons in the subthalamic nucleus 
and midbrain (Martin et al. 2004). In zebrafish, although the effect of Pitx2 on dopaminergic 
neuron development has not been studied, expression of pitx2 the developing diencephalon 
has been observed (Liu & Semina 2012). It is possible that in zebrafish Pitx2 may be involved 
in development of dopaminergic neurons, therefore the effect of miR-133b knockdown may 
be through regulation of this gene rather than pitx3. Alternatively, upregulation of Pitx2 by 
miR-133b may result in the downregulation of Pitx3 protein levels observed and the neuronal 
phenotype is elicited through an alternate mechanism. 
Future work 
The mechanism of the observed increase in dopaminergic neuron number in miR-133b 
morphants is unknown and therefore future work must aim to elucidate this mechanism. 
The unexpected finding that neither pitx3 mRNA nor protein levels are elevated at 3dpf in 
miR-133b morphants suggests that this mechanism may be Pitx3-independant.  
Data from EdU experiments show that the population of th+ dopaminergic neurons begin to 
develop very early (10-12hpf). Therefore, it is possible that an interaction between pitx3 and 
miR-133b is more crucial earlier in development. As discussed above it is possible that an 
early upregulation of Pitx3 leads to the observed increase in dopaminergic neurons and also 
initiates another regulatory mechanism to normalise its expression. This may be why no 
increase in Pitx3 mRNA or protein levels is observed at 3dpf. An assessment of Pitx3 mRNA 
and protein levels should be repeated at younger ages to assess whether this interaction is 
only present at an early age. If an increase in Pitx3 protein levels are detectable at earlier 
time points, the effect on negative regulators of pitx3 should be explored. 
Alternatively, other targets of miR-133b may be responsible for the increase in dopaminergic 
neurons. There are a small number of targets of miR-133b which have been previously 
130 
 
validated in zebrafish, of these the majority are involved in muscle development (Mishima 
et al. 2009). Another validated target of miR-133b in zebrafish is mps1, a regulator of 
blastemal proliferation (Yin et al. 2008). However, there are a large number of interesting 
targets of miR-133b which have been validated in mice and humans. Although these have 
not yet been examined in zebrafish, bioinformatics analyses predict that an interaction is 
likely. A selection of these targets are listed in Table 17 with a description of how 
upregulation of these targets may be beneficial in PD. 
Table 17. Potential targets of miR-133b of interest in Parkinson’s disease. 
Target Tissue used for 
validation 
Relevance to PD References 
Fibroblast 
growth factor 
receptor 1 
Gastric cancer cell lines Activation of the fibroblast 
growth factor receptor is able to 
protect dopaminergic neurons 
against toxic insults in a toxin-
induced rat model of PD 
(Wen et al. 2013; 
Claus et al. 2004; 
Sleeman et al. 
2012) 
Insulin-like 
growth factor 
1 receptor 
Adipose tissue-derived 
stem cells and 
osteosarcoma cell lines 
Activated IGF1R signalling may 
be neuroprotective. Decreased 
IGF1R signalling in PD brain. 
(Ning et al. 2010; 
Tong et al. 2010; 
Xu et al. 2009; 
Zhao et al. 2013) 
GLI family zinc 
finger 1 
Human gastric cancer 
cells and cell lines 
Neuronal expression of Gli1 is 
protective in a toxin-induced rat 
model of PD 
(Suwelack et al. 
2004; Zhao et al. 
2014) 
Glutathione-S-
transferase pi 
HeLa cells Mutations in this gene appear in 
a higher rate in PD patients with 
pesticide exposure suggesting its 
involvement in detoxification. 
(Patron et al. 
2012; Liu et al. 
2013) 
MCL-1  Osteosarcoma cell lines 
and adenocarcinoma 
cell lines 
Anti-apoptotic factor, 
mitochondrial pro-survival 
factor. Parkin helps maintain 
levels of MCL-1. Loss of parkin 
leads to a loss of MCL-1 
sensitising cells to oxidative 
stress. 
(Crawford et al. 
2009; Zhao et al. 
2013; Ekholm-
Reed et al. 2013) 
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Despite the exact mechanism being unclear, this study shows that miR-133b plays a role in 
dopaminergic neuron development and survival. Intriguingly, this was not observed in 
miR-133b knockout mice. In this model the dopaminergic neurons were unaffected (Heyer 
et al. 2012). It is possible that there are differences in dopaminergic neuron development in 
mice, as conditional knockout mouse models of PD-genes fail to accurately model 
dopaminergic neuron loss (reviewed by Blesa & Przedborski (2014)). Models of genetic PD in 
zebrafish, however, are able to model dopaminergic neuron loss (Flinn et al. 2009; Flinn et 
al. 2013).  
Other neuronal populations should also be examined to determine whether miR-133b 
knockdown results in a specific increase in dopaminergic neurons or whether other neuronal 
populations are also affected by miR-133b. This work would help elucidate a mechanism for 
neuronal increase. Lineage tracing analysis could be combined with these experiments to 
determine at what stage in development an increase in proliferation occurs. Understanding 
the effects of miR-133b knockdown on other neural populations would also help determine 
whether miR-133b has a specific enough effect to be used as a therapeutic target without 
causing unwanted side effects. 
Finally, a stable mutant line with miR-133b knockout could be generated to validate the 
results seen in this study. The reliability of MO-based experiments has recently been 
criticised (Kok et al. 2015). This study shows a rescue effect, and therefore this is unlikely to 
be due to off-target toxic effects that are associated with MOs, such as neural apoptosis. 
However, validation of this data using a stable mutant line is still required. As miR-133b has 
been shown to have important roles elsewhere, for example in muscle development, 
limitation of this knockdown to relevant regions of the brain may be beneficial. 
Once a stable mutant line or a line possessing a tissue specific knockdown of miR-133b is 
generated, it would also be possible to cross this line with a number of other zebrafish lines 
which demonstrate dopaminergic neuron loss. Currently, dopaminergic neuron loss has only 
been validated in the pink1-/- and gba1-/- mutant lines (Flinn et al. 2013; Keatinge et al. 2015), 
however with the rapid development of CRISPR/Cas9 genome editing technology new 
zebrafish models of PD are continually being generated. Using these lines the effect of 
miR-133b deficiency in later development and in adulthood could also be studied and would 
help confirm miR-133b as a therapeutic target for PD. 
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Chapter 4. Investigating the interaction between miR-205 
and lrrk2 in zebrafish 
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4.1 Introduction 
Lrrk2 and Parkinson’s disease 
LRRK2 is a very large, highly conserved protein with many functional domains. Human LRRK2 
consists of 51 exons which encode a 286kDa protein. LRRK2 belongs to the ROCO family of 
proteins, which typically contain a Ras-like G-domain (ROC), a C-terminal of ROC (COR) 
domain and a kinase domain (Gilsbach & Kortholt 2014). The domain structure of human 
LRRK2 is shown in Figure 55.  
 
Figure 55. Lrrk2 domain structure, domain functions and mutations associated with PD. Figure adapted with 
permission from Sheng et al. (2010). 
Although the definitive function of LRRK2 is unclear, distinct functions have been associated 
with each of the domains of LRRK2. The armadillo repeat (ARM), ankyrin repeat (ANK), 
leucine rich repeat (LRR) and WD40 domains are all associated with protein-protein 
interactions (Mills et al. 2014). The ROC domain is a GTPase and the associated COR domain 
is able to interact with the ROC domain and functions as a dimerisation device. Most GTPases 
are activated by G-protein activation proteins (GAPs) (Bernards & Settleman 2004). However, 
there have been few reports of GAPs specific for LRRK2 suggesting activation by a different 
mechanism (Gilsbach & Kortholt 2014). Monomeric LRRK2 has a much slower GTP hydrolysis 
rate than dimeric LRRK2, this suggests that the LRRK2 GTPase is activated by dimerisation 
(Gotthardt et al. 2008). GTP binding has been shown to regulate kinase activity in LRRK2 
(Biosa et al. 2013). The kinase domain is a serine/threonine specific protein kinase. It is 
activated, like most protein kinases, by autophosphorylation (Li et al. 2010).  
In 2002, a study of a large Japanese family found that a novel locus (12p11.2-q13.1) 
segregated with autosomal dominant PD (Funayama et al. 2002), this was named the PARK8 
locus. In 2004, LRRK2 was identified as the gene which contained missense mutations which 
segregated with the PARK8 locus and were associated with PD (Paisán-Ruíz et al. 2004; 
Zimprich et al. 2004). These studies confirmed the association of mutations in LRRK2 with PD 
in two families in North America and five families in the UK and Spain (Paisán-Ruíz et al. 2004; 
Zimprich et al. 2004).  
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Mutations in LRRK2 are the most common cause of familial and sporadic PD (Li et al. 2014). 
A large number of mutations have been identified in LRRK2, six of these been shown to be 
pathogenic, these are shown in Figure 55. In familial cases, PD associated with these 
mutations is inherited in an autosomal dominant fashion and results in “classical” 
Parkinsonism (Haugarvoll & Wszolek 2009). These mutations are all present within the 
enzymatic ROC, COR or kinase domains of LRRK2.  
The most common and most well studied of these mutations is the G2019S mutation. This 
mutation is responsible for 5-6% of familial cases and 1-2% sporadic cases of PD in those of 
Caucasian origin. It has been shown to have a penetrance of approximately 75% at the age 
of 79 years (Kumari & Tan 2009). This mutation increases the catalytic rate of the enzyme, 
leading to a toxic increase in kinase activity (West et al. 2005). The other mutations have also 
been associated with increased kinase activity, however this increase is much more variable 
than the consistent increase shown with the G2019S mutation. This variation may be due to 
the different substrates used and different data collection methods by the different studies 
(Esteves et al. 2014).  
There is a mutational “hotspot” at R1441. Three different mutations at this site, R1441G/H/C, 
have been are associated with PD. These mutations and the Y1699C mutation in the COR 
domain are thought to reduce GTP-hydrolysis, resulting in an increase in GTP-bound LRRK2. 
It has been speculated that this may result in increased activation of kinase activity (West et 
al. 2007).  
Mutations in LRRK2 are also commonly identified in sporadic PD patients and are responsible 
for 1-5% of all sporadic cases of the disease (Kumari & Tan 2009). A GWAS has also identified 
risk variants upstream of LRRK2 which may play a role in transcriptional regulation of the 
gene (Satake et al. 2009). 
LRRK2 is expressed in most organs, with particularly high levels in the kidney and lung 
(Paisán-Ruíz et al. 2004). Expression within the brain is diffuse, with relatively low expression 
in dopaminergic neurons of the substantia nigra and ventral tegmentum. LRRK2 is detected 
at higher levels in the striatum, cortex, cerebellum and hippocampus (Esteves et al. 2014). 
Within cells, LRRK2 is associated with many intracellular membrane structures. These 
include: endosomes, lysosomes, the outer mitochondrial membrane, endoplasmic reticulum 
and lipid rafts. The membrane association of LRRK2 is thought to alter its biochemical 
function, with membrane-associated LRRK2 having greater kinase activity (Berger et al. 
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2010). The unique and varied intracellular location of LRRK2 is likely to reflect its involvement 
in a number of cellular pathways, including: Wnt signalling, vesicular trafficking, cytoskeletal 
function, mitochondrial function, protein synthesis, autophagy and regulation of neurite 
outgrowth (Esteves et al. 2014). 
The mechanism by which mutations in LRRK2 result in PD is unclear, however as most 
pathogenic mutations have been shown to alter enzymatic activity it is thought to be a toxic 
gain of function mechanism. To support this, LRRK2 knockout models rarely mimic 
Parkinson’s pathology. LRRK2 knockout mice do not display any loss of dopaminergic 
neurons or change in dopamine dynamics (Hinkle et al. 2012), however they do display a 
motor phenotype. Kinase activity was originally thought to be required for the toxic effects 
of LRRK2 (Greggio et al. 2006) as kinase inhibitors and mutation of autophosphorylation sites 
can rescue the neurite outgrowth phenotype of neurons containing mutant LRRK2 (Esteves 
et al. 2014). However, more recent data using techniques to measure LRRK2 level and detect 
toxicity at single-cell resolution suggest that the toxic activity of LRRK2 depends on the 
relative level of LRRK2 and presence of ɑ-synuclein rather than a specific increase in kinase 
activity (Skibinski et al. 2014). 
miR-205 is a regulator of Lrrk2 
miR-205 has been identified as a key regulator of LRRK2 (Cho et al. 2013). A two-fold increase 
in LRRK2 was observed in the frontal cortex of sporadic PD and PDD (PD with dementia) 
patients compared to non-pathological controls (NPCs). LRRK2 mRNA levels, however, were 
not altered, thus suggesting altered post-transcriptional regulation of LRRK2 in patient 
brains. A number of miRNAs have predicted binding sites in the LRRK2 3’UTR. As the miR-205 
binding site is highly conserved among vertebrates the authors studied the expression levels 
of miR-205. A significant decrease of miR-205, but not other miRNAs which are also predicted 
to target LRRK2, was detected in the frontal cortex of PD and PDD patients compared to 
NPCs. When correlated, the expression levels of miR-205 and LRRK2 protein levels revealed 
an inverse correlation. The interaction of miR-205 with LRRK2 was then confirmed by a 
luciferase assay. In HEK293T cells transfection of pre-miR-205 resulted in a 60% decrease of 
LRRK2 levels. 
To further investigate the expression and interaction between miR-205 and LRRK2 a rodent 
model was used. Similarly to the findings from human brain samples, in the mouse brain an 
inverse correlation between miR-205 expression and LRRK2 protein levels was also observed. 
miR-205 demonstrated the highest expression in dopaminergic neurons in the mouse 
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midbrain. This is where LRRK2 protein levels are at their lowest. Over the course of aging (1 
month-18 months of age) miR-205 expression levels appear to increase while LRRK2 protein 
levels decrease; Lrrk2 mRNA levels remain stable. 
The therapeutic potential of miR-205 was also examined in this study. Neurons were derived 
from transgenic mice which overexpress the R1441G mutant form of LRRK2; these displayed 
a shortened neurite phenotype. This neurite defect was rescued by overexpression of miR-
205 and exacerbated by inhibition of miR-205. These data show that miR-205 has the 
potential to be a therapeutic target in PD by reducing the load of toxic LRRK2 protein. 
The decrease in miR-205 sporadic PD brain suggests that it may be used as a biomarker. The 
mechanism of the decrease in miR-205 expression is unknown, but the authors suggest that 
this may be pathogenic. Discovery of regulators of miR-205 expression may help uncover 
pathogenic mechanisms in PD. 
Zebrafish Lrrk2 
Zebrafish possess one orthologue of lrrk2 on chromosome 25. Overall, the zebrafish Lrrk2 
protein has 47% similarity with human LRRK2, however there is higher homology within 
some of the discrete domains. The kinase domain has the highest homology of 71% similarity 
to the human LRRK2 kinase domain (Figure 56). Similarly to humans, rat and mouse, zebrafish 
lrrk2 expression is ubiquitous within the brain. In embryos lrrk2 expression is limited to the 
brain and in adult zebrafish lrrk2 mRNA was also detected in the gut, muscle and ovaries 
(Sheng et al. 2010). Functions of zebrafish Lrrk2 have not yet been confirmed. 
 
 
Figure 56. Conservation of amino acid sequences and functional domains of LRRK2 between human and 
zebrafish. This figure shows that human and zebrafish share an overall homology of amino acids of 47%. 
Homologies between the individual functional domains vary with the highest homology being in the kinase domain 
of this protein. ANK = ankyrin repeats domain, LRR = leucine rich repeats domain, Roc = Ras-like G-domain, COR = 
C-terminal of ROC domain. Figure reproduced from Sheng et al. (2010).  
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Functions of miR-205 
Despite the above described role of miR-205 in the brain, miR-205 is mainly expressed in 
epithelial tissues. In mice, miR-205 is strongly expressed in the skin and is detectable in 
squamous stratified epithelial derived organs, including the stomach, pancreas, uterus and 
bladder (Farmer et al. 2013). In adult mice miR-205 is also detectable in the brain (Cho et al. 
2013). miR-205 has been shown to be a regulate epithelial to mesenchyme transition (EMT) 
through ZEB1 and SIP1/ZEB2. Downregulation of miR-205 (and members of the miR-200 
family) was shown to initiate EMT by releasing their targets from repression. EMT is 
important for tissue remodelling in embryogenesis and also plays a role in tumour metastasis 
(Gregory et al. 2008).  
Due to its involvement in metastatic pathways miR-205 has been implicated in a number of 
cancers and is thought to have a tumour suppressor function. It has been shown to be 
downregulated in gastric cancer, prostate cancer, bladder cancer and head and neck 
squamous cell carcinomas (Gandellini et al. 2009; Yin et al. 2014; Childs et al. 2009; Wiklund 
et al. 2011). In breast cancer patients decreased miR-205 expression was associated with 
shorter disease free intervals and overall survival times (Markou et al. 2014).  
The aim of this study is to determine whether the interaction between miR-205 and lrrk2 is 
conserved in zebrafish, and whether knockdown of miR-205 has a neurotoxic effect on 
dopaminergic neurons through an increase in Lrrk2 protein levels.  
4.2 Characterisation of miR-205 and lrrk2 
To determine whether it is possible for miR-205 and lrrk2 to interact the spatial and temporal 
expression was investigated by WISH at 3dpf, and qPCR from 1-5dpf, respectively.  
4.2.1 Optimisation 
4.2.1.1 WISH probe for lrrk2 
Lrrk2 is a very large gene containing 51 exons. Firstly, a probe previously used by another 
group which investigated the expression pattern of zebrafish lrrk2 was tested (Sheng et al. 
2010). This probe was designed to target the region of mRNA which encodes the WD40 
domain. When this probe was tested staining took over 5 days to develop. This suggests that 
this probe did not have optimal annealing properties. Within this staining period a similar 
staining pattern also developed when the sense probe was used. This suggests that the 
staining seen with the antisense probe may not be specific to lrrk2. Another probe was 
designed to the region of the mRNA encoding the ROC domain of Lrrk2. 
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Figure 57 shows the approximate locations of the forward and reverse primers used to 
generate a PCR product from which the WISH probe was transcribed. To allow both a sense 
and antisense probe to be transcribed the forward and reverse primers were tagged with the 
SP6 and T7 promoter sequences, respectively. WISH using the antisense probe transcribed 
from this PCR produced staining which developed within 2 hours. Within the same time scale, 
WISH performed with the sense control probe did not produce any staining, therefore 
indicating that staining produced with the antisense probe is specific for lrrk2. 
 
 
Figure 57. Design of a WISH probe for lrrk2. The top panel shows a schematic of exons 27-34 of the lrrk2 gene. 
The first amino acid encoded by both exons 28 and 33 is labelled and how this matches up to the domain structure 
of Lrrk2 protein is shown. The bottom panel shows the location of the primers used to generate a PCR product 
from which the WISH probe is transcribed. LRR = leucine rich repeats domain, ROC = Ras-like G-Domain, COR = C-
terminal of ROC domain.  
 
4.2.2 Results 
4.2.2.1 miR-205 sequence is conserved in zebrafish 
miR-205 is highly conserved across a wide range of species (miR-Base and Ensembl). There is 
good homology between the human and zebrafish miR-205 sequences. Figure 58A shows the 
alignment of the whole miR-205 exon between humans and zebrafish. Over the whole exon 
there is an 78% similarity over 100% of the zebrafish sequence (the human sequence is 21bp 
longer). The mature miRNA sequence of zebrafish miR-205 is 100% homologous to both 
human and mouse miR-205 (Figure 58B).  
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Figure 58. Conservation of miR-205 across species. A shows the sequence alignment of the whole miR-205 exon 
from human and zebrafish and B shows the mature miRNA sequences of human, mouse and zebrafish miR-205. 
 
4.2.2.2 Expression and localisation of miR-205 
To determine the expression pattern in zebrafish WISH was performed at 3dpf. A LNA probe 
specific for miR-205 was used. As shown in Figure 59, miR-205 appears to be expressed in 
brain, epidermis, the epithelia of the pharyngeal arches and in the intersegmental cells.  
 
 
Figure 59. Spatial expression of miR-205 at 3dpf. This figure shows the spatial expression pattern of miR-205, as 
determined by WISH, at 3dpf. 
 
4.2.2.3 Expression and localisation of lrrk2 
For an interaction between miR-205 and lrrk2 to be possible these two genes must be 
co-expressed. The spatial expression pattern of lrrk2 was investigated by WISH at 3dpf and 
the temporal expression pattern between 1-5dpf was determined by qPCR. 
Figure 60A shows the spatial expression of lrrk2; at 3dpf it is not spatially restricted and 
diffuse staining within the head can be seen (Figure 60A). The qPCR data shows that between 
1-3dpf the expression of lrrk2 increases slightly and is then stable from 3-5dpf (Figure 60B). 
Together, these data show that miR-205 and lrrk2 are both expressed in the brain at 3dpf, 
therefore it would be possible for miR-205 to exert a regulatory effect on lrrk2. 
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Figure 60. Expression and localisation of lrrk2. A shows the spatial expression pattern of lrrk2 as determined by 
WISH, at 3dpf. The sense control probe for lrrk2 did not show any staining indicating that the staining shown 
above is specific to lrrk2. B shows the relative temporal expression of lrrk2 from 1-5dpf, as determined by qPCR. 
Error bars represent standard deviation. 
 
4.3 Knockdown of miR-205 and effect on dopaminergic neurons 
In order to study the role of miR-205 in the development of dopaminergic neurons a MO was 
used to generate a transient knockdown of this miRNA. Once a knockdown had been 
validated the number of dopaminergic neurons present in both control MO injected and 
miR-205 morphants was determined. 
4.3.1 Optimisation 
4.3.1.1 Dosage optimisation of MO and validation of knockdown 
MOs can be used to knockdown miRNAs as well as protein coding genes. For miR-205 a MO 
targeting the overlapping loop region of the pri-miRNA was used (see Materials and Methods 
Figure 12 on page 50). This MO was previously used by (Kloosterman et al. 2007) who tested 
a number of MOs targeting different regions of the miR-205 pri-miRNA transcript. The 
knockdown of the miR-205 was visualised by WISH and quantified by qPCR. 
To determine the optimal dose of the miR-205 MO it was injected at three different doses 
into one-cell stage embryos. A control MO was also injected to control for death and 
deformity attributable to the injection process and presence of MO. The three doses of MO 
were injected, these were: 2.5ng, 5ng or 7.5ng MO. The toxicity was assessed visually and by 
counting death rates. The miR-205 MO was very well tolerated and none of the groups 
displayed any deformity or increase in death rate above the WTs (5-10% death). As the MO 
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was well tolerated all doses the middle dose, 5ng, was chosen as the working concentration 
for subsequent experiments. The efficacy of MO at 3dpf was assessed by qPCR. The qPCR 
data show that a near-complete knockdown was achieved with this MO (Figure 61). 
 
 
Figure 61. Knockdown of miR-205 using MO. miR-205 levels were quantified at 3dpf by qPCR. Injection of miR-
205 MO results in a 95% decrease in miR-205 levels at 3dpf. The data shown are from experiments using the 
chosen dose of MO, that is, injection of 5ng of miR-205 MO. miR-133b was used as a reference gene. Error bars 
represent standard deviation. Data are from 4 biological replicates and are analysed by an unpaired t-test with 
Welch’s correction, *** = p<0.001. 
 
4.3.2 Results 
4.3.2.1 Effect of miR-205 knockdown on dopaminergic neurons 
Two methods were used to assess the effect of miR-205 knockdown on dopaminergic 
neurons. Firstly, the mRNA levels of th were assessed by qPCR. As shown in Figure 62 
knockdown of miR-205 does not cause any change in th mRNA levels at 3dpf.  
 
 
Figure 62. miR-205 knockdown has no effect on th mRNA levels at 3dpf. th mRNA levels were assessed at 3dpf 
by qPCR. There is no change in th mRNA levels after knockdown of miR-205. ef1a was used as a reference gene. 
These data are from 3 biological replicates. Data is analysed by an unpaired t-test with Welch’s correction, p>0.05. 
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To further investigate the effect of miR-205 knockdown on dopaminergic neurons the 
number of th+ dopaminergic neurons were counted after WISH for th was performed. This 
experiment revealed a slight but significant decrease in the number of th+ dopaminergic 
neurons in the miR-205 morphants compared to the control MO injected embryos (Figure 
63). 
 
Figure 63. miR-205 knockdown results in a small decrease in th+ dopaminergic neurons at 3dpf. A shows a 
representative image of the th+ dopaminergic neurons in both control MO and miR-205 MO injected embryos. 
Scale bar = 100µm. B shows the quantified number of th+ dopaminergic neurons normalised to WT control MO 
injected. A slight but significant decrease of 8% is observed in miR-205 MO injected embryos. Error bars represent 
standard deviation. These data are from four biological replicates. In each biological replicate the number of 
dopaminergic neurons is counted in 20 embryos and the average taken. Data are analysed with an unpaired t-test 
with Welch’s correction. * = p<0.05. On axis labels, DA = dopaminergic. 
4.4 Effect of miR-205 knockdown on lrrk2/Lrrk2  
LRRK2 has been validated as a target of miR-205 in humans and mice (Cho et al. 2013). Both 
TargetScanFish (Resease 6.2, June 2012) and the miRanda algorithm predict the presence of 
a miR-205 binding site in the 3’UTR of lrrk2. Figure 64 shows the predicted binding site in the 
3’UTR of zebrafish lrrk2. To investigate the effect of miR-205 knockdown on lrrk2, mRNA 
levels were measured by qPCR and Lrrk2 protein levels were quantified using western 
blotting. 
 
Figure 64. Validated and predicted binding sites for miR-205 in lrrk2 3’UTR. The left panel shows the validated 
interactions between human and mouse miR-205 and the 3’UTR of LRRK2 (Cho et al. 2013). The right panel shows 
a potential binding site for miR-205 in the 3’UTR of lrrk2 in zebrafish. The seed region of miR-205 is highlighted in 
both cases. 
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4.4.1 Optimisation 
4.4.1.1 Western blotting 
Currently there are no commercially available antibodies designed to specifically detect 
zebrafish Lrrk2. However, the human and zebrafish Lrrk2 proteins are approximately 50% 
homologous (Figure 56), therefore a search was performed to identify an antibody with an 
epitope which has a high homology to zebrafish Lrrk2. 
Morpholinos for Lrrk2 
In order to test the specificity of antibodies for Lrrk2, lrrk2 knockdowns were generated using 
MOs. The chosen MOs were selected from a publication studying deletion of the WD40 
domain of Lrrk2 in zebrafish (Ren et al. 2011). The first MO targets the boundary of intron 38 
and exon 39, this in the region of the gene that encodes part of the kinase domain; it will be 
referred to as kinase MO. The second MO targets the boundary of exon 44 and intron 44, the 
region of the gene which encodes part of the WD40 domain; it will be referred to as WD40 
MO. Before purchasing the MOs, the sequence of the target was confirmed using direct 
sequencing to confirm that no SNPs are present which may prevent MO binding. A BLAST 
search of the MO sequence against the zebrafish genome was also performed to ensure 
specificity for lrrk2. 
The MOs were tested at two different doses, 8ng and 10ng. As these MOs were only being 
used for generating morphants from which protein could be collected the any toxic effects 
of these MOs were largely ignored as long as the embryo developed sufficiently for protein 
collection to be possible. The 10ng dose of the kinase MO was discarded as the majority of 
these embryos did not survive until 3dpf, those that did were grossly deformed and it was 
not possible to collect protein. At 3dpf RNA was collected from the morphants and 
uninjected embryos to assess the modification of lrrk2 by RT-PCR. A complete loss of the WT 
lrrk2 transcript was seen with the kinase MO and approximately a 50% loss with the WD40 
MO (Figure 65). 
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Figure 65. RT-PCR analysis of the effect of the lrrk2 MOs. This figure shows the assessment of the effect of both 
the kinase and WD40 MOs by RT-PCR. Arrows indicate the WT transcript and the shorter transcript, thought to be 
an exon skip, present in the MO injected samples 
 
These MOs both cause deletions of all or part of the exon they target and then a premature 
stop codon, this was confirmed by direct sequencing. The kinase MO causes an exon skip, 
exon 39 is deleted (113bp). This causes a frame shift and a premature stop codon resulting 
in a truncated protein 72kDa smaller than full length Lrrk2. The WD40 MO causes a 98bp 
deletion corresponding to the second half of exon 44; this may be due to activation of a 
cryptic splice site. This also results in a frame shift and a premature stop codon thus 
generating a truncated protein 39.6kDa smaller than full length Lrrk2. This is shown in Figure 
66. These MOs will be used to assess the specificity of any Lrrk2 antibodies tested. 
 
 
Figure 66. Effect of lrrk2 MOs on the lrrk2 transript. This figure shows the exon structure of WT zebrafish lrrk2 
and the effect of the kinase and WD40 MOs on this. The kinase MO results in a deletion of exon 39 which generates 
a frameshift and subsequent premature stop codon, resulting in loss of 72kDa of Lrrk2. The WD40 MO results in a 
deletion of the second half of exon 44, presumably by activation of a cryptic splice site. This also causes a frame 
shift and premature stop codon resulting in loss of 39.6kDa of Lrrk2. 
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Testing of a commercially available antibody for Lrrk2 
Davies and colleagues, tested a range of anti-LRRK2 monoclonal antibodies (Davies et al. 
2013). The antibody recommended by this study was chosen for testing in zebrafish. This 
antibody was raised to a synthetic peptide corresponding to amino acids 970-2527 of human 
LRRK2. It was shown to react with the C-terminal end of human LRRK2 (aa1326-end). This 
region has a 55% identity with zebrafish Lrrk2 and 77% positive matches. When a BLAST 
search is performed to compare this amino acid sequence against the zebrafish proteome, 
the next closest match after Lrrk2 only has 30% similarity over 23% of the sequence. This 
suggests that this antibody will not recognise any other proteins other than Lrrk2. 
Lrrk2 is a large protein with a molecular weight of 280kDa therefore the western blotting 
protocol was optimised for large proteins. Modifications of the protocol included: using a 
low percentage acrylamide gel (7.5% resolving gel and 4% stacking gel), reducing the 
percentage of methanol in the transfer buffer to 5% and transferring the blot over night at 
90mA. 
The antibody was first tested using protein lysates from whole, deyolked 3dpf embryos and 
protein lysates from fibroblasts were used as a positive control. Tubulin was used as a loading 
control. Figure 67 shows that there is a clear band at the correct weight, 280kDa, in the 
fibroblast sample, however a band at this weight is not present in zebrafish samples; instead 
a clear band is present just below 150kDa. It is possible that this could be a C terminal 
fragment of Lrrk2.  
To ensure that the antibody is functioning within its linear range and is therefore can be used 
to quantify protein levels, a range of protein concentrations were loaded onto the gel and 
the protein levels were quantified using densitometry. The relative levels of Lrrk2 and 
Tubulin from 10, 20 and 30 embryos are very similar, but differ in the 40 embryo lane, where 
Tubulin levels appear to level off. This is likely due to overloading of the gel and saturation 
of the Tubulin antibody. The levels of “Lrrk2” protein were normalised to the Tubulin loading 
control. For 10-30 embryos the values are very close to 1 showing that the level of protein is 
accurately corrected by the loading control and the antibodies were working within their 
linear range. For subsequent experiments protein from approximately 20 embryos was 
loaded onto the gel. 
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Figure 67. Initial testing of Lrrk2 antibody. A shows a blot testing the antibody on protein from zebrafish embryos 
at a range of concentrations and from fibroblasts as a positive control. In fibroblasts a band just above 250kDa 
can be seen. As Lrrk2 (in humans and zebrafish) is a 280kDa protein this band is very likely to be LRRK2. In the 
lanes loaded with zebrafish protein a band of this weight is not visible, however a clear band and approximately 
150kDa is visible. It is possible that this could be a fragment of Lrrk2. B shows a quantification of the “Lrrk2” and 
Tubulin bands. The relative levels of Lrrk2 and Tubulin from 10, 20 and 30 embryos are very similar, but differ in 
the 40 embryo lane. C shows the “Lrrk2” protein levels normalised to the loading control.  
 
To determine whether the band observed 150kDa is a fragment of Lrrk2, two MOs were used 
to knockdown Lrrk2. If the band at 150kDa is indeed Lrrk2 then injection of the kinase MO or 
WD40 MO injection would cause the band to be present at a lower weight as part of the 
protein has been deleted, or the antibody would not be able to bind to the truncated protein 
as a sufficient proportion of the epitope is no longer present. Protein was collected from MO 
injected and WT embryos at 3dpf, a western blot was performed using these samples to test 
the specificity of the antibody. 
 
Figure 68. Investigating the specificity of the Lrrk2 antibody using MOs. This figure shows the western blot with 
samples from uninjected and MO injected embryos. No band can be detected in kinase MO injected embryos. 
Tubulin was used a loading control. 
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The western blot using protein from both WT and lrrk2 morphant embryos is shown in Figure 
68. There is no visible band at 150kDa in the embryos injected with the kinase MO. This 
suggests that a sufficiently large portion of the protein is missing in these morphants that 
the antibody is unable to recognise this band. This indicates that this band at 150kDa is likely 
to be a fragment of Lrrk2. Unexpectedly, injection with WD40 MO does not have any visible 
effect on this band. This suggests that the truncation of Lrrk2 caused by this MO is not large 
enough to disrupt antibody binding, however if this is the case a bandshift should be visible 
as the truncation results in a loss of 39.6kDa. The reason why a band shift is undetectable is 
unclear. One explanation could be that the truncated protein was not translated due to 
nonsense mediated decay of the mutated transcript and the residual full length is translated 
at a higher rate to compensate. 
Design of a custom antibody for Lrrk2 
To complement the use of the commercially available antibody described above a custom 
antibody for zebrafish Lrrk2 was commissioned from Eurogentec (Seraing, Belgium). Two 15-
amino acid epitopes, unique to zebrafish Lrrk2, assessed by local alignment against the 
zebrafish proteome, using BLAST (NCBI) were chosen. 
The first peptide to which a custom antibody will be raised corresponds to amino acids 1656-
1671 of zebrafish Lrrk2. This is within the COR domain of the protein. The second peptide 
corresponds to amino acids 2076-2091, this is towards the end of the kinase domain of Lrrk2. 
These peptides either have partial (80%) or total homology with human LRRK2, therefore 
they may also be useful in cell culture applications. The antibodies generated will be rabbit 
polyclonal antibodies. These antibodies provided by Eurogentec are affinity purified against 
the peptide they were raised to enrich for antibodies specific to Lrrk2. 
4.4.2 Results 
4.4.2.1 Assessment of lrrk2 mRNA levels 
Firstly, the effect of miR-205 knockdown on lrrk2 mRNA levels was determined by qPCR. If 
miR-205 is able to regulate lrrk2 by mRNA cleavage and degradation, knockdown of miR-205 
would result in an increase in lrrk2 mRNA. No change in lrrk2 mRNA level was observed 
(Figure 69), therefore if miR-205 is able target lrrk2 in zebrafish this is by translational 
repression. 
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Figure 69. miR-205 knockdown has no effect on lrrk2 mRNA levels at 3dpf. Lrrk2 mRNA levels were assessed by 
qPCR. Error bars represent standard deviation. Data are from three biological replicates and are analysed by an 
unpaired t-test with Welch’s correction, p>0.05. 
 
4.4.2.2 Assessment of Lrrk2 protein levels 
Next, it was investigated whether miR-205 can repress the translation of Lrrk2. Lrrk2 protein 
levels were quantified using western blotting in embryos injected with either the control MO 
or miR-205 MO  
Although the optimisation data for the commercially available antibody do not definitively 
prove that this antibody is indeed detecting Lrrk2, no other antibodies were available, 
therefore this antibody was used generate preliminary data regarding the ability of miR-205 
to regulate lrrk2 at the translational level. Protein was collected from 3dpf embryos which 
had been injected with either miR-205 MO or with the control MO. These samples were run 
on a western blot to assess levels of Lrrk2 protein (Figure 70). 
 
 
Figure 70. miR-205 knockdown has no effect on Lrrk2 protein levels at 3dpf. A shows the western blot where 
Lrrk2 protein levels are compared between lysates from control MO and miR-205 MO injected embryos. Tubulin 
was used as a loading control. B shows a quantification of this western blot. Lrrk2 protein levels are normalised 
to tubulin levels. Data are from three biological replicates and analysed by an unpaired t-test with Welch’s 
correction, p>0.05. 
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Figure 70 shows that, using this antibody, there is no detectable change in the band at 
150kDa in miR-205 morphants. This may indicate that miR-205 is unable to regulate Lrrk2 
protein levels in zebrafish. Due to the concerns regarding the specificity of this antibody for 
Lrrk2 another antibody must be used to confirm this result. The custom antibody will be 
optimised and used to repeat this experiment in the future. 
4.5 Discussion 
This study aimed to investigate the effect of miR-205 on the development of dopaminergic 
neurons. The hypothesis was that knockdown of miR-205 would result in an increase in Lrrk2 
protein levels which would result in neurotoxicity. The present study is the first to attempt 
to elucidate a function of miR-205 in zebrafish. 
Characterisation of miR-205 and lrrk2 in zebrafish 
miR-205 is conserved in a wide variety of species. The mature miRNA sequence is 100% 
homologous to human and mouse miR-205, thus indicating that the function of miR-205 is 
conserved in zebrafish. 
The observed expression pattern of miR-205 is similar to that determined by a group which 
investigated a large number of miRNAs as part of a large scale study assessing the differences 
in vertebrate miRNA expression where strong staining in the epidermis around the 
pharyngeal arches is observed (Ason et al. 2006). The present study also detects diffuse 
staining in the brain of the zebrafish and within the intersegmental cells in the zebrafish tail. 
A sense control probe should also be used to determine that the expression pattern observed 
is specific to miR-205 rather than non-specific background staining. 
In developing mice, miR-205 expression was detected in the skin, and squamous stratified 
epithelium derived organs such as the stomach, pancreas and bladder. No expression was 
observed in the developing mouse brain (Farmer et al. 2013). Expression of miR-205 has been 
confirmed in the brain of 1 month old mice. It was detectable in the mouse cortex, 
hippocampus, midbrain, striatum and cerebellum with the highest expression in the 
midbrain (Cho et al. 2013). 
To ensure that observed staining for miR-205 in the head of the zebrafish is not solely 
attributable to staining in the skin, WISH should be performed on sections to confirm that 
miR-205 is indeed expressed in the developing zebrafish brain. Investigation of the 
expression of miR-205 in the brains of adult zebrafish would also be interesting to determine 
whether regions of the brain containing the dopaminergic neurons exhibit a higher level of 
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expression of miR-205 than other regions, as is seen in brains of both humans and mice (Cho 
et al. 2013). 
Zebrafish lrrk2 was observed to have ubiquitous expression within the brain at 3dpf. This is 
in agreement with other studies (Sheng et al. 2010). In adult zebrafish Sheng and colleagues 
were able to detect lrrk2 expression in the brain, muscle, gut and ovary. Using their own 
custom Lrrk2 antibody, full length Lrrk2 protein was detected in the adult zebrafish brain by 
western blot. 
To date, only two studies have been published on the function of zebrafish Lrrk2 (Sheng et 
al. 2010; Ren et al. 2011). These studies represent a dichotomy in the literature over the 
effect of deletion of the WD40 domain of zebrafish Lrrk2.  
Sheng and colleagues report that knockdown of Lrrk2 through use of start site MOs to block 
translation results in severe embryonic lethality and developmental abnormalities. The 
defects described are very similar to the standard toxic and off targets effects often caused 
by MOs through p53 activation. These include gross neuronal apoptosis and developmental 
delay (Robu et al. 2007). To allow further study of the function of Lrrk2, a MO was used that 
introduces a stop codon before the WD40 domain. They showed that truncation of zebrafish 
Lrrk2 resulted in loss of th+ neurons, disorganisation of axon tracts, increased apoptosis 
within the brain and a locomotion defect. They also demonstrated that these defects could 
be, at least partially, rescued by overexpression of either human or zebrafish full length lrrk2 
(Sheng et al. 2010). Another group studying the function of Lrrk2 in zebrafish, however, were 
unable to replicate these findings. Ren and colleagues used the same MOs and validated the 
deletion of the WD40 domain however were not able to reproduce the results seen by Sheng 
and colleagues. No neuronal loss or locomotion defect could be detected (Ren et al. 2011).  
The protein homology and expression of lrrk2 suggests a conserved role in zebrafish. 
However, the data presented by the two studies above highlight the need for additional 
studies to be performed to elucidate the role of Lrrk2 in zebrafish. Furthermore, 
overexpression models containing WT and mutated Lrrk2 may be more relevant for the study 
of the role of Lrrk2 in PD. 
Knockdown of miR-205 and effect on dopaminergic neurons 
Prior to this study the effect of knockdown of miR-205 had not been investigated in zebrafish. 
Another group had previously used miR-205 MOs however this was purely to demonstrate 
the effects of designing the MO to different regions of the pri-miRNA (Kloosterman et al. 
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2007). This previous validation of a miR-205 MO was utilised by this study; the non-
overlapping loop MO was used for knockdown of miR-205. MO optimisation was successful 
and a near complete knockdown of miR-205 was achieved without any noticeable 
deformities or increase in death rate of injected embryos. 
The effect of miR-205 knockdown on dopaminergic neurons was investigated, and a small 
but significant decrease in dopaminergic neuron number was observed. Despite this result 
reaching significant an 8% decrease only equates to 2 fewer neurons, as WT embryos have 
approximately 20-25 th+ dopaminergic neurons in Wulliman-Rink groups 1, 2, 4 and 5. 
Therefore it is unlikely that this is a meaningful defect at this age, however it may indicate 
the beginnings of increased susceptibility of these neurons to a toxic load of Lrrk2. To 
determine whether miR-205 causes a meaningful decrease in th+ dopaminergic neurons 
these must be counted at later time points. As knockdown by MO is transient, to do this a 
stable miR-205 knockout line could be generated. 
The neurotoxic effect of overexpression of WT LRRK2 is disputed. While increase in LRRK2 
activity has been suggested to be a risk factor for PD (Cho et al. 2013; Satake et al. 2009) a 
number of studies have failed to identify any neurotoxic effects of upregulation of WT LRRK2 
alone (Cho et al. 2013; Parisiadou et al. 2009; Lin et al. 2009). 
Cho and colleagues saw that although de-repression of mutant LRRK2 in neuron culture by 
inhibition of miRNA-205 resulted in reduced neurite out-growth, inhibition of miR-205 in 
non-transgenic neurons, thus resulting in an increased load of WT LRRK2 did not result in any 
neurotoxic effects. These results are in agreement with a study from the same group where 
a direct, rather than miR-205 mediated, upregulation of WT and G2019S LRRK2 was 
investigated (Parisiadou et al. 2009). In an in vivo mouse model it has similarly been 
demonstrated that upregulation of LRRK2 alone did not cause neurodegeneration. However, 
the upregulation of WT LRRK2 exacerbated progression of neuropathological abnormalities 
developed in mice harbouring the A53T α-synuclein mutation (Lin et al. 2009).  
The studies discussed above were all performed in mice. It is possible that, in mice, there are 
differences the susceptibility of dopaminergic neurons to toxic effects as classical knockout 
mouse models of PD also fail to accurately model dopaminergic neuron loss (reviewed by 
Blesa & Przedborski (2014)). Models of genetic PD in zebrafish, however, are able to model 
dopaminergic neuron loss (Flinn et al. 2009; Flinn et al. 2013). Therefore it is possible that 
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upregulation of LRRK2 in zebrafish may have a more damaging effect of dopaminergic 
neurons. 
In a human cell culture model of PD (dopaminergic neurons differentiated from iPSCs) it was 
shown that LRRK2 protein levels were a strong predictor of cell death. This was show to be 
independent of kinase activity of LRRK2. However in the absence of ɑ-synuclein the toxicity 
of increased LRRK2 levels was reduced (Skibinski et al. 2014). Although the effect on neuronal 
survival were not investigated, zebrafish which were induced to transiently overexpress 
either WT or G2019S-mutant-LRRK2 (a human construct) displayed an similar impairment in 
protein clearance suggesting that this defect is more dependent on expression levels than 
the specific LRRK2 mutation (Lichtenberg et al. 2011). In drosophila the effect of 
overexpression of WT LRRK2 is disputed. Two studies have shown that overexpression of WT 
LRRK2, either systemically or in dopaminergic neurons only, results in a dopaminergic neuron 
loss, albeit in a less severe manner than expression of G2019S-mutant-LRRK2 (Liu et al. 2008; 
Venderova et al. 2009). However this finding was not replicated in a third study which 
showed that expression of three Parkinson’s-related LRRK2 alleles resulted in neuronal loss 
however expression of WT LRRK2 did not (Ng et al. 2009).  
Zebrafish do not possess an orthologue of α-synuclein (Milanese et al. 2012). Therefore the 
effects of LRRK2 will be interesting to study in zebrafish as this model allows the study of 
toxicity independent of α-synuclein to be studied. Interestingly, ɑ-synuclein knockout mice 
are resistant to MPTP toxicity (Dauer et al. 2002). Zebrafish, despite being α-synuclein 
deficient are not resistant to this toxin (Bretaud et al. 2004; the present study). This suggests 
that either, this toxin induces neurotoxicity in a different manner in zebrafish, or, other genes 
are present in zebrafish which compensate for the lack of ɑ-synuclein.  
Effect of miR-205 knockdown on lrrk2/Lrrk2 
It has previously been shown that miR-205 regulates LRRK2 in mice and humans through a 
binding site in the 3’UTR of LRRK2. This repression was shown to be due to translational 
repression rather than through transcript degradation, therefore it was expected that no 
change in mRNA level of lrrk2 in miR-205 morphants was observed. To determine whether a 
change in Lrrk2 protein levels was detectable western blots were performed. The anti-Lrrk2 
antibody used did not detect any chance in protein levels however the specificity of the 
antibody used for Lrrk2 has not been conclusively validated. 
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Two custom anti-Lrrk2 antibodies specific for zebrafish have been commissioned and will be 
used to repeat this experiment in the future. Before these antibodies are used for 
experimental applications the optimal working conditions of these antibodies must be 
determined and the specificity of these antibodies for Lrrk2 must be validated. To do this a 
similar protocol will be followed as for the Pitx3 custom antibody, this is described in Chapter 
3 section 3.5.1.2. 
As expression of mouse miR-205 is not detectable in the brain until 1 month it may be 
possible that the miR-205-lrrk2 interaction is not meaningful in zebrafish until later in 
development. To ensure that data suggesting that the interaction is not present in zebrafish 
is not false-negative, these interaction experiments should be carried out in relevant tissue 
at a range of ages. As knockdown using MOs is transient, to do this a miR-205 inhibitor, mimic 
or a stable knockout line could be used. 
Future work for investigation of miR-205 and Lrrk2 in zebrafish 
Firstly, the presence of an interaction between miR-205 and lrrk2 in zebrafish must be 
validated. The strategy for achieving this is discussed above. Once this interaction is validated 
the functional consequences may be examined in more detail. 
As discussed in the previous sections further work to determine whether miR-205 has true 
expression in the brain should be performed. In mice the expression of miR-205 in the brain 
gradually increases from 1 month to 18 months, this correlates with the decrease in LRRK2 
protein levels (Cho et al. 2013). Once an antibody has been validated for zebrafish Lrrk2 these 
experiments could be replicated to provide indirect evidence of an interaction and show that 
the expression of both miR-205 and Lrrk2 is relevant over the life of the zebrafish. 
The loss of dopaminergic neurons must be investigated in more detail to determine whether 
this observed effect is specific or a toxic effect of the injected MO. To do this a stable miR-205 
knockout line could be generated to assess the effects of this knockdown over a longer 
period. In mice knockout of miR-205 resulted in partially-penetrant postnatal lethality 
(Farmer et al. 2013). These mice exhibit skin defects. Although the internal organs which 
exhibited miR-205 appeared morphologically normal, the authors speculate that the lethality 
may be due to a digestive dysfunction. It would be interesting to investigate whether 
miR-205 plays the same developmental role in zebrafish. If premature death due to 
non-neuronal related phenotypes was observed a conditional knockout of miR-205 in brain 
tissue could be utilised to study the specific neuronal effects of this miRNA. 
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As Cho and colleagues suggest, miR-205 has potential as a therapeutic target in PD, however 
the beneficial effects of miR-205 overexpression have only been studied in cell culture 
models (Cho et al. 2013). It would be beneficial to study this in an in vivo model which 
displays neurotoxicity related to LRRK2 overexpression or mutation. As there is minimal 
evidence of neurodegeneration in murine models expressing WT or mutated LRRK2 (Li et al. 
2009) new models which are able to demonstrate the neurotoxicity of mutant LRRK2 (or 
overexpression of WT LRRK2) are needed. In the Bandmann lab the CRISPR/Cas9 system is 
currently being utilised to generate a point mutation in zebrafish lrrk2 corresponding to the 
G2019S mutation. Once developed, characterisation of this line will help add to the body of 
knowledge of the effect of this mutation, specifically the ɑ-synuclein-independent effects of 
this mutation. If a neurotoxic effect is seen with this model, miR-205 overexpression can be 
tested to determine whether this modulation of expression levels of the mutated Lrrk2 is 
able to ameliorate the phenotype. 
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Chapter 5. miR-155 and the role of neuroinflammation in 
neurodegeneration 
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5.1 Introduction 
Inflammation in Parkinson’s disease 
Inflammation in the brain is a common contributor in neurodegenerative diseases (Amor et 
al. 2014). In post-mortem studies of PD patient brains, activated microglia and increased 
concentrations of pro-inflammatory cytokines have been identified within the substantia 
nigra (McGeer et al. 1988; Boka et al. 1994). These data show that there is an increase in 
inflammatory processes in the brain of PD sufferers, however they do not determine 
whether this effect is causative or a consequence of neuronal cell death. It has been shown 
that neuromelanin, which is released from dying dopaminergic neurons, is able to elicit an 
immune response (Wilms et al. 2003). In vivo studies in PD patients and studies in animal 
models of disease can help elucidate the role of inflammation in PD. An increase of pro-
inflammatory cytokines has been detected in patient serum and cerebrospinal fluid (CSF) 
(Dobbs et al. 1999; Mogi et al. 1994), showing that these changes are taking place during the 
course of disease. Genetic studies of risk factors for PD and epidemiological studies also 
support the role of inflammation. Mutations in a number of genes involved in inflammation 
are associated with increased risk of PD, while a decreased risk of PD has been associated 
with use of ibuprofen (a non-steroidal anti-inflammatory drug), reviewed by Hirsch & Hunot 
(2009).  
Many of the inflammatory changes observed in PD patients can be identified in animal 
models of PD. In a mouse model of PD it was shown that microglial activation caused by 
injections of MPTP preceded neuronal loss. Furthermore, the inhibition of microglial 
activation mitigates the damage to neurons (Wu et al. 2002). To further support the role of 
inflammation as a causative mechanism of neuronal loss in PD, directly inducing an episode 
of neuronal inflammation in rodent brains by exposure to bacterial lipopolysaccharide (LPS), 
a potent activator of both peripheral immune cells and glial cells, results in a specific loss of 
dopaminergic neurons reminiscent of PD (Dutta et al. 2008). 
The involvement of miR-155 in inflammation and immunity 
miRNAs have been implicated in inflammation, including critical roles in inflammation in the 
CNS mediated by microglia (Su et al. 2015). Perhaps the best studied of these miRNAs is miR-
155.  
Before the discovery of miRNAs the primary transcript of miR-155 was known as bic (B-cell 
integration cluster). This was characterised as a gene that was activated in B-cell lymphomas 
by a promoter insertion upstream of this gene at a common retroviral integration site. It was 
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later discovered that pre-miR-155 is encoded within bic, this gene is now more commonly 
referred to as the miR-155 host gene. miR-155 is highly conserved in all jawed vertebrates. 
Jawless vertebrates utilise an alternative system for receptor diversification, thus suggesting 
that miR-155 developed alongside the beginnings of antigen receptors (Vigorito et al. 2013).  
Figure 71A shows the alignment of pre-miR-155 sequences from humans, mice, chickens, 
Xenopus tropicalis, zebrafish and Ciona intestinalis. C. intestinalis is the most primitive 
species which contains miR-155. Although it does not contain a well-developed adaptive 
immune system as is present in jawed vertebrates it is thought to contain core elements of 
rearranging antigen receptors (Kasahara et al. 2004). This alignment shows that the mature 
sequence of miR-155 (but not miR-155*) is highly conserved in all of these species and the 
seed sequence, the major determinant of target specificity, is 100% conserved. Figure 71B 
shows a relationship tree based on the alignment in Figure 71A. 
 
 
Figure 71. Conservation of miR-155 across species. Reproduced with permission from Vigorito et al. (2013). 
 
miR-155 is a typical multifunctional miRNA which is involved in haematopoiesis, B-cell and 
T-cell regulation, immunity and inflammatory process (Faraoni et al. 2009). It was also one 
of the first miRNAs to be considered “oncogenic” after it was shown that overexpression of 
miR-155 in B-cells in mice leads to B-cell lymphoma (Costinean et al. 2006). 
miR-155 is upregulated in activated T and B-cells and is thought to play an important role in 
their development and function (Rodriguez et al. 2007). In miR-155 deficient mice, both T-cell 
dependent and independent functions are impaired. miR-155 deficient mice have reduced 
number and size of germinal centres, the outcome of germinal centres is also impaired 
resulting in decreased production of high-affinity antibody and reduced number of memory 
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B-cells (Thai et al. 2007). After infection with Salmonella mice containing miR-155 deficient 
B-cells also demonstrate reduced production of IgM and IgG antibodies (Vigorito et al. 2013).  
T-cells are also influenced by miR-155 expression. Overexpression of miR-155 in CD4+ T cells 
drove Th1 cell proliferation (Banerjee et al. 2010) while miR-155 deficient mice have a 
reduced number of both Th1 and Th17 cells (O’Connell et al. 2010). Th17 cells are involved 
in mediation of chronic autoimmune inflammation (Langrish et al. 2005), these data 
therefore suggest the miR-155 is important for T-cell mediated immunity and autoimmune 
responses. This is further evidenced by the finding that miR-155 deficient mice are highly 
resistant to experimental autoimmune encephalitis (EAE) and autoimmune arthritis (Blüml 
et al. 2011; O’Connell et al. 2010). 
Pro-inflammatory stimuli, such as LPS, and inflammatory mediators, such as TNFɑ are able 
to upregulate miR-155 expression in a number of immune cells, including macrophages and 
microglia (Cardoso et al. 2012; O’Connell et al. 2007). In microglia, the resident immune cells 
of the CNS, miR-155 has been shown to be activated by p53 and push microglia towards a 
pro-inflammatory phenotype through suppression of the anti-inflammatory transcription 
factor c-Maf (Su et al. 2013). 
Other notable targets of miR-155 which mediate its pro-inflammatory function include 
suppressor of cytokine signalling-1 (SOCS1) and src homology 2 domain-containing inositol-
5-phosphatase 1 (SHIP1) (O’Connell et al. 2009; Wang et al. 2010). These genes are negative 
regulators of the immune response through inhibition of JAK-STAT signalling and mediation 
of proteosomal degradation of key elements of pro-inflammatory pathways (SOCS1), and 
suppression of the P13K pathway though negative regulation of Akt (SHIP1). 
miR-155 and neurodegenerative disease 
Inflammation in the brain is associated with many neurodegenerative disorders and brain 
injury. As discussed above microglia are the resident immune cells of the brain, their function 
is regulated by miR-155 thus suggesting this miRNA may play an important role in mediating 
inflammatory responses in neurodegenerative disease. 
Studies in patients have shown that miR-155 is upregulated in tissue from patients suffering 
from both multiple sclerosis and MND (Junker et al. 2009; Butovsky et al. 2015). Increases in 
the expression of this miRNA is also seen in animal models of neurodegenerative disease, 
including rodent models of Alzheimer’s Disease, multiple sclerosis and MND (Guedes et al. 
2014; Butovsky et al. 2015; Murugaiyan & Beynon 2011) and other animal models which 
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exhibit neuroinflammation through alcohol consumption (Lippai et al. 2013) or through 
infection with the Japanese Encephalitis Virus (Thounaojam et al. 2014). Knockdown of miR-
155 has also been shown to be neuroprotective. Loss of miR-155 ameliorated disease 
severity in both SOD1 mutant mice (a model of MND) and in EAE (a model of multiple 
sclerosis) showing that it plays a key role in the pathogenesis of these diseases (Butovsky et 
al. 2015; Murugaiyan & Beynon 2011). 
The aim of this study is to assess whether miR-155 is involved in inflammation in zebrafish 
models of PD. Expression of miR-155 will be investigated in two models of early onset PD, 
that is, pink1- and parkin-deficient zebrafish, and a third model which demonstrates gba1-
deficiency.  
In humans, mutations in GBA are the most common risk factor for PD (Neumann et al. 2009), 
whilst homozygous mutations in this gene cause Gaucher’s disease, a lysosomal storage 
disorder. Gaucher’s disease patients exhibit a wide range of symptoms of varying severity. A 
key feature of Gaucher’s disease which is thought to underlie the multi-systemic features of 
this disease is the accumulation of Gaucher’s cells. These are glycolipid-engorged 
macrophages, which accumulate in many organs including the brain (Baris et al. 2014). It is 
thought that these pathological macrophages are the source of increased inflammatory 
markers observed in Gaucher’s disease patients (Panicker et al. 2014). Moreover, 
neuroinflammation is thought to be a contributing feature to the neurodegeneration in 
neuronopathic forms of Gaucher’s disease. Progressive microglial activation and increases in 
inflammatory markers in the brain of mouse models of neuronopathic Gaucher’s disease 
correlate with neuron loss (Vitner et al. 2012; Farfel-Becker et al. 2011).  
Glial activation is a common feature in both Parkinson’s and Gaucher’s disease brain (Ginns 
et al. 2014), and increased levels of inflammatory markers have been identified in PD patients 
carrying GBA mutations (Chahine et al. 2013) suggesting neuroinflammation is a common 
feature of these diseases. miR-155 has not yet been implicated in the pathology of either 
Parkinson’s or Gaucher’s disease. 
5.2 Expression levels of miR-155 in PD zebrafish models 
In order to investigate the expression of miR-155 by qPCR a suitable reference gene first had 
to be determined. In previous chapters, qPCR for miRNA was only performed to validate 
specific changes in miRNA expression caused by injection of a MO or miRNA mimic. For these 
experiments an unrelated miRNA, which was not expected to be altered by this specific 
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MO/mimic, was used as a reference gene. In this chapter, this method cannot be used as it 
is possible that a large number of miRNAs may have altered expression in the genetic models 
of PD utilised in this study. Therefore, a miRNA reference gene must be chosen with care to 
ensure its stability in the models being used. 
5.2.1 Optimisation  
5.2.1.1 Testing miRNA qPCR reference genes 
In order to choose a small number of miRNAs for testing as potential reference genes a 
literature search was performed to investigate what miRNAs have been used as reference 
genes by other groups performing qPCR, specifically using the taqman miRNA assays, for 
miRNAs in zebrafish. The most commonly used reference gene was U6 small RNA. 
Unexpectedly, very few publications provided evidence that the miRNA they used as a 
reference gene has stable expression in the range of samples being investigated.  
Applied Biosystems do not produce a taqman miRNA assay specific for zebrafish U6, however 
it is possible to order custom assays, therefore a U6 assay was ordered. Another miRNA of 
interest is miR-24. This miRNA has already been used in-house as a reference gene for human 
PD samples (Mandal 2014). The zebrafish miR-24 sequence is 100% homologous to the 
human sequence. The stability of miR-24 and U6 snRNA were assessed in a range of RNA 
samples from zebrafish brain. To ensure accurate levels of RNA loaded into the reverse 
transcription reaction the QuantiFluorTM RNA system (Promega) and the Qubit® fluorometer 
(Life Technologies) were used. Firstly, the efficiency of the primers was assessed. Both assays 
had an efficiency of close to 100%. The samples used to test the stability of these small RNAs, 
all from zebrafish brain, were: 6 WT samples (of varying ages), 2 pink1-/- samples, 2 gba1+/- 
and 2 gba1-/- samples. The Ct values for U6 were highly variable in this range of samples, thus 
showing it is unsuitable for use as a reference gene (Figure 72A). miR-24 is much more stable 
in this range of samples (Figure 72B and C). miR-24 demonstrated stable expression in 
samples from wild type and pink1-/- brains, however the expression was not stable in gba1 
mutant zebrafish brains. This shows that this miRNA is unsuitable for use as a reference gene 
in this range of samples. 
163 
 
 
Figure 72. Stability of zebrafish U6 snRNA and miR-24 in a range of samples. A and B show the amplification 
plots of U6 and miR-24, respectively. The amplification plot for U6 shows that the Ct vary dramatically in this 
range of samples and are very high. This indicates that U6 is not a suitable reference gene for these samples. The 
amplification plot for miR-24 show that the Ct values are much more similar. C shows the Ct values for each of the 
12 groups tested. miR-24 expression levels are stable in samples from wild types and pink-/- zebrafish brains with 
a Ct value of close to 20. However miR-24 is not stable in gba1 mutant zebrafish brains who show a higher Ct 
value. 
 
5.2.1.2 Validation of using the QuantiFluorTM RNA system to control for loading 
As a suitable reference gene was not identified, use of the QuantiFluorTM RNA system to 
accurately measure RNA levels was investigated to determine whether this system could be 
used to control for loading rather than using a reference gene. To do this two of WT samples 
and gba1 mutant samples used for the previous experiments were used to repeat the entire 
process, from RNA quantification to qPCR, to assess the similarity of the results. These results 
were expressed as a fold change compared to the average of the WT expression levels. As 
shown in Figure 73, the two replicates match very closely with the fold change differing by 
no more than 0.2. For subsequent experiments miRNA expression analysis will be performed 
using the QuantiFluorTM RNA system to accurately measure RNA levels so exactly 100ng can 
be loaded into the reverse transcription reaction. As this is not a standard protocol due care 
will be taken to ensure the loading is as accurate as possible and small fold changes will be 
treated with caution. 
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Figure 73. Reliability of qPCR results using accurate RNA quantification. These data show the similarity of the 
results from two separate replicates performed with the same samples. In each experiment the results are 
expressed as fold change from the average of the WT samples. The variation between the two replicates is 
minimal; the fold change differs by no more than 0.2. 
 
5.2.2 Results 
5.2.2.1 miR-155 expression levels in gba1 mutant zebrafish 
As discussed above inflammation is a major feature of Gaucher’s disease. The expression 
levels of miR-155 were examined in whole gba1 mutant larvae and 3 month old brains (Figure 
74). In larvae a 2 fold increase in miR-155 levels was observed in the gba1-/- compared to WT. 
This indicates that inflammation is being driven from a very early age in gba1-deficient 
zebrafish. At the 3 month time point there is a striking 5 fold increase in gba1-/- compared to 
WT. 3 months of age is the end-stage of disease in the gba1-/- zebrafish. There is no change 
in miR-155 expression levels in gba1+/- brains at this age.  
 
 
Figure 74. miR-155 expression levels are increased in gba1 mutant brains and larvae. miR-155 levels are 
analysed by qPCR. A shows miR-155 expression in 5dpf larvae. B shows miR-155 expression in 3month old brains. 
Error bars represent standard deviation. Data were analysed by one-way ANOVA with Bonferroni post-tests. * = 
p<0.05, ** = p<0.01.  
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5.2.2.2 Spatial expression of miR-155 in gba1 mutant larvae 
To determine if the upregulation of miR-155 indicated by qPCR is driven by overexpression 
in a particular organ or whether this expression is diffuse within the embryo WISH was 
performed using an LNA probe for miR-155. The spatial expression pattern of miR-155 in 
5dpf gba1 mutant zebrafish is shown in Figure 75. 
In gba1+/+ (WT) larvae miR-155 does not appear to be spatially restricted and displays diffuse 
expression within the brain and trunk of the larvae. In gba1+/- larvae this staining pattern and 
intensity was very similar to the WT larvae. In gba1-/- larvae the staining intensity appears to 
be darker over the whole larvae, indicating that the increased expression of miR-155 is 
systemic rather than specific to a particular organ. 
 
 
Figure 75. Spatial expression of miR-155 in gba1 mutants.  WISH for miR-155 was performed in gba genotypes 
to determine spatial expression of this miRNA.  
 
5.2.2.3 miR-155 expression levels in pink1 and parkin deficient zebrafish  
miR-155 expression was then assessed in zebrafish models of early onset PD, in both adult 
brain and in 5dpf larvae. No change in miR-155 expression can be detected in 5dpf larvae or 
aged brains of pink1-/- or parkin-/- zebrafish. Brains were from 2.5 year old pink1-/- and WT 
siblings or 1.5 year old parkin-/- and WT siblings. Although there is a very slight increase in 
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both pink1-/- and parkin-/- 5dpf larvae this is not significant. The expression data is highly 
variable in the aged brains. 
 
Figure 76. miR-155 expression is not altered in PD zebrafish larvae and adult brains. miR-155 expression was 
assessed by qPCR. A shows the expression data for WT, pink1-/- and parkin-/- 5dpf larvae. Data are analysed by 
one-way ANOVA with Bonferroni post-tests, p>0.05. B shows expression data for WT and pink1-/- 2.5 year old 
brains and C shows expression data from WT and parkin-/- 1.5 year old brain. Error bars represent standard 
deviation. Data in B and C are analysed by an unpaired t-test with Welch’s correction, p>0.05. 
 
5.3 Expression of downstream markers of miR-155 in GD zebrafish 
5.3.1 Optimisation 
5.3.1.1 Identification of suitable markers 
To determine whether the observed increase in miR-155 expression in gba1-/- zebrafish also 
has an effect on downstream markers of inflammation relevant to Gaucher’s disease and PD 
a literature search was carried out to identify suitable markers. Three publications describing 
gene expression changes in PD patients with and without GBA mutations (Chahine et al. 
2013), in Gaucher’s disease patient serum (Barak et al. 1999) and in the brain of a mouse 
model of Gaucher’s disease (Vitner et al. 2012) were studied to generate a short list of 
inflammatory markers that are increased. 
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Table 18. Inflammatory markers increased in GD patients, gba1 deficient mouse brains and PD patients with 
GBA mutations. 
Inflammatory marker Increased in reference 
Interleukin-8 (IL-8) PD patients with GBA 
mutations (blood plasma) 
(Chahine et al. 2013) 
Monocyte chemoattractant 
protein-1 (MCP-1) 
PD patients with GBA 
mutations 
(blood plasma) 
(Chahine et al. 2013) 
interleukin-1 receptor 
antagonist (IL-1RA) 
Gaucher’s disease patient 
serum 
(Barak et al. 1999) 
Soluble interleukin-2 receptor 
(sIL-2R) 
Gaucher’s disease patient 
serum 
(Barak et al. 1999) 
Interleukin-1 beta (IL-1β) Gaucher’s disease patient 
serum and brain of a Gba-
deficient mouse 
(Barak et al. 1999; 
Vitner et al. 2012) 
Tumour necrosis factor-α 
(TNFα) 
Gaucher’s disease patient 
serum and brain of a Gba-
deficient mouse 
(Barak et al. 1999; 
Vitner et al. 2012) 
Tumour necrosis factor-α 
receptor (TNFα-r) 
Brain of a Gba-deficient mouse (Vitner et al. 2012) 
Macrophage colony stimulating 
factor (M-CSF) 
Brain of a Gba-deficient mouse (Vitner et al. 2012) 
Transforming growth factor β 
(TGFβ) 
Brain of a Gba-deficient mouse (Vitner et al. 2012) 
From the short-list shown in Table 18, IL-8 and TNFα were chosen as markers of interest as 
these have also previously been shown to be regulated by miR-155 (Min et al. 2014; Pathak 
et al. 2015; Lippai et al. 2013).  
5.3.2 Results 
5.3.2.1 Expression of TNFα and IL8 orthologues in gba1 mutants 
Zebrafish possess two orthologues of both TNFα (tnfa and tnfb) and IL-8 (CXCL8-l1 and 
CXCL8-l2). For both genes both orthologues are thought to be functional (Bates et al. 2007; 
de Oliveira et al. 2013). qPCR was performed for these markers to assess their expression 
level in 5dpf larvae and 3 month brains of gba1+/+ and gba1-/- zebrafish. In the 5dpf larvae 
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there is a trend towards an increase in expression in three out of the four markers. Although 
none of these markers reach significance individually the overall effect of gba1 deficiency on 
these markers is significant (p=0.0353). In 3 month old brains both orthologues of IL-8 and 
tnfb show a substantial 15- to 20-fold increase (Figure 77C). A two-fold increase of tnfa is 
observed however this is not significant.  
  
 
Figure 77. Expression of inflammatory markers in gba1 mutant brains and larvae. mRNA levels of zebrafish 
orthologues of inflammatory markers TNFα (tnfa and tnfb) and IL8 (CXCL8-l1 and CXCL8-l2) were assessed by 
qPCR. A shows expression of inflammatory markers in 5dpf larvae. Although none of the markers reach 
significance individually the overall effect of gba1-deficiency on these markers is significant (p=0.0353). B shows 
expression of inflammatory markers in 3 month brains. tnfb, CXCL8-l1 and CXCL8-l2 have significantly increased 
expression at this age. Error bars represent standard deviation. Data are from 3 biological replicates and are 
analysed by two-way ANOVA with Bonferroni post-tests. * = p<0.05, ** = p<0.01. 
 
5.4 Using the CRISPR/Cas9 system to create a miR-155 KO zebrafish line  
In order to generate a stable mutant line deficient for miR-155 the CRISPR/Cas9 system was 
utilised. This system is present in bacteria as a prokaryotic immune system. Fragments of 
DNA from invading viruses are stored by the bacteria and spliced into a region of the bacterial 
genome containing clustered regularly interspaced short palindromic repeats or CRISPRs. 
When this region is transcribed, the guide-RNA can then be used to guide CRISPR-associated 
(Cas) nucleases to the viral DNA and cleave it, thus preventing replication of the virus (Bhaya 
et al. 2011).  
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Figure 78. CRISPR/Cas9 gene editing system. A shows the design of an ultramer, from which the guide RNA can 
be transcribed. B shows the guide RNA recruiting the cas9 nuclease to the CRISPR site. 
 
The potential of this system was realised in 2012 (Hale et al. 2013); since then the 
development of the CRISPR/Cas9 system for gene-specific editing has gained momentum and 
is now a popular tool in many model organisms (Varshney et al. 2015; Wang et al. 2013; Hou 
& Zhang 2013). To generate site specific mutations a user-designed target sequence is placed 
between a T7 promoter and a guide RNA scaffold sequence (Figure 78A). When transcribed 
the target sequence binds to the genomic DNA and the guide RNA scaffold recruits Cas9 
nuclease to the CRISPR site within the gene of interest (Figure 78B). Cas9 will cleave the DNA 
3 bases upstream of the PAM site (NGG). Mutations can then be generated due to error 
prone repair, homology directed repair (for example if another fragment of DNA is co-
injected), or large (targeted) deletions can be generated if two CRISPR sites are cut 
simultaneously. 
5.4.1 Design and testing of CRISPR/Cas9 targets sites in miR-155 
To allow mutations caused by the CRISPR/Cas9 system to be easily identified PAM sites close 
to large restriction sites such as Mwo1 and Bsl1 are preferable. These are optimal sites to 
use for CRISPR as they are large and therefore relatively easy to disrupt. Mwo1 site is 
GCNNNNNNNNGC and the Bsl1 site is CCNNNNNNNCC. Bsl1 sites naturally contain PAM sites 
which gRNAs can be targeted to. miR-155 contains a number of Bsl1 and Mwo1 sites which 
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can be used as CRISPR targets. Four gRNAs were designed to such sites. The aim was to either 
generate a large deletion removing the miR-155 coding sequence entirely or to cause a 
disruption within the miR-155 coding sequence. Figure 79 shows these sites and where the 
CRISPR cuts the DNA.  
 
 
Figure 79. CRISPR sites in miR-155 region. This figure shows CRISPR sites present within and in the region around 
miR-155. A shows an overview of the miR-155 region with the miR-155 exon shown in orange and CRISPR sites 
marked. All Bsl1 and Mwo1 restriction sites are also labelled. B-D show the individual sites in detail. The restriction 
site is shaded on the DNA and its cut site labelled with a red line. The PAM site is circled in green with an arrow 
and dotted line marking the site where Cas9 will cut the DNA. US = upstream, DS = downstream. 
 
The gRNAs listed above were injected into one-cell stage zebrafish embryos in pairs. The 
injected pairs were: gRNA1+4, gRNA2+4, gRNA3+4 and gRNA2+3. To test the efficacy of the 
injected CRISPRs DNA was extracted from four embryos from each injected group. PCR was 
performed to amplify the region of interest. This was run on an analytical gel to determine 
whether any large deletions had been created. As shown in Figure 80A, no large deletions 
were detected after injection of these pairs of gRNAs. As no large deletions were detectable, 
it was determined whether gRNAs 2 or 3 had induced any mutations. To do this the PCR 
product from embryos injected with this pair of gRNAs was digested with Bsl1. If the Bsl1 site 
is disrupted in the injected embryos a 734bp fragment would be expected. Figure 80B shows 
the fragments after digest with Bsl1. A very faint band the size of the undigested fragment is 
detectable in the gRNA injected samples suggesting the Bsl1 site present at the beginning of 
the miR-155 exon is disrupted in some cells. As the cut site for gRNAs 2 and 3 are within the 
exon of miR-155 mutations caused by this CRISPR may disrupt the transcription, processing 
or mature sequence of miR-155. 
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Figure 80. Analysis of efficacy of miR-155 CRISPRs. The efficacy of miR-155 CRISPRs was analysed by PCR (to 
screen for large deletions/insertions) and restriction digest to screen for disruption of restriction sites by small 
mutations. A shows an analytical gel showing the PCR products generated from uninjected embryos and embryos 
injected with each of the 4 pairs of gRNAs. No large deletions or insertions are detected. B shows an analytical gel 
of the PCR products from embryos injected with gRNA2 and/or 3 digested by Bsl1. In uninjected embryos the 
expected fragments can be seen (44bp and 287bp and 447bp). In the injected embryos a faint band at ~734bp 
(marked with an arrow) can be seen. This suggests that the Bsl1 restriction site is disrupted in some cells. 
 
To determine what mutations are caused by disruption of CRIPSR sites 2 or 3 the products 
generated by the original PCR were cloned into the TOPO® vector. This method allows the 
individual products to be separated so they can be analysed individually. 90 colonies were 
analysed and it was assessed whether any of these fragments were mutated by PCR and 
digestion with Bsl1. No mutated products were detected. This shows that although the 
undigested fragment was detected in the first experiment these CRISPRs are not efficacious 
and very few mutations are created.  
Although there are no other suitable CRISPR target sites within Mwo1 or Bsl1 restriction sites, 
there are other target sites which can be assayed using different restriction enzymes. A site 
within the mature miR-155 sequence was found. This site is within an Hpy188III (TCNNGA) 
restriction site. A gRNA (gRNA5) was designed to recruit Cas9 to this site. As the site is within 
the mature miR-155 sequence it is likely that miR-155 function will be disrupted by this 
CRISPR, even if only small mutations are made. Figure 81A shows the location of the gRNA5 
target site within the miR-155 coding region. After injection of gRNA5 embryos were 
collected at 24hpf to extract DNA. PCR was performed to amplify this region and the efficacy 
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of the CRISPR was assessed by digestion with Hpy188III. This CRISPR appears to have a high 
efficacy as the digested products are virtually undetectable in gRNA5 injected embryos 
(Figure 81B). This shows that in almost all cells the Hpy188III restriction site present within 
the miR-155 exon is disrupted and therefore this DNA fragment cannot be digested. 
 
 
Figure 81. Design and efficacy of miR-155 gRNA5. A shows the miR-155 exon, the primers which will be used to 
amplify it and the location of the target site for gRNA5. The Hpy188III restriction site is shaded on the DNA and its 
cut site labelled with a red line. The PAM site is circled in green with an arrow and dotted line marking the site 
where Cas9 will cut the DNA. B shows an analytical gel showing the uncut product (120bp) and fragments from 
the digest with Hpy188III in uninjected and gRNA5 injected embryos. 
 
In order to examine individual mutations caused by this CRISPR, TOPO® TA cloning was 
performed and 30 samples were sent for direct sequencing. Table 19 shows a selection of 
the mutations that are generated by injection of gRNA5 and Cas9 protein. These mutations 
are likely to disrupt the function of miR-155 as a large part of the mature sequence is deleted 
or there is an insertion the will likely disrupt the correct processing of the pri-miRNA. 
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Table 19. Mutations caused by miR-155 CRISPR5. Mature miRNA sequence is shown in red. 
 Sequence mutation 
 
WT  
 
GTGGATGTGCGTTGATCTCCTGGTGCAGGTTTAATGCTAATCGTGATAGGGGTTTA
GTGCTGATGAACACCTATGCTGTTAGCATTAATCTTGCGCTAGTGAGCGAACCGTC
TGAACATC 
 
- 
1 NNNNNTGTGCGTTGNTCNCCTGGT------------------------GGGGTTTA
GTGCTGANNANCACCT 
24bp del 
2 GTGCGTTGATCTCCTGGTGCAGGTTTAATGCTAAT-[+24bp]-GATAGGGGTTTA
GTGC 
Insertion: [CGGGNTTAGTGCTGGGGGTTAGGG] 
9bp del + 
24bp ins 
3 NNNNATGTGCGTTGNTNTCCTGGTGCAGGTTTAATGCT------------------
-----GANNAACACNTATGCTGTNAGCATTAATCTTGCGCTAGTGAGCGAANCGTC
TGAAC 
23bp del 
4 NNNNNNNTGCGTTGATCTCCTNGTGCAGGTTTAATGC[+8bp]TGATAGGGGTTTA
GTGCTGANNANNNCCT 
Insertion: [AGGCTTAA] 
6bp del + 
8bp ins 
5 NNNNNNGTGCGTTGATCTCCTGGTNCAGGTTTAATGCTAATCG-GATAGGGGTTTA
GTGCTGATGAACACCNATGCTGTTAGCATTAATCTTGCGCTAGTGAGCGAACCGTC
TGAA 
Insertion: [CGGGNGGTTTAGTAGGGGGTTTAGTGCTA] 
1dp del + 
27bp ins 
 
5.4.2 Raising miR-155 CRISPR injected zebrafish and line management 
Embryos which were injected with gRNA5 were raised. When they reach breeding age 
individual zebrafish will be out-crossed to a WT zebrafish. DNA will be extracted from a 
selection of embryos from each pairing. This will be examined by PCR and subsequent 
digestion with to Hpy188III to determine whether they carry a mutation in miR-155. If any of 
these embryos carry a mutation this would indicate that the parent is a founder as it carries 
mutations for miR-155 in its germ line. Embryos from such founders will be raised, this is the 
F1 generation. When the F1 zebrafish are large enough for fin clipping to be performed, the 
mutation each carries will be determined by PCR and direct sequencing of the PCR product. 
The F1 zebrafish will be heterozygous for an individual mutation in the miR-155 gene. These 
zebrafish only carry one type of mutation for this gene; however each individual F1 zebrafish 
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is likely to carry a different mutation. The zebrafish carrying the largest or most easily 
detectable mutations will be kept to ensure time and cost-effective screening for mutations 
in the future. If any zebrafish of opposite sexes carry the same or very similar mutation they 
may be mated together to produce progeny which are either WT, heterozygous (for either 
mutation) or compound homozygous in the F2 generation. If this is not possible, for example 
if founders are only of one sex, the F1 zebrafish with the selected mutations will be out 
crossed again to produce the F2 generation. The F2 generation can then be in-crossed to 
generate homozygous mutants. 
5.5 Discussion 
The aim of this study was to investigate the involvement of miR-155 and inflammation in the 
pathology of pink1-, parkin- and gba1- deficient zebrafish. To do this miR-155 expression 
levels and the expression of relevant inflammatory markers regulated by miR-155 were 
assessed. A miR-155 knockout zebrafish line was also generated using the CRISPR/Cas9 
system. 
miR-155 expression in zebrafish models of PD and Gaucher’s disease 
In 3 month old gba1-/- brains a significant 5-fold increase in miR-155 was detected. At this 
age these zebrafish are close to the end of their life. Gaucher cells are present within the 
ventricles and the cerebellum of gba1-/- zebrafish and an increased microglial infiltration of 
the brain has been detected at this age. These microglial cells have retracted processes, 
indicating they are activated (Keatinge et al. 2015). These data show that inflammatory 
pathology is present in 3 month old gba1-/- zebrafish. To further investigate the role miR-155 
in aged gba1-/- brains, WISH could be performed on sections to examine the localisation of 
this miRNA within the brain. This would determine whether miR-155 is primarily expressed 
in the Gaucher cells or activated microglia. The proximity of miR-155-expressing cells to the 
affected dopaminergic neurons could also be determined. 
The expression of miR-155 in gba1 mutants was also assessed in whole 5dpf larvae. In larvae 
a significant 2 fold increase in miR-155 expression was detected in gba1-/-. When assessed 
by WISH miR-155 expression appeared to be increased systemically rather than originating 
from a specific organ. These data suggest that inflammation is an important feature of 
Gaucher’s disease pathology from an early age. At 5dpf a significant change in microglial 
morphology was also detected (Keatinge et al. 2015) thus providing more evidence for in 
inflammatory phenotype in gba1-/- larvae.  
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To determine when an increase in miR-155 expression is first detectable in the brain and 
whether this precedes neuronal loss more time points need to be examined to quantify both 
miR-155 expression levels and correlate this with the number dopaminergic neurons.  
No change in miR-155 expression levels could be detected in 5dpf larvae or aged brains from 
pink1- or parkin- deficient zebrafish. As PD is a heterogeneous disease with many causative 
factors, it is possible that some subtypes of PD have more inflammatory involvement than 
others. Therefore, although miR-155 upregulation is not detected in pink1- and parkin-
deficient zebrafish models it is possible this miRNA may be important other forms of the 
disease. To test this in zebrafish the MPP+ toxin-induced Parkinson’s model could be used. 
As miR-155 has not previously been associated with PD it would be interesting to examine 
the expression levels of miR-155 in a range of murine models and in human post mortem 
brain and peripheral tissues from patients to determine whether this miRNA is elevated. 
Expression of relevant inflammatory markers in gba1 mutant zebrafish 
IL-8 and TNFα were chosen as relevant inflammatory markers to study in gba1 mutant 
zebrafish. IL-8 has been shown to be increased in the blood plasma of PD patients carrying 
GBA mutations (Chahine et al. 2013) and TNFα is increased in the serum of Gaucher’s disease 
patients and in the brains of a Gba1-deficient mouse (Barak et al. 1999; Vitner et al. 2012). 
These inflammatory markers have also been shown to be downstream of miR-155. Two 
groups studying ulcerative colitis showed that IL-8 can be positively regulated by miR-155 
through repression of its direct targets SOCS1 and FOXO3a (Min et al. 2014; Pathak et al. 
2015). Inflammation in alcohol fed mice has also been shown also regulated by miR-155, 
which is induced in a TLR-4-dependent manner. Chronic exposure of WT mice to ethanol 
leads to an increase of a number of inflammatory markers, including TNFα, in the cerebellum. 
NF-κB was also activated in these mice. In miR-155 deficient mice, chronic alcohol exposure 
does not increase the expression of TNFα suggesting that miR-155 drives the increase in 
expression of these inflammatory marker through activation of the NF-κB (Lippai et al. 2013). 
In the brains of 3 month old gba1-/- zebrafish large significant increases in three out of the 
four markers was observed. For tnfa a smaller non-significant 2 fold increase was detected. 
In 5dpf larvae the overall effect of the gba1-/- genotype confers significant effect on the 
expression of inflammatory markers. This result is encouraging and supports the notion that 
inflammation precedes the neurodegenerative phenotype in these zebrafish. However the 
observed changes are not sufficient to assume that these inflammatory markers are truly 
increased at this age. To further validate these findings analysis of protein levels is necessary. 
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Generation of a miR-155 knockout line and future work 
The CRISPR/Cas9 system was used to generate mutations in miR-155. Analysis of the 
mutations in the F0 generation identified a number mutations which are likely to completely 
remove miR-155 function (i.e. the mature miRNA sequence is deleted). At the time of writing 
(August 2015) this colony is in the F0 generation. As discussed in section 5.4.2, these 
zebrafish need to be outcrossed and founders identified to raise zebrafish from which a 
colony of miR-155 knockout zebrafish can be produced. Once established the miR-155 
knockout line may be crossed with the gba1-/- line to determine whether loss of miR-155 is 
protective and can increase health and longevity of these zebrafish through prevention or 
modulation of inflammatory pathways. 
By 3 months of age gba1-/- display a marked increase in chitotriosidase activity. The activity 
of this enzyme is commonly used as a biomarker to monitor disease in Gaucher Disease 
patients. Chitotriosidate is mainly produced by activated macrophages and epithelial cells 
and therefore is indicative of the inflammatory involvement of Gaucher’s disease. Other 
inflammatory phenotypes of the gba1-/- zebrafish are the increased infiltration of microglial 
cells in the brain and the presence of Gaucher cells in the brain and other organs.  
Further work that could be performed on this project is increased investigation of the 
inflammatory phenotype in gba1-/- zebrafish. Experiments which could be performed are 
further examination of microglial activation at a range of time points. The protein levels of a 
range of inflammatory markers could be assessed and microglial production of reactive 
oxygen or nitrogen species could be analysed. Reactive oxygen species in the brain are 
known to contribute to neurotoxicity (Block et al. 2007). miR-155 has previously been shown 
to drive nitric oxide production of microglia through its target SOCS1 (Cardoso et al. 2012). 
RNA-sequencing on WT microglia compared to microglia from gba1-/- could be performed to 
identify altered expression patterns. This could be used to determine important downstream 
targets of miR-155 if compared to microglia from miR-155 deficient zebrafish. An assessment 
of the numbers of microglial cells in the brain should also be performed a range of ages to 
determine when an increase is first detectable and whether this precedes neuronal loss. The 
effect of genetic miR-155 inactivation on these key phenotypes could be then examined. 
To investigate the wider effect of miR-155 in Gaucher’s disease pathology, the effect of 
miR-155 knockout on mitochondrial function, number of dopaminergic neurons and the 
movement phenotype of the gba1-/- zebrafish could be assessed. 
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No change in miR-155 expression was seen in the gba1+/- brains at 3 months. As heterozygous 
mutations in gba1 are a common risk factor for PD it would be interesting to assess the miR-
155 expression in gba1+/- zebrafish at a much older time point when they may begin to 
develop a parkinsonian phenotype. The movement and neurodegenerative of aged gba1+/- 
should also be characterised. If any phenotype is present this is relevant to PD pathology and 
miR-155 knockdown could be performed to determine whether this ameliorates any 
observed phenotype.  
Finally, a miR-155 overexpressing line could be generated and subsequently crossed with 
Parkinson’s and Gaucher’s zebrafish models to determine whether miR-155 upregulation 
results in increased inflammation and if so, whether this results in the predicted exacerbation 
of dopaminergic cell loss. 
Summary  
This study provides the first evidence of miR-155 involvement in Gaucher’s disease and 
demonstrates that this miRNA is upregulated in gba1-deficient zebrafish before the presence 
of a neurodegenerative phenotype. The inflammatory phenotype observed in these 
zebrafish must also be characterised further to determine whether this precedes, or even 
drives, the neurodegeneration observed. 
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Chapter 6. Developing a high throughput imaging system 
for zebrafish larval brains 
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6.1 Introduction 
Zebrafish are an ideal model organism for use in phenotypic drug discovery. The embryos 
develop rapidly, allowing the study of effects of drugs and toxins at a whole system level. 
Their small size allows for efficient handling in 96-well plates, which are commonly used for 
drug screening and are compatible with automated liquid handling machinery. The large 
number of progeny ensures enough embryos are easily available for high throughput studies 
and their transparent nature also means they are highly suitable for imaging. Ease of genetic 
manipulation allows the creation of transgenic fluorescent reporter lines which provide 
easily quantifiable read outs that can be used for high throughput screening. Examples of 
this include a screen performed by McGown and colleagues (2013), aiming to identify 
compounds able to reduce stress in the interneurons in a sod1-mutant zebrafish. For this 
screen a transgenic zebrafish containing dsRED under the control of the Hsp70 promoter was 
utilised. Under increased oxidative stress dsRED fluorescence increases thus allowing the 
authors to quantify changes in the oxidative stress response exhibited after treatment 
(McGown et al. 2013). In another screen, a transgenic line with GFP-tagged neutrophils was 
used to identify compounds able to modulate resolution of inflammation after fin injury 
(Robertson et al. 2014). Use of this transgenic line allowed the authors to score the number 
of neutrophils remaining at the site of injury 12 hours post injury. These are just two 
examples of drug screens which utilise the tools available enabling zebrafish to be a powerful 
model organism for use in high throughput screens which use imaging as a read out. 
Compared to traditional target-driven drug discovery, where on average it takes 12-15 years 
for a drug to enter the clinic, phenotypic drug discovery has the potential to significantly 
reduce the time taken for a promising drug to enter human trials and eventually clinical use. 
Typical pipelines and approximate timings for both target-driven drug discovery and 
phenotype-driven drug discovery are shown in Figure 82. With target-driven drug discovery 
a large number of initially promising compounds fail upon animal testing due to 
bioavailability and toxicity issues, thus resulting in a large amount of wasted time and 
resources. These problems are largely eliminated by usage of animal models in the initial 
drug discovery phase as the effects of the drug in the environment of a whole organism can 
be analysed, thus allowing an assessment of bioavailability, toxicity and efficacy to be made 
in the earliest stages of drug testing (Bowman & Zon 2010). 
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Figure 82. Comparison of strategies for drug discovery. This flow diagram illustrates the typical pipeline of both 
target-driven drug discovery and phenotype-driven drug discovery. Adapted with permission from Bowman & Zon 
(2010). 
As there are currently no disease modifying treatments available for PD, research into 
developing such drugs is of critical importance. In order to identify compounds of interest 
drug screening platforms must be available with read outs which are relevant to the disease 
process. Likewise, a similar process could be used to identify toxins that contribute to PD 
pathology. Only a small proportion of PD diagnoses are attributable to a known cause (de 
Lau & Breteler 2006). Although a large number of genetic risk factors have been identified 
by GWAS, the overall heritability of PD is only estimated at approximately 27% (Keller et al. 
2012). It is clear that there are unidentified genetic and environmental factors which increase 
the risk of developing PD. Thus, a toxin screen to identify potential modifiers of dopaminergic 
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neuron survival would be extremely valuable to help uncover other mechanisms which infer 
increased risk for PD.  
In the field of PD research, study of the survival of dopaminergic neurons is key. A method 
for counting dopaminergic neurons in zebrafish using WISH for th has previously been 
established and is described in detail in 0 section 2.15.1 (page 70). One limitation of using 
WISH for th and subsequently counting the neurons as a drug screening tool is that it is a 
very labour intensive protocol. Robots are available to automate and therefore increase the 
throughput of the WISH process; however, post-WISH, the embryos need to be mounted 
dorsally and the neurons manually counted. Another limitation is unintentional bias and 
inconsistency in counting. It is possible to blind the researcher to the individual samples 
which are being counted; however, some treatments, such as MPP+ or particular MOs, 
produce a remarkably different appearance in the embryo morphology, making the 
treatment condition apparent. Despite these limitations, in 2012 a study was published that 
screened the effect of 5000 compounds on the development and survival of dopaminergic 
neurons. To do this, IHC for TH was performed post-drug treatment and subsequently the 
fluorescence was assessed using confocal microscopy (Sun et al. 2012). This study shows that 
it is indeed possible to perform a drug screen using methods that stain the neurons of 
interest and perform manual imaging to assess the effects of the compounds on the staining. 
However, this is an extremely time consuming and expensive process. To develop more time 
and cost effective methods for studying the effects of small molecules on dopaminergic 
neuron development and survival, alternative methods to measure dopaminergic neuron 
number and screen large numbers of embryos must be established. Fluorescent reporter 
lines which label cells of interest are a useful tool that remove the need for manual staining 
techniques, allowing for more cost effective visualisation of the region of interest. 
Although there are currently no reporter lines which specifically label only the th+ 
dopaminergic neurons, a fluorescent reporter line is available which expresses GFP in 
monoaminergic neurons (Wen et al. 2008). The production of this transgenic line used 
enhancer trap technology to insert the transgene (GFP linked to the zebrafish gata2 minimal 
promoter) into the second intron of vmat2. Vmat2, vesicular monoamine transporter 2, is 
responsible for transport of monoaminergic neurotransmitters from the cytosol to the 
synapse. The insertion of GFP into the vmat2 intronic region allows GFP to be expressed in 
vmat2 containing neurons as it is placed under control of the vmat2 enhancer. The authors 
verified that the expression pattern of GFP recapitulates that of vmat2, including expression 
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in the th+ neurons of the ventral diencephalon. They discuss that this line may be a useful 
tool for drug studies relevant to PD in the future. This transgenic reporter line is referred to 
as the ETvmat2:GFP reporter line. 
The first aim of this section of my thesis was to develop a method to use the ETvmat2:GFP 
reporter line for study of the dopaminergic neuron cluster. As discussed above, using WISH 
to stain the dopaminergic neurons is a time-consuming process, and therefore use of a 
fluorescent reporter line to measure the number of dopaminergic neurons would be 
beneficial as it is possible to image live embryos and visualise the diencephalic 
catecholaminergic cluster. This prevents the need to fix embryos at the desired time point 
and perform WISH, thus reducing sample processing time greatly and increasing capacity for 
high throughput analysis. The second aim of this section is to use the ETvmat2:GFP reporter 
line to generate a high throughput imaging process, from which analyses of dopaminergic 
neurons can be made, and subsequently be used as a read-out for a phenotypic drug screen. 
6.2 Using the ETvmat2:GFP neuronal reporter line to study dopaminergic 
neurons 
6.2.1 Optimisation 
6.2.1.1 Validation of GFP expression in th+ neurons 
To successfully use the ETvmat2:GFP reporter line to replace neuron counting experiments 
it must first be determined whether this reporter line accurately labels the th+ dopaminergic 
neurons. To do this, a dual WISH-IHC was performed to label th and GFP-positive neurons 
simultaneously. 
Figure 83A shows the brain of a 3dpf zebrafish embryo and the neuronal groups labelled by 
the ETvmat2:GFP reporter line. As well as the diencephalic catecholaminergic cluster, which 
contains the neurons which are detected using WISH for th, other GFP positive neuronal 
groups include: the raphe nuclei, and hypothalamic, pretectal and telencephalic neuron 
populations. Figure 83B shows the diencephalic catecholaminergic cluster in more detail and 
indicates co-localisation of GFP and th. These data show that this reporter line can indeed be 
used to study this neuronal group. 
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Figure 83. Neuronal groups labelled by the ETvmat2:GFP reporter line. A shows neuronal groups labelled by the 
ETvmat2:GFP reporter line. B shows co-localisation of th positive neurons and GFP labelled neurons in the 
ETvmat2:GFP reporter line. Scale bar = 100μm 
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6.2.1.2 Development of a method to image and analyse dopaminergic neurons in the 
ETvmat2:GFP reporter line 
To utilise the ETvmat2:GFP reporter line to analyse dopaminergic neuron number, a method 
was developed which aimed to use total fluorescence intensity of the diencephalic 
catecholaminergic cluster as an indication of dopaminergic neuron number. Total 
fluorescence intensity takes into account the fluorescence intensity of the GFP positive pixels 
and the number of GFP positive pixels. As zebrafish which contain the ETvmat2:GFP 
transgene express GFP in the dopaminergic neurons the hypothesis behind this method was 
that, in embryos with more dopaminergic neurons more pixels will be GFP positive therefore 
the total fluorescence intensity reading will be increased. 
To ensure that copy number of the transgene did not obscure any otherwise quantifiable 
changes in fluorescence, the WT ETvmat2:GFP zebrafish, which are either homozygous or 
heterozygous for the transgene, were outcrossed to WTs for all experiments. These zebrafish 
will be referred to as ETvmat2:GFP;WT. This ensured that all GFP positive zebrafish were 
heterozygous for the transgene. Using a mixed population of homozygous and heterozygous 
embryos, as would be generated from an incross, would allow copy numbers to differ 
between embryos. At 24hpf the embryos were screened to select for GFP-positive embryos.  
To image the ETvmat2:GFP;WT embryos, at 3dpf the embryos were anaesthetised in tricaine 
and mounted on a glass coverslip in 1% LMP agarose. To ensure the best orientation of the 
embryo to allow capture of a high quality image of the developing brain, the embryo was 
held in the dorsal position using fine forceps or a mounted needle as the agarose had set. 
Images were captured using the 10x objective on an UltraViewVoX spinning-disk confocal 
microscope (PerkinElmer Life and Analytical Sciences). A z-stack encompassing the entire 
fluorescent portion of the zebrafish brain with 3μm slices was generated for each embryo.  
To quantitatively measure the fluorescence levels of the diencephalic catecholaminergic 
cluster an image analysis process was developed using ImageJ (Figure 84). Each image was 
rotated and cropped (136.54μm x 136.54μm) around the diencephalic catecholaminergic 
cluster. A substack was created which included only slices containing the diencephalic 
catecholaminergic cluster in order to exclude neurons from other groups. A maximum 
intensity projection of this substack was generated; this is where the maximum fluorescence 
intensity reading for each pixel in the specified stack is recorded and projected onto the final 
image. In order to analyse the images, the total fluorescence intensity above a determined 
threshold was measured in the maximum projection image; shown in Figure 84.  
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Figure 84. Image analysis process with ETvmat2:GFP embryos. A shows the whole image taken on the spinning 
disk microscope. B shows this image rotated and a box drawn around the region of interest. C shows the cropped 
image which only contains the diencephalic catecholaminergic cluster which we are interested in. D shows a 
montage of all the slices present in this cropped image. E shows a substack (slices 3-19) of the same image; this 
only contains slices that show the neuronal group of interest. F shows a montage of the slices present in the 
substack. G shows the maximum projection image of the substack. H shows how the total fluorescence intensity 
(no of pixels reaching threshold value multiplied by the mean intensity of the selected area) of the maximum 
projection image is acquired. 
 
 
187 
 
To determine the most suitable threshold, a range of thresholds were tested. The threshold 
function in ImageJ allows the user to set the threshold value and view which regions of the 
image are above this threshold value. By viewing the regions of the image captured by a 
range of thresholds, it was determined that a threshold of 4000 accurately captures the 
majority of the neurons of interest. If the value is set much higher than 4000, only the central 
regions of the brighter neurons are included and some fainter neurons which would be 
included in a manual neuron count are excluded. If the threshold is set much lower than 
4000, some background noise reaches the threshold value. This is shown in Figure 84H where 
the red masking highlights the areas captured by this threshold; the unmasked image is 
shown in Figure 84G. As there was no significant variation between the background noise 
level of the images between individual embryos or experiments, this threshold value was 
used for all subsequent experiments. The number of overexposed pixels and number of 
captured pixels was also monitored; if any particular image had more than 15% overexposed 
pixels it was excluded. Likewise, if less than 200 pixels are above the threshold then this 
image was also excluded.  
To validate the suitability of ETvmat2:GFP reporter line and the image analysis method 
described above, results using this method were compared to previously established data 
sets where dopaminergic neurons were manually counted using after WISH for th. If able to 
replicate previous results, this technique has the potential to remove researcher bias as the 
process may be automated rather than relying on manual counting of neurons.  
6.2.2 Results 
6.2.2.1 Validation of the ETvmat2:GFP reporter line to count dopaminergic neurons 
To validate the use of the ETvmat2:GFP reporter line and the image analysis method, three 
experimental groups which have previously been shown to have altered dopaminergic 
neuron numbers were used. These are: miR-133b morphants, treatment with MPP+ and 
pink1 deficiency. The first of these groups, miR-133b morphants, demonstrate an increase in 
dopaminergic neuron number; this is shown in Chapter 3 section 3.3.2.1. Secondly, 
treatment with MPP+ results in a loss of dopaminergic neurons. Finally, pink1 deficiency 
results in a more moderate decrease in dopaminergic neurons. ETvmat2:GFP zebrafish were 
previously crossed with pink1-/- zebrafish to generate zebrafish which express this transgene 
on a pink1-/- background. To generate embryos for image analysis, these zebrafish are 
outcrossed to pink1-/- zebrafish which do not possess the ETvmat2:GFP transgene. Resulting 
progeny were screened for fluorescence prior to confocal microscopy. 
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miR-133b morphants demonstrate a 20% increase in th+ dopaminergic neuron number 
compared to WT as measured by manual neuron counting after WISH for th (Figure 85A). To 
determine whether this result could be replicated using the ETvmat2:GFP reporter line, miR-
133b MO injections were performed in the ETvmat2:GFP;WT embryos. For each biological 
replicate ten embryos from each group were mounted and imaged at 3dpf. The total 
fluorescence intensity was measured using the image analysis method described above. For 
each biological replicate the total fluorescence intensity is normalised to the average of the 
WT. Measuring fluorescence intensity in morphants compared to WTs also detects a 
significant increase of approximately 40% (Figure 85). This is a larger increase than is 
detectable in neuron number seen by counting th+ dopaminergic neurons after staining by 
WISH. This may be due to the increased expression levels of dopaminergic markers as well 
as the increased number of neurons. These data show that an increase in dopaminergic 
neuron number can be detected by measuring fluorescence intensity measurements in the 
ETvmat2:GFP reporter line. 
 
Figure 85. th+ dopaminergic neuron counts and fluorescence intensity in WT and miR-133b morphants. A shows 
previous data collected by counting the number of neurons labelled after WISH for th. In miR-133b MO injected 
embryos there is a 20% increase in th+ dopaminergic neuron number. B shows the total fluorescence intensity 
measurements of the same population of neurons. In miR-133b MO injected embryos there is a 40% increase in 
fluorescence intensity compared to WT. Data are from three biological replicates with a minimum of 10 images 
are analysed per biological replicate and the average taken.  C shows a representative maximum projection image 
from each WT and miR-133b MO injected embryos. The yellow bounded areas are the regions which reach the set 
threshold and will be included in the image analysis. Error bars represent standard deviation. Both data sets 
analysed using an unpaired t-test with Welch’s correction, * = p<0.05, ** = p<0.01. On axis DA = dopaminergic. 
189 
 
It was also important to determine whether this method is also able to detect a decrease in 
dopaminergic neurons. For this experiment, embryos were treated with a high dose of MPP+; 
6mM MPP+ was added to E3 medium at 1dpf and replaced at 2dpf. Neurons were counted 
at 3dpf. This high dose of MPP+ causes approximately a 60% decrease in th+ dopaminergic 
neurons, as measured by neuron counting using WISH for th (neuron counting was 
performed by Rebecca Wilcock, Figure 86A). Similarly, when ETvmat2:GFP;WT embryos are 
treated with this dose of MPP+ a 60% decrease in fluorescence intensity is also detected 
(Figure 86B). When the percentage changes in the measurements of dopaminergic neuron 
number collected by these two different methods are compared by a two-way ANOVA there 
is no significant difference between these two data sets. This shows that this method can be 
used to accurately measure large decreases in dopaminergic neuron number. 
 
 
Figure 86. th+ dopaminergic neuron counts and fluorescence intensity in WT and MPP+ treated embryos. A 
shows previous data collected by counting the number of neurons labelled after WISH for th data is from 3 
biological repeats with 10 zebrafish per group per experiment. These data were collected by Rebecca Wilcock. B 
shows fluorescence intensity after MPP+ treatment. Data is from 1 biological repeat with 9 embryos per group. 
Both data sets show a 60% decrease in fluorescence intensity after treatment with MPP+. C shows a representative 
maximum projection image from each WT and MPP+ treated embryos. The yellow bounded areas are the regions 
which reach the set threshold and will be included in the image analysis. Error bars represent standard deviation. 
Both data sets analysed by an unpaired t-test with Welch’s correction, *** = p<0.001, **** = p<0.0001. On axis 
DA = dopaminergic. 
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Finally, in order to determine whether more subtle decreases in dopaminergic neuron 
number can be detected, ETvmat2:GFP zebrafish raised on a pink1-/- background were 
analysed and compared to ETvmat2:GFP with a WT background. pink1 deficiency causes a 
more moderate decrease of around 25% of dopaminergic neurons at 3dpf (Flinn et al. 2013). 
The fluorescence intensity method was unable to detect a decrease in the pink1-/- zebrafish 
compared to WT (Figure 87A). Generation of a maximum projection image may have masked 
some neurons which are in the same XY plane but different Z position. Therefore, an 
alternative method for analysing the images was tested to determine whether it could be 
more accurate in determining the number of neurons present. To achieve this, the total 
fluorescence intensity above a threshold of 4000 was calculated for each individual slice in 
the substack (Figure 84I). The sum of the total fluorescence intensity from each slice was 
calculated. This method was slightly more sensitive; the mean change in fluorescence 
intensity was an 8% decrease in pink1-/- compared to WT. However, this decrease does not 
represent the known decrease of dopaminergic neurons and is not significant (Figure 87B). 
As fluorescence intensity methods were unable to detect any change, we tested whether it 
is possible to accurately count neurons using images generated using the ETvmat2:GFP 
reporter line. To count neurons the substack image was opened in ImageJ. To identify 
neurons and count individual neurons, each slice of the stack was examined and the centre 
of each neuron was marked using the “point picker” tool. This tool allows the researcher to 
mark a particular point with a cross. Figure 87C shows a representative slices from 
ETvmat2:GFP embryos on a WT and pink1-/- background which have the neurons present 
marked. Once the whole stack has been examined for neurons the “point picker” tool 
generates a report which includes the coordinates of the points marked and allows the 
researcher to count the number of marks made. To reduce researcher bias counting the 
neurons in these images was performed whilst blinded to genotype.  
Neuron counting was able to detect a 25% decrease in neuron number. These data are not 
statistically significant. However, this experiment is only pilot data with an n of 2, therefore 
these data have weak statistical power (Figure 87C and D). As these data replicate the 25% 
decrease in dopaminergic neuron observed by neuron counting after WISH for th this shows 
that the images generated from the ETvmat2:GFP line have sufficient resolution that 
individual neurons can be accurately identified.  
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Figure 87. Image analysis methods with WT and pink1-/- embryos. A and B show the fluorescence intensity 
analyses, using the maximum projection image and the substack image respectively. C shows an example slice 
and point picking of individual neruons from a WT and pink1-/- substack. D shows the normalised neuron count 
from WT and pink1-/-. Around a 25% decrease in neuron number is detectable. Data are from two biological 
replicates. A minimum of 10 images are analysed per biological replicate and the average taken. Error bars 
represent standard deviation. 
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6.3 Development of a high throughput orientation and imaging system for 
assessment of dopaminergic neuron number in zebrafish embryos 
In the previous section it was demonstrated that it is possible to use the ETvmat2:GFP 
reporter line to measure dopaminergic neuron number. This is progress toward a high 
throughput screen through time-savings inherent to using a reporter line rather than 
performing WISH. However, one major limitation of this system that would prevent a high 
throughput screen being performed is the need for manual orientation of the zebrafish 
embryos. In order to capture high quality images of the zebrafish larval brain, the embryos 
must be carefully orientated into a dorsal position. The data in the previous section were 
collected by manually mounting each embryo onto a cover slip in 1% LMP agarose. This 
process is time consuming as the embryo must be held in the correct orientation until the 
agarose has set. In this section, the generation and testing of a mould which improves the 
speed of orientation of embryos and therefore allows high throughput imaging will be 
presented as a step towards automating the process of analysing dopaminergic neuron 
numbers. 
A need for tools to allow high throughput orientation of zebrafish embryos was also 
recognised by Jens Westhoff and colleagues. This group is interested in the development of 
the zebrafish larval kidney and identification of compounds which may affect this process 
(Westhoff et al. 2013). The need to carefully orientate zebrafish for imaging of the brain is 
similarly required for visualisation of internal organs such as the kidney. To increase the 
accuracy and speed of orientation of zebrafish embryos, the authors designed and generated 
a mould which allows the generation of agarose wells within a 96-well plate. Zebrafish 
embryos could be accurately orientated in these wells allowing generation of standardised 
views of the developing kidney. Use of this tool to quickly and consistently orient the 
zebrafish embryos allowed the authors to develop an automated imaging platform. This 
method was used to perform a pilot toxin screen which was able to identify morphological 
changes caused by nephrotoxic compounds in a fluorescent reporter line which labels the 
developing kidney (Westhoff et al. 2013). As the authors discuss, this system may be easily 
adapted for analysis of other organ systems, including the developing brain.  
The aim of this section of my thesis is to develop a high throughput imaging system to study 
changes in dopaminergic neuron number using the ETvmat2:GFP reporter line with the view 
of performing a phenotypic drug screen in the future. This project shares many similarities 
with the aims of the study performed by Westhoff and colleagues. In their study, the imaging 
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pipeline could only be used to score gross morphological changes. However, for this study a 
more subtle read out must be detectable. For this reason optimisations to the imaging 
protocol must be performed to develop this pipeline further; these will be discussed in this 
chapter. 
6.3.1 Optimisation 
6.3.1.1 Generation of a 3D printed mould to allow high throughput orientation of 
zebrafish embryos 
The original mould described by Jens Westhoff and colleagues was produced by CNC milling 
from brass; this is a relatively expensive and specialised technique. To improve dissemination 
of the mould to allow other researchers to benefit the same group generated a second 
version of the mould by 3D printing on a standard desktop 3D printer (Wittbrodt et al. 2014), 
thus making the mould reproducible in Sheffield. This mould comprises of 8 strips of 12 pins 
which slot into a base plate. The pins are cuboid and tapered at the end. The tip of the pin 
has a very fine point of 0.1mm width; this allows the production of deep V-shaped agarose 
wells which are able to accurately hold zebrafish embryos in the desired orientation. Figure 
88 shows the mould, how wells are generated in a 96 well plate, and how embryos are 
mounted into these wells.  
Following the protocol described by Wittbrodt and colleagues, 100μl of molten 1% agarose 
was added to each well and was left to cool in the wells of the 96-well plate for a two minutes 
before the mould was added. The mould was left inside the 96-well plate for 15 minutes until 
the agarose set before being carefully removed. Anaesthetised zebrafish embryos were 
added to each well in up to 150μl of E3 medium using a cut 200μl pipette tip. Prior cutting of 
the pipette tip widens the tip and helps to prevent damage to the embryos. Embryos were 
then carefully manipulated into the correct orientation within the well using a mounted 
needle. A small number of embryos fell into the well in the correct orientation of their own 
accord; however the majority required gentle orientation. This process was considerably 
more time and cost effective than individual mounting of embryos. By individual mounting 
each embryo took approximately 2 minutes to mount, a total of 48 minutes for 24 embryos; 
using the mould it was possible to orient 24 embryos in approximately 5 minutes. 
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Figure 88. Using a 3D printed mould for zebrafish orientation for imaging. A-D show the mould, the mould inside 
a clear 96-well plate and a view of the wells made in the agarose by the mould. E shows the mounting method for 
individual embryos where the embryos are held in the dorsal position in a bubble of LMP agarose on top of a thin 
glass coverslip. F shows how embryos are mounted in the wells created by the mould, the steep sides of the well 
hold the embryo in the dorsal position once they have been manipulated into the well using a mounted needle. G 
and H show close up images of the wells and embryos mounted within the well taken from above on a dissecting 
microscope.  
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6.3.1.2 Testing imaging systems to accurately measure dopaminergic neuron number 
in high throughput manner 
Two different imaging systems were tested to determine the best method of capturing 
fluorescent images of the zebrafish larval brains in a high throughput manner. These were, 
the IN Cell Analyzer 2000 (GE Healthcare Life Sciences) high throughput fluorescent 
microscope and UltraViewVoX spinning-disk confocal microscope (PerkinElmer Life and 
Analytical Sciences).  
The IN Cell Analyzer 2000 is a high content imaging system. It is commonly used for live and 
fixed cell culture imaging and has also been successfully used for rapid zebrafish screening 
to identify embryos containing a fluorescent transgene (Alex McGown, personal 
correspondence). This system combines the advantages of a high power fluorescent 
microscope with those of an automated plate reader, thus allowing a large number of 
samples to be processed quickly and high quality images produced. Other advantages of this 
system include the ability to control the environment of the microscope chamber, allowing 
long time-lapses to be performed. The IN Cell Analyzer system also uses IN Cell Investigator 
software which allows the user to develop an analysis routine to select regions of interest 
and perform analyses in an objective manner.  
The UltraViewVoX spinning-disk confocal microscope is also commonly used in house for 
acquiring images for time-laspe microscopy and other experiments which require 
automation (Gray et al. 2011; Wilkinson et al. 2012). Confocal imaging allows capture of 
higher resolution images of discrete optical sections in a thick sample compared to standard 
wide-field microscopy as any out-of-focus signal is eliminated by the pin hole. However, the 
time taken to generate an image using confocal microscopy is hugely increased compared to 
wide-field microscopy as the thin laser beam scans the sample sequentially rather than 
illuminating the whole sample simultaneously. Also, long exposure times are often required 
as the increased resolution reduces the signal intensity. Spinning-disk confocal microscopy 
uses a number moving pin-holes, allowing an array of laser beam to scan the image 
simultaneously thus using the multiplex principle to increase image capture time. The 
UltraViewVoX spinning-disk system also possesses a movable stage which can accept 
microtitre plates. The controlling software, Volocity, allows the user to pre-set to a number 
of X, Y and Z positions to allow directed imaging of the region of interest. 
Firstly, the IN Cell Analyzer 2000 was tested for this application. In order to capture the 
zebrafish brain in enough detail, the 20x objective was used. As the head of the embryo was 
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not in exactly the same position in every well, a grid of 9, slightly overlapping, fields of view 
were used to ensure that images of the head were captured. To ensure the head was 
captured in focus in each well a standard initial focus point can be set. As the sample is not 
in the same z-position in each well, due to variation in the well depth and position of the 
embryo within the well, the microscope then was set to use a large adaptive software 
autofocus system to identify the region of interest in the region around this pre-set focal 
point. The software generally selected the bright raphe nuclei to focus on. As the 
diencephalic catecholaminergic cluster is slightly ventral to the raphe nuclei the z-range was 
set accordingly. Figure 89 shows the location of these fields of view and example images 
captured using this process. 
 
Figure 89. Testing high throughput imaging of zebrafish embryos using the IN Cell Analyzer 2000. A shows the 
set up of the well to capture 9 overlapping fields of view (FOV) to ensure that the head of the embryo is captured. 
B-D shows the brightfield images captured of three example embryos. The FOV of interest, i.e. that captures the 
region of the brain of interest, is highlighted in red. Sometimes more than one FOV captures the region of interest 
due to the overlap (D,G). E-G show the fluorescent image captured in the FOV(s) of interest. The images shown 
are maximum projections of the stack taken.  
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When tested on a plate containing 12 embryos the head of the zebrafish embryo was present 
in one of the 9 fields of view in all cases. The focus set up also ensured that the region of 
interest was in focus in all images captured. This demonstrates that it is possible to image 
the brain of zebrafish embryos mounted into a 96-well plate using the IN Cell Analyzer 2000. 
Advantages of this system include the ability to save the imaging program. This minimised 
researcher input in the imaging stage as the plate can be inserted and imaging begun. 
However, this system has some major disadvantages. As 9 fields of view must be used to 
ensure that the head of each zebrafish is captured and a large z-stack is performed to ensure 
the region of interest is captured, the imaging process is very slow. This also results in a very 
large number of images that need to be manually processed to select the images which 
contain the region of interest. 
This system took approximately 45 minutes to image 6 wells of the plate. If a full plate were 
to be run this would take approximately 12 hours. As the end goal for this project is to use 
this process for drug or toxin screening this is not practical. Firstly, realistically one plate per 
day could be processed which is a severe limitation to the high throughput nature of the 
screen. Secondly, as live zebrafish will be used for this screen, the long imaging time may 
also introduce biological variation through either differences in exposure time to 
drugs/toxins or continued neuronal development over the course of the experiment. For 
these reasons the IN Cell Analyser 2000 is not suitable for this experiment. 
Secondly, the UltraViewVoX spinning-disk confocal microscope was tested. This microscope 
was previously used to acquire images of the individually mounted zebrafish (shown in 
section 6.2.1.2 on page 185), thus showing it is capable of producing high quality images from 
which the number of neurons in the diencephalic catecholaminergic cluster can be 
quantified. Using the stage on this microscope it was possible to pre-set the X, Y and Z 
positions in each well before setting the system to take images at all of these points. This 
process required much more initial user input, but dramatically reduced the total time of the 
imaging process and increases accuracy as all images included the region of interest and were 
in focus. On this microscope it was recommended that the outside wells of the plate are not 
used to avoid any damage to the objective while moving between wells, leaving 60 usable 
wells on the plate. It was possible to pre-set all the points in around 30 minutes. Once the 
imaging started the microscope took 45-60 minutes to image the whole plate, depending on 
the exposure time and number of slices in the stack. To ensure the region of interest was 
captured in each well, a range of approximately 120μm was set to be included in the stack 
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with 2μm z slices. This was a larger region than was typically used for individually imaged 
embryos, but it allowed for any slight movement of the plate as it was moved between wells. 
This imaging system was used for all subsequent experiments. 
To improve the image quality Greiner μClear 96 well plates, designed specifically for imaging 
purposes, were used. These plates have black walls and an optical-quality base allowing 
better imaging of the subject inside the well. To further increase the clarity of the acquired 
images the composition of the mounting media was optimised. When imaging individually 
mounted embryos, the embryo was pressed directly against the cover slip with the agarose 
bubble over the top to hold the embryo in place (Figure 88E). This meant there was less 
medium between the objective and the region to be imaged; and therefore, minimal 
distortion and a higher resolution image. When imaging the embryos loaded into the wells, 
there was a small amount of agarose between the embryo and the base of the plate which 
varied slightly between wells (Figure 88F). To ensure as high image quality as possible the 
material composing the well should be as transparent as possible. For this reason a range of 
materials were tested. These were: silicone, and a variety of concentrations of both standard 
and LMP agarose.  
Sylgard® 184 Silicone Elastomer (Dow Corning) was combined as a base and curing agent at 
a ratio of 10:1 (weight:weight). This was incubated at room temperature for 48 hours to set 
in a 96 well plate using the mould. Although this product has a high optical quality, removal 
of the mould resulted in damage to a high proportion of the wells, making it unsuitable for 
using for this purpose. 
Figure 90 shows a comparison between images taken from individually mounted embryos 
(Figure 90A) and embryos mounted in wells made from a range of concentrations of standard 
and LMP agarose (Figure 90D and E). An overview of the wells made with standard and LMP 
agarose is shown in Figure 90B and C respectively. Towards the lower concentrations of both 
standard and LMP agarose the wells become less defined, the embryos sit higher within 
these well and were held less securely. The lowest concentrations tested were not used as 
they failed to make defined wells. The images of embryos mounted in LMP agarose wells are 
clearer than with standard agarose. A concentration of 1.6% LMP agarose was taken forward 
to future experiments as it was the lowest concentration of LMP agarose which gave the 
highest quality images. 
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Figure 90. Testing different concentrations of agarose to make wells. A, D and E are maximum projection images 
of the diencephalic catecholaminergic cluster. A shows an example of images taken from individually mounted 
embryos for comparison. D and E show images taken of embryos mounted in wells made of different 
concentrations of standard and LMP agarose respectively. B and C show an overview of the wells made with 
standard and LMP agarose respectively.  
 
6.3.2 Results 
6.3.2.1 Validation of high throughput imaging process 
To validate whether the image quality and reliability of the images taken using this method 
were sufficient to replicate results obtained with individually mounted embryos, the MPP+ 
treatment was repeated. Two biological replicates of this experiment were performed with 
10 embryos per group. The variation between the two experiments was larger than 
expected. In the first replicate there is only a small and non-significant decrease in total 
fluorescence intensity in the MPP+ treated group (Figure 91A). However, in the second 
replicate the results are very similar to what was seen with individually mounted embryos. 
To determine whether the variation between these results and previous results are due to 
image quality issues or due to variation in the MPP+ treatment, the number of neurons 
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present in each image were counted. This was performed whilst blinded to treatment group 
of each image.  
Although images obtained using the mould did not have the same resolution as images from 
individually mounted embryos, it was still possible to identify the individual neurons in these 
images. However the variation in the resolution of the images was noticeable. This is likely 
to be due to variation in the depth of the well; in some wells the embryo is further from the 
objective than in others. This is likely to introduce some of the variation in fluorescence 
intensity readings in the results shown below. The neuron counting results are shown in 
Figure 91B. These data show a statistically significant decrease in neuron number in both 
replicates. However, this decrease is not as large as in previous MPP+ treatment experiment 
where a 60% decrease in neuron number was observed (Figure 86). These results show that 
whilst the fluorescence intensity measurements are not as robust using this imaging system 
it is still possible to detect significant changes in dopaminergic neuron number by performing 
neuron counting on images captured in this way. With the ongoing development of a 
software to automatically count neurons in this region, it is likely that this system can be 
used to generate robust and reproducible data sets in the near future. 
 
 
Figure 91. Fluorescence intensity measurements using new mounting and imaging technique. A shows data 
analysed by measurement of the total fluorescence intensity and B shows data analysed by neuron counting of 
the same images. Error bars represent standard deviation. 10 embryos were imaged per group, data was analysed 
using an unpaired t-test with Welch’s correction, * = p<0.05 and *** = p<0.001. 
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6.4 Discussion 
The aims of this chapter were to develop a method by which the ETvmat2:GFP reporter line 
can be used to replace traditional neuron counting experiments and to develop a high 
throughput image analysis system allowing the first method to be implemented as the read 
out of a phenotypic drug screen. Data in this chapter validate the use of the ETvmat2:GFP 
reporter line for dopaminergic neuron counting, and progress has been made towards 
developing a high throughput imaging system. This system may, in the future, be used to 
perform a phenotypic drug or toxin screen to identify compounds that modify the number 
of dopaminergic neurons using the measurement methods developed with the ETvmat2:GFP 
reporter line as a read out. 
Using the ETvmat2:GFP reporter line to measure dopaminergic neuron number 
In this study it has been demonstrated that the ETvmat2:GFP reporter line labels the th+ 
dopaminergic neurons and can be used to measure the number of dopaminergic neurons in 
the diencephalic catecholaminergic cluster. Compared to using WISH to identify 
dopaminergic neurons for manual counting, using this fluorescent reporter line to measure 
number of dopaminergic neurons allows for a large time saving as these embryos may be 
used live at 3dpf and do not require additional staining protocols. Although WISH is a 
powerful tool for determining expression patterns, the protocol is labour intensive and there 
is potential for error due to the inadvertent mixing of groups as there are many wash steps. 
Simplification of any protocol is always desirable as it reduces the number of stages at which 
errors can be made and therefore increases efficiency and accuracy of the experiment. 
Decreasing the process time of the experiment also increases the efficiency of the 
experiment as it allows a greater number of samples that can be processed in a given period.  
The staining intensity using WISH can also be quite variable. Variation in the bleaching and 
permeabilisation of embryos, differences in the length of time the embryos are present in 
stain solution and clearing solution, may all affect the staining intensity and clarity. If the 
staining intensities or clarity of the staining varies between groups or experiments this may 
introduce error in neuron counting, and a number of samples may need to be excluded if 
neuron counting is not possible. When using a fluorescent reporter line, as long as care is 
taken to ensure all groups carry the same number of copies of the transgene, the 
fluorescence intensity is less likely to vary considerably between individuals. However, care 
must always be taken to ensure groups are treated as similarly as possible.  
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One disadvantage of using a fluorescent reporter line, however, is that as the zebrafish must 
be imaged live; therefore these experiments have a fixed time in which they must be 
performed. This decreases the flexibility of the experimental process and increases the 
reliance on availability of equipment. 
For experiments described in this chapter, care was taken to ensure that only embryos which 
were heterozygous for the ETvmat2:GFP transgene were included in experiments. To do this, 
our colony of ETvmat2:GFP which is a mix of zebrafish which are heterozygous and 
homozygous for this gene were outcrossed to WTs then GFP positive embryos were selected 
at 24hpf. This adds another manual step in the process. In order to use this line for high 
throughput analyses, a colony of zebrafish which are exclusively homozygous for the 
transgene could be created. Progeny from an incross or outcross of this colony would all be 
homozygous or heterozygous, respectively, thus ensuring the copy number of the transgene 
remains equal and removing the requirement for manual sorting of the embryos.  
The first method developed to detect changes in neuron number in the diencephalic 
catecholaminergic cluster using the ETvmat2:GFP reporter line involved measuring the total 
fluorescence intensity of a maximum projection image of this region. This method is 
desirable as it is easily automated using standard image analysis software ImageJ and avoids 
subjective manual counting of neurons which may introduce researcher bias. This method 
was able to detect large changes in dopaminergic neuron number. The large 60% decrease 
detected by neuron counting after MPP+ treatment was accurately replicated by 
measurement of fluorescence intensity (Figure 86). There was no significant difference in the 
percentage change detected by either method. It has been previously established by the 
researchers who generated the ETvmat2:GFP reporter line that the GFP labelled neurons 
corresponding to th+ neurons are sensitive to MPP+ treatment (Wen et al. 2008). However, 
the present study is the first to develop a method that can accurately quantify this decrease 
in neuron number using the ETvmat2:GFP reporter line. 
In miR-133b morphants that display a 20% increase in dopaminergic neurons, as detected by 
traditional neuron counting, the increase in neuron number as measured by total 
fluorescence intensity was over estimated; an increase of 40% was identified using this 
method (Figure 85). The total fluorescence intensity is calculated by multiplying the area 
above threshold by the mean fluorescence intensity of this region. It is possible that the large 
increase calculated by this measurement is due to the increased expression levels of 
dopaminergic markers as well as the increased number of neurons. As shown in Figure 28 in 
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Chapter 3 (page 95), miR-133b knockdown resulted in a 40% increase in th expression at 3dpf 
as assessed by qPCR; although this change is not significant there is a strong trend. Therefore 
vmat2 may also be upregulated in miR-133b morphants. For GFP expression to be influenced 
by increased vmat2 expression in the ETvmat2:GFP reporter line, increased activation of the 
enhancer must be the cause of vmat2 upregulation. To determine the individual involvement 
of the two components making up the total fluorescence intensity reading these two 
readings were plotted individually.  
 
Figure 92. Contribution of area and intensity to total fluorescence intensity reading in WT and miR-133b 
morphants. The contribution of the two factors making up the total fluorescence intensity reading are plotted 
individually in this graph. A shows the area reaching the threshold in WT and miR-133b morphants. There is a 25% 
increase in area above the threshold in the morphants. B shows the mean fluorescence intensity of the area above 
the threshold, there is a slight but non-significant increase in mean fluorescence intensity in the morphants. Data 
are from three biological replicates. Error bars represent standard deviation. Data are analysed by an unpaired t-
test with Welch’s correction, ** = p<0.01. 
As shown in Figure 92, an increase in both area above the threshold (measured a number of 
pixels) and mean fluorescence intensity is present in the morphants. The increase in area 
above the threshold in the morphants (25%) more accurately recapitulates the increase in 
number of neurons calculated by neuron counting (20%). Although the increase in mean 
fluorescence intensity does not reach significance alone, it does contribute a portion of the 
variation in total fluorescence intensity (area above threshold multiplied by mean 
fluorescence intensity). Although it may be possible for an increase in Pitx3 to be driving 
increased activity of the vmat2 enhancer due to the Pitx3 binding site present here (Hwang 
et al. 2009), the direct regulation of Pitx3 by miR-133b has not been confirmed in this study.  
More subtle changes in dopaminergic neuron number were not detectable by measuring 
total fluorescence intensity. However, it was possible to accurately measure these 
differences using the ETvmat2:GFP reporter line by counting neurons using the substack 
image. These data show that the images taken using this reporter line are of sufficient quality 
to precisely identify individual neurons (Figure 87).  
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Neuron counting is a more sensitive method as, unlike measurement of total fluorescence 
intensity in this region which measures any pixels which reach the set threshold value, it is 
possible to discriminate the sub-populations of dopaminergic neurons. For changes in 
neuron number relevant to PD, the population of dopaminergic neurons with ascending 
projections are important. These neurons are analogous to the neurons of the substantia 
nigra in humans. In the developing zebrafish brain the dopaminergic neurons which belong 
to Wulliman-Rink groups 1, 2, 4 and 5 are those neurons with ascending projections into the 
sub-pallium (analogous to the human striatum). For this reason, only neurons from these 
groups are counted in neuron counting experiments.  
When performing neuron counting post-WISH the whole head is mounted. Any distinct 
morphological changes, such as small head induced by the treatment conditions or genotype 
can be easily recognised and potentially introduce researcher bias. Using images of a small 
region of the brain to count neurons, such as those processed from images of the 
ETvmat2:GFP reporter line, provides less distinguishing features between treatment groups. 
This may reduce researcher bias despite sill relying on subjective neuron counting.  
In order to automate the image analysis process further, a collaboration with Professor Alex 
Frangi in the Department of Mechanical Engineering in Sheffield was established. His group 
are developing software that can automatically, and therefore objectively, count the neurons 
in the diencephalic dopaminergic cluster. At first this software was being developed using 
images from WISH for th; however, it is currently being adapted for use with images of the 
ETvmat2:GFP reporter line. This software will be a powerful tool for us to use in our research 
as it will eliminate researcher bias from our neuron counts and also speed up the process of 
image analysis considerably. 
Development of a high throughput imaging process  
The future direction of this project is to generate a high throughput imaging process which 
in conjunction with the ETvmat2:GFP reporter line may be used to perform a phenotypic 
drug or toxin screen.  
One limitation of imaging studies that require standardised views of the zebrafish embryo is 
the lack of tools that allow consistent and quick mounting of zebrafish. For the initial 
experiments performed using the ETvmat2:GFP reporter line the embryos were individually 
mounted in 1% agarose; a time consuming process. Recently, a tool was developed by 
Westhoff and colleagues which enables quicker mounting of zebrafish for imaging studies. 
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The same group published a second version of the tool which was generated by 3D printing 
(Wittbrodt et al. 2014), enabling the reproduction of this tool in Sheffield. The second part 
of this chapter consisted of preliminary work to develop a high throughput mounting and 
imaging system using this tool. 
Use of the tool to generate wells in a 96-well plate able to hold zebrafish embryos in the 
desired position drastically reduced the amount of time spent mounting and imaging 
embryos. Two imaging systems were tested to assess the quality of images captured from 
zebrafish mounted in this way. The UltraViewVoX spinning-disk confocal microscope was 
chosen as the most suitable system for imaging these embryos. This system is compatible 
with imaging in microtitre plates and allows the user to pre-set the X, Y and Z position for 
each well before allowing the system to image each well. Although this requires more user 
input, it ensures that the region of interest is captured in every well. The overall image 
acquisition speed of this microscope was also much faster than the other system tested. As 
the embryos are imaged live, reduced imaging time is extremely important to reduce 
variation between the first and last embryos to be imaged. The UltraViewVoX spinning-disk 
confocal microscope was also used to capture images of individually mounted zebrafish in 
the initial development of use of the ETvmat2:GFP reporter line showing that is able to 
capture high quality images that can be used to measure dopaminergic neuron number. 
One limitation of using the UltraViewVoX spinning-disk confocal microscope is that the outer 
wells of the 96 well plate cannot be used for automated imaging. This is to reduce the risk of 
damage to the objective. If the outer wells are used it is possible the objective may come 
into contact with the stage as it moves around the plate. This leaves 60 usable wells per 
plate. Another limitation is that as this is an inverted microscope, the embryo must be 
imaged through the base of the plate and a small amount of agarose that comprises the well, 
this is depicted in Figure 88F (page 194). The depth of the well and the position of the embryo 
within the well are slightly variable, resulting in quality differences between the images 
captured. To reduce the variability caused by this optical quality plates were used and 
material composing the well was optimised to ensure it was transparent as possible and 
consistent wells could be produced.  
The quality of the images generated using this mounting and imaging system was tested 
using WT and MPP+ treated embryos. Using individually mounted embryos, a 60% decrease 
in fluorescence intensity was measured after MPP+ treatment. Using a measurement of 
fluorescence intensity a 15% decrease was measured in replicate1, this was not significant, 
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and a 60% decrease was measured in replicate2, p<0.001. The variation between the 
biological repeats is unexpected, further experiments must be performed to determine 
whether this variation is inherent of this technique or whether the result from the first 
experiment is anomalous. The variation within the groups (images of 10 embryos was taken 
and analysed per group) is also very high. The standard deviation of these groups was 
compared to the standard deviation of WT and MPP+ treated embryos imaged after 
individual mounting. To ensure these standard deviations are comparable the standard 
deviation was taken from groups with contain the same number of data points. The standard 
deviation of the measurement normalised to the average of the WT value was used. This 
comparison is shown in Figure 93. 
 
 
Figure 93. Comparison of standard deviation from image analysis data from mould mounted and individually 
mounted zebrafish embryos. This graph shows the variation in the fluorescence intensity values calculated from 
images captured from embryos mounted within the mould (n=4) is significantly higher than the variation in the 
fluorescence intensity values calculated from images captured from individually mounted embryos (n=2). To 
ensure the standard deviations presented here are comparable, the standard deviations used were calculated 
from WT and MPP+ treated groups where the fluorescence intensity measurement were normalised to the 
average of the WT value. The same number of embryos were analysed per group. Error bars represent standard 
deviation. These data are analysed by an unpaired t-test with Welch’s correction, *** = p<0.001. 
This shows that the fluorescence intensity measurements within groups taken from images 
of embryos mounted within the mould are significantly more variable than individually 
mounted embryos. This is likely to be due to the variability in the depth of the well and the 
position of the embryo within the well as mentioned above. These data show that the images 
taken with mould-mounted embryos are not consistent enough to enable this measurement 
to be used. As the neuron counting has already been established as the more robust read 
out from these images it was important to determine whether the image quality of embryos 
imaged within the mould is sufficient for neuron counting. It was possible to identify and 
count individual neurons using these images and significant differences in the neuron 
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number between the WT and MPP+ treated groups where detectable. While these decreases 
are not as large as expected further work needs to be performed to determine whether this 
is an inherent shortcoming of image quality and whether data generated in future 
experiments is reliable and reproducible. Images generated using embryos mounted within 
the mould must be tested with the software being developed by Professor Alex Frangi and 
Bo Dong.  
An upright (non-inverted) fluorescence microscope may be capable of generating higher 
quality images as the issue of distortion is caused by imaging through the base of the plate 
and well. Although no upright microscopes which can capture images of a high enough 
quality are currently available within the department, these may become available in the 
future. Another possibility which may allow capture of higher quality images while 
maintaining high throughput mounting and imaging techniques is to investigate the 
development of a microtitre plate which has similar shaped wells to the ones produced using 
this mould. This would remove the need for using agarose or other medium within the well 
and therefore may increase optical clarity of the captured images. 
Future prospects for phenotypic drug screening using the described method 
The present study aimed to develop methods which allow for a more time and cost effective 
analysis of dopaminergic neurons which may be applied to a high throughput screen. To do 
this the use of the ETvmat2:GFP reporter line was combined with the use of a mould for 
quick and accurate orientation of zebrafish allowing a standardised view of the zebrafish 
embryo to be captured. 
Until now, the barrier preventing us from performing such a screen has been a technical one. 
Manual staining of the dopaminergic neurons by WISH followed by neuron counting is 
preventatively time consuming and would only allow a very small number of compounds to 
be tested. Despite this, a previous study has been performed that assessed the effects of 
over 5000 compounds on the development and survival of dopaminergic neurons using IHC 
for TH and subsequent manual imaging of these embryos (Sun et al. 2012). Although this 
study was successful in identifying compounds which had previously unknown neurotoxic 
effects on dopaminergic neurons, this model for performing drug screens is highly time 
consuming and not economically viable for most laboratories to perform. As discussed 
above, using a combination of the reporter line and the mould for mounting embryos allows 
for a large time saving thus hugely increasing the potential for processing large numbers of 
samples in a time and cost effective manner. The 96-well plate format of the mould increases 
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compatibility with liquid handling machinery that is commonly used for high throughput 
compound screens. In this section, the features of the drug screen which may be performed 
using the method described in this chapter will be discussed and compared to other similar 
drug screens.  
For reasons previously discussed, zebrafish are a popular model organism for use in drug 
screens. To increase the number of compounds it is possible to screen, these studies are 
designed to have very simple read outs, such as a change in fluorescence which is present in 
a large area, and often do not require manual manipulation to generate the images needed. 
A study by McGown and colleagues used fluorescence from embryo homogenates as the 
read out. Using this simple read out, the authors were able to screen 2000 compounds from 
the spectrum library. Using their highly automated set up it was possible for an individual to 
screen approximately 250 compounds per day (McGown et al. 2013 and personal 
correspondance). Screens which require more complex read outs are often limited to smaller 
number of compounds. The group which originally designed the mould used in this study 
were able to perform a pilot drug screen examining the effects of 7 different compounds at 
5 different doses on a number of morphological features of the developing kidney (Westhoff 
et al. 2013). This drug screening pipeline used by this group is easily modifiable for a number 
of readouts, such as the readout described in this study. 
Fully automated systems are much more amenable for high content screening and larger 
numbers of compounds can be tested. Technologies are continually being developed to allow 
a larger proportion of the steps in the drug screening process to be automated. One such 
study screened 640 compounds to identify modulators of the acute-immune response in 
transgenic zebrafish which express GFP in neuromasts and RFP in granulocytes. The authors 
developed a method to chemically injure the zebrafish thus removing the need to manually 
injure the embryos. The chemical insult and drug treatment were performed with a liquid 
handling system before the embryos were imaged using a high content microscope. The 
images were analysed using custom developed software which allowed measurement of 
granulocyte presence around the injured neuromasts (Wittmann et al. 2012).  
The phenotypic drug screen we hope to be able to perform in the future shares many 
commonalities with the studies mentioned. Primarily the use of fluorescent reporter lines is 
key. The orientation technique developed by Westhoff and colleagues will be used. However, 
unlike their screen where the gross morphology of the developing kidney is scored, our 
proposed screen will have a quantitative read out indicating change in neuron number in a 
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specific region of the brain. Similar to the study performed by Wittmann and colleagues, this 
read out will be generated by custom developed software. Similar to the screens described 
by Westhoff and Wittmann, another benefit using the imaging method described in this 
chapter is that any toxic or off target effects can be identified in the same screen as an image 
of the whole head is captured, and therefore any toxic compounds can be identified quickly 
and easily and removed from analysis. A potential pipeline for this drug screen is shown in 
Figure 94. 
 
 
Figure 94. Potential drug screening pipeline. 
 
With the advances described in this chapter and further development of the image analysis 
technique and the automated neuron counting software, it is plausible to assume that is will 
soon be possible to undertake a PD-orientated phenotypic drug or toxin screen in our group 
in the near future.  
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7.1 Overview 
The first aim of this thesis was investigate the function of three miRNAs, which may be 
relevant to PD, in zebrafish. These miRNAs were chosen as a single, well conserved 
orthologues of these miRNAs and their relevant target genes are present in zebrafish. The 
first two chapters investigated whether modulation of miR-133b and miR-205 expression 
resulted in a change in dopaminergic neuron number through altered regulation of their 
targets pitx3 and lrrk2. As hypothesised, knockdown of miR-133b resulted in an increase in 
dopaminergic neuron number. However, this study was not able to elucidate the mechanism 
for through which this occurs. Neither pitx3 nor lrrk2 were confirmed as direct targets of 
miR-133b or miR-205 in zebrafish. The third chapter investigated the involvement of miR-155 
in three zebrafish models of neurodegeneration. No change in miR-155 was observed in 
zebrafish models of pink1- or parkin-deficiency, however an increase in miR-155 was 
observed in a zebrafish model of Gaucher’s disease. This is the first study which has 
implicated miR-155 in the pathogenesis of Gaucher’s disease. 
The second aim of this study was to develop an imaging system which would allow high 
throughput screening of the zebrafish larval brain. This project was successful in validating 
use of the ETvmat2:GFP reporter line as an alternative method for measuring dopaminergic 
neuron number. Progress has been made towards developing an imaging system, however 
further work needs to be performed to validate the quality of the images captured. 
The results of each individual study and suggested future work is discussed in the respective 
chapters. In this chapter the overall findings and limitations of this study will be discussed. 
7.2 Main limitations 
The main limitation of this study is that all work was carried out in zebrafish. Although this 
model organism confers many advantages for the study of human diseases, not least their 
practical simplicity and low cost, they are less closely related to humans than rodents or 
primates. In order to draw conclusions from animal models of disease there must be 
evolutionary conservation of the involved biological processes. More than 90% of human 
genes have a recognisable orthologue in mice, while in zebrafish the percentage of conserved 
genes is closer to 70% (Chinwalla et al. 2002; Howe et al. 2013). Despite the fact that 
zebrafish are more distantly related to humans than rodents, zebrafish models of PD have 
shown promise in modelling neurodegeneration while the majority of mouse models have 
failed to demonstrate neurodegeneration (Blesa & Przedborski 2014; Flinn et al. 2013). 
However, the more recently developed rat models are a promising mammalian model of PD. 
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Although the zebrafish CNS has a similar overall organisation to the human brain there are 
many structural differences. Of particular relevance to PD research are the dopaminergic 
neurons. In mammals the ascending dopaminergic neurons are present in the midbrain, 
whereas in zebrafish they are present in the forebrain. However, the ventral telencephalon 
(subpallium) and the posterior tuberculum and their containing neurons display many 
similarities to the human nigrostriatal system (Xi, Noble, et al. 2011; Rink & Wullimann 2001). 
Although the factors involved in development of the ascending dopaminergic system in 
zebrafish is not as well studied as the development of the human system, many transcription 
factors involved in this process are thought to have conserved roles in zebrafish (Filippi et al. 
2007). To validate that PD-causing mutations in zebrafish accurately model 
neurodegeneration, the effect of these developmental factors must be studied to ensure 
that any decrease in dopaminergic neurons observed is due to degeneration of neurons, 
rather than a developmental phenotype. 
A major difference between zebrafish and humans which may impact research into 
mechanisms of neurodegeneration is that zebrafish have a high regenerative capacity and 
are able to regenerate many tissues which humans cannot. Neural stem cells and 
neurogenesis has been detected in the zebrafish brain. Although neurogenesis does occur in 
adult human brains the zebrafish brain has higher proliferative potential (Schmidt et al. 
2013). This feature of zebrafish does present some advantages as research may be 
undertaken allowing a deeper understanding of the mechanisms behind regeneration, with 
the aim of stimulating similar regeneration in human tissues. However, for modelling 
neurodegenerative diseases, such regeneration is a disadvantage as neuron loss may 
stimulate regenerative pathways thus obscuring pathogenic changes. 
Another feature of the zebrafish to consider is that approximately 20% of human genes have 
multiple orthologues in zebrafish (Postlethwait et al. 2004). This is due to a large genome 
duplication event in teleost ancestry which has resulted in functional redundancy for many 
genes (Postlethwait 2000; Prince & Pickett 2002). The majority of the genes directly 
investigated in this study are thought to have only one orthologue in zebrafish. However, 
wider pathways involved in pathogenesis may be affected by multiple copies of a gene, thus 
complicating investigation of these affected pathways.  
For the above reasons findings in zebrafish models would benefit from validation in 
mammalian animal models or in human cell culture. Previously, the effect of modulating 
miR-205 and miR-133b have been studied in cell culture models. The effect of knockdown of 
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miR-205 has been studied in primary neurons derived from transgenic mice expressing 
mutant LRRK2; in these cells knockdown of miR-205 exacerbated the neurite outgrowth 
defect through increasing the load of mutant LRRK2 (Cho et al. 2013). The effect of miR-133b 
knockdown was also examined in in mouse embryonic stem cells; an increase in expression 
of dopaminergic markers TH and DAT was observed after miR-133b knockdown (Kim et al. 
2007). However, a miR-133b knockout mouse did not display any neuronal phenotype (Heyer 
et al. 2012). This is unexpected, however may reflect differences in dopaminergic neuron 
vulnerability in mice. The present study represents the first to uncover an effect of miR-133b 
knockdown at a system level. However, in light of the mouse knockout data the effect 
observed in this study must be reproduced in another animal model to ensure this is not a 
teleost-specific effect. Study of the effect of these miRNAs in rat models may be more 
appropriate than studies in mice. 
Although human cell culture models are not able to represent a whole system, study of these 
miRNAs in human cells will be important to validate that the effects of these miRNAs are 
relevant in a human model system. In human patient fibroblasts, neither miR-133b nor miR-
205 were detectable (Mandal 2014). However, as both of these miRNAs are thought to be 
expressed specifically in midbrain neurons, iPSCs differentiated to a dopaminergic 
phenotype may be a suitable model to study the effect of knockdown of these miRNAs. 
Zebrafish larvae are highly suited to phenotypic drug screening. One of the advantages of 
zebrafish for drug screening is their permeability, allowing drugs to be placed into the 
medium surrounding the larvae. However, limitations to consider when using this system for 
drug discovery for neurodegenerative disorders include the differences in the blood brain 
barrier (BBB). One of the major obstacles limiting development of drugs to treat brain 
disorders is that less than 2% of small molecules are able to cross the BBB (Pardridge 2005). 
In zebrafish the BBB is thought to mature between 3dpf and 10dpf. Fleming and colleagues 
used 5-10dpf zebrafish to examine penetration of the BBB by a number of compounds which 
are either known to be penetrant or excluded from the brain in mammals. Although the BBB 
had not fully matured in these larvae, differences in concentration, which increased with age, 
were observed between the trunk and head for molecules which are known to be excluded 
from the brain in mammals (Fleming et al. 2013). These data suggest that although the BBB 
is not fully formed, non-penetrant compounds will have, at least, a reduced bioavailability in 
the brain. Therefore when performing compound screens in zebrafish further analysis of 
compounds of interest must be performed to show that these can indeed penetrate the BBB. 
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Another important limitation of this study is the method used to generate knockdowns. MOs 
were used to generate a knockdown of both miR-133b and miR-205. Findings with MOs 
should be validated with a stable mutant, especially as recent studies have identified 
differences between MO-induced knockdown and stable mutant lines (Kok et al. 2015; Rossi 
et al. 2015). MOs may also result in off-target effects (Robu et al. 2007). While these are 
unlikely to have resulted in the increase of dopaminergic neurons observed after miR-133b 
knockdown, the mild decrease in dopaminergic neurons after miR-205 knockdown may have 
been due to developmental delay or non-specific apoptosis. Therefore longer term studies 
with a stable mutant are required to validate this.  
7.3 Neuroinflammation and PD 
It is currently unclear whether neuroinflammation is a primary or secondary feature of PD, 
however attenuation of this inflammatory response has been shown to have beneficial 
effects in animal models (Wu et al. 2002). While moderately activated microglia play a 
homeostatic and protective role in the brain by removing dying cells and releasing trophic 
factors such as BDNF, fully activated microglia release inflammatory cytokines and reactive 
oxygen species. The substantia nigra may be more vulnerable than other regions to oxidative 
damage due to increased content of oxidisable species, including dopamine and 
neuromelanin, and reduced anti-oxidant capacity (Block et al. 2007). Oxidative stress is 
known as a key pathogenic factor in PD however this is usually studied in the context of 
mitochondrial dysfunction (Celardo et al. 2014). Activated microglia, as well as increased 
levels of inflammatory cytokines, have been identified in the substantia nigra and other 
affected brain regions of PD patients (Imamura et al. 2003). Breaking the neuroinflammatory 
cycle by attenuation of oxidant producing enzymes in MPTP-induced mouse models of PD 
have been shown to ameliorate neuron loss and protein oxidation (Choi et al. 2005; Wu et 
al. 2003).  
One of the aims of this study was to investigate the involvement of miR-155, a 
pro-inflammatory miRNA which modulates microglial activation, in PD pathology. In this 
study miR-155 was not found to be upregulated in either 5dpf larvae or adult brains of pink1- 
or parkin-deficient zebrafish. This suggests that miR-155 may not play a role in the 
pathogenesis of pink1 and parkin related PD. This does not, however, prove that 
inflammation is not important in the pathogenesis of PD. Inflammation may be driven 
through different mechanisms that do not involve miR-155, miR-155 may be more relevant 
in other genetic forms or sporadic cases of PD, or zebrafish may be more resistant to 
216 
 
inflammation as a result of mutations in pink1 and parkin. Previously pink1-deficient 
zebrafish have been shown to have an increased number of microglia. However inhibition of 
PU-1 to, prevent microglial maturation, did not result in rescue of dopaminergic neuron 
number (Flinn et al. 2013). 
The expression of miR-155 was also examined in gba1-deficient zebrafish. Although no 
change in miR-155 was observed in zebrafish carrying one mutant copy of gba1, increases in 
miR-155 were observed in both the larvae and adult brain of homozygous mutant zebrafish. 
The contribution of neuroinflammation to neuronal cell death in Gaucher’s disease has 
previously been investigated (Vitner et al. 2012), however this is the first study to implicate 
miR-155 in Gaucher’s disease. The early upregulation of miR-155 is intriguing as this 
upregulation occurs before any neuronal loss is observed. This suggests that inflammation 
may be an early feature of Gaucher’s disease which precedes neurodegeneration. The oldest 
heterozygote zebrafish studied were 3 months old. It is possible that any inflammatory 
phenotype in these zebrafish may manifest much later and therefore older zebrafish should 
be studied to investigate this.  
Microglial activation has been associated with many other neurodegenerative disorders, 
including MND, Huntington’s disease, Alzheimer’s disease and multiple sclerosis (Pavese et 
al. 2006; Schlachetzki & Hüll 2009; Brettschneider et al. 2012; Giunti et al. 2014). This 
suggests that neuroinflammation may provide a link between these disorders. As 
neurodegeneration appears to result in excessive inflammation which in turn results in 
further neuronal toxicity and cell death, breaking this cycle by inhibition of microglial 
activation and release of inflammatory factors may be a valuable therapeutic strategy.  
7.4 miRNA involvement in neurodegeneration and therapeutic potential 
miRNAs are implicated in a large number of biological processes and expression changes of 
miRNAs have been implicated in many human diseases (Esteller 2011). The Human microRNA 
Disease Database lists miRNA associations with human diseases (this is accessible at: 
http://210.73.221.6/hmdd (Lu et al. 2008). There are also reported cases where mutations 
in either a single miRNA or miRNA binding site have been shown to be causative of a disease. 
For example, deletion of an intragenic region containing miR-361 results in Choroideraemia 
(van Bokhoven et al. 1994), and two point mutations identified in the 3’UTR of REEP1 have 
been associated with autosomal dominant form hereditary spastic paraplegia (Beetz et al. 
2008; Züchner et al. 2006). Other such mutations are reviewed by Meola et al. (2009).  
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Approximately 70% of miRNAs are expressed in the CNS (Cao et al. 2006). As previously 
discussed, deletion of dicer in neuronal populations results in the death of many neuronal 
populations (Kim et al. 2007; Schaefer et al. 2007; Huang et al. 2010). These data show that 
miRNAs are required for development and survival of many neuronal groups, therefore 
disruption of the miRNA network may contribute to neurodegeneration. In many 
neurodegenerative disorders there is a clear gene dosage effect which contributes to 
pathology. For example, duplication or triplication of the SNCA-containing locus is causative 
of PD (Singleton et al. 2003). Similarly, duplication of the amyloid precursor protein encoding 
gene (APP) results in early onset Alzheimer’s disease (Rovelet-Lecrux et al. 2006). Moreover, 
in PD altered levels of both ɑ-synuclein and LRRK2 have been detected in sporadic cases of 
PD (Chiba-Falek et al. 2006; Cho et al. 2013). As such dosage effects are apparent in 
neurodegenerative disorders it is conceivable that dysregulation of miRNAs that negatively 
regulate these genes may contribute to disease pathology. Even if this is cannot be proven, 
the miRNAs which target these genes may be overexpressed as a therapy to reduce the toxic 
load of these proteins.  
Huntington’s disease is caused by a CAG repeat expansion in huntingtin (htt) resulting in an 
expanded polyglutamine stretch which is prone to misfolding and aggregation. miR-196a has 
been shown to indirectly alter the expression of htt and has been suggested as a therapy to 
reduce the toxic load of the mutant HTT protein. Overexpression of miR-196a ameliorates 
the phenotype of a transgenic mouse model of Huntington’s disease and was able to reduce 
the number of protein aggregates in human iPSCs differentiated to neurons (Cheng et al. 
2013). This demonstrates the therapeutic potential of this miRNA for Huntington’s disease.  
Inhibition of miR-155 has been shown to be protective in animal models of both multiple 
sclerosis and MND (Butovsky et al. 2015; Murugaiyan & Beynon 2011). Th1 and Th17 T-helper 
cells are involved in several autoimmune diseases including multiple sclerosis. Genetic 
ablation of miR-155 in the EAE mouse model of multiple sclerosis resulted in reduced Th1 
and Th17 responses and reduced inflammation in the CNS (Murugaiyan & Beynon 2011). In 
a SOD1 mouse model of MND, loss of miR-155 normalised the abnormal and pro-
inflammatory molecular signature associated with microglia in SOD1 mice. miR-155 deficient 
SOD1 mice demonstrated a delayed onset of symptoms and increased life-span (Butovsky et 
al. 2015). In both the EAE mouse model and the SOD1 model of MND, inhibition of miR-155 
after the onset of symptoms was also effective at reducing symptoms or extending the life-
span of the animal to some degree. As increased inflammation and microglial activation have 
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been implicated in a number of neurodegenerative diseases (as discussed above) it is 
tempting to hypothesise that the protective effects of silencing this miRNA will extend to 
other neurodegenerative diseases. 
Development of miRNAs for therapeutics is still in its early stages, however new potential 
miRNA therapeutic targets are continuously being discovered and enter preclinical 
development, particularly in the field of cancer. There are two different strategies for miRNA-
based therapeutics. Firstly, miRNA mimics can be used to downregulate specific target genes. 
Secondly, anti-miRNAs may be used to release specific targets from repression. Currently, 
there are two miRNA-based therapies in clinical trials. These are an antagonist for miR-122 
for treatment of hepatitis C and a miR-34 replacement therapy for a variety of cancers 
(Janssen et al. 2013; Agostini & Knight 2014). miR-122 is highly expressed in the liver and 
appears to stabilise the hepatitis C virus by protecting it from the host innate immune 
response (Shimakami et al. 2012). This therapy is currently yielding promising results in phase 
2 clinical trials; no adverse effects were observed in healthy volunteers in phase 1 (Janssen 
et al. 2013). The members of the miR-34 family have key roles as tumour suppressors in many 
cancers with targets including BCL2, CDK4 and MET. Suppression of targets by miR-34 arrests 
the cell cycle and induces apoptosis (Agostini & Knight 2014). A miR-34 replacement therapy, 
MRX34, is currently in phase 1 clinical trials. There are also a number of miRNA therapies in 
preclinical development for diseases including cancer, cardiovascular disease and insulin 
resistance. A selection of these are summarised in Table 20. 
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Table 20. Selected miRNA therapies currently in development. Reproduced with permission from Li & Rana (2014) 
 
There are still, however, many challenges facing the development of miRNA therapies, 
particularly for neurodegenerative disorders. The main obstacle, as with all therapies for 
brain diseases, is the issue of delivery to the brain. Many strategies to aid delivery of miRNA 
based therapies are being developed; progress in delivery strategies is reviewed by Zhang et 
al. (2013). One promising strategy for delivery of miRNA therapeutics to the brain are 
exosomes; these are naturally occurring nanovesicles which transport mRNA and proteins. 
Alvarez-Erviti and colleagues showed that exosomes purified from dendritic cells from a 
particular animal did not result in an immune response when injected intravenously to the 
brain of the same animal. These exosomes were able to deliver siRNA to the brain of mice 
(Alvarez-Erviti et al. 2011). It has been suggested that miRNAs may be an active therapeutic 
element in some herbal medicines, after plant miRNAs were identified in human tissue after 
ingestion of such medication (Sala-Cirtog et al. 2015). Although the functional effects of 
these miRNAs are yet to be validated, study of the delivery of these plant miRNAs may 
present new strategies for encapsulation of known therapeutic miRNAs. 
Another important feature of miRNA-based therapies which can be both an advantage and 
a limitation is the large number of potential targets of each miRNA. For the promising anti-
cancer miR-34 based therapy, inhibition of a large number of targets is beneficial and a 
network of potentially oncogenic genes is repressed. For other potential therapies, however, 
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researchers must be aware of the wide range of targets that each miRNA may have and 
ensure that modulation of these targets does not result in unwanted side effects. 
Despite the challenges that remain for the development of miRNA therapies for 
neurodegenerative disorders, the rapidly advancing field of miRNA research may uncover 
new directions for potential therapies. This is not only possible by identifying miRNAs that 
may be directly useful as therapeutic targets but also by elucidating novel cellular 
mechanisms involved in pathogenesis through miRNA research.  
7.5 Concluding remarks 
One of the main aims of this study was to investigate miRNAs which may have therapeutic 
potential. Although further investigation is required to validate the findings presented in this 
thesis, these data suggest that knockdown of miR-133b may be beneficial by increasing 
development or survival of dopaminergic neurons. The observation that miR-155 expression 
levels are increased in gba1 mutant zebrafish suggest that inhibition of this miRNA may 
modulate the inflammatory phenotype demonstrated in these mutants. Further 
investigation into the action of miRNAs may uncover pathways that may be therapeutically 
modified to provide a beneficial effect for PD patients or may validate the miRNA itself as a 
potential therapeutic target. Finally, study of these miRNAs in a model organism such as 
zebrafish allows for system level analysis of their effects. Therefore it is possible to identify 
both beneficial effects and any unexpected targets of these miRNAs. 
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